

VACCINES AGAINST CHLAMYDIAL INFECTION

FIELD OF THE INVENTION

5 The present invention relates generally to the treatment or prevention of Chlamydial infection. In particular, the invention is related to compositions of polypeptides comprising a *Chlamydia* antigen and combinations thereof, and to compositions of polynucleotides encoding a *Chlamydia* antigen and combinations thereof, and to the use of such compositions for prophylactic or therapeutic treatment of Chlamydial infection.

10

BACKGROUND OF THE INVENTION

Chlamydiae are intracellular bacterial pathogens that are responsible for a wide variety of important human and animal infections.

Chlamydia trachomatis is transmitted between human beings through social or sexual contact. A number of *Chlamydia trachomatis* serovars exist, and although the identification and
15 classification of serovars continues to evolve, at least 18 have been reported to date. Serovars A to C are primarily associated with ocular trachoma, serovars D to K with oculogenital disease and serovars L1 to L3 with lymphogranuloma venereum (LGV) (Brunham, RC et al. *J. Nat. Rev. Immunol.* 2005 5:149-161).

Chlamydia trachomatis is one of the most common causes of sexually transmitted
20 diseases and can lead to pelvic inflammatory disease (PID), resulting in tubal obstruction and infertility. *Chlamydia trachomatis* may also play a role in male infertility. In 1990, the cost of treating PID in the US was estimated to be \$4 billion. The World Health Organisation estimated that in 1999 over 90 million new cases of sexually transmitted *Chlamydia trachomatis* occurred worldwide (Global Prevalence and Incidence of Selected Curable Sexually Transmitted
25 Infections, World Health Organisation, Geneva, 2001). Furthermore, ulcerative sexually transmitted diseases such as *Chlamydia trachomatis* infection are a major risk factor for HIV acquisition (Brunham, RC et al. *J. Nat. Rev. Immunol.* 2005 5:149-161; Igiertseme, JU et al. *Expert Rev. Vaccines* 2003 2(1):129-146).

Trachoma, due to ocular infection with *Chlamydia trachomatis*, is the leading cause of
30 preventable blindness worldwide and is estimated to affect 300-500 million people (West, SK *Prog. Ret. Eye Res.* 2004 23:381-401). Current treatment involves the use of antibiotics such as tetracycline (daily, for a period of 4 to 6 weeks) or azithromycin (single dose). Although effective in combating infection, re-infection generally occurs due to the endemic nature of the infection. Repeated infection over many years leads to scarring of the eyelid, distortion of the lid
35 margin and rubbing of the eye lashes against the cornea (trichiasis). Constant trauma to the

cornea is both painful and leads to corneal opacity and blindness (Mabey, DCW et al. *The Lancet* 2003 362:223-229).

Chlamydia pneumoniae is a major cause of acute respiratory tract infections in humans and is also believed to play a role in the pathogenesis of atherosclerosis and, in particular, coronary heart disease. Individuals with a high titer of antibodies to *Chlamydia pneumoniae* have been shown to be at least twice as likely to suffer from coronary heart disease as seronegative individuals.

Often chlamydial infection is asymptomatic and subclinical, such that severe and often irreversible complications may present as the first symptoms of genital infection. Infants born from a mother with a genital chlamydial infection may develop pneumonia and *Chlamydia trachomatis* is considered the most common causative agent of pneumonia during the first six months of life (de la Maza, LM et al. *Curr. Opin. Investig. Drugs* 2002 3(7):980-986).

Chlamydial infections thus constitute a significant health problem both in developed and developing countries. In light of the public health concerns, and the fact that the cost of current treatments is excessive in many developing countries, the development of vaccines for *Chlamydia* species has been an important research target. As the genomic make-up of *Chlamydia trachomatis* is relatively stable, and since the presence of animal reservoirs is negligible, even vaccines with limited efficacy may have a significant impact on the prevalence of infections.

There thus remains a need in the art for improved vaccines and pharmaceutical compositions for the prevention and treatment of *Chlamydia* infections. There also remains a need in the art for multivalent vaccines for the prevention and treatment of *Chlamydia trachomatis* infections which are effective against a range of serovars. The present invention fulfills these needs and further provides other related advantages.

SUMMARY OF THE INVENTION

The present invention relates to compositions comprising antigens of bacterial pathogens of *Chlamydia*. Such bacterial pathogens include *Chlamydia trachomatis*, *Chlamydia psittaci*, *Chlamydia pneumonia*, and *Chlamydia muridarum*. The *Chlamydia* antigens may be derived from any number of serovars within a *Chlamydia* species.

It should be noted that *Chlamydia muridarum* was previously known as *Chlamydia trachomatis* mouse pneumonitis strain (MoPn), both names are still in common use, although they refer to the same bacterium. For consistency, only the name *Chlamydia muridarum* is used herein.

The present invention is based, in part, on the inventors' discovery that *Chlamydia* polypeptides possess immunogenic and antigenic properties and can offer protection against

chlamydial infection when administered as prophylactic vaccines. Some level of cross reactivity may be seen between antigens of different serovars and species, and therefore *Chlamydia* antigens are predicted to provide a protective immune response against a species or serovar other than the one from which the antigen was obtained.

5 More specifically, the inventors have discovered that certain combinations of *Chlamydia* polypeptides provide a good immune response. Certain combinations of *Chlamydia* polypeptides have been shown to provide protection against *Chlamydia* infection in mouse models.

10 In a specific embodiment, the isolated or purified *Chlamydia* polypeptides of the invention may be formulated as pharmaceutical compositions for administration into a subject in the prevention and/or treatment of *Chlamydia* infection. The immunogenicity of the protein composition may be enhanced by the inclusion of an adjuvant.

In a specific embodiment, the isolated or purified *Chlamydia* polypeptides are administered as combinations of individual antigens, optionally in combination with an adjuvant.
15 Alternatively, the *Chlamydia* polypeptides are administered in the form of a fusion protein, optionally in combination with an adjuvant.

In another aspect of the invention, isolated or purified polynucleotides are used to produce recombinant polypeptide antigens *in vitro*. Alternatively, the polynucleotides may be administered into a subject as polynucleotide vaccines to cause antigen expression in the
20 subject, and the subsequent induction of an anti-*Chlamydia* immune response.

In a further aspect of the invention, certain combinations of *Chlamydia* polypeptides according to the present invention, immunogenic fragments thereof or polynucleotides encoding them which are derived from a first *Chlamydia trachomatis* serovar may be administered to a subject for the treatment or prevention of *Chlamydia* infection from a second *Chlamydia*
25 *trachomatis* serovar.

It is also an object of the invention that the polypeptides be used in *in vitro* assays for detecting humoral antibodies or cell-mediated immunity against *Chlamydia* for diagnosis of infection or monitoring of disease progression. Alternatively, the polypeptides may be used as immunogens to generate anti-*Chlamydia* antibodies in a non-human animal. The antibodies
30 can be used to detect the target antigens *in vivo* and *in vitro*.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows Day 7 bacterial shedding data in Balb/c mice, representing data from three experiments in which groups of 5 Balb/c mice were immunized with the indicated combinations of antigens in AS01B. Graph represents data from three experiments in which groups of 5
35 Balb/c mice were immunized with the indicated combination of antigens in AS01B adjuvant.

UVEB from serovar E formulated with AS01B served as a positive control of protection, and AS01B sham-immunized mice were used as positive control of infection. Progesterone-treated mice were challenged with an intra-vaginal dose of 5×10^5 IFU of serovar K. Bacterial shedding was quantified by taking swabs on day 7 post infection and determining the IFU using McCoy cells. Data from one back to back experiment were pooled.

Figure 2 shows Chlamydial shedding in the LGT and chlamydial load post challenge with *Chlamydia trachomatis* serovar K in the UGT of Balb/c mice immunized with antigen combinations. Graphs represent data from back to back experiments in which groups of 8 balb/c mice were immunized with the indicated combination of antigens in AS01B adjuvant. UVEB from serovar E formulated with AS01B served as a positive control of protection, and AS01B sham-immunized mice were used as control of infection. Progesterone-treated mice were challenged with an intra-vaginal dose of 5×10^5 IFU of serovar K. Bacterial shedding was quantified by taking swabs on day 7 post challenge and determining the IFU using McCoy cells. Mice were sacrificed 10 days post infection to determine the chlamydial load in the upper genital tract by homogenizing half of the UGT and determining IFU using McCoy cells. It should be noted that the limit of detection was 10 in respect of both of the above plots.

Figure 3 shows Day 7 bacterial shedding data in C57Bl/6 mice immunized with the indicated combinations of antigens in AS01B. Graphs represent data from back to back experiments in which groups of 8 C57Bl/6 mice were immunized with the indicated combination of antigens in AS01B. UVEB from serovar E formulated with AS01B served as a positive control of protection, and AS01B sham-immunized mice were used as control of infection. Progesterone-treated mice were challenged with an intra-vaginal dose of 5×10^5 IFU of serovar K. Bacterial shedding was quantified by taking swabs on day 7 post challenge and determining the IFU using McCoy cells.

Figure 4 shows Day 7 bacterial shedding data in Balb/c mice immunized with the indicated combinations of antigens in AS01B. Graphs represent pooled data from 5 experiments in which groups of 5-8 Balb/c mice were immunized with the indicated combination of antigens in AS01B. UVEB from serovar E formulated with AS01B served as a positive control of protection, and AS01B sham-immunized mice were used as control of infection. Progesterone-treated mice were challenged with an intra-vaginal dose of 5×10^5 IFU of serovar K. Bacterial shedding was quantified by taking swabs on day 7 post challenge and determining the IFU using McCoy cells.

Figure 5 shows Day 7 bacterial shedding data in C57Bl/6 mice immunized with the indicated combinations of antigens in AS01B. Graphs represent pooled data from 3 experiments in which groups of 5- 8 C57Bl/6 mice were immunized with the indicated combination of antigens in

AS01B. UVEB from serovar E formulated with AS01B served as a positive control of protection, and AS01B sham-immunized mice were used as control of infection. Progesterone-treated mice were challenged with an intra-vaginal dose of 5×10^5 IFU of serovar K. Bacterial shedding was quantified by taking swabs on day 7 post challenge and determining the IFU using McCoy cells.

5

Figure 6 shows the sequence alignment for Ct-089 from *Chlamydia trachomatis* serovar E with Ct-089 from a range of other *Chlamydia trachomatis* serovars.

Figures 7a and 7b show the sequence alignment for Ct-858 from *Chlamydia trachomatis* serovar E with Ct-858 from a range of other *Chlamydia trachomatis* serovars.

- 10 Figures 8a and 8b show the sequence alignment for Ct-875 from *Chlamydia trachomatis* serovar E with Ct-875 from a range of other *Chlamydia trachomatis* serovars.

Figure 9 shows the results of an amino acid sequence identity comparison of Ct-089 from *Chlamydia trachomatis* serovar E with Ct-089 from a range of other *Chlamydia trachomatis* serovars.

- 15 Figure 10 shows the results of an amino acid sequence identity comparison of Ct-858 from *Chlamydia trachomatis* serovar E with Ct-858 from a range of other *Chlamydia trachomatis* serovars.

Figure 11 shows the results of an amino acid sequence identity comparison of Ct-875 from *Chlamydia trachomatis* serovar E with Ct-875 from a range of other *Chlamydia trachomatis* serovars.

20

Figure 12 shows the sequence alignment for Ct-089 from *Chlamydia trachomatis* serovar E with equivalent proteins from other *Chlamydia trachomatis* serovars and *Chlamydia* species.

Figure 13 shows the sequence alignment for Ct-858 from *Chlamydia trachomatis* serovar E with equivalent proteins from other *Chlamydia trachomatis* serovars and *Chlamydia* species.

- 25 Figure 14 shows the sequence alignment for Ct-875 from *Chlamydia trachomatis* serovar E with equivalent proteins from other *Chlamydia trachomatis* serovars and *Chlamydia* species.

Figure 15 shows swab results taken from *Chlamydia trachomatis* serovar E Ct-089, Ct-858 and Ct-875 immunised mice four days after challenge from *Chlamydia trachomatis* serovars D, K or J. UV EB in each case are derived from the same serovar used for challenge (i.e. J, D and K

respectively). Both UV EB and the combination treatment are performed in the presence of the adjuvant (i.e. AS01B).

Figure 16 shows swab results taken from *Chlamydia trachomatis* serovar E Ct-089, Ct-858 and Ct-875 immunised mice seven days after challenge from *Chlamydia trachomatis* serovars D, K or J. UV EB in each case are derived from the same serovar used for challenge (i.e. J, D and K respectively). Both UV EB and the combination treatment are performed in the presence of the adjuvant (i.e. AS01B).

Figure 17 shows colonisation of the UGT from *Chlamydia trachomatis* serovar E Ct-089, Ct-858 and Ct-875 immunised mice ten days after challenge from *Chlamydia trachomatis* serovars D, K or J. UV EB in each case are derived from the same serovar used for challenge (i.e. J, D and K respectively). Both UV EB and the combination treatment are performed in the presence of the adjuvant (i.e. AS01B).

Figure 18 shows swab results taken from *Chlamydia trachomatis* serovar E Ct-089, Ct-858 and Ct-875 immunised mice four days after challenge from *Chlamydia trachomatis* serovars K or J. UV EB in each case are derived from the same serovar used for challenge (i.e. J and K respectively). Both UV EB and the combination treatment are performed in the presence of the adjuvant (i.e. AS01B).

Figure 19 shows swab results taken from *Chlamydia trachomatis* serovar E Ct-089, Ct-858 and Ct-875 immunised mice seven days after challenge from *Chlamydia trachomatis* serovars K or J. UV EB in each case are derived from the same serovar used for challenge (i.e. J and K respectively). Both UV EB and the combination treatment are performed in the presence of the adjuvant (i.e. AS01B).

Figure 20 shows colonisation of the UGT from *Chlamydia trachomatis* serovar E Ct-089, Ct-858 and Ct-875 immunised mice ten days after challenge from *Chlamydia trachomatis* serovars K or J. UV EB in each case are derived from the same serovar used for challenge (i.e. J and K respectively). Both UV EB and the combination treatment are performed in the presence of the adjuvant (i.e. AS01B).

Figure 21 shows the proportion of CD4 responders (for a signal to noise S/N cut-off of at least 2:1) to stimulation with a range of antigens for a number of seropositive subject groups.

Figure 22 shows the proportion of CD4 responders (for a signal to noise cut-off of at least 3:1) to stimulation with a range of antigens for a number of seropositive subject groups.

Figure 23 shows the proportion of CD4 responders (for a signal to noise cut-off of at least 2:1) to stimulation with a range of antigens and combinations thereof for a number of seropositive subject groups.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

5 The present invention relates to compositions comprising combinations of antigens useful for the diagnosis, prevention and treatment of *Chlamydia* infection, polynucleotides encoding such antigens, and methods for their use. The antigens of the present invention are polypeptides of *Chlamydia* antigens and immunogenic fragments thereof.

10 In particular, compositions of the present invention may comprise a combination of two or more *Chlamydia* proteins or immunogenic fragments thereof. Such proteins may be selected from Swib (also known as Ct-460), Momp (major outer membrane protein, also known as Ct-681), Ct-858, Ct-875, Ct-622, Ct-089 (also known as CopN), passenger domain of PmpG (PmpGpd, also known as Ct-871) and passenger domain of PmpD (PmpDpd, also known as Ct-812).

15 For example, the composition of the present invention may comprise Ct-089 and Ct-858 or immunogenic fragments thereof and optionally further antigens which may be selected for example from Momp, Ct-875, Ct-622, PmpGpd and PmpDpd. In a further example, the composition of the present invention may comprise Ct-875 and Ct-858 or immunogenic fragments thereof and optionally further antigens which may be selected for example from
20 Momp, Ct-622, Ct-089, PmpGpd and PmpDpd.

 For example the composition of the present invention may comprise one of the following combinations of *Chlamydia* polypeptides or immunogenic fragments thereof:

1. Momp, PmpDpd, Ct-858, Ct-089, Swib
- 25 1'. PmpDpd, Ct-858, Ct-089, Swib
2. Momp, PmpDpd, Ct-858, Ct-622, Ct-089, Swib
3. Momp, PmpDpd, Ct-858, PmpGpd, Ct-622, Ct-089
4. Ct-858, Ct-875, Ct-622, Ct-089
5. Ct-858, Ct-875, Ct-089
- 5'. PmpDpd, Ct-858, Ct-875, Ct-089
- 30 6. Momp, PmpD, Ct-858, PmpGpd, Ct-089

 All of the above combinations comprise Ct-089 and Ct-858.

 In a further set of examples, the composition of the present invention comprises one of the following combinations, provided that all of the combinations comprise Ct-089 and Ct-858:

- 1a. All five of: Momp, PmpDpd, Ct-858, PmpGpd and Ct-089
- 35 1'a. Three out of: PmpDpd, Ct-858, Ct-089, Swib

- 2a. Five out of: Momp, PmpDpd, Ct-858, Ct-622, Ct-089 and Swib
- 3a. Five out of: Momp, PmpDpd, Ct-858, PmpGpd, Ct-622 and Ct-089
- 4a. Three out of: Ct-858, Ct-875, Ct-622 and Ct-089
- 5a. Two out of: Ct-858, Ct-875 and Ct-089
- 5 5'a. Three out of: PmpDpd, Ct-858, Ct-875, Ct-089
- 6a. Four out of: Momp, PmpD, Ct-858, PmpGpd and Ct-089
or alternatively
- 1a". Five out of: Swib, Momp, PmpDpd, Ct-858, PmpGpd and Ct-089

Other example compositions of the present invention may comprise one of the following
10 combinations of *Chlamydia* polypeptides or immunogenic fragments thereof:

- 1b. Momp, PmpDpd, Ct-858, Ct-875, Swib, Ct-089
- 1b'. PmpDpd, Ct-858, Ct-875, Swib, Ct-089
- 2b. Momp, PmpDpd, Ct-858, Ct-622, Ct-875, Swib, Ct-089
- 3b. Momp, PmpDpd, Ct-858, PmpGpd, Ct-622, Ct-875, Ct-089
- 15 4b. Ct-858, Ct-875
- 5b. Momp, Ct-858, Ct-875, Ct-089
- 5b'. Momp, Ct-858, Ct-875
- 6b. Momp, PmpD, Ct-858, PmpGpd, Ct-875, Ct-089

All of the above combinations comprise Ct-875 and Ct-858.

20 In a further set of examples, the composition of the present invention comprises one of the following combinations, provided that all of the combinations comprise Ct-875 and Ct-858:

- 1c. Five out of: Swib, Momp, PmpDpd, Ct-858, PmpGpd and Ct-875
- 1c'. Three out of: PmpDpd, Ct-858, Ct-0875, Swib
- 2c. Five out of: Momp, PmpDpd, Ct-858, Ct-622, Ct-875 and Swib
- 25 3c. Five out of: Momp, PmpDpd, Ct-858, PmpGpd, Ct-622 and Ct-875
- 4c. Three out of: Ct-858, Ct-875, Ct-622 and Ct-089
- 5c'. Three out of: PmpDpd, Ct-858, Ct-875, Ct-089
- 6c. Four out of: Momp, PmpD, Ct-858, PmpGpd and Ct-875

The compositions according to the invention comprise two or more *Chlamydia* proteins
30 or immunogenic fragments, for example 3, 4, 5, 6, 7, 8, 9 or 10 proteins or immunogenic fragments. For a composition comprising each of the combinations listed above under numbers 1-6, 1a-6a, 1b-6b and 1c-6c (e.g. 1-6 and 1a-6a) the combination may include further *Chlamydia* antigens, for example one further *Chlamydia* antigen, or it may contain no more *Chlamydia* antigens than those listed. For example, composition 1a" may contain only five antigens which
35 are a combination of those *Chlamydia* antigens as listed and no other antigens, or composition 1a" may comprise a combination of five of the *Chlamydia* antigens as listed (such as all six

antigens listed, or five of the six antigens listed plus one other *Chlamydia* antigen), and so forth for compositions 2-6, 2a-6a, 1b-6b and 1c-6c (e.g. 2-6 and 2a-6a).

It will be evident that in the case of the passenger domains of PmpD and PmpG, these may be present in the context of a larger portion of the PmpD or PmpG antigen or

5 polynucleotide, for example full length PmpD or PmpG or a fragment thereof, provided that the fragment comprises the passenger domain.

The Momp and Swib proteins or immunogenic fragments may be for example from *Chlamydia trachomatis*, or they may be from other species of *Chlamydia*. The antigens above designated "Ct" may be *Chlamydia trachomatis* proteins or immunogenic fragments, or, where
10 possible, they may be the equivalent proteins from different species of *Chlamydia* (i.e. a *Chlamydia* species other than *Chlamydia trachomatis*). In one example, all of the antigens in the composition according to the invention are from *Chlamydia trachomatis*.

Compositions of the present invention may alternatively comprise polynucleotides encoding the combination of two or more *Chlamydia* proteins or immunogenic fragments which
15 may be selected from Swib (also known as Ct-460), Momp (major outer membrane protein also known as Ct-681), Ct-858, Ct-875, Ct-622, Ct-089, passenger domain of PmpG (PmpGpd, also known as Ct-871) and passenger domain of PmpD (PmpDpd, also known as Ct-812), for example the combinations of antigens listed above as 1-6, 1a-6a, 1b-6b and 1c-6c (e.g. 1-6). The compositions of polynucleotides according to the invention include those which encode the
20 combinations of antigens according to the invention as described herein (for example Ct-858 and Ct-875). The polynucleotides encoding the different antigens may be present as separate nucleic acids or they may be present together in a single nucleic acid, or a combination of separate and combined nucleic acids.

The following provides polynucleotide and polypeptide sequences for some of the
25 antigens, which may be used in the compositions of the invention and which have been listed above.

BRIEF DESCRIPTION OF SEQUENCE IDENTIFIERS

SEQ ID NO:1 is the cDNA sequence of Ct-460, also known as Swib from *Chlamydia trachomatis*, serovar LGVII (serovar LGVII is also referred to as serovar LII).

30 SEQ ID NO:2 is the protein sequence of Ct-460, also known as Swib from *Chlamydia trachomatis*, serovar LGVII, which protein is encoded by SEQ ID NO:1.

SEQ ID NO:3 is the cDNA sequence of the *Chlamydia* antigen known as Major Outer Membrane Protein (Momp) from *Chlamydia trachomatis*, serovar F.

35 SEQ ID NO:4 is the protein sequence of the chlamydia antigen known as Major Outer Membrane Protein (Momp) from *Chlamydia trachomatis*, serovar F, which protein is encoded by SEQ ID NO:3.

SEQ ID NO:5 is the cDNA sequence of Ct-858 from *Chlamydia trachomatis*, serovar E.

SEQ ID NO:6 is the protein sequence of Ct-858 *Chlamydia trachomatis*, serovar E, which protein is encoded by SEQ ID NO:5.

SEQ ID NO:7 is the cDNA sequence of Ct-875 from *Chlamydia trachomatis*, serovar E.

5 SEQ ID NO: 8 is the protein sequence of Ct-875 from *Chlamydia trachomatis*, serovar E, which protein is encoded by SEQ ID NO: 7.

SEQ ID NO: 9 is the cDNA sequence of Ct-622 from *Chlamydia trachomatis*, serovar E.

SEQ ID NO: 10 is the protein sequence of Ct-622 from *Chlamydia trachomatis*, serovar E, which protein is encoded by SEQ ID NO: 9.

10 SEQ ID NO: 11 is the cDNA sequence of the passenger domain of PmpG also known as Ct-871 from *Chlamydia trachomatis*, serovar LGVII.

SEQ ID NO: 12 is the protein sequence of the passenger domain of PmpG, also known as Ct-871 from *Chlamydia trachomatis*, serovar LGVII, which protein is encoded by SEQ ID NO: 11.

15 SEQ ID NO: 13 is the cDNA sequence of the passenger domain of PmpD, also known as Ct-812, from *Chlamydia trachomatis*, serovar LGVII.

SEQ ID NO: 14 is the protein sequence of the passenger domain of PmpD, also known as Ct-812, from *Chlamydia trachomatis*, serovar LGVII, which protein is encoded by SEQ ID NO: 13.

20 SEQ ID NO: 15 is the cDNA sequence of the Ct-089 from *Chlamydia trachomatis*, serovar E.

SEQ ID NO: 16 is the protein sequence of Ct-089 from *Chlamydia trachomatis*, serovar E, which protein is encoded by SEQ ID NO: 15.

25 SEQ ID NO: 17 is the cDNA sequence of the chlamydia antigen known as Major Outer Membrane Protein (Momp) from *Chlamydia psittaci*.

SEQ ID NO: 18 is the protein sequence of the chlamydia antigen known as Major Outer Membrane Protein (Momp) from *Chlamydia psittaci*, which protein is encoded by SEQ ID NO: 17.

30 SEQ ID NO: 19 is the cDNA sequence of the *Chlamydia* antigen known as Major Outer Membrane Protein (Momp) from *Chlamydia pneumoniae*.

SEQ ID NO: 20 is the protein sequence of the chlamydia antigen known as Major Outer Membrane Protein (Momp) from *Chlamydia pneumoniae*, which protein is encoded by SEQ ID NO: 19.

35 SEQ ID NO: 21 is the cDNA sequence of Ct-875 from *Chlamydia trachomatis*, serovar D.

SEQ ID NO: 22 is the protein sequence of Ct-875 from *Chlamydia trachomatis*, serovar D which protein is encoded by SEQ ID NO: 21.

SEQ ID NO: 23 is the cDNA sequence of Ct-875 from *Chlamydia muridarum*.

SEQ ID NO: 24 is the protein sequence of Ct-875 from *Chlamydia muridarum*, which protein is encoded by SEQ ID NO:23.

SEQ ID NO: 25 is the cDNA sequence of Ct-875 from *Chlamydia psitacci*

5 SEQ ID NO: 26 is the protein sequence of Ct-875 from *Chlamydia psitacci*, which protein is encoded by SEQ ID NO:25.

SEQ ID NO: 27 is the cDNA sequence PmpG also known as Ct-871 from from *Chlamydia trachomatis*, serovar D.

10 SEQ ID NO: 28 is the protein sequence of PmpG, also known as Ct-871 from *Chlamydia trachomatis*, serovar D , which protein is encoded by SEQ ID NO:27.

SEQ ID NO: 29 is the cDNA sequence PmpG also known as Ct-871 from from *Chlamydia muridarum*.

SEQ ID NO: 30 is the protein sequence of PmpG, also known as Ct-871 from *Chlamydia muridarum*, which protein is encoded by SEQ ID NO:29.

15 SEQ ID NO: 31 is the cDNA sequence PmpG also known as Ct-871 from from *Chlamydia psitacci*.

SEQ ID NO: 32 is the protein sequence of PmpG, also known as Ct-871 from *Chlamydia psitacci*, which protein is encoded by SEQ ID NO:31.

20 SEQ ID NO: 33 is the cDNA sequence of Ct-858 from *Chlamydia trachomatis*, serovar D.

SEQ ID NO: 34 is the protein sequence of Ct-858 *Chlamydia trachomatis*, serovar D, which protein is encoded by SEQ ID NO: 33.

SEQ ID NO: 35 is the cDNA sequence of Ct-858 from *Chlamydia muridarum*.

25 SEQ ID NO: 36 is the protein sequence of Ct-858 *Chlamydia muridarum*, which protein is encoded by SEQ ID NO: 35.

SEQ ID NO: 37 is the cDNA sequence of Ct-858 from *Chlamydia psitacci*.

SEQ ID NO: 38 is the protein sequence of Ct-858 *Chlamydia psitacci*, which protein is encoded by SEQ ID NO: 37.

SEQ ID NO: 39 is the cDNA sequence of Ct-858 from *Chlamydia pneumoniae*.

30 SEQ ID NO: 40 is the protein sequence of Ct-858 *Chlamydia pneumoniae*, which protein is encoded by SEQ ID NO: 39.

SEQ ID NO: 41 is the cDNA sequence of PmpD, also known as Ct-812, from *Chlamydia trachomatis*, serovar D.

35 SEQ ID NO: 42 is the protein sequence of PmpD, also known as Ct-812, from *Chlamydia trachomatis*, serovar D, which protein is encoded by SEQ ID NO: 41. The passenger domain spans amino acids 31 to 1203.

SEQ ID NO: 43 is the cDNA sequence of PmpD, also known as Ct-812, from *Chlamydia muridarum*.

SEQ ID NO: 44 is the protein sequence of PmpD, also known as Ct-812, from *Chlamydia muridarum*, which protein is encoded by SEQ ID NO: 43.

5 SEQ ID NO: 45 is the cDNA sequence of PmpD, also known as Ct-812, from *Chlamydia psittaci*.

SEQ ID NO: 46 is the protein sequence of PmpD, also known as Ct-812, from *Chlamydia psittaci*, which protein is encoded by SEQ ID NO: 45.

10 SEQ ID NO: 47 is the cDNA sequence of the *Chlamydia* antigen known as Major Outer Membrane Protein (Momp), also known as Ct-681 from *Chlamydia trachomatis*, serovar LGVII.

SEQ ID NO: 48 is the protein sequence of the chlamydia antigen known as Major Outer Membrane Protein (Momp), also known as Ct-681 from *Chlamydia trachomatis*, serovar LGVII, which protein is encoded by SEQ ID NO: 47.

15 SEQ ID NO: 49 is the cDNA sequence of the *Chlamydia* antigen known as Major Outer Membrane Protein (Momp), also known as Ct-681 from *Chlamydia trachomatis*, serovar J.

SEQ ID NO: 50 is the protein sequence of the chlamydia antigen known as Major Outer Membrane Protein (Momp), also known as Ct-681 from *Chlamydia trachomatis*, serovar J, which protein is encoded by SEQ ID NO: 49.

20 SEQ ID NO: 51 is the cDNA sequence of the *Chlamydia* antigen known as Major Outer Membrane Protein (Momp), also known as Ct-681 from *Chlamydia trachomatis*, serovar H.

SEQ ID NO: 52 is the protein sequence of the chlamydia antigen known as Major Outer Membrane Protein (Momp), also known as Ct-681 from *Chlamydia trachomatis*, serovar H, which protein is encoded by SEQ ID NO: 51.

25 SEQ ID NO: 53 is the cDNA sequence of the *Chlamydia* antigen known as Major Outer Membrane Protein (Momp), also known as Ct-681 from *Chlamydia trachomatis*, serovar E.

SEQ ID NO: 54 is the protein sequence of the chlamydia antigen known as Major Outer Membrane Protein (Momp), also known as Ct-681 from *Chlamydia trachomatis*, serovar E, which protein is encoded by SEQ ID NO: 53.

30 SEQ ID NO: 55 is the cDNA sequence of the *Chlamydia* antigen known as Major Outer Membrane Protein (Momp), also known as Ct-681 from *Chlamydia trachomatis*, serovar D.

SEQ ID NO: 56 is the protein sequence of the chlamydia antigen known as Major Outer Membrane Protein (Momp), also known as Ct-681 from *Chlamydia trachomatis*, serovar D, which protein is encoded by SEQ ID NO: 55.

35 SEQ ID NO: 57 is the cDNA sequence of Ct-622 from *Chlamydia trachomatis*, serovar D.

SEQ ID NO: 58 is the protein sequence of Ct-622 from *Chlamydia trachomatis*, serovar D, which protein is encoded by SEQ ID NO: 57.

SEQ ID NO: 59 is the cDNA sequence of Ct-622 from *Chlamydia psittaci*.

SEQ ID NO: 60 is the protein sequence of Ct-622 from *Chlamydia psittaci*, which protein is encoded by SEQ ID NO: 59.

SEQ ID NO: 61 is the cDNA sequence of Ct-622 from *Chlamydia pneumoniae*.

5 SEQ ID NO: 62 is the protein sequence of Ct-622 from *Chlamydia pneumoniae*, which protein is encoded by SEQ ID NO: 61.

SEQ ID NO: 63 is the cDNA sequence of Ct-460, also known as Swib from *Chlamydia trachomatis*, serovar D.

10 SEQ ID NO: 64 is the protein sequence of Ct-460, also known as Swib from *Chlamydia trachomatis*, serovar D, which protein is encoded by SEQ ID NO: 63.

SEQ ID NO: 65 is the cDNA sequence of Ct-460, also known as Swib from *Chlamydia muridarum*.

SEQ ID NO: 66 is the protein sequence of Ct-460, also known as Swib from *Chlamydia muridarum*, which protein is encoded by SEQ ID NO: 65.

15 SEQ ID NO: 67 is the cDNA sequence of Ct-460, also known as Swib from *Chlamydia psittaci*.

SEQ ID NO: 68 is the protein sequence of Ct-460, also known as Swib from *Chlamydia psittaci*, which protein is encoded by SEQ ID NO: 67.

20 SEQ ID NO: 69 is the cDNA sequence of Ct-460, also known as Swib from *Chlamydia pneumoniae*.

SEQ ID NO: 70 is the protein sequence of Ct-460, also known as Swib from *Chlamydia pneumoniae*, which protein is encoded by SEQ ID NO: 69.

SEQ ID NO: 71 is the cDNA sequence of the Ct-089 from *Chlamydia trachomatis*, serovar D.

25 SEQ ID NO: 72 is the protein sequence of Ct-089 from *Chlamydia trachomatis*, serovar D, which protein is encoded by SEQ ID NO: 71.

SEQ ID NO: 73 is the cDNA sequence of the Ct-089 from *Chlamydia muridarum*.

SEQ ID NO: 74 is the protein sequence of Ct-089 from *Chlamydia muridarum*, which protein is encoded by SEQ ID NO: 73.

30 SEQ ID NO: 75 is the cDNA sequence of the Ct-089 from *Chlamydia psittaci*.

SEQ ID NO: 76 is the protein sequence of Ct-089 from *Chlamydia psittaci*, which protein is encoded by SEQ ID NO: 75.

SEQ ID NO: 77 is the cDNA sequence of the Ct-089 from *Chlamydia pneumoniae*.

35 SEQ ID NO: 78 is the protein sequence of Ct-089 from *Chlamydia pneumoniae*, which protein is encoded by SEQ ID NO: 77.

SEQ ID NO: 79 is the cDNA sequence of the Ct-089 from *Chlamydia trachomatis*, serovar A.

SEQ ID NO: 80 is the protein sequence of Ct-089 from *Chlamydia trachomatis*, serovar A, which protein is encoded by SEQ ID NO: 79.

SEQ ID NO: 81 is the cDNA sequence of the Ct-089 from *Chlamydia trachomatis*, serovar B.

5 SEQ ID NO: 82 is the protein sequence of Ct-089 from *Chlamydia trachomatis*, serovar B, which protein is encoded by SEQ ID NO: 81.

SEQ ID NO: 83 is the cDNA sequence of the Ct-089 from *Chlamydia trachomatis*, serovar G.

10 SEQ ID NO: 84 is the protein sequence of Ct-089 from *Chlamydia trachomatis*, serovar G, which protein is encoded by SEQ ID NO: 83.

SEQ ID NO: 85 is the cDNA sequence of the Ct-089 from *Chlamydia trachomatis*, serovar H.

SEQ ID NO: 86 is the protein sequence of Ct-089 from *Chlamydia trachomatis*, serovar H, which protein is encoded by SEQ ID NO: 85.

15 SEQ ID NO: 87 is the cDNA sequence of the Ct-089 from *Chlamydia trachomatis*, serovar I.

SEQ ID NO: 88 is the protein sequence of Ct-089 from *Chlamydia trachomatis*, serovar I, which protein is encoded by SEQ ID NO: 87.

20 SEQ ID NO: 89 is the cDNA sequence of the Ct-089 from *Chlamydia trachomatis*, serovar J.

SEQ ID NO: 90 is the protein sequence of Ct-089 from *Chlamydia trachomatis*, serovar J, which protein is encoded by SEQ ID NO: 89.

SEQ ID NO: 91 is the cDNA sequence of the Ct-089 from *Chlamydia trachomatis*, serovar K.

25 SEQ ID NO: 92 is the protein sequence of Ct-089 from *Chlamydia trachomatis*, serovar K, which protein is encoded by SEQ ID NO: 91.

SEQ ID NO: 93 is the cDNA sequence of the Ct-089 from *Chlamydia trachomatis*, serovar L2.

30 SEQ ID NO: 94 is the protein sequence of Ct-089 from *Chlamydia trachomatis*, serovar L2, which protein is encoded by SEQ ID NO: 93.

SEQ ID NO: 95 is the cDNA sequence of the Ct-858 from *Chlamydia trachomatis*, serovar A.

SEQ ID NO: 96 is the protein sequence of Ct-858 from *Chlamydia trachomatis*, serovar A, which protein is encoded by SEQ ID NO: 95.

35 SEQ ID NO: 97 is the cDNA sequence of the Ct-858 from *Chlamydia trachomatis*, serovar B.

SEQ ID NO: 98 is the protein sequence of Ct-858 from *Chlamydia trachomatis*, serovar B, which protein is encoded by SEQ ID NO: 97.

SEQ ID NO: 99 is the cDNA sequence of the Ct-858 from *Chlamydia trachomatis*, serovar G.

5 SEQ ID NO: 100 is the protein sequence of Ct-858 from *Chlamydia trachomatis*, serovar G, which protein is encoded by SEQ ID NO: 99.

SEQ ID NO: 101 is the cDNA sequence of the Ct-858 from *Chlamydia trachomatis*, serovar H.

10 SEQ ID NO: 102 is the protein sequence of Ct-858 from *Chlamydia trachomatis*, serovar H, which protein is encoded by SEQ ID NO: 101.

SEQ ID NO: 103 is the cDNA sequence of the Ct-858 from *Chlamydia trachomatis*, serovar I.

SEQ ID NO: 104 is the protein sequence of Ct-858 from *Chlamydia trachomatis*, serovar I, which protein is encoded by SEQ ID NO: 103.

15 SEQ ID NO: 105 is the cDNA sequence of the Ct-858 from *Chlamydia trachomatis*, serovar J.

SEQ ID NO: 106 is the protein sequence of Ct-858 from *Chlamydia trachomatis*, serovar J, which protein is encoded by SEQ ID NO: 105.

20 SEQ ID NO: 107 is the cDNA sequence of the Ct-858 from *Chlamydia trachomatis*, serovar K.

SEQ ID NO: 108 is the protein sequence of Ct-858 from *Chlamydia trachomatis*, serovar K, which protein is encoded by SEQ ID NO: 107.

SEQ ID NO: 109 is the cDNA sequence of the Ct-858 from *Chlamydia trachomatis*, serovar L2.

25 SEQ ID NO: 110 is the protein sequence of Ct-858 from *Chlamydia trachomatis*, serovar L2, which protein is encoded by SEQ ID NO: 109.

SEQ ID NO: 111 is the cDNA sequence of the Ct-875 from *Chlamydia trachomatis*, serovar A.

30 SEQ ID NO: 112 is the protein sequence of Ct-875 from *Chlamydia trachomatis*, serovar A, which protein is encoded by SEQ ID NO: 111.

SEQ ID NO: 113 is the cDNA sequence of the Ct-875 from *Chlamydia trachomatis*, serovar B.

SEQ ID NO: 114 is the protein sequence of Ct-875 from *Chlamydia trachomatis*, serovar B, which protein is encoded by SEQ ID NO: 113.

35 SEQ ID NO: 115 is the cDNA sequence of the Ct-875 from *Chlamydia trachomatis*, serovar G.

SEQ ID NO: 116 is the protein sequence of Ct-875 from *Chlamydia trachomatis*, serovar G, which protein is encoded by SEQ ID NO: 115.

SEQ ID NO: 117 is the cDNA sequence of the Ct-875 from *Chlamydia trachomatis*, serovar H.

5 SEQ ID NO: 118 is the protein sequence of Ct-875 from *Chlamydia trachomatis*, serovar H, which protein is encoded by SEQ ID NO: 117.

SEQ ID NO: 119 is the cDNA sequence of the Ct-875 from *Chlamydia trachomatis*, serovar I.

10 SEQ ID NO: 120 is the protein sequence of Ct-875 from *Chlamydia trachomatis*, serovar I, which protein is encoded by SEQ ID NO: 119.

SEQ ID NO: 121 is the cDNA sequence of the Ct-875 from *Chlamydia trachomatis*, serovar J.

SEQ ID NO: 122 is the protein sequence of Ct-875 from *Chlamydia trachomatis*, serovar J, which protein is encoded by SEQ ID NO: 121.

15 SEQ ID NO: 123 is the cDNA sequence of the CT875 from *Chlamydia trachomatis*, serovar K.

SEQ ID NO: 124 is the protein sequence of Ct-875 from *Chlamydia trachomatis*, serovar K, which protein is encoded by SEQ ID NO: 123.

20 SEQ ID NO: 125 is the cDNA sequence of the Ct-875 from *Chlamydia trachomatis*, serovar L2.

SEQ ID NO: 126 is the protein sequence of Ct-875 from *Chlamydia trachomatis*, serovar L2, which protein is encoded by SEQ ID NO: 125.

25 Certain of the above sequences and other related *Chlamydia* polypeptides and polynucleotides from a number of serovars are known and available in the art. Further related sequences can be found in issued US patents numbers 6,447,779, 6,166,177, 6,565,856, 6,555,115, 6,432,916, and 6,448,234 and are also disclosed in U.S. patent applications Nos. 10/197,220, 10/762,058 and 10/872,155, each of which is herein incorporated by reference.

30 The sequence of Ct-089 from serovar D and the potential application of this protein as an antigen has been publicly disclosed, for example in WO02/08267 (Corixa Corporation). The sequence of Ct-089 from serovar L2 was disclosed in WO99/28475 (Genset). The role of CopN (also known as Ct-089) as a putative exported regulator of type III protein secretion systems is discussed in Fields, KA and Hackstadt, T *Mol. Microbiol.* 2000 38(5):1048-1060.

35 The sequences of Ct-858 and Ct-875 from serovar D are available from the Swiss-Prot database, primary accession numbers O84866 and O84883 respectively. For further information see Stephens, RS et al. *Science* 1998 282:754-759.

The use of Ct-858 as an antigen is disclosed, for example, in WO02/08267 (Corixa Corporation).

The sequence of Ct-875 from serovar E (incorporating a His-tag) and its use as an antigen is disclosed, for example, in US 20040137007. However, the document incorrectly
5 refers to Sequence 139 as being Ct-875, when it is in fact Sequence 140 therein.

Individuals who have been exposed to *Chlamydia trachomatis* have been shown to develop some degree of natural immunity to reinfection, at least in the case of the same serovar (Katz, BP et al. *Sex. Transm. Dis.* 1987 14:160-164), although the extent of protection may depend upon the time elapsed since the prior infection occurred. Age has also been shown to
10 be important in the duration of infection, with older individuals demonstrating a shorter duration of infection by ocular *Chlamydia trachomatis* (Bailey, R et al. *Epidemiol. Infect.* 1999 123:479-486), again suggesting the existence of adaptive immunological protection. It has been suggested that the use of antibiotics may in fact hamper the development of natural immunity to *Chlamydia trachomatis* (Brunham, RC et al. *J. Nat. Rev. Immunol.* 2005 5:149-161).

The major outer membrane protein (Momp) constitutes approximately 60% of the protein mass of the bacterial outer membrane and is believed to be important in the determination of serotype specificity. The amino acid sequence contains four regions which are externally exposed and in which the majority of sequence variations occur. Of the ca. 400 amino acids in the Momp sequence, up to 70 amino acids differ between Momp from different serovars.
15 Particularly surprising is the finding that serovar grouping based on amino acid sequence identity does not correspond to the serovar grouping based on disease state (i.e. ocular, oculogenital and LGV) (Stothard, DR et al. *Infect. Immun.* 1998 66(8):3618-3625). Similarly, nucleotide sequence identity comparisons for the *ompA* gene which encodes Momp do not correspond to disease states (Meijer, A et al. *J. Bacteriol.* 1999 181(15):4469-4475; Lysen, M et al. *J. Clin. Microbiol.* 2004 42(4):1641-1647). Monoclonal antibodies for Momp are effective in
20 culture and in some animal models, however, protection can be limited and is generally serovar specific.

Mice immunised subcutaneously or orally with a monoclonal anti-idiotypic body to the exoglycolipid antigen developed a protective response to serovar C, though remained
30 susceptible to challenge with serovar K (Whittum-Hudson, JA et al. *Nat. Med.* 1996 2(10):1116-1121).

One protein which has been disclosed to date and which shows a high level of sequence homology among different serovars, namely class I accessible protein-1 (referred to as Cap1, or Ct-529), such proteins have potential use in the development of vaccines which stimulate
35 protection against more than one serovar (Fling, SP et al. *PNAS* 2001 98(3):1160-1165). However, in addition to the requirement for high levels of sequence homology between serovars, proteins of use in vaccines must also elicit sufficient immune response.

Surprisingly, it has been found that *Chlamydia trachomatis* proteins Ct-089, Ct-858 and Ct-875 in particular are both highly antigenic and have a high degree of sequence identity across the different *Chlamydia trachomatis* serovars. There is particularly high conservation in the region of the predicted epitopes. In light of this finding, the possibility exists for the development of *Chlamydia* vaccines which are effective against a broad range of *Chlamydia trachomatis* serovars (i.e. which may be of use in cross-protection).

According to this aspect of the present invention there is provided the use of one or more Chlamydial proteins, immunogenic fragments thereof or polynucleotides encoding them, selected from the list consisting of Ct-089, Ct-858 and Ct-875, and which are derived from a first *Chlamydia trachomatis* serovar, in the manufacture of a vaccine for the treatment or prevention of Chlamydial infection by a second *Chlamydia trachomatis* serovar.

In a further aspect of the present invention there is provided a method for the treatment or prevention of Chlamydial infection by a second *Chlamydia trachomatis* serovar, comprising the administration of a vaccine comprising one or more Chlamydial proteins, immunogenic fragments thereof or polynucleotides encoding them, selected from the list consisting of Ct-089, Ct-858 and Ct-875, and which are derived from a first *Chlamydia trachomatis* serovar.

In one embodiment of the invention the cross-protection vaccine comprises one protein, immunogenic fragment thereof or polynucleotide encoding them, selected from the list consisting of Ct-089, Ct-858 and Ct-875. Vaccines which comprise only one protein, immunogenic fragment thereof or polynucleotide encoding them, selected from the list consisting of Ct-089, Ct-858 and Ct-875 will suitably further comprise at least one additional Chlamydial antigen (for example 1 or 2 additional antigens).

In a second embodiment of the invention the cross-protection vaccine comprises two proteins, immunogenic fragments thereof or polynucleotides encoding them, selected from the list consisting of Ct-089, Ct-858 and Ct-875. For example: Ct-089 and Ct-858; Ct-089 and Ct-875; or Ct-858 and Ct-875.

In a third embodiment of the invention the cross-protection vaccine comprises Ct-089, Ct-858 and Ct-875, immunogenic fragments thereof or polynucleotides encoding them.

The first *Chlamydia trachomatis* serovar may be any *Chlamydia trachomatis* serovar.

The second *Chlamydia trachomatis* serovar may be any *Chlamydia trachomatis* serovar, excluding that of the first *Chlamydia trachomatis* serovar.

In one embodiment of the invention the first *Chlamydia trachomatis* serovar is selected from the list consisting of *Chlamydia trachomatis* serovars A, B, Ba, C, D, Da, E, F, G, H, I, Ia, J, Ja, K, L1, L2 and L3. In a second embodiment of the invention the first *Chlamydia trachomatis* serovar is selected from the *Chlamydia trachomatis* ocular serovars (for example A, B, Ba and C). In another embodiment of the invention the first *Chlamydia trachomatis* serovar is selected from the *Chlamydia trachomatis* oculogenital serovars (for example D, Da, E, F, G, H, I, Ia, J, Ja

and K). In a further embodiment of the invention the first *Chlamydia trachomatis* serovar is selected from the *Chlamydia trachomatis* LGV serovars (for example L1, L2 and L3).

In one embodiment of the invention the second *Chlamydia trachomatis* serovar is selected from the list consisting of *Chlamydia trachomatis* serovars A, B, Ba, C, D, Da, E, F, G, H, I, Ia, J, Ja, K, L1, L2 and L3. In a second embodiment of the invention the second *Chlamydia trachomatis* serovar is selected from the *Chlamydia trachomatis* ocular serovars (for example A, B, Ba and C). In another embodiment of the invention the second *Chlamydia trachomatis* serovar is selected from the *Chlamydia trachomatis* oculogenital serovars (for example D, Da, E, F, G, H, I, Ia, J, Ja and K). In a further embodiment of the invention the second *Chlamydia trachomatis* serovar is selected from the *Chlamydia trachomatis* LGV serovars (for example L1, L2 and L3).

In order to maximise the breadth of action of the method and use of the present invention, it may be desirable that the first *Chlamydia trachomatis* serovar is selected such that there is a high level of sequence identity (for example at least 90%, especially 95%, in particular 98%, more particularly 99% sequence identity) with the majority of other *Chlamydia trachomatis* serovars (for example at least 50%, especially 70%, in particular 80%, more particularly 90% of other *Chlamydia trachomatis* serovars).

In order to maximise the practical application of the method and use of the present invention, it may be desirable that the first *Chlamydia trachomatis* serovar is selected such that there is a high level of sequence identity (for example at least 90%, especially 95%, in particular 98%, more particularly 99% sequence identity) with the majority (for example at least 50%, especially 70%, in particular 80%, more particularly 90%) of common *Chlamydia trachomatis* serovars (such as the common ocular serovars, the common oculogenital serovars, the common LGV serovars, or a combination of any two of these serovar groups, for example, the common ocular and oculogenital serovars). Common *Chlamydia trachomatis* ocular serovars include A and B. Common *Chlamydia trachomatis* oculogenital serovars include D, E, F and I (Lan, J et al. *J. Clin. Microbiol.* 1995 33(12):3194-3197; Singh, V et al. *J. Clin. Microbiol.* 2003 41(6):2700-2702). Common *Chlamydia trachomatis* LGV serovars include L2.

In one embodiment of the present invention the first *Chlamydia trachomatis* serovar is *Chlamydia trachomatis* serovar E. In a second embodiment of the invention the first *Chlamydia trachomatis* serovar is *Chlamydia trachomatis* serovar K.

In one embodiment of the invention the second *Chlamydia trachomatis* serovar is selected from *Chlamydia trachomatis* serovars D, J and K (for example *Chlamydia trachomatis* serovar K or J).

In another embodiment of the invention the first *Chlamydia trachomatis* serovar is *Chlamydia trachomatis* serovar E and the second *Chlamydia trachomatis* serovar is selected

from *Chlamydia trachomatis* serovars D, J and K (for example *Chlamydia trachomatis* serovar K or J).

In one example of the present invention, where the vaccine comprises Ct-089, an immunogenic fragment thereof or polynucleotide encoding it, derived from *Chlamydia*
 5 *trachomatis* serovar E, the vaccine may be used in the treatment or prophylaxis of infections arising from *Chlamydia trachomatis* serovars A, B, D, G, H, I, J, K or L2; in particular A, B, D, G, H, I or K; especially A or B.

In a second example of the present invention, where the vaccine comprises Ct-858, an immunogenic fragment thereof or polynucleotide encoding it, derived from *Chlamydia*
 10 *trachomatis* serovar E, the vaccine may be used in the treatment or prophylaxis of infections arising from *Chlamydia trachomatis* serovars A, B, D, G, H, I, J, K or L2; in particular J or L2.

In a further example of the present invention, where the vaccine comprises Ct-875, an immunogenic fragment thereof or polynucleotide encoding it, derived from *Chlamydia*
 15 *trachomatis* serovar E, the vaccine may be used in the treatment or prophylaxis of infections arising from *Chlamydia trachomatis* serovars A, B, D, G, H, I, J, K or L2; in particular A, B, D, G, H, I or K.

The first and second *Chlamydia trachomatis* serovars may be associated with the same disease state (for example they may both be ocular serovars or both be oculogenital serovars), or the first and second *Chlamydia trachomatis* serovars may be associated with different
 20 disease states (for example the first *Chlamydia trachomatis* serovar may an oculogenital serovar and the second *Chlamydia trachomatis* serovar may be an ocular serovar, or *vice versa*).

In the event that the vaccine of use in the present invention comprises more than one protein, immunogenic fragment thereof or polynucleotide encoding them, selected from the list
 25 consisting of Ct-089, Ct-858 and Ct-875, it should be noted that each protein, immunogenic fragment thereof or polynucleotide encoding them, may optionally be derived from a different first *Chlamydia trachomatis* serovar which may be independently selected.

Cross-protection vaccines of use in the present invention may also comprise additional *Chlamydia* antigens (i.e. antigens other than Ct-089, Ct-858 and Ct-875 proteins, immunogenic
 30 fragments thereof or polynucleotides encoding them), for example 1, 2, 3, 4 or 5 other antigens (selected for example from Momp, Ct-622, PmpGpd and PmpDpd). Additional antigens in cross-protection vaccines may also include Ct-089, Ct-858 and Ct-875 proteins, immunogenic fragments thereof or polynucleotides encoding them which are derived from the second serovar.

In a further embodiment of the invention *Chlamydia* polypeptides and polynucleotides
 35 that may be used in accordance with the invention include those from serovars associated with trachoma such as serovars A, B, Ba and C.

Thus the compositions according to the invention may employ the polypeptide sequences given above or immunogenic fragments of these, or polynucleotide sequences encoding these which may be for example the polynucleotide sequences given above or fragments of these encoding immunogenic fragments of the polypeptides.

5 In particular embodiments:

(i) the Ct-089 and Ct-858 components of the composition according to the invention may be a polypeptide having at least 95% homology to the polypeptide of SEQ ID NO: 16 (*C. trachomatis* serovar E) or an immunogenic fragment thereof, or a polypeptide having at least 95% homology to the polypeptide of SEQ ID NO: 6 (*C. trachomatis* serovar E) or an immunogenic fragment thereof, respectively, or polynucleotides encoding these. Alternatively the Ct-089 and Ct-858 components of the composition may show at least 95% homology to any one of the Ct-089 and Ct-858 polypeptide and polynucleotide sequences from other *C. trachomatis* serovars which are described herein.

(ii) A Ct-875 component may be a polypeptide having at least 95% homology to the polypeptide of SEQ ID NO: 8 (*C. trachomatis* serovar E) or an immunogenic fragment thereof, or polynucleotides encoding these. Alternatively the Ct-875 component of the composition may show at least 95% homology to any one of the Ct-875 polypeptide and polynucleotide sequences from other *C. trachomatis* serovars which are described herein.

(iii) A PmpDpd component may be a polypeptide having at least 95% homology to the polypeptide of SEQ ID NO: 14 (*C. trachomatis* serovar LII) or an immunogenic fragment thereof, or polynucleotides encoding these.

(iv) A PmpGpd component may be a polypeptide having at least 95% homology to the polypeptide of SEQ ID NO: 12 (*C. trachomatis* serovar LII) or an immunogenic fragment thereof, or polynucleotides encoding these.

(v) A Momp component may be a polypeptide having at least 95% homology to the polypeptide of SEQ ID NO: 4 (*C. trachomatis* serovar F) or an immunogenic fragment thereof, or polynucleotides encoding these.

(vi) A Swib component may be a polypeptide having at least 95% homology to the polypeptide of SEQ ID NO: 8 (*C. trachomatis* serovar LII) or an immunogenic fragment thereof, or polynucleotides encoding these.

The antigens described herein include polymorphic variants and conservatively modified variations, as well as inter-strain and interspecies *Chlamydia* homologues. In addition, the antigens described herein include subsequences or truncated sequences.

35 The antigens described herein may be in the form of fusion proteins. The fusion proteins may also contain additional polypeptides, optionally heterologous peptides from *Chlamydia* or other sources. These antigens may be modified, for example, by adding linker peptide

sequences as described below. These linker peptides may be inserted between one or more polypeptides which make up each of the fusion proteins.

The antigens described herein may also be in the form of chemical conjugates.

The invention further relates to immunogenic compositions and vaccine compositions comprising the compositions of *Chlamydia* antigens according to the invention, together with a pharmaceutically acceptable carrier and optionally an immunostimulant. The compositions of the present invention may further comprise other components designed to enhance the antigenicity of the antigens or to improve these antigens in other aspects, for example, the isolation of these antigens through addition of a stretch of histidine residues at one end of the antigen. The addition of a stretch of histidine residues at one end of the antigen may also improve expression. The compositions of the invention can comprise additional copies of antigens, or additional polypeptides or polynucleotides from *Chlamydia* sp. The compositions of the invention can also comprise additional heterologous polypeptides or polynucleotides from other non-*Chlamydia* sources. For example, the compositions of the invention can include polypeptides or nucleic acids encoding polypeptides, wherein the polypeptide enhances expression of the antigen, e.g., NS1, an influenza virus protein, or an immunogenic portion thereof (see, e.g. WO99/40188 and WO93/04175). The nucleic acids of the invention can be engineered based on codon preference in a species of choice, e.g., humans.

The compositions of the invention may further comprise adjuvants, e.g., MPL, 3D-MPL, IFA, ENHANZYN (Detox), QS21, CWS, TDM, AGP, CPG, Leif, saponin, and saponin mimetics, and derivatives thereof. Alternatively or in addition, the compositions of the invention can comprise BCG or Pvac as an adjuvant.

DEFINITIONS

25

"Fusion polypeptide" or "fusion protein" refers to a protein having at least two *Chlamydia* polypeptides (which may be the same, or may be different) covalently linked, either directly or via an amino acid linker. The polypeptides forming the fusion protein are typically linked C-terminus to N-terminus, although they can also be linked C-terminus to C-terminus, N-terminus to N-terminus, or N-terminus to C-terminus. The polypeptides of the fusion protein can be in any order. This term also refers to conservatively modified variants, polymorphic variants, alleles, mutants, subsequences, interspecies homologs, and immunogenic fragments of the antigens that make up the fusion protein. Fusion proteins of the invention can also comprise additional copies of a component antigen or immunogenic fragment thereof.

35

A polynucleotide sequence encoding a fusion protein of the invention hybridizes under stringent conditions to at least two nucleotide sequences, each encoding an antigen polypeptide selected from the group consisting of Ct-681 (Momp) or an immunogenic fragment thereof, Ct-

871 (PmpG) or an immunogenic fragment thereof, Ct-812 (PmpD) or an immunogenic fragment thereof, Ct-089 or an immunogenic fragment thereof, Ct-858 or an immunogenic fragment thereof, Ct-875 or an immunogenic fragment thereof, Ct-460 (swib) or an immunogenic fragment thereof, and Ct-622 or an immunogenic fragment thereof. The polynucleotide sequences encoding the individual antigens of the fusion polypeptide therefore include conservatively modified variants, polymorphic variants, alleles, mutants, subsequences, immunogenic fragments, and interspecies homologs of Ct-681 (Momp), Ct-871 (PmpG), Ct-812 (PmpD), Ct-089, Ct-858, Ct-875, Ct-460 (swib), and Ct-622. The polynucleotide sequences encoding the individual polypeptides of the fusion protein can be in any order.

In some embodiments, the individual polypeptides of the fusion protein are in order (N- to C- terminus) from large to small. Large antigens are approximately 30 to 150 kD in size, medium antigens are approximately 10 to 30 kD in size, and small antigens are approximately less than 10 kD in size. The sequence encoding the individual polypeptide may be as small as, e.g., an immunogenic fragment such as an individual CTL epitope encoding about 8 to 9 amino acids, or, e.g., an HTL or B cell epitope. The fragment may also include multiple epitopes.

A fusion polypeptide of the invention specifically binds to antibodies raised against at least two antigen polypeptides selected from Ct-681 (Momp) or an immunogenic fragment thereof, Ct-871 (PmpG) or an immunogenic fragment thereof, Ct-812 (PmpD) or an immunogenic fragment thereof, Ct-089 or an immunogenic fragment thereof, Ct-858 or an immunogenic fragment thereof, Ct-875 or an immunogenic fragment thereof, Ct-460 (swib) or an immunogenic fragment thereof, and Ct-622 or an immunogenic fragment thereof. The antibodies can be polyclonal or monoclonal. Optionally, the fusion polypeptide specifically binds to antibodies raised against the fusion junction of the antigens, which antibodies do not bind to the antigens individually, i.e., when they are not part of a fusion protein. The fusion polypeptides optionally comprise additional polypeptides, e.g., three, four, five, six, or more polypeptides, up to about 25 polypeptides, optionally heterologous polypeptides or repeated homologous polypeptides, fused to the at least two antigens. The additional polypeptides of the fusion protein are optionally derived from *Chlamydia* as well as other sources, such as other bacterial, viral, or invertebrate, vertebrate, or mammalian sources. The individual polypeptides of the fusion protein can be in any order. As described herein, the fusion protein can also be linked to other molecules, including additional polypeptides. The compositions of the invention can also comprise additional polypeptides that are unlinked to the fusion proteins of the invention. These additional polypeptides may be heterologous or homologous polypeptides.

The term "fused" refers to the covalent linkage between two polypeptides in a fusion protein. The polypeptides are typically joined via a peptide bond, either directly to each other or via an amino acid linker. Optionally, the peptides can be joined via non-peptide covalent linkages known to those of skill in the art.

"FL" refers to full-length, i.e., a polypeptide that is the same length as the wild-type polypeptide.

The term "immunogenic fragment thereof" refers to a polypeptide comprising an epitope that is recognized by cytotoxic T lymphocytes, helper T lymphocytes or B cells. Methods of determining epitope regions of a sequence are described elsewhere herein. Suitably, the immunogenic fragment will comprise at least 30%, suitably at least 50%, especially at least 75% and in particular at least 90% (e.g. 95% or 98%) of the amino acids in the reference sequence. The immunogenic fragment will suitably comprise all of the epitope regions of the reference sequence.

An adjuvant refers to the components in a vaccine or therapeutic composition that increase the specific immune response to the antigen (see, e.g., Edelman, *AIDS Res. Hum Retroviruses* 8:1409-1411 (1992)). Adjuvants induce immune responses of the Th1-type and Th-2 type response. Th1-type cytokines (e.g., IFN- γ , IL-2, and IL-12) tend to favor the induction of cell-mediated immune response to an administered antigen, while Th-2 type cytokines (e.g., IL-4, IL-5, IL-6, IL-10 and TNF- β) tend to favor the induction of humoral immune responses. Any of a variety of adjuvants may be employed in the vaccines of this invention to enhance the immune response. Some adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a specific or nonspecific stimulator of immune responses, such as lipid A, Bortadella pertussis or Mycobacterium tuberculosis. Suitable adjuvants are commercially available and include, for example, Freund's Incomplete Adjuvant and Freund's Complete Adjuvant (Difco Laboratories) and Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.). Other suitable adjuvants include alum, biodegradable microspheres, monophosphoryl lipid A, quil A, SBAS1c, SBAS2 (Ling et al., 1997, Vaccine 15:1562-1567), SBAS7, Al(OH)₃ and CpG oligonucleotide (WO96/02555). Suitable adjuvants for use in the invention are discussed in more detail below.

"Nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).

Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third

position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer *et al.*, *Nucleic Acid Res.* 19:5081 (1991); Ohtsuka *et al.*, *J. Biol. Chem.* 260:2605-2608 (1985); Rossolini *et al.*, *Mol. Cell. Probes* 8:91-98 (1994)). The term nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide.

The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms also apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ -carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.

Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

"Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of

the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid that encodes a polypeptide is implicit in each described sequence.

A polynucleotide of the invention may contain a number of silent variations (for example, 1-5, in particular 1 or 2, and especially 1 codon(s) may be altered) when compared to the reference sequence. A polynucleotide of the invention may contain a number of non-silent conservative variations (for example, 1-5, in particular 1 or 2, and especially 1 codon(s) may be altered) when compared to the reference sequence. Those skilled in the art will recognise that a particular polynucleotide sequence may contain both silent and non-silent conservative variations.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.

A polypeptide of the invention may contain a number of conservative variations (for example, 1-5, in particular 1 or 2, and especially 1 amino acid residue(s) may be altered) when compared to the reference sequence. In general, such conservative substitutions will fall within one of the amino-acid groupings specified below, though in some circumstances other substitutions may be possible without substantially affecting the immunogenic properties of the antigen. The following eight groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Glycine (G);
 - 2) Aspartic acid (D), Glutamic acid (E);
 - 3) Asparagine (N), Glutamine (Q);
 - 4) Arginine (R), Lysine (K);
 - 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V);
 - 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W);
 - 7) Serine (S), Threonine (T); and
 - 8) Cysteine (C), Methionine (M)
- (see, e.g., Creighton, *Proteins* (1984)).

Suitably amino-acid substitutions are restricted to non-epitope regions of an antigen.

Polypeptide sequence variants may also include those wherein additional amino acids are inserted compared to the reference sequence, for example, such insertions may occur at 1 or 2 locations (suitably 1) and may involve the addition of 50 or fewer amino acids (such as 20 or fewer, in particular 10 or fewer, especially 5 or fewer) at each location. Suitably such
5 insertions so not occur in the region of an epitope, and do not therefore have a significant impact on the immunogenic properties of the antigen. One example of insertions includes a short stretch of histidine residues (e.g. 1-6 residues) to aid expression and/or purification of the antigen in question.

Other polypeptide sequence variants include those wherein amino acids have been
10 deleted compared to the reference sequence, for example, such deletions may occur at 1 or 2 locations (suitably 1) and may, for example, involve the deletion of 50 or fewer amino acids (such as 20 or fewer, in particular 10 or fewer, especially 5 or fewer) at each location. Suitably such insertions so not occur in the region of an epitope, and do not therefore have a significant impact on the immunogenic properties of the antigen.

15 Methods of determining the epitope regions of an antigen are described and exemplified elsewhere herein.

The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly
20 produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

25 The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).

The phrase "stringent hybridization conditions" refers to conditions under which a probe
30 will hybridize to its target subsequence, typically in a complex mixture of nucleic acid, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, *Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes*, "Overview of principles of hybridization
35 and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength pH. The T_m is the temperature (under defined ionic strength, pH, and nucleic

concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T_m , 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, optionally 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 65°C.

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides that they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 1X SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency.

"Antibody" refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one "heavy" chain (about 50-70 kDa). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (V_L) and variable heavy chain (V_H) refer to these light and heavy chains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce $F(ab)'_2$, a dimer of Fab

which itself is a light chain joined to V_H-C_H1 by a disulfide bond. The $F(ab)'_2$ may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the $F(ab)'_2$ dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (*see Fundamental Immunology* (Paul ed., 3d ed. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized *de novo* either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized *de novo* using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (*see, e.g., McCafferty et al., Nature* 348:552-554 (1990)).

For preparation of monoclonal or polyclonal antibodies, any technique known in the art can be used (*see, e.g., Kohler & Milstein, Nature* 256:495-497 (1975); Kozbor *et al., Immunology Today* 4: 72 (1983); Cole *et al.*, pp. 77-96 in *Monoclonal Antibodies and Cancer Therapy* (1985)). Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (*see, e.g., McCafferty et al., Nature* 348:552-554 (1990); Marks *et al., Biotechnology* 10:779-783 (1992)).

The phrase "specifically (or selectively) binds" to an antibody or "specifically (or selectively) immunoreactive with," when referring to a protein or peptide, refers to a binding reaction that is determinative of the presence of the protein in a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein at least two times the background and do not substantially bind in a significant amount to other proteins present in the sample. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, polyclonal antibodies raised to fusion proteins can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with fusion protein and not with individual components of the fusion proteins. This selection may be achieved by subtracting out antibodies that cross-react with the individual antigens. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (*see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual* (1988), for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity). Typically a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 to 100 times background.

Polynucleotides may comprise a native sequence (i.e., an endogenous sequence that encodes an individual antigen or a portion thereof) or may comprise a variant of such a sequence. Polynucleotide variants may contain one or more substitutions, additions, deletions and/or insertions such that the biological activity of the encoded fusion polypeptide is not diminished, relative to a fusion polypeptide comprising native antigens. Variants preferably exhibit at least about 70% identity, more preferably at least about 80% identity and most preferably at least about 90% identity to a polynucleotide sequence that encodes a native polypeptide or a portion thereof.

The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., 70% identity, optionally 75%, 80%, 85%, 90%, or 95% (e.g. 98%) identity over a specified region), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Such sequences are then said to be "substantially identical." This definition also refers to the complement of a test sequence. Optionally, the identity exists over a region that is at least about 25 to about 50 amino acids or nucleotides in length, or optionally over a region that is 75-100 amino acids or nucleotides in length.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A "comparison window", as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 25 to 500, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted by, for example, the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr.,

Madison, WI), or by manual alignment and visual inspection (*see, e.g., Current Protocols in Molecular Biology* (Ausubel *et al.*, eds. 1995 supplement)).

One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a tree or dendrogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, *J. Mol. Evol.* 35:351-360 (1987). The method used is similar to the method described by Higgins & Sharp, *CABIOS* 5:151-153 (1989). The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. Using PILEUP, a reference sequence is compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps. PILEUP can be obtained from the GCG sequence analysis software package, e.g., version 7.0 (Devereaux *et al.*, *Nuc. Acids Res.* 12:387-395 (1984)).

Another example of algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul *et al.*, *Nuc. Acids Res.* 25:3389-3402 (1997) and Altschul *et al.*, *J. Mol. Biol.* 215:403-410 (1990), respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the

cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) or 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, *Proc. Nat'l. Acad. Sci. USA* 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.

POLYNUCLEOTIDE COMPOSITIONS

As used herein, the terms "DNA segment" and "polynucleotide" refer to a DNA molecule that has been isolated free of total genomic DNA of a particular species. Therefore, a DNA segment encoding a polypeptide refers to a DNA segment that contains one or more coding sequences yet is substantially isolated away from, or purified free from, total genomic DNA of the species from which the DNA segment is obtained. Included within the terms "DNA segment" and "polynucleotide" are DNA segments and smaller fragments of such segments, and also recombinant vectors, including, for example, plasmids, cosmids, phagemids, phage, viruses, and the like.

As will be understood by those skilled in the art, the DNA segments of this invention can include genomic sequences, extra-genomic and plasmid-encoded sequences and smaller engineered gene segments that express, or may be adapted to express, proteins, polypeptides, peptides and the like. Such segments may be naturally isolated, or modified synthetically by the hand of man.

The terms "isolated," "purified," or "biologically pure" therefore refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Of course, this refers to the DNA segment as originally isolated, and does not exclude other isolated proteins, genes, or coding regions later added to the composition by the hand of man. Purity and homogeneity are typically determined using analytical chemistry

techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein that is the predominant species present in a preparation is substantially purified. An isolated nucleic acid is separated from other open reading frames that flank the gene and encode proteins other than the gene.

5 As will be recognized by the skilled artisan, polynucleotides may be single-stranded (coding or antisense) or double-stranded, and may be DNA (genomic, cDNA or synthetic) or RNA molecules. RNA molecules include HnRNA molecules, which contain introns and correspond to a DNA molecule in a one-to-one manner, and mRNA molecules, which do not contain introns. Additional coding or non-coding sequences may, but need not, be present
10 within a polynucleotide of the present invention, and a polynucleotide may, but need not, be linked to other molecules and/or support materials.

Polynucleotides may comprise a native sequence (i.e., an endogenous sequence that encodes a *Chlamydia* antigen or a portion thereof) or may comprise a variant, or a biological or antigenic functional equivalent of such a sequence. Polynucleotide variants may contain one or
15 more substitutions, additions, deletions and/or insertions, as further described below, preferably such that the immunogenicity of the encoded polypeptide is not diminished, relative to a native tumor protein. The effect on the immunogenicity of the encoded polypeptide may generally be assessed as described herein. The term "variants" also encompasses homologous genes of xenogenic origin.

20 In additional embodiments, the present invention provides isolated polynucleotides and polypeptides comprising various lengths of contiguous stretches of sequence identical to or complementary to one or more of the sequences disclosed herein. For example, polynucleotides are provided by this invention that comprise at least about 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500 or 1000 or more contiguous nucleotides of one or more of the
25 sequences disclosed herein as well as all intermediate lengths there between. It will be readily understood that "intermediate lengths", in this context, means any length between the quoted values, such as 16, 17, 18, 19, etc.; 21, 22, 23, etc.; 30, 31, 32, etc.; 50, 51, 52, 53, etc.; 100, 101, 102, 103, etc.; 150, 151, 152, 153, etc.; including all integers through 200-500; 500-1,000, and the like.

30 The polynucleotides of the present invention, or fragments thereof, regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with
35 the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol. For example, illustrative DNA segments with total lengths of about 10,000, about 5000, about 3000, about 2,000, about 1,000, about 500, about 200, about 100,

about 50 base pairs in length, and the like, (including all intermediate lengths) are contemplated to be useful in many implementations of this invention.

Moreover, it will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear minimal homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present invention, for example polynucleotides that are optimized for human and/or primate codon selection. Further, alleles of the genes comprising the polynucleotide sequences provided herein are within the scope of the present invention. Alleles are endogenous genes that are altered as a result of one or more mutations, such as deletions, additions and/or substitutions of nucleotides. The resulting mRNA and protein may, but need not, have an altered structure or function. Alleles may be identified using standard techniques (such as hybridization, amplification and/or database sequence comparison).

POLYNUCLEOTIDE IDENTIFICATION AND CHARACTERIZATION

Polynucleotides may be identified, prepared and/or manipulated using any of a variety of well-established techniques. For example, a polynucleotide may be identified, as described in more detail below, by screening a microarray of cDNAs. Such screens may be performed, for example, using a Synteni microarray (Palo Alto, CA) according to the manufacturer's instructions (and essentially as described by Schena *et al.*, *Proc. Natl. Acad. Sci. USA* 93:10614-10619 (1996) and Heller *et al.*, *Proc. Natl. Acad. Sci. USA* 94:2150-2155 (1997)). Alternatively, polynucleotides may be amplified from cDNA prepared from cells expressing the proteins described herein, such as *C. trachomatis* cells. Such polynucleotides may be amplified via polymerase chain reaction (PCR). For this approach, sequence-specific primers may be designed based on the sequences provided herein, and may be purchased or synthesized.

An amplified portion of a polynucleotide of the present invention may be used to isolate a full-length gene from a suitable library (e.g., a *C. trachomatis* cDNA library) using well-known techniques. Within such techniques, a library (cDNA or genomic) is screened using one or more polynucleotide probes or primers suitable for amplification. Preferably, a library is size-selected to include larger molecules. Random primed libraries may also be preferred for identifying 5' and upstream regions of genes. Genomic libraries are preferred for obtaining introns and extending 5' sequences.

For hybridization techniques, a partial sequence may be labeled (e.g., by nick-translation or end-labeling with ³²P) using well-known techniques. A bacterial or bacteriophage library is

then generally screened by hybridizing filters containing denatured bacterial colonies (or lawns containing phage plaques) with the labeled probe (see Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual* (1989)). Hybridizing colonies or plaques are selected and expanded, and the DNA is isolated for further analysis. cDNA clones may be analyzed to determine the

5 amount of additional sequence by, for example, PCR using a primer from the partial sequence and a primer from the vector. Restriction maps and partial sequences may be generated to identify one or more overlapping clones. The complete sequence may then be determined using standard techniques, which may involve generating a series of deletion clones. The resulting overlapping sequences can then be assembled into a single contiguous sequence. A full-
10 length cDNA molecule can be generated by ligating suitable fragments, using well-known techniques.

Alternatively, there are numerous amplification techniques for obtaining a full-length coding sequence from a partial cDNA sequence. Within such techniques, amplification is generally performed via PCR. Any of a variety of commercially available kits may be used to
15 perform the amplification step. Primers may be designed using, for example, software well known in the art. Primers are preferably 22-30 nucleotides in length have a GC content of at least 50% and anneal to the target sequence at temperatures of about 68°C to 72°C. The amplified region may be sequenced as described above, and overlapping sequences assembled into a contiguous sequence.

20 One such amplification technique is inverse PCR (see Triglia *et al.*, *Nucl. Acids Res.* 16:8186 (1988)), which uses restriction enzymes to generate a fragment in the known region of the gene. The fragment is then circularized by intramolecular ligation and used as a template for PCR with divergent primers derived from the known region. Within an alternative approach, sequences adjacent to a partial sequence may be retrieved by amplification with a primer to a
25 linker sequence and a primer specific to a known region. The amplified sequences are typically subjected to a second round of amplification with the same linker primer and a second primer specific to the known region. A variation on this procedure, which employs two primers that initiate extension in opposite directions from the known sequence, is described in WO 96/38591. Another such technique is known as "rapid amplification of cDNA ends" or RACE. This
30 technique involves the use of an internal primer and an external primer, which hybridizes to a polyA region or vector sequence, to identify sequences that are 5' and 3' of a known sequence. Additional techniques include capture PCR (Lagerstrom *et al.*, *PCR Methods Applic.* 1:111-19 (1991)) and walking PCR (Parker *et al.*, *Nucl. Acids. Res.* 19:3055-60 (1991)). Other methods employing amplification may also be employed to obtain a full length cDNA sequence.

35 In certain instances, it is possible to obtain a full length cDNA sequence by analysis of sequences provided in an expressed sequence tag (EST) database, such as that available from GenBank. Searches for overlapping ESTs may generally be performed using well known

programs (e.g., NCBI BLAST searches), and such ESTs may be used to generate a contiguous full length sequence. Full length DNA sequences may also be obtained by analysis of genomic fragments.

5 POLYNUCLEOTIDE EXPRESSION IN HOST CELLS

In other embodiments of the invention, polynucleotide sequences or fragments thereof which encode polypeptides of the invention, or fusion proteins or functional equivalents thereof, may be used in recombinant DNA molecules to direct expression of a polypeptide in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences that encode substantially the same or a functionally equivalent amino acid sequence may be produced and these sequences may be used to clone and express a given polypeptide.

As will be understood by those of skill in the art, it may be advantageous in some instances to produce polypeptide-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce a recombinant RNA transcript having desirable properties, such as a half-life that is longer than that of a transcript generated from the naturally occurring sequence.

Moreover, the polynucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter polypeptide encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. For example, DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. In addition, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, or introduce mutations, and so forth.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of polypeptide activity, it may be useful to encode a chimeric protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the polypeptide-encoding sequence and the heterologous protein sequence, so that the polypeptide may be cleaved and purified away from the heterologous moiety.

Sequences encoding a desired polypeptide may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M. H. *et al.*, *Nucl. Acids Res. Symp. Ser.* pp. 215-223 (1980), Horn *et al.*, *Nucl. Acids Res. Symp. Ser.* pp. 225-232 (1980)). Alternatively, the protein itself may be produced using chemical methods to synthesize the

amino acid sequence of a polypeptide, or a portion thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge *et al.*, *Science* 269:202-204 (1995)) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer, Palo Alto, CA).

5 A newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, *Proteins, Structures and Molecular Principles* (1983)) or other comparable techniques available in the art. The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure). Additionally, the amino acid sequence of a polypeptide, or any part
10 thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

 In order to express a desired polypeptide, the nucleotide sequences encoding the polypeptide, or functional equivalents, may be inserted into appropriate expression vector, i.e., a vector that contains the necessary elements for the transcription and translation of the inserted
15 coding sequence. Methods that are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding a polypeptide of interest and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described in Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (1989),
20 and Ausubel *et al.*, *Current Protocols in Molecular Biology* (1989).

 A variety of expression vector/host systems may be utilized to contain and express polynucleotide sequences. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression
25 vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.

 The "control elements" or "regulatory sequences" present in an expression vector are those non-translated regions of the vector--enhancers, promoters, 5' and 3' untranslated
30 regions--which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the PBLUESCRIPT phagemid (Stratagene, La
35 Jolla, Calif.) or PSPO1 plasmid (Gibco BRL, Gaithersburg, MD) and the like may be used. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are generally preferred. If it is necessary to generate a cell line that contains multiple copies of the

sequence encoding a polypeptide, vectors based on SV40 or EBV may be advantageously used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for the expressed polypeptide. For example, when large quantities are
 5 needed, for example for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene), in which the sequence encoding the polypeptide of interest may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β -
 10 galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke & Schuster, *J. Biol. Chem.* 264:5503-5509 (1989)); and the like. pGEX Vectors (Promega, Madison, Wis.) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free
 15 glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. Other
 20 vectors containing constitutive or inducible promoters include GAP, PGK, GAL and ADH. For reviews, see Ausubel *et al.* (*supra*), Grant *et al.*, *Methods Enzymol.* 153:516-544 (1987) and Romas *et al.* *Yeast* 8 423-88 (1992).

In cases where plant expression vectors are used, the expression of sequences encoding polypeptides may be driven by any of a number of promoters. For example, viral
 25 promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, *EMBO J.* 6:307-311 (1987)). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi *et al.*, *EMBO J.* 3:1671-1680 (1984); Broglie *et al.*, *Science* 224:838-843 (1984); and Winter *et al.*, *Results Probl. Cell Differ.* 17:85-105 (1991)). These constructs can be
 30 introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (*see, e.g., Hobbs in McGraw Hill Yearbook of Science and Technology* pp. 191-196 (1992)).

An insect system may also be used to express a polypeptide of interest. For example, in one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a
 35 vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia larvae*. The sequences encoding the polypeptide may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful

insertion of the polypeptide-encoding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, *S. frugiperda* cells or *Trichoplusia larvae* in which the polypeptide of interest may be expressed (Engelhard *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 91 :3224-3227 (1994)).

5 In mammalian host cells, a number of viral-based expression systems are generally available. For example, in cases where an adenovirus is used as an expression vector, sequences encoding a polypeptide of interest may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable
10 virus that is capable of expressing the polypeptide in infected host cells (Logan & Shenk, *Proc. Natl. Acad. Sci. U.S.A.* 81:3655-3659 (1984)). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be used to achieve more efficient translation of
15 sequences encoding a polypeptide of interest. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding the polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control
20 signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers that are appropriate for the particular cell system which is used, such as those described in the literature
25 (Scharf. *et al.*, *Results Probl. Cell Differ.* 20:125-162 (1994)).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which
30 cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, HEK293, and WI38, which have specific cellular machinery and characteristic mechanisms for such post-translational activities, may be chosen to ensure the correct modification and processing of the foreign protein.

35 For long-term, high-yield production of recombinant proteins, stable expression is generally preferred. For example, cell lines that stably express a polynucleotide of interest may be transformed using expression vectors which may contain viral origins of replication and/or

endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells that successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler *et al.*, *Cell* 11:223-32 (1977)) and adenine phosphoribosyltransferase (Lowy *et al.*, *Cell* 22:817-23 (1990)) genes which can be employed in tk.sup.- or aprt.sup.- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 77:3567-70 (1980)); npt, which confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin *et al.*, *J. Mol. Biol.* 150:1-14 (1981)); and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, *supra*). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman & Mulligan, *Proc. Natl. Acad. Sci. U.S.A.* 85:8047-51 (1988)). Recently, the use of visible markers has gained popularity with such markers as anthocyanins, β -glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes *et al.*, *Methods Mol. Biol.* 55:121-131 (1995)).

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding a polypeptide is inserted within a marker gene sequence, recombinant cells containing sequences can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a polypeptide-encoding sequence under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells that contain and express a desired polynucleotide sequence may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques that include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein.

A variety of protocols for detecting and measuring the expression of polynucleotide-encoded products, using either polyclonal or monoclonal antibodies specific for the product are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA),

radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on a given polypeptide may be preferred for some applications, but a competitive binding assay may also be employed. These and other assays are described, among other places, in Hampton *et al.*, *Serological Methods, a Laboratory Manual* (1990) and Maddox *et al.*, *J. Exp. Med.* 158:1211-1216 (1983).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences, or any portions thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits. Suitable reporter molecules or labels, which may be used include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with a polynucleotide sequence of interest may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides of the invention may be designed to contain signal sequences that direct secretion of the encoded polypeptide through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may be used to join sequences encoding a polypeptide of interest to nucleotide sequence encoding a polypeptide domain that will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, Calif.) between the purification domain and the encoded polypeptide may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing a polypeptide of interest and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography) as described in Porath *et al.*, *Prot. Exp. Purif.* 3:263-281 (1992) while the enterokinase cleavage site provides a means for purifying the desired polypeptide from the

fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll *et al.*, *DNA Cell Biol.* 12:441-453 (1993)).

In addition to recombinant production methods, polypeptides of the invention, and fragments thereof, may be produced by direct peptide synthesis using solid-phase techniques (Merrifield, *J. Am. Chem. Soc.* 85:2149-2154 (1963)). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Alternatively, various fragments may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

IN VIVO POLYNUCLEOTIDE DELIVERY TECHNIQUES

In additional embodiments, genetic constructs comprising the compositions of polynucleotides of the invention are introduced into cells *in vivo*. This may be achieved using any of a variety of well-known approaches, several of which are outlined below for the purpose of illustration.

1. ADENOVIRUS

One of the preferred methods for *in vivo* delivery of one or more nucleic acid sequences involves the use of an adenovirus expression vector. "Adenovirus expression vector" is meant to include those constructs containing adenovirus sequences sufficient to (a) support packaging of the construct and (b) to express a polynucleotide that has been cloned therein in a sense or antisense orientation. Of course, in the context of an antisense construct, expression does not require that the gene product be synthesized.

The expression vector comprises a genetically engineered form of an adenovirus. Knowledge of the genetic organization of adenovirus, a 36 kb, linear, double-stranded DNA virus, allows substitution of large pieces of adenoviral DNA with foreign sequences up to 7 kb (Grunhaus & Horwitz, 1992). In contrast to retrovirus, the adenoviral infection of host cells does not result in chromosomal integration because adenoviral DNA can replicate in an episomal manner without potential genotoxicity. Also, adenoviruses are structurally stable, and no genome rearrangement has been detected after extensive amplification. Adenovirus can infect virtually all epithelial cells regardless of their cell cycle stage. So far, adenoviral infection appears to be linked only to mild disease such as acute respiratory disease in humans.

Adenovirus is particularly suitable for use as a gene transfer vector because of its mid-sized genome, ease of manipulation, high titer, wide target-cell range and high infectivity. Both ends of the viral genome contain 100-200 base pair inverted repeats (ITRs), which are *cis* elements necessary for viral DNA replication and packaging. The early (E) and late (L) regions

of the genome contain different transcription units that are divided by the onset of viral DNA replication. The E1 region (E1A and E1B) encodes proteins responsible for the regulation of transcription of the viral genome and a few cellular genes. The expression of the E2 region (E2A and E2B) results in the synthesis of the proteins for viral DNA replication. These proteins are involved in DNA replication, late gene expression and host cell shut-off (Renan, 1990). The products of the late genes, including the majority of the viral capsid proteins, are expressed only after significant processing of a single primary transcript issued by the major late promoter (MLP). The MLP, (located at 16.8 m.u.) is particularly efficient during the late phase of infection, and all the mRNA's issued from this promoter possess a 5'-tripartite leader (TPL) sequence which makes them preferred mRNA's for translation.

In a current system, recombinant adenovirus is generated from homologous recombination between shuttle vector and provirus vector. Due to the possible recombination between two proviral vectors, wild-type adenovirus may be generated from this process. Therefore, it is critical to isolate a single clone of virus from an individual plaque and examine its genomic structure.

Generation and propagation of the current adenovirus vectors, which are replication deficient, depend on a unique helper cell line, designated 293, which was transformed from human embryonic kidney cells by Ad5 DNA fragments and constitutively expresses E1 proteins (Graham *et al.*, 1977). Since the E3 region is dispensable from the adenovirus genome (Jones & Shenk, 1978), the current adenovirus vectors, with the help of 293 cells, carry foreign DNA in either the E1, the D3 or both regions (Graham & Prevec, 1991). In nature, adenovirus can package approximately 105% of the wild-type genome (Ghosh-Choudhury *et al.*, 1987), providing capacity for about 2 extra kB of DNA. Combined with the approximately 5.5 kB of DNA that is replaceable in the E1 and E3 regions, the maximum capacity of the current adenovirus vector is under 7.5 kB, or about 15% of the total length of the vector. More than 80% of the adenovirus viral genome remains in the vector backbone and is the source of vector-borne cytotoxicity. Also, the replication deficiency of the E1-deleted virus is incomplete. For example, leakage of viral gene expression has been observed with the currently available vectors at high multiplicities of infection (MOI) (Mulligan, 1993).

Helper cell lines may be derived from human cells such as human embryonic kidney cells, muscle cells, hematopoietic cells or other human embryonic mesenchymal or epithelial cells. Alternatively, the helper cells may be derived from the cells of other mammalian species that are permissive for human adenovirus. Such cells include, e.g., Vero cells or other monkey embryonic mesenchymal or epithelial cells. As stated above, the currently preferred helper cell line is 293.

Recently, Racher *et al.* (1995) disclosed improved methods for culturing 293 cells and propagating adenovirus. In one format, natural cell aggregates are grown by inoculating

individual cells into 1 liter siliconized spinner flasks (Techne, Cambridge, UK) containing 100-200 ml of medium. Following stirring at 40 rpm, the cell viability is estimated with trypan blue. In another format, Fibracel microcarriers (Bibby Sterlin, Stone, UK) (5 g/l) is employed as follows. A cell inoculum, resuspended in 5 ml of medium, is added to the carrier (50 ml) in a 250 ml Erlenmeyer flask and left stationary, with occasional agitation, for 1 to 4 h. The medium is then replaced with 50 ml of fresh medium and shaking initiated. For virus production, cells are allowed to grow to about 80% confluence, after which time the medium is replaced (to 25% of the final volume) and adenovirus added at an MOI of 0.05. Cultures are left stationary overnight, following which the volume is increased to 100% and shaking commenced for another 72 h.

Other than the requirement that the adenovirus vector be replication defective, or at least conditionally defective, the nature of the adenovirus vector is not believed to be crucial to the successful practice of the invention. The adenovirus may be of any of the 42 different known serotypes or subgroups A-F. Adenovirus type 5 of subgroup C is the preferred starting material in order to obtain a conditional replication-defective adenovirus vector for use in the present invention, since Adenovirus type 5 is a human adenovirus about which a great deal of biochemical and genetic information is known, and it has historically been used for most constructions employing adenovirus as a vector.

As stated above, the typical vector according to the present invention is replication defective and will not have an adenovirus E1 region. Thus, it will be most convenient to introduce the polynucleotide encoding the gene of interest at the position from which the E1-coding sequences have been removed. However, the position of insertion of the construct within the adenovirus sequences is not critical to the invention. The polynucleotide encoding the gene of interest may also be inserted in lieu of the deleted E3 region in E3 replacement vectors as described by Karlsson *et al.* (1986) or in the E4 region where a helper cell line or helper virus complements the E4 defect.

Adenovirus is easy to grow and manipulate and exhibits broad host range *in vitro* and *in vivo*. This group of viruses can be obtained in high titers, e.g., 10^9 - 10^{11} plaque-forming units per ml, and they are highly infective. The life cycle of adenovirus does not require integration into the host cell genome. The foreign genes delivered by adenovirus vectors are episomal and, therefore, have low genotoxicity to host cells. No side effects have been reported in studies of vaccination with wild-type adenovirus (Couch *et al.*, 1963; Top *et al.*, 1971), demonstrating their safety and therapeutic potential as *in vivo* gene transfer vectors.

Adenovirus vectors have been used in eukaryotic gene expression (Levrero *et al.*, 1991; Gomez-Foix *et al.*, 1992) and vaccine development (Grunhaus & Horwitz, 1992; Graham & Prevec, 1992). Recently, animal studies suggested that recombinant adenovirus could be used for gene therapy (Stratford-Perricaudet & Perricaudet, 1991; Stratford-Perricaudet *et al.*, 1990;

Rich *et al.*, 1993). Studies in administering recombinant adenovirus to different tissues include trachea instillation (Rosenfeld *et al.*, 1991; Rosenfeld *et al.*, 1992), muscle injection (Ragot *et al.*, 1993), peripheral intravenous injections (Herz & Gerard, 1993) and stereotactic inoculation into the brain (Le Gal La Salle *et al.*, 1993).

5

2. RETROVIRUSES

The retroviruses are a group of single-stranded RNA viruses characterized by an ability to convert their RNA to double-stranded DNA in infected cells by a process of reverse-transcription (Coffin, 1990). The resulting DNA then stably integrates into cellular chromosomes as a provirus and directs synthesis of viral proteins. The integration results in the retention of the viral gene sequences in the recipient cell and its descendants. The retroviral genome contains three genes, gag, pol, and env that code for capsid proteins, polymerase enzyme, and envelope components, respectively. A sequence found upstream from the gag gene contains a signal for packaging of the genome into virions. Two long terminal repeat (LTR) sequences are present at the 5' and 3' ends of the viral genome. These contain strong promoter and enhancer sequences and are also required for integration in the host cell genome (Coffin, 1990).

In order to construct a retroviral vector, a nucleic acid encoding one or more oligonucleotide or polynucleotide sequences of interest is inserted into the viral genome in the place of certain viral sequences to produce a virus that is replication-defective. In order to produce virions, a packaging cell line containing the gag, pol, and env genes but without the LTR and packaging components is constructed (Mann *et al.*, 1983). When a recombinant plasmid containing a cDNA, together with the retroviral LTR and packaging sequences is introduced into this cell line (by calcium phosphate precipitation for example), the packaging sequence allows the RNA transcript of the recombinant plasmid to be packaged into viral particles, which are then secreted into the culture media (Nicolas & Rubenstein, 1988; Temin, 1986; Mann *et al.*, 1983). The media containing the recombinant retroviruses is then collected, optionally concentrated, and used for gene transfer. Retroviral vectors are able to infect a broad variety of cell types. However, integration and stable expression require the division of host cells (Paskind *et al.*, 1975).

A novel approach designed to allow specific targeting of retrovirus vectors was recently developed based on the chemical modification of a retrovirus by the chemical addition of lactose residues to the viral envelope. This modification could permit the specific infection of hepatocytes *via* sialoglycoprotein receptors.

A different approach to targeting of recombinant retroviruses was designed in which biotinylated antibodies against a retroviral envelope protein and against a specific cell receptor were used. The antibodies were coupled *via* the biotin components by using streptavidin (Roux *et al.*, 1989). Using antibodies against major histocompatibility complex class I and class II

35

antigens, they demonstrated the infection of a variety of human cells that bore those surface antigens with an ecotropic virus *in vitro* (Roux *et al.*, 1989).

3. ADENO-ASSOCIATED VIRUSES

5 AAV (Ridgeway, 1988; Hermonat & Muzyczka, 1984) is a parovirus, discovered as a contamination of adenoviral stocks. It is a ubiquitous virus (antibodies are present in 85% of the US human population) that has not been linked to any disease. It is also classified as a dependovirus, because its replications is dependent on the presence of a helper virus, such as adenovirus. Five serotypes have been isolated, of which AAV-2 is the best characterized. AAV
10 has a single-stranded linear DNA that is encapsidated into capsid proteins VP1, VP2 and VP3 to form an icosahedral virion of 20 to 24 nm in diameter (Muzyczka & McLaughlin, 1988).

The AAV DNA is approximately 4.7 kilobases long. It contains two open reading frames and is flanked by two ITRs. There are two major genes in the AAV genome: *rep* and *cap*. The *rep* gene codes for proteins responsible for viral replications, whereas *cap* codes for capsid
15 protein VP1-3. Each ITR forms a T-shaped hairpin structure. These terminal repeats are the only essential *cis* components of the AAV for chromosomal integration. Therefore, the AAV can be used as a vector with all viral coding sequences removed and replaced by the cassette of genes for delivery. Three viral promoters have been identified and named p5, p19, and p40, according to their map position. Transcription from p5 and p19 results in production of *rep*
20 proteins, and transcription from p40 produces the capsid proteins (Hermonat & Muzyczka, 1984).

There are several factors that prompted researchers to study the possibility of using rAAV as an expression vector. One is that the requirements for delivering a gene to integrate into the host chromosome are surprisingly few. It is necessary to have the 145-bp ITRs, which
25 are only 6% of the AAV genome. This leaves room in the vector to assemble a 4.5-kb DNA insertion. While this carrying capacity may prevent the AAV from delivering large genes, it is amply suited for delivering the antisense constructs of the present invention.

AAV is also a good choice of delivery vehicles due to its safety. There is a relatively complicated rescue mechanism: not only wild type adenovirus but also AAV genes are required
30 to mobilize rAAV. Likewise, AAV is not pathogenic and not associated with any disease. The removal of viral coding sequences minimizes immune reactions to viral gene expression, and therefore, rAAV does not evoke an inflammatory response.

4. OTHER VIRAL VECTORS AS EXPRESSION CONSTRUCTS

35 Other viral vectors may be employed as expression constructs in the present invention for the delivery of oligonucleotide or polynucleotide sequences to a host cell. Vectors derived from viruses such as vaccinia virus (Ridgeway, 1988; Coupar *et al.*, 1988), lentiviruses,

polioviruses and herpes viruses may be employed. They offer several attractive features for various mammalian cells (Friedmann, 1989; Ridgeway, 1988; Coupar *et al.*, 1988; Horwich *et al.*, 1990).

With the recent recognition of defective hepatitis B viruses, new insight was gained into the structure-function relationship of different viral sequences. *In vitro* studies showed that the virus could retain the ability for helper-dependent packaging and reverse transcription despite the deletion of up to 80% of its genome (Horwich *et al.*, 1990). This suggested that large portions of the genome could be replaced with foreign genetic material. The hepatotropism and persistence (integration) were particularly attractive properties for liver-directed gene transfer. Chang *et al.* (1991) introduced the chloramphenicol acetyltransferase (CAT) gene into duck hepatitis B virus genome in the place of the polymerase, surface, and pre-surface coding sequences. It was cotransfected with wild-type virus into an avian hepatoma cell line. Culture media containing high titers of the recombinant virus were used to infect primary duckling hepatocytes. Stable CAT gene expression was detected for at least 24 days after transfection (Chang *et al.*, 1991).

Additional 'viral' vectors include virus like particles (VLPs) and phages.

5. NON-VIRAL VECTORS

In order to effect expression of the oligonucleotide or polynucleotide sequences of the present invention, the expression construct must be delivered into a cell. This delivery may be accomplished *in vitro*, as in laboratory procedures for transforming cells lines, or *in vivo* or *ex vivo*, as in the treatment of certain disease states. As described above, one preferred mechanism for delivery is *via* viral infection where the expression construct is encapsulated in an infectious viral particle.

Once the expression construct has been delivered into the cell the nucleic acid encoding the desired oligonucleotide or polynucleotide sequences may be positioned and expressed at different sites. In certain embodiments, the nucleic acid encoding the construct may be stably integrated into the genome of the cell. This integration may be in the specific location and orientation *via* homologous recombination (gene replacement) or it may be integrated in a random, non-specific location (gene augmentation). In yet further embodiments, the nucleic acid may be stably maintained in the cell as a separate, episomal segment of DNA. Such nucleic acid segments or "episomes" encode sequences sufficient to permit maintenance and replication independent of or in synchronization with the host cell cycle. How the expression construct is delivered to a cell and where in the cell the nucleic acid remains is dependent on the type of expression construct employed.

In certain embodiments of the invention, the expression construct comprising one or more oligonucleotide or polynucleotide sequences may simply consist of naked recombinant

DNA or plasmids. Transfer of the construct may be performed by any of the methods mentioned above which physically or chemically permeabilize the cell membrane. This is particularly applicable for transfer *in vitro* but it may be applied to *in vivo* use as well. Dubensky *et al.* (1984) successfully injected polyomavirus DNA in the form of calcium phosphate precipitates into liver and spleen of adult and newborn mice demonstrating active viral replication and acute infection. Benvenisty & Reshef (1986) also demonstrated that direct intraperitoneal injection of calcium phosphate-precipitated plasmids results in expression of the transfected genes. It is envisioned that DNA encoding a gene of interest may also be transferred in a similar manner *in vivo* and express the gene product.

Another embodiment of the invention for transferring a naked DNA expression construct into cells may involve particle bombardment. This method depends on the ability to accelerate DNA-coated microprojectiles to a high velocity allowing them to pierce cell membranes and enter cells without killing them (Klein *et al.*, 1987). Several devices for accelerating small particles have been developed. One such device relies on a high voltage discharge to generate an electrical current, which in turn provides the motive force (Yang *et al.*, 1990). The microprojectiles used have consisted of biologically inert substances such as tungsten or gold beads.

Selected organs including the liver, skin, and muscle tissue of rats and mice have been bombarded *in vivo* (Yang *et al.*, 1990; Zelenin *et al.*, 1991). This may require surgical exposure of the tissue or cells, to eliminate any intervening tissue between the gun and the target organ, i.e., *ex vivo* treatment. Again, DNA encoding a particular gene may be delivered via this method and still be incorporated by the present invention.

POLYPEPTIDE COMPOSITIONS

The present invention provides polypeptide compositions as described herein. Generally, a polypeptide composition of the invention will be a combination of isolated polypeptides or immunogenic fragments thereof. Alternatively, some or all of the polypeptide antigens in an inventive composition may be within a fusion protein. For example, in an inventive composition comprising three antigens: (i) the antigens may be provided in the form of three isolated polypeptides (ii) all three polypeptides antigens may be provided in a single fusion protein (iii) two of the antigens may be provided in a fusion protein, with the third provided in isolated form. The polypeptides of the combination may be encoded by a polynucleotide sequence or sequences disclosed herein or a sequence or sequences that hybridize under moderately stringent conditions to a polynucleotide sequence or sequences disclosed herein. Alternatively, the polypeptides may be defined as polypeptides each comprising a contiguous

amino acid sequence from an amino acid sequence disclosed herein, or which polypeptides each comprise an entire amino acid sequence disclosed herein.

Immunogenic portions may generally be identified using well-known techniques, such as those summarized in Paul, *Fundamental Immunology*, 3rd ed., 243-247 (1993) and references cited therein. Such techniques include screening polypeptides for the ability to react with antigen-specific antibodies, antisera and/or T-cell lines or clones. As used herein, antisera and antibodies are "antigen-specific" if they specifically bind to an antigen (i.e., they react with the protein in an ELISA or other immunoassay, and do not react detectably with unrelated proteins). Such antisera and antibodies may be prepared as described herein, and using well-known techniques. An immunogenic portion of a *Chlamydia* sp. protein is a portion that reacts with such antisera and/or T-cells at a level that is not substantially less than the reactivity of the full-length polypeptide (e.g., in an ELISA and/or T-cell reactivity assay). Such immunogenic portions may react within such assays at a level that is similar to or greater than the reactivity of the full-length polypeptide. Such screens may generally be performed using methods well known to those of ordinary skill in the art, such as those described in Harlow & Lane, *Antibodies: A Laboratory Manual* (1988). For example, a polypeptide may be immobilized on a solid support and contacted with patient sera to allow binding of antibodies within the sera to the immobilized polypeptide. Unbound sera may then be removed and bound antibodies detected using, for example, ¹²⁵I-labeled Protein A.

Polypeptides may be prepared using any of a variety of well-known techniques. Recombinant polypeptides encoded by DNA sequences as described above may be readily prepared from the DNA sequences using any of a variety of expression vectors known to those of ordinary skill in the art. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast, and higher eukaryotic cells, such as mammalian cells and plant cells. Preferably, the host cells employed are *E. coli*, yeast or a mammalian cell line such as COS or CHO. Supernatants from suitable host/vector systems that secrete recombinant protein or polypeptide into culture media may be first concentrated using a commercially available filter. Following concentration, the concentrate may be applied to a suitable purification matrix such as an affinity matrix or an ion exchange resin. Finally, one or more reverse phase HPLC steps can be employed to further purify a recombinant polypeptide.

Polypeptides of the invention, immunogenic fragments thereof which may have for example less than about 100 amino acids, or less than about 50 amino acids, may also be generated by synthetic means, using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino

acids are sequentially added to a growing amino acid chain. See Merrifield, *J. Am. Chem. Soc.* 85:2149-2146 (1963). Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems Division (Foster City, CA), and may be operated according to the manufacturer's instructions.

5 Within certain specific embodiments, a polypeptide may be a fusion protein that comprises multiple polypeptides as described herein, or that comprises at least one polypeptide as described herein and an unrelated sequence, such as a known protein. Such a fusion partner may, for example, assist in providing T helper epitopes (an immunological fusion partner), preferably T helper epitopes recognized by humans, or may assist in expressing the
10 protein (an expression enhancer) at higher yields than the native recombinant protein. Certain preferred fusion partners are both immunological and expression enhancing fusion partners. Other fusion partners may be selected so as to increase the solubility of the protein or to enable the protein to be targeted to desired intracellular compartments. Still further fusion partners include affinity tags, which facilitate purification of the protein.

15 Fusion proteins may generally be prepared using standard techniques, including chemical conjugation. Thus, a fusion protein may be expressed as a recombinant protein, allowing the production of increased levels, relative to a non-fused protein, in an expression system. Briefly, DNA sequences encoding the polypeptide components may be assembled separately, and ligated into an appropriate expression vector. The 3' end of the DNA sequence
20 encoding one polypeptide component is ligated, with or without a peptide linker, to the 5' end of a DNA sequence encoding the second polypeptide component so that the reading frames of the sequences are in phase. This permits translation into a single fusion protein that retains the biological activity of both component polypeptides. Typically fusion proteins comprising two or more antigens may omit the initiation codon (Met) from the second and subsequent antigens.

25 A peptide linker sequence may be employed to separate the first and second polypeptide components by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible
30 extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be
35 usefully employed as linkers include those disclosed in Maratea *et al.*, *Gene* 40:39-46 (1985); Murphy *et al.*, *Proc. Natl. Acad. Sci. USA* 83:8258-8262 (1986); U.S. Patent No. 4,935,233 and U.S. Patent No. 4,751,180. The linker sequence may generally be from 1 to about 50 amino

acids in length. Linker sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.

The ligated DNA sequences are operably linked to suitable transcriptional or translational regulatory elements. The regulatory elements responsible for expression of DNA are located only 5' to the DNA sequence encoding the first polypeptides. Similarly, stop codons required to end translation and transcription termination signals are only present 3' to the DNA sequence encoding the second polypeptide.

Thus the compositions according to the invention may comprise one or more fusion proteins. Such proteins comprise a polypeptide component of the composition as described herein together with an unrelated immunogenic protein. The immunogenic protein may for example be capable of eliciting a recall response. Examples of such proteins include tetanus, tuberculosis and hepatitis proteins (*see, e.g., Stoute et al., New Engl. J. Med.* 336:86-91 (1997)).

Within certain embodiments, an immunological fusion partner is derived from protein D, a surface protein of the gram-negative bacterium *Haemophilus influenza* B (WO 91/18926). A protein D derivative may comprise approximately the first third of the protein (e.g., the first N-terminal 100-110 amino acids), and a protein D derivative may be lipidated. Within certain embodiments, the first 109 residues of a lipoprotein D fusion partner is included on the N-terminus to provide the polypeptide with additional exogenous T-cell epitopes and to increase the expression level in *E. coli* (thus functioning as an expression enhancer). The lipid tail ensures optimal presentation of the antigen to antigen presenting cells. Other fusion partners include the non-structural protein from influenzae virus, NS1 (hemagglutinin). Typically, the N-terminal 81 amino acids are used, although different fragments that include T-helper epitopes may be used.

In another embodiment, the immunological fusion partner is the protein known as LYTA, or a portion thereof (preferably a C-terminal portion). LYTA is derived from *Streptococcus pneumoniae*, which synthesizes an N-acetyl-L-alanine amidase known as amidase LYTA (encoded by the *LytA* gene; *Gene* 43:265-292 (1986)). LYTA is an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LYTA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been exploited for the development of *E. coli* C-LYTA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LYTA fragment at the amino terminus has been described (*see Biotechnology* 10:795-798 (1992)).

Within a preferred embodiment, a repeat portion of LYTA may be incorporated into a fusion protein. A repeat portion is found in the C-terminal region starting at residue 178. A particularly preferred repeat portion incorporates residues 188-305.

In general, polypeptides (including fusion proteins) and polynucleotides as described herein are isolated. An "isolated" polypeptide or polynucleotide is one that is removed from its original environment. For example, a naturally-occurring protein is isolated if it is separated from some or all of the coexisting materials in the natural system. Preferably, such polypeptides are at least about 90% pure, more preferably at least about 95% pure and most preferably at least about 99% pure. A polynucleotide is considered to be isolated if, for example, it is cloned into a vector that is not a part of the natural environment.

T CELLS

Immunotherapeutic compositions may also, or alternatively, comprise T cells specific for a *Chlamydia* antigen. Such cells may generally be prepared *in vitro* or *ex vivo*, using standard procedures. For example, T cells may be isolated from bone marrow, peripheral blood, or a fraction of bone marrow or peripheral blood of a patient, using a commercially available cell separation system, such as the Isolex™ System, available from Nexell Therapeutics, Inc. (Irvine, CA; see also U.S. Patent No. 5,240,856; U.S. Patent No. 5,215,926; WO 89/06280; WO 91/16116 and WO 92/07243). Alternatively, T cells may be derived from related or unrelated humans, non-human mammals, cell lines or cultures.

T cells may be stimulated with a polypeptide of the invention, polynucleotide encoding such a polypeptide, and/or an antigen presenting cell (APC) that expresses such a polypeptide. Such stimulation is performed under conditions and for a time sufficient to permit the generation of T cells that are specific for the polypeptide. Preferably, the polypeptide or polynucleotide is present within a delivery vehicle, such as a microsphere, to facilitate the generation of specific T cells.

T cells are considered to be specific for a polypeptide of the invention if the T cells specifically proliferate, secrete cytokines or kill target cells coated with the polypeptide or expressing a gene encoding the polypeptide. T cell specificity may be evaluated using any of a variety of standard techniques. For example, within a chromium release assay or proliferation assay, a stimulation index of more than two fold increase in lysis and/or proliferation, compared to negative controls, indicates T cell specificity. Such assays may be performed, for example, as described in Chen *et al.*, *Cancer Res.* 54:1065-1070 (1994)). Alternatively, detection of the proliferation of T cells may be accomplished by a variety of known techniques. For example, T cell proliferation can be detected by measuring an increased rate of DNA synthesis (e.g., by pulse-labeling cultures of T cells with tritiated thymidine and measuring the amount of tritiated thymidine incorporated into DNA). Contact with a polypeptide of the invention (100 ng/ml - 100 µg/ml, preferably 200 ng/ml - 25 µg/ml) for 3 - 7 days should result in at least a two fold increase in proliferation of the T cells. Contact as described above for 2-3 hours should result in

activation of the T cells, as measured using standard cytokine assays in which a two fold increase in the level of cytokine release (e.g., TNF or IFN- γ) is indicative of T cell activation (*see Coligan et al., Current Protocols in Immunology*, vol. 1 (1998)). T cells that have been activated in response to a polypeptide, polynucleotide or polypeptide-expressing APC may be CD4⁺ and/or CD8⁺. Protein-specific T cells may be expanded using standard techniques. Within preferred embodiments, the T cells are derived from a patient, a related donor or an unrelated donor, and are administered to the patient following stimulation and expansion.

For therapeutic purposes, CD4⁺ or CD8⁺ T cells that proliferate in response to a polypeptide, polynucleotide or APC can be expanded in number either *in vitro* or *in vivo*.

Proliferation of such T cells *in vitro* may be accomplished in a variety of ways. For example, the T cells can be re-exposed to a polypeptide, or a short peptide corresponding to an immunogenic portion of such a polypeptide, with or without the addition of T cell growth factors, such as interleukin-2, and/or stimulator cells that synthesize the polypeptide. Alternatively, one or more T cells that proliferate in the presence of the protein can be expanded in number by cloning.

Methods for cloning cells are well known in the art, and include limiting dilution.

DIAGNOSTIC METHODS

Prior infection of an individual by *Chlamydia* will often be detectable by ELISA. Individuals carrying *Chlamydia* specific antibodies ('seropositive') having been infected previously. However, it is not uncommon for individuals who have been infected by *Chlamydia* previously to be found to be seronegative upon testing, i.e. no *Chlamydia* specific antibodies may be detected. As a result of the prior infection, despite testing seronegative, such individuals respond strongly to restimulation by Chlamydial antigens (relative to seronegative individuals which have not previously been infected), in particular to the various *Chlamydial* antigen combinations which have been described previously herein.

Therefore, in a further aspect of the present invention there is provided a method for determining prior Chlamydial infection in an individual comprising:

- (i) obtaining a sample from the individual;
- (ii) contacting said sample with a combination of two or more Chlamydia proteins or immunogenic fragments thereof or a polynucleotide or polynucleotides encoding them, said two or more proteins or immunogenic fragments selected from Swib, Momp, Ct-858, Ct-875, Ct-622, Ct-089, passenger domain of PmpG (PmpGpd) and passenger domain of PmpD (PmpDpd);
- (iii) quantifying the sample response.

The sample may for example be whole blood or purified cells. Suitably the sample will contain peripheral blood mononucleated cells (PBMC). In one embodiment of the invention the individual will be seropositive. In a second embodiment of the invention the individual will be seronegative.

The sample response may be quantified by a range of means known to those skilled in the art, including the monitoring of lymphocyte proliferation or the production of specific cytokines or antibodies in the presence of the combination of Chlamydial antigens. For example, T-cell ELISPOT may be used to monitor cytokines such as interferon gamma (IFN γ), interleukin 2 (IL2) and interleukin 5 (IL5). B-cell ELLISPOT may be used to monitor the stimulation of *Chlamydia* specific antigens.

Methods of quantifying sample response are illustrated in the Examples herein (specifically Example 9). When using such method, a positive response to an antigen may be defined by a signal to noise ratio (S/N ratio) of at least 2:1 (for example, at least 3:1).

In a further aspect of the present invention methods are provided for using one or more of the antigen combinations (or immunogenic fragments thereof or nucleotides encoding them) described above to diagnose prior Chlamydial infection using a skin test. As used herein, a "skin test" is any assay performed directly on a patient in which a delayed-type hypersensitivity (DTH) reaction (such as swelling, reddening or dermatitis) is measured following intradermal injection of an antigen combination (or immunogenic fragments thereof or nucleotides encoding them) as described above. Such injection may be achieved using any suitable device sufficient to contact the antigen combinations with dermal cells of the patient, such as a tuberculin syringe or 1 mL syringe. The reaction is measured after a period of time, for example at least 48 hours after injection, especially 48-72 hours.

The DTH reaction is a cell-mediated immune response, which is greater in patients that have been exposed previously to the test antigen. The response may be measured visually, using a ruler. In general, a response that is greater than about 0.5 cm in diameter, especially greater than about 1.0 cm in diameter, is a positive response, indicative of prior Chlamydial infection, which may or may not be manifested as an active disease.

For use in a skin test, the combinations of this invention are suitably formulated as pharmaceutical compositions containing a physiologically acceptable carrier. Suitably, the

carrier employed in such pharmaceutical compositions is a saline solution with appropriate preservatives, such as phenol and/or Tween 80™.

PHARMACEUTICAL COMPOSITIONS

5 In additional embodiments, the present invention concerns formulation of the polynucleotide, polypeptide, T-cell and/or antibody compositions disclosed herein in pharmaceutically-acceptable or physiologically-acceptable solutions for administration to a cell or an animal, either alone, or in combination with one or more other modalities of therapy. Such compositions are also useful for diagnostic uses.

10 It will also be understood that, if desired, the nucleic acid segments, RNA, DNA or PNA compositions that express a composition of polypeptides as disclosed herein may be administered in combination with other agents as well, such as, e.g., other proteins or polypeptides or various pharmaceutically-active agents. In fact, there is virtually no limit to other components that may also be included, given that the additional agents do not cause a
15 significant adverse effect upon contact with the target cells or host tissues. The compositions may thus be delivered along with various other agents as required in the particular instance. Such compositions may be purified from host cells or other biological sources, or alternatively may be chemically synthesized as described herein. Likewise, such compositions may further comprise substituted or derivatized RNA or DNA compositions.

20 Formulation of pharmaceutically-acceptable excipients and carrier solutions is well-known to those of skill in the art, as is the development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens, including e.g., oral, parenteral, intravenous, intranasal, and intramuscular administration and formulation. Other routes of administration include via the mucosal surfaces,
25 for example intravaginal administration.

1. ORAL DELIVERY

 In certain applications, the pharmaceutical compositions disclosed herein may be delivered *via* oral administration to an animal. As such, these compositions may be formulated
30 with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft-shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.

 The active compounds may even be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the
35 like (Mathiowitz *et al.*, 1997; Hwang *et al.*, 1998; U. S. Patent 5,641,515; U. S. Patent 5,580,579 and U. S. Patent 5,792,451, each specifically incorporated herein by reference in its entirety).

The tablets, troches, pills, capsules and the like may also contain the following: a binder, as gum tragacanth, acacia, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin. 5 may be added or a flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar, or both. A syrup or elixir may contain the active compound sucrose as a 10 sweetening agent methyl and propylparabens as preservatives, a dye and flavoring, such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compounds may be incorporated into sustained-release preparation and formulations.

Typically, these formulations may contain at least about 0.1% of the active compound or 15 more, although the percentage of the active ingredient(s) may, of course, be varied and may conveniently be between about 1 or 2% and about 60% or 70% or more of the weight or volume of the total formulation. Naturally, the amount of active compound(s) in each therapeutically useful composition may be prepared in such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half- 20 life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.

For oral administration the compositions of the present invention may alternatively be incorporated with one or more excipients in the form of a mouthwash, dentifrice, buccal tablet, 25 oral spray, or sublingual orally-administered formulation. For example, a mouthwash may be prepared incorporating the active ingredient in the required amount in an appropriate solvent, such as a sodium borate solution (Dobell's Solution). Alternatively, the active ingredient may be incorporated into an oral solution such as one containing sodium borate, glycerin and potassium bicarbonate, or dispersed in a dentifrice, or added in a therapeutically-effective amount to a 30 composition that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants. Alternatively the compositions may be fashioned into a tablet or solution form that may be placed under the tongue or otherwise dissolved in the mouth.

2. INJECTABLE DELIVERY

35 In certain circumstances it will be desirable to deliver the pharmaceutical compositions disclosed herein parenterally, intravenously, intramuscularly, or even intraperitoneally as described in U. S. Patent 5,543,158; U. S. Patent 5,641,515 and U. S. Patent 5,399,363 (each

specifically incorporated herein by reference in its entirety). Solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (U. S. Patent 5,466,468, specifically incorporated herein by reference in its entirety). In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be facilitated by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, a sterile aqueous medium that can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion (see, e.g., *Remington's Pharmaceutical Sciences*, 15th Edition, pp. 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, and the general safety and purity standards as required by FDA Office of Biologics standards.

Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated

above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

The compositions disclosed herein may be formulated in a neutral or salt form. Pharmaceutically-acceptable salts, include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms such as injectable solutions, drug-release capsules, and the like.

As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

The phrase "pharmaceutically-acceptable" refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human. The preparation of an aqueous composition that contains a protein as an active ingredient is well understood in the art. Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The preparation can also be emulsified.

3. MUCOSAL DELIVERY

(i) Nasal Delivery

In certain embodiments, the pharmaceutical compositions may be delivered by intranasal sprays, inhalation, and/or other aerosol delivery vehicles. Methods for delivering genes, nucleic acids, and peptide compositions directly to the lungs via nasal aerosol sprays has been described e.g., in U. S. Patent 5,756,353 and U. S. Patent 5,804,212 (each

specifically incorporated herein by reference in its entirety). Likewise, the delivery of drugs using intranasal microparticle resins (Takenaga *et al.*, 1998) and lysophosphatidyl-glycerol compounds (U. S. Patent 5,725,871, specifically incorporated herein by reference in its entirety) are also well-known in the pharmaceutical arts. Likewise, transmucosal drug delivery in the form of a polytetrafluoroethylene support matrix is described in U. S. Patent 5,780,045 (specifically incorporated herein by reference in its entirety).

(ii) *Intravaginal Delivery*

In other embodiments of the invention the pharmaceutical compositions may be formulated for intravaginal delivery. Such formulations may be prepared as liquids, semi-solids or solids (including for example, creams, ointments, gels etc), or may be contained within a physical delivery system such as a pessary, sponge, vaginal ring or film.

(iii) *Ocular Delivery*

In further embodiments of the invention the pharmaceutical compositions may be formulated for ocular delivery. Such formulations will desirably be clear and colorless.

5. *LIPOSOME-, NANOCAPSULE-, AND MICROPARTICLE-MEDIATED DELIVERY*

In certain embodiments, the inventors contemplate the use of liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, and the like, for the introduction of the compositions of the present invention into suitable host cells. In particular, the compositions of the present invention may be formulated for delivery either encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, or a nanoparticle or the like.

Such formulations may be preferred for the introduction of pharmaceutically-acceptable formulations of the nucleic acids or constructs disclosed herein. The formation and use of liposomes is generally known to those of skill in the art (see for example, Couvreur *et al.*, 1977; Couvreur, 1988; Lasic, 1998; which describes the use of liposomes and nanocapsules in the targeted antibiotic therapy for intracellular bacterial infections and diseases). Recently, liposomes were developed with improved serum stability and circulation half-times (Gabizon & Papahadjopoulos, 1988; Allen and Choun, 1987; U. S. Patent 5,741,516, specifically incorporated herein by reference in its entirety). Further, various methods of liposome and liposome like preparations as potential drug carriers have been reviewed (Takakura, 1998; Chandran *et al.*, 1997; Margalit, 1995; U. S. Patent 5,567,434; U. S. Patent 5,552,157; U. S. Patent 5,565,213; U. S. Patent 5,738,868 and U. S. Patent 5,795,587, each specifically incorporated herein by reference in its entirety).

Liposomes have been used successfully with a number of cell types that are normally resistant to transfection by other procedures including T cell suspensions, primary hepatocyte cultures and PC 12 cells (Renneisen *et al.*, 1990; Muller *et al.*, 1990). In addition, liposomes are free of the DNA length constraints that are typical of viral-based delivery systems. Liposomes

have been used effectively to introduce genes, drugs (Heath & Martin, 1986; Heath *et al.*, 1986; Balazsovits *et al.*, 1989; Fresta & Puglisi, 1996), radiotherapeutic agents (Pikul *et al.*, 1987), enzymes (Imaizumi *et al.*, 1990a; Imaizumi *et al.*, 1990b), viruses (Faller & Baltimore, 1984), transcription factors and allosteric effectors (Nicolau & Gersonde, 1979) into a variety of
 5 cultured cell lines and animals. In addition, several successful clinical trials examining the effectiveness of liposome-mediated drug delivery have been completed (Lopez-Berestein *et al.*, 1985a; 1985b; Coune, 1988; Sculier *et al.*, 1988). Furthermore, several studies suggest that the use of liposomes is not associated with autoimmune responses, toxicity or gonadal localization after systemic delivery (Mori & Fukatsu, 1992).

10 Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs). MLVs generally have diameters of from 25 nm to 4 μ m. Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500 Å, containing an aqueous solution in the core.

15 Liposomes bear resemblance to cellular membranes and are contemplated for use in connection with the present invention as carriers for the peptide compositions. They are widely suitable as both water- and lipid-soluble substances can be entrapped, i.e. in the aqueous spaces and within the bilayer itself, respectively. It is possible that the drug-bearing liposomes may even be employed for site-specific delivery of active agents by selectively modifying the
 20 liposomal formulation.

In addition to the teachings of Couvreur *et al.* (1977; 1988), the following information may be utilized in generating liposomal formulations. Phospholipids can form a variety of structures other than liposomes when dispersed in water, depending on the molar ratio of lipid to water. At low ratios the liposome is the preferred structure. The physical characteristics of
 25 liposomes depend on pH, ionic strength and the presence of divalent cations. Liposomes can show low permeability to ionic and polar substances, but at elevated temperatures undergo a phase transition which markedly alters their permeability. The phase transition involves a change from a closely packed, ordered structure, known as the gel state, to a loosely packed, less-ordered structure, known as the fluid state. This occurs at a characteristic phase-transition
 30 temperature and results in an increase in permeability to ions, sugars and drugs.

In addition to temperature, exposure to proteins can alter the permeability of liposomes. Certain soluble proteins, such as cytochrome c, bind, deform and penetrate the bilayer, thereby causing changes in permeability. Cholesterol inhibits this penetration of proteins, apparently by packing the phospholipids more tightly. It is contemplated that the most useful liposome
 35 formations for antibiotic and inhibitor delivery will contain cholesterol.

The ability to trap solutes varies between different types of liposomes. For example, MLVs are moderately efficient at trapping solutes, but SUVs are extremely inefficient. SUVs

offer the advantage of homogeneity and reproducibility in size distribution, however, and a compromise between size and trapping efficiency is offered by large unilamellar vesicles (LUVs). These are prepared by ether evaporation and are three to four times more efficient at solute entrapment than MLVs.

5 In addition to liposome characteristics, an important determinant in entrapping compounds is the physicochemical properties of the compound itself. Polar compounds are trapped in the aqueous spaces and nonpolar compounds bind to the lipid bilayer of the vesicle. Polar compounds are released through permeation or when the bilayer is broken, but nonpolar compounds remain affiliated with the bilayer unless it is disrupted by temperature or exposure to lipoproteins. Both types show maximum efflux rates at the phase transition temperature.

10 Liposomes interact with cells via four different mechanisms: endocytosis by phagocytic cells of the reticuloendothelial system such as macrophages and neutrophils; adsorption to the cell surface, either by nonspecific weak hydrophobic or electrostatic forces, or by specific interactions with cell-surface components; fusion with the plasma cell membrane by insertion of the lipid bilayer of the liposome into the plasma membrane, with simultaneous release of liposomal contents into the cytoplasm; and by transfer of liposomal lipids to cellular or subcellular membranes, or vice versa, without any association of the liposome contents. It often is difficult to determine which mechanism is operative and more than one may operate at the same time.

20 The fate and disposition of intravenously injected liposomes depend on their physical properties, such as size, fluidity, and surface charge. They may persist in tissues for h or days, depending on their composition, and half lives in the blood range from min to several h. Larger liposomes, such as MLVs and LUVs, are taken up rapidly by phagocytic cells of the reticuloendothelial system, but physiology of the circulatory system restrains the exit of such large species at most sites. They can exit only in places where large openings or pores exist in the capillary endothelium, such as the sinusoids of the liver or spleen. Thus, these organs are the predominate site of uptake. On the other hand, SUVs show a broader tissue distribution but still are sequestered highly in the liver and spleen. In general, this *in vivo* behavior limits the potential targeting of liposomes to only those organs and tissues accessible to their large size.

30 These include the blood, liver, spleen, bone marrow, and lymphoid organs.

Targeting is generally not a limitation in terms of the present invention. However, should specific targeting be desired, methods are available for this to be accomplished. Antibodies may be used to bind to the liposome surface and to direct the antibody and its drug contents to specific antigenic receptors located on a particular cell-type surface. Carbohydrate determinants (glycoprotein or glycolipid cell-surface components that play a role in cell-cell recognition, interaction and adhesion) may also be used as recognition sites as they have potential in directing liposomes to particular cell types. Mostly, it is contemplated that

35

intravenous injection of liposomal preparations would be used, but other routes of administration are also conceivable.

Alternatively, the invention provides for pharmaceutically-acceptable nanocapsule formulations of the compositions of the present invention. Nanocapsules can generally entrap compounds in a stable and reproducible way (Henry-Michelland *et al.*, 1987; Quintanar-Guerrero *et al.*, 1998; Douglas *et al.*, 1987). To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 μm) should be designed using polymers able to be degraded *in vivo*. Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are contemplated for use in the present invention. Such particles may be easily made, as described (Couvreur *et al.*, 1980; 1988; zur Muhlen *et al.*, 1998; Zambaux *et al.* 1998; Pinto-Alphandry *et al.*, 1995 and U. S. Patent 5,145,684, specifically incorporated herein by reference in its entirety).

VACCINES

In certain preferred embodiments of the present invention, vaccines are provided. The vaccines will generally comprise one or more pharmaceutical compositions, such as those discussed above, in combination with an immunostimulant. An immunostimulant may be any substance that enhances or potentiates an immune response (including antibody and/or cell-mediated) to an exogenous antigen. Examples of immunostimulants include adjuvants, biodegradable microspheres (e.g., polylactic galactide) and liposomes (into which the compound is incorporated; *see, e.g.*, Fullerton, U.S. Patent No. 4,235,877). Vaccine preparation is generally described in, for example, Powell & Newman, eds., *Vaccine Design* (the subunit and adjuvant approach) (1995). Pharmaceutical compositions and vaccines within the scope of the present invention may also contain other compounds, which may be biologically active or inactive. For example, one or more immunogenic portions of other tumor antigens may be present, either incorporated into a fusion polypeptide or as a separate compound, within the composition or vaccine.

Illustrative vaccines may contain DNA encoding two or more of the polypeptides as described above, such that the polypeptides are generated *in situ*. As noted above, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Numerous gene delivery techniques are well known in the art, such as those described by Rolland, *Crit. Rev. Therap. Drug Carrier Systems* 15:143-198 (1998), and references cited therein. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal). Bacterial delivery systems involve the administration of a bacterium (such as *Bacillus-Calmette-Guerrin*)

that expresses an immunogenic portion of the polypeptide on its cell surface or secretes such an epitope. In a preferred embodiment, the DNA may be introduced using a viral expression system (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication competent virus. Suitable systems are disclosed, for example, in Fisher-Hoch *et al.*, *Proc. Natl. Acad. Sci. USA* 86:317-321 (1989); Flexner *et al.*, *Ann. N.Y. Acad. Sci.* 569:86-103 (1989); Flexner *et al.*, *Vaccine* 8:17-21 (1990); U.S. Patent Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89/01973; U.S. Patent No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91/02805; Berkner, *Biotechniques* 6:616-627 (1988); Rosenfeld *et al.*, *Science* 252:431-434 (1991); Kolls *et al.*, *Proc. Natl. Acad. Sci. USA* 91:215-219 (1994); Kass-Eisler *et al.*, *Proc. Natl. Acad. Sci. USA* 90:11498-11502 (1993); Guzman *et al.*, *Circulation* 88:2838-2848 (1993); and Guzman *et al.*, *Cir. Res.* 73:1202-1207 (1993).

Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA may also be "naked," as described, for example, in Ulmer *et al.*, *Science* 259:1745-1749 (1993) and reviewed by Cohen, *Science* 259:1691-1692 (1993).

The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells. It will be apparent that a vaccine may comprise both a polynucleotide and a polypeptide component. Such vaccines may provide for an enhanced immune response.

It will be apparent that a vaccine may contain pharmaceutically acceptable salts of the polynucleotides and polypeptides provided herein. Such salts may be prepared from pharmaceutically acceptable non-toxic bases, including organic bases (e.g., salts of primary, secondary and tertiary amines and basic amino acids) and inorganic bases (e.g., sodium, potassium, lithium, ammonium, calcium and magnesium salts).

While any suitable carrier known to those of ordinary skill in the art may be employed in the vaccine compositions of this invention, the type of carrier will vary depending on the mode of administration. Compositions of the present invention may be formulated for any appropriate manner of administration, including for example, topical, oral, nasal, intravenous, intracranial, intraperitoneal, subcutaneous or intramuscular administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a fat, a wax or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed. Biodegradable microspheres (e.g., polylactate polyglycolate) may also be employed as carriers for the pharmaceutical compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Patent Nos. 4,897,268; 5,075,109; 5,928,647; 5,811,128; 5,820,883; 5,853,763; 5,814,344 and 5,942,252. One may also employ a carrier comprising the

particulate-protein complexes described in U.S. Patent No. 5,928,647, which are capable of inducing a class I-restricted cytotoxic T lymphocyte responses in a host.

Such compositions may also comprise buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, bacteriostats, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide), solutes that render the formulation isotonic, hypotonic or weakly hypertonic with the blood of a recipient, suspending agents, thickening agents and/or preservatives. Alternatively, compositions of the present invention may be formulated as a lyophilizate. Compounds may also be encapsulated within liposomes using well known technology.

Any of a variety of immunostimulants may be employed in the vaccines of this invention. For example, an adjuvant may be included. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bordetella pertussis* or *Mycobacterium* species or *Mycobacterium* derived proteins. For example, delipidated, deglycolipidated *M. vaccae* ("pVac") can be used. In another embodiment, BCG is used as an adjuvant. In addition, the vaccine can be administered to a subject previously exposed to BCG. Suitable adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); CWS, TDM, Leif, aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF or interleukin-2, -7, or -12, may also be used as adjuvants.

Within the vaccines provided herein, the adjuvant composition may be designed to induce an immune response predominantly of the Th1 type. High levels of Th1-type cytokines (e.g., IFN- γ , TNF α , IL-2 and IL-12) tend to favor the induction of cell-mediated immune responses to an administered antigen. In contrast, high levels of Th2-type cytokines (e.g., IL-4, IL-5, IL-6 and IL-10) tend to favor the induction of humoral immune responses. Following application of a vaccine as provided herein, a patient will support an immune response that includes Th1- and Th2-type responses. Within one embodiment, in which a response is predominantly Th1-type, the level of Th1-type cytokines will increase to a greater extent than the level of Th2-type cytokines. The levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines, see Mosmann & Coffman, *Ann. Rev. Immunol.* 7:145-173 (1989).

Suitable adjuvants for use in eliciting a predominantly Th1-type response include, for example, a combination of monophosphoryl lipid A, for example 3-de-O-acylated

monophosphoryl lipid A (3D-MPL), together with an aluminum salt. MPL adjuvants are available from Corixa Corporation (Seattle, WA; see US Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094). CpG-containing oligonucleotides (in which the CpG dinucleotide is unmethylated) also induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and U.S. Patent Nos. 6,008,200 and 5,856,462. Immunostimulatory DNA sequences are also described, for example, by Sato *et al.*, *Science* 273:352 (1996). Another suitable adjuvant comprises a saponin, such as Quil A, or derivatives thereof, including QS21 and QS7 (Aquila Biopharmaceuticals Inc., Framingham, MA); Escin; Digitonin; or *Gypsophila* or *Chenopodium quinoa* saponins. Other suitable formulations include more than one saponin in the adjuvant combinations of the present invention, for example combinations of at least two of the following group comprising QS21, QS7, Quil A, β -escin, or digitonin.

Alternatively the saponin formulations may be combined with vaccine vehicles composed of chitosan or other polycationic polymers, polylactide and polylactide-co-glycolide particles, poly-N-acetyl glucosamine-based polymer matrix, particles composed of polysaccharides or chemically modified polysaccharides, liposomes and lipid-based particles, particles composed of glycerol monoesters, etc. The saponins may also be formulated in the presence of cholesterol to form particulate structures such as liposomes or ISCOMs. Furthermore, the saponins may be formulated together with a polyoxyethylene ether or ester, in either a non-particulate solution or suspension, or in a particulate structure such as a paucilamellar liposome or ISCOM. The saponins may also be formulated with excipients such as Carbopol[®] to increase viscosity, or may be formulated in a dry powder form with a powder excipient such as lactose.

In one embodiment, the adjuvant system includes the combination of a monophosphoryl lipid A and a saponin derivative, such as the combination of QS21 and 3D-MPL[®] adjuvant, as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol containing liposomes, as described in WO 96/33739. Other suitable formulations comprise an oil-in-water emulsion and tocopherol. Another suitable adjuvant formulation employing QS21, 3D-MPL[®] adjuvant and tocopherol in an oil-in-water emulsion is described in WO 95/17210.

Another enhanced adjuvant system involves the combination of a CpG-containing oligonucleotide and a saponin derivative particularly the combination of CpG and QS21 as disclosed in WO 00/09159. Preferably the formulation additionally comprises an oil in water emulsion and tocopherol.

Other suitable adjuvants include Montanide ISA 720 (Seppic, France), SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron), the SBAS series of adjuvants (SmithKline Beecham, Rixensart, Belgium), Detox (Corixa, Hamilton, MT), RC-529 (Corixa,

Hamilton, MT) and other aminoalkyl glucosaminide 4-phosphates (AGPs), such as those described in pending U.S. Patent Application Serial Nos. 08/853,826 and 09/074,720, the disclosures of which are incorporated herein by reference in their entireties, and polyoxyethylene ether adjuvants such as those described in WO 99/52549A1.

5 Other suitable adjuvants include adjuvant molecules of the general formula (I):



wherein, n is 1-50, A is a bond or $-\text{C}(\text{O})-$, R is C_{1-50} alkyl or Phenyl C_{1-50} alkyl.

10 A further adjuvant of interest is shiga toxin b chain, used for example as described in WO2005/112991.

One embodiment of the present invention consists of a vaccine formulation comprising a polyoxyethylene ether of general formula (I), wherein n is between 1 and 50, preferably 4-24, most preferably 9; the R component is C_{1-50} , preferably $\text{C}_4\text{-C}_{20}$ alkyl and most preferably C_{12} alkyl, and A is a bond. The concentration of the polyoxyethylene ethers should be in the range 0.1-20%, preferably from 0.1-10%, and most preferably in the range 0.1-1%. Preferred polyoxyethylene ethers are selected from the following group: polyoxyethylene-9-lauryl ether, polyoxyethylene-9-stearyl ether, polyoxyethylene-8-stearyl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether, and polyoxyethylene-23-lauryl ether. Polyoxyethylene ethers
15 such as polyoxyethylene lauryl ether are described in the Merck index (12th edition: entry 7717). These adjuvant molecules are described in WO 99/52549.

Any vaccine provided herein may be prepared using well known methods that result in a combination of antigen, immune response enhancer and a suitable carrier or excipient. The compositions described herein may be administered as part of a sustained release formulation
25 (i.e., a formulation such as a capsule, sponge or gel (composed of polysaccharides, for example) that effects a slow release of compound following administration). Such formulations may generally be prepared using well known technology (see, e.g., Coombes *et al.*, *Vaccine* 14:1429-1438 (1996)) and administered by, for example, oral, rectal or subcutaneous implantation, or by implantation at the desired target site. Sustained-release formulations may
30 contain a polypeptide, polynucleotide or antibody dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling membrane.

Carriers for use within such formulations are biocompatible, and may also be biodegradable; preferably the formulation provides a relatively constant level of active component release. Such carriers include microparticles of poly(lactide-co-glycolide),
35 polyacrylate, latex, starch, cellulose, dextran and the like. Other delayed-release carriers include supramolecular biovectors, which comprise a non-liquid hydrophilic core (e.g., a cross-linked polysaccharide or oligosaccharide) and, optionally, an external layer comprising an

amphiphilic compound, such as a phospholipid (see, e.g., U.S. Patent No. 5,151,254 and PCT applications WO 94/20078, WO/94/23701 and WO 96/06638). The amount of active compound contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.

5 Any of a variety of delivery vehicles may be employed within pharmaceutical compositions and vaccines to facilitate production of an antigen-specific immune response that targets tumor cells. Delivery vehicles include antigen presenting cells (APCs), such as dendritic cells, macrophages, B cells, monocytes and other cells that may be engineered to be efficient APCs. Such cells may, but need not, be genetically modified to increase the capacity for
10 presenting the antigen, to improve activation and/or maintenance of the T cell response, to have anti-tumor effects *per se* and/or to be immunologically compatible with the receiver (i.e., matched HLA haplotype). APCs may generally be isolated from any of a variety of biological fluids and organs, including tumor and peritumoral tissues, and may be autologous, allogeneic, syngeneic or xenogeneic cells.

15 Certain embodiments of the present invention use dendritic cells or progenitors thereof as antigen-presenting cells. Dendritic cells are highly potent APCs (Banchereau & Steinman, *Nature* 392:245-251 (1998)) and have been shown to be effective as a physiological adjuvant for eliciting prophylactic or therapeutic antitumor immunity (see Timmerman & Levy, *Ann. Rev. Med.* 50:507-529 (1999)). In general, dendritic cells may be identified based on their typical
20 shape (stellate *in situ*, with marked cytoplasmic processes (dendrites) visible *in vitro*), their ability to take up, process and present antigens with high efficiency and their ability to activate naïve T cell responses. Dendritic cells may, of course, be engineered to express specific cell-surface receptors or ligands that are not commonly found on dendritic cells *in vivo* or *ex vivo*, and such modified dendritic cells are contemplated by the present invention. As an alternative
25 to dendritic cells, secreted vesicles antigen-loaded dendritic cells (called exosomes) may be used within a vaccine (see Zitvogel *et al.*, *Nature Med.* 4:594-600 (1998)).

Dendritic cells and progenitors may be obtained from peripheral blood, bone marrow, tumor-infiltrating cells, peritumoral tissues-infiltrating cells, lymph nodes, spleen, skin, umbilical cord blood or any other suitable tissue or fluid. For example, dendritic cells may be
30 differentiated *ex vivo* by adding a combination of cytokines such as GM-CSF, IL-4, IL-13 and/or TNF α to cultures of monocytes harvested from peripheral blood. Alternatively, CD34 positive cells harvested from peripheral blood, umbilical cord blood or bone marrow may be differentiated into dendritic cells by adding to the culture medium combinations of GM-CSF, IL-3, TNF α , CD40 ligand, LPS, flt3 ligand and/or other compound(s) that induce differentiation,
35 maturation and proliferation of dendritic cells.

Dendritic cells are conveniently categorized as "immature" and "mature" cells, which allow a simple way to discriminate between two well characterized phenotypes. However, this

nomenclature should not be construed to exclude all possible intermediate stages of differentiation. Immature dendritic cells are characterized as APC with a high capacity for antigen uptake and processing, which correlates with the high expression of Fcγ receptor and mannose receptor. The mature phenotype is typically characterized by a lower expression of these markers, but a high expression of cell surface molecules responsible for T cell activation such as class I and class II MHC, adhesion molecules (e.g., CD54 and CD11) and costimulatory molecules (e.g., CD40, CD80, CD86 and 4-1BB).

APCs may generally be transfected with a polynucleotide encoding a protein (or portion or other variant thereof) such that the polypeptide, or an immunogenic portion thereof, is expressed on the cell surface. Such transfection may take place *ex vivo*, and a composition or vaccine comprising such transfected cells may then be used for therapeutic purposes, as described herein. Alternatively, a gene delivery vehicle that targets a dendritic or other antigen presenting cell may be administered to a patient, resulting in transfection that occurs *in vivo*. *In vivo* and *ex vivo* transfection of dendritic cells, for example, may generally be performed using any methods known in the art, such as those described in WO 97/24447, or the gene gun approach described by Mahvi *et al.*, *Immunology and Cell Biology* 75:456-460 (1997). Antigen loading of dendritic cells may be achieved by incubating dendritic cells or progenitor cells with the polypeptide, DNA (naked or within a plasmid vector) or RNA; or with antigen-expressing recombinant bacterium or viruses (e.g., vaccinia, fowlpox, adenovirus or lentivirus vectors). Prior to loading, the polypeptide may be covalently conjugated to an immunological partner that provides T cell help (e.g., a carrier molecule). Alternatively, a dendritic cell may be pulsed with a non-conjugated immunological partner, separately or in the presence of the polypeptide.

Vaccines and pharmaceutical compositions may be presented in unit-dose or multi-dose containers, such as sealed ampoules or vials. Such containers are preferably hermetically sealed to preserve sterility of the formulation until use. In general, formulations may be stored as suspensions, solutions or emulsions in oily or aqueous vehicles. Alternatively, a vaccine or pharmaceutical composition may be stored in a freeze-dried condition requiring only the addition of a sterile liquid carrier immediately prior to use.

DIAGNOSTIC KITS

The present invention further provides kits for use within any of the above diagnostic methods. Such kits typically comprise two or more components necessary for performing a diagnostic assay. Components may be compounds, reagents, containers and/or equipment. For example, one container within a kit may contain a monoclonal antibody or fragment thereof that specifically binds to a protein. Such antibodies or fragments may be provided attached to a support material, as described above. One or more additional containers may enclose

elements, such as reagents or buffers, to be used in the assay. Such kits may also, or alternatively, contain a detection reagent as described above that contains a reporter group suitable for direct or indirect detection of antibody binding.

Alternatively, a kit may be designed to detect the level of mRNA encoding a protein in a biological sample. Such kits generally comprise at least one oligonucleotide probe or primer, as described above, that hybridizes to a polynucleotide encoding a protein. Such an oligonucleotide may be used, for example, within a PCR or hybridization assay. Additional components that may be present within such kits include a second oligonucleotide and/or a diagnostic reagent or container to facilitate the detection of a polynucleotide encoding a protein of the invention.

Other diagnostics kits include those designed for the detection of cell mediated responses (which may, for example, be of use in the diagnostic methods of the present invention). Such kits will typically comprise:

- (i) apparatus for obtaining an appropriate cell sample from a subject;
- (ii) means for stimulating said cell sample with a combination of *Chlamydia* antigens according to the present invention (or immunogenic fragments thereof, or DNA encoding such antigens or fragments);
- (iii) means for detecting or quantifying the cellular response to stimulation.

Suitable means for quantifying the cellular response include a B-cell ELISPOT kit or alternatively a T-cell ELISPOT kit, which are known to those skilled in the art.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

EXAMPLES

The following examples are provided by way of illustration only and not by way of limitation. Those of skill in the art will readily recognize a variety of noncritical parameters that could be changed or modified to yield essentially similar results.

Example 1: Expression and purification of *Chlamydia trachomatis* recombinant proteins

Several *Chlamydia trachomatis* genes were cloned into plasmid incorporating a 6X histidine tag at the N-terminal to allow for expression and purification of recombinant protein.

Two full-length recombinant proteins, Ct-622 and Ct-875, were expressed in *E. coli*. Both of these genes were identified using CtL2 and CtE expression screening and the serovar E homologues were expressed. The primers used to amplify these genes were based on serovar L2/E sequences. The genes were amplified using serovar E genomic DNA as the template. Once amplified, the fragments were cloned in pET-17b with a N-terminal 6X-His Tag. After transforming the recombinant plasmid in XL-I blue cells, the DNA was prepared and the clones fully sequenced. The DNA was then transformed into the expression host BL21-pLysS (Novagen) for production of the recombinant proteins. The proteins were induced with IPTG and purified on Ni-NTA agarose using standard methods. The DNA sequences for CTE622 and CTE875 are disclosed in SEQ ID NO: 9 and 7 respectively, and their amino acid sequences are disclosed in SEQ ID NO: 10 and 8, respectively.

One full-length recombinant protein, Ct-089, was expressed in *E. coli*. The gene was identified using CtL2 expression screening but the serovar E homologue was expressed. The primers used to amplify this gene was based on serovar L2 sequence. The gene was amplified using serovar E genomic DNA as the template. Once amplified, the fragment was cloned in pET-17b with a N-terminal 6X-His Tag. After transforming the recombinant plasmid in XL-I blue cells, the DNA was prepared and the clone fully sequenced. The DNA was then transformed into the expression host BL21-pLysS cells (Novagen) for production of the recombinant proteins. The protein was induced with IPTG and purified on Ni-NTA agarose using standard methods.

One full-length recombinant protein, Ct-460, was expressed in *E. coli*. The gene was identified using CtL2 and CTE expression screening but the serovar L2 homologue was expressed. The primers used to amplify this gene was based on serovar L2 sequence. The genes were amplified using serovar L2 genomic DNA as the template. Once amplified, the fragment was cloned in pET-17b with a N-terminal 6X-His Tag. After transforming the recombinant plasmid in XL-I blue cells, the DNA was prepared and the clone fully sequenced. The DNA was then transformed into the expression host BL21-pLysE cells (Novagen) for production of the recombinant proteins. The protein was induced with IPTG and purified on Ni-NTA agarose using standard methods.

One full-length recombinant protein, Ct-858, was expressed in *E. coli*. The gene was identified using CtL2 and CTE expression screening but the serovar E homologue was expressed. The primers used to amplify this gene was based on serovar L2/E sequence. The genes were amplified using serovar E genomic DNA as the template. Once amplified, the fragment was cloned in pCRX2 with a N-terminal 6X-His Tag. After transforming the recombinant plasmid in XL-I blue cells, the DNA was prepared and the clone fully sequenced.

The DNA was then transformed into the expression host Tuner DE3 cells (Novagen) for production of the recombinant proteins. The protein was induced with IPTG and purified on Ni-NTA agarose using standard methods.

One full-length recombinant protein, Ct-681, was expressed in *E. coli*. The gene was identified using CtL2 and CTE expression screening but the serovar F homologue was expressed. *Clone/pET-15-construct was obtained from GSK (MompF)*. Once amplified, the fragment was cloned in pET-15b with a N-terminal 6X-His Tag. After transforming the recombinant plasmid in XL-I blue cells, the DNA was prepared and the clone fully sequenced. The DNA was then transformed into the expression host BL21-pLysS cells for production of the recombinant proteins. The protein was induced with IPTG and purified on Ni-NTA agarose using standard methods.

The passenger domain of two recombinant proteins, Ct-812 and Ct-871, were expressed in *E. coli*. Ct-812 was identified using CtL2 and CtE expression screening and Ct-871 was identified using CtE expression. For both genes the serovar L2 homologues were expressed. The primers used to amplify these genes were based on serovar L2 sequences. The genes were amplified using serovar L2 genomic DNA as the template. Once amplified, the fragments were cloned in pET-17b with a N-terminal 6X-His Tag. After transforming the recombinant plasmid in XL-I blue cells, the DNA was prepared and the clones fully sequenced. The DNA was then transformed into the expression host BL21-pLysS cells (Novagen) for production of the recombinant proteins. The proteins were induced with IPTG and purified on Ni-NTA agarose using standard methods.

Example 2: Formulation of five different combinations of *Chlamydia trachomatis* antigens with adjuvant

The antigen combinations in the table below were prepared as follows. 5 µg of each antigen was combined in 50 µl of PBS and then mixed with 50 µl AS01B adjuvant which comprises 3D-MPL and QS21 formulated with cholesterol containing liposomes, to a total volume per dose of 100 µl.

After mixing with the antigen the final composition of the adjuvant is:

3D-MPL	100 ug/ml
QS21	100 ug/ml
DOPC	2 mg/ml
Cholesterol	0.5 mg/ml

COMBO	Swib CT460	Momp CT681	Ct-858	Ct-875	Ct-622	Ct-089	PmpGpd CT871	PmpDpd CT812
1	X	X	X			X		X
1'	X		X			X		X
2	X	X	X		X	X		X
3		X	X		X	X	X	X
4			X	X	X	X		
5			X	X		X		
5'			X	X		X		X
6		X	X			X	X	X

Example 3: Testing of combinations of *Chlamydia trachomatis* antigens in a mouse model – immunization against Chlamydia genital tract infection

5 This example demonstrates that vaccination with *Chlamydia* antigen combinations as described in Example 2 can significantly protect against *Chlamydia* infection in mice.

A murine model of genital tract infection with human serovar K strain of *Chlamydia trachomatis* (Ct) was developed that closely resembles the pathology of infection in humans. This model was used to evaluate the effectiveness of immunizing mice with a number of combinations of Ct-specific antigens from different serovars. Specifically, Balb/c mice and C57Bl/6 mice were vaccinated with formulations of adjuvant combinations as described in Example 2. This model was also attempted with a third mouse strain, DBA, but this model did not allow protection against Ct challenge to be demonstrated either in the positive control (UV irradiated chlamydial elementary bodies (UEB) formulated in AS01B) or in mice vaccinated with the antigen combinations.

Two injections, separated by a three week time interval, were administered to the mice at the base of the tail. Four weeks following the final vaccination, the animals were treated with 1.25mg of progesterone prior to being intra-vaginally infected with 5×10^5 Inclusion Forming Units (IFU) of purified *Chlamydia trachomatis*, serovar K. Mice were immunized with 10 μ g UEB formulated in AS01B as a positive control and the adjuvant AS01B alone as a negative control. Seven days post-infection, the lower genital tracts were swabbed to determine bacterial shedding values by determining IFU using McCoy cells. In some experiments mice were sacrificed at day 10 post-infection and bacterial load in the upper genital tract was determined by homogenizing the UGT and determining IFU using McCoy cells.

As shown in Figures 1 and 2, vaccination of mice with combinations 1, 1', 2, 3, 4, 5, 5' or 6 shows the surprising result of offering significant protection ($p < 0.01$ - $p < 0.001$) against *Chlamydia* infection in a Balb/c mouse model. Furthermore, as shown in Figures 3 and 5 the protection results are confirmed in a second mouse protection model, C57Bl/6, vaccinated with combinations 1, 1', 5 and 5' and challenged with serovar K. ($p < 0.001$ Dunnet's multiple comparison test).

For better statistical analysis the day 7 shedding data from three experiments in Balb/c mice were pooled (Figure 1). The mean bacterial shedding in the UVEB-immunized groups was reduced by 1.8 log compared to the mean of the AS01B control group. The mean bacterial shedding in the UVEB-immunized groups was significantly lower when compared to all other tested groups (two-tailed t-test, $p < 0.05$). All antigen combinations significantly reduced the mean of bacterial shedding by approximately one log (0.8-1.1) when compared to the AS01B control group ($p < 0.01$; Dunnett's multiple comparison test). The statistical analysis did not detect any difference in the protection induced by the 6 antigen combinations (Tukey and t-test). Thus, immunizations of Balb/c mice with antigen combinations tested induced significant protection against bacterial shedding in the vaginal challenge model with serovar K.

Next, we initiated a set of back to back confirmation experiments in Balb/c and C57Bl/6 mice comparing the combinations 1 and 5 to the two modified versions of combination 1 and 5, combination 5' (adding PmpD-pd to combination 5) and combination 1' (taking MompF out of combination 1). Groups of 8 progesterone-treated Balb/c or C57Bl/6 mice were challenged with an intra-vaginal dose of 5×10^5 IFU of serovar K four weeks after the second immunization. The data for experiments in Balb/c mice are shown in Figure 2. Bacterial shedding was determined from swabs taken on day 7 post chlamydial challenge. Mice were sacrificed on day 10 to determine the chlamydial load in the UGT. The data of these experiments have been pooled together for statistical analysis (Figure 2). UVEB immunization protected 12 out of 16 mice completely against bacterial shedding in the lower genital tract (day 7 post challenge) and there were no *Chlamydia* detected in the UGT of 11 out of the 16 mice on day 10 post challenge. The medians of both, the bacterial shedding in the LGT and the bacterial load in the UGT, were reduced by at least 1 log in mice immunized with combination 1 or combination 5 when compared to the AS01B-only control. The modification (increase or reduction in number of antigens) of the composition of combination 1 and combination 5 (combination 1' and combination 5') did not improve protection. There were statistically significant differences between the means of bacterial shedding of all the groups when compared to the mean of the AS01B control group using the Dunnett's multiple comparison test with the following p values:

- AS01B vs. UVEB $p < 0.001$
- AS01B vs. combination 5 $p < 0.001$
- AS01B vs. combination 5' $p < 0.001$
- AS01B vs. combination 1 $p < 0.001$

- AS01B vs. combination 1' $p < 0.05$

Like in the previous confirmation experiments in Balb/c mice, the statistical analysis has not allowed to distinguish between the antigen combinations. Statistical analysis of the bacterial load in the UGT determined that only the median of the UVEB immunized group was significant lower than the median of the AS01B control group.

The bacterial shedding for the back to back experiments with combinations 1 and 5 in C57Bl/6 mice are shown in Figure 3. The data from the back to back experiments were pooled for statistical analysis. The experiments followed the Balb/c protocol. Bacterial shedding was determined from swabs taken on day 7 post chlamydial challenge. Immunization with the antigen combination 1, 1', 5 and 5' induced significant protection against shedding by 1 to 2 logs, respectively ($p < 0.001$; Dunnet's multiple comparison test). The statistical analysis did not determine any statistical significance between the bacterial shedding means of mice immunized with the combos.

For a final statistical analysis the data from the five confirmation experiments in Balb/c (31 mice per group) and three confirmation experiments in C57Bl/6 mice (21 mice per group) were pooled and are shown in Figures 4 and 5. The confirmation experiments demonstrated that the selected combinations 1 and 5 induce significant protection against bacterial shedding in both Balb/c ($p < 0.001$) and C57Bl/6 mice ($p < 0.001$). The data confirm that antigen combinations identified in the experimental design experiment in Balb/c mice also induce protection in C57Bl/6 mice. The data also show that immunizations with these combinations as well as immunizations with UVEB induce higher protection levels in C57Bl/6 mice than in Balb/c mice.

Example 4 – Ct-089, Ct-858 and Ct-875 Sequence Comparisons

Method

Chlamydia trachomatis serovar E is a common oculogenital serovar and was chosen as a basis to which the other sequences would be compared.

A multiple alignment of amino-acid sequences for comparison has been conducted using the CLUSTAL W program, available in the Lasergene software package, version 5.0 (sold by DNASTAR, Inc., Madison, WI)). The basic multiple alignment algorithm involves a three-step procedure: all pairs of sequences are aligned separately in order to calculate a distance matrix giving the divergence of each pair of sequences, then a guide tree is calculated from the distance matrix and finally the sequences are progressively aligned according to the guide tree.

CLUSTAL W algorithm is described in *Thompson et al., Nuc. Acids Res. 22: 4673-4680 (1994)*. The alignments are shown in Figures 6, 7a/7b and 8a/8b.

The T-helper cell epitopes are peptides bound to HLA class II molecules and recognized by T-helper cells. The prediction of putative T-helper cell epitopes, present on CT089, CT858 and CT875 *Chlamydia trachomatis* polypeptides from serovar E, was based on the TEPITOPE method described by *Sturniolo et al., Nature Biotech. 17:555-561 (1999)*. The peptides comprising good, potential T-cell epitopes are highlighted (grey boxes) in Figures 6, 7a/7b and 8a/8b.

Results

Figure 9 shows the results of comparison of Ct-089 sequences. Figure 10 shows the results of comparison of Ct-858 sequences. Figure 11 shows the results of comparison of Ct-875 sequences.

Ct-089 from *Chlamydia trachomatis* serovar E shows a high level of sequence identity to Ct-089 from *Chlamydia trachomatis* serovars A, B, D, G, H, I, J, K and L2. The minimum level of identity was 97.4%, with eight of the ten serovars having at least 98% identity. The ocular serovars A and B show particularly high identity to serovar E, with values of 99.5% and 99.8% respectively.

Ct-858 from *Chlamydia trachomatis* serovar E shows a very high level of sequence identity to Ct-858 from *Chlamydia trachomatis* serovars A, B, D, G, H, I, J, K and L2. The minimum level of identity was 99.7%, with ocular serovar J and LGV serovar L2 showing complete identity.

Ct-875 from *Chlamydia trachomatis* serovar E shows a high level of sequence identity to Ct-089 from *Chlamydia trachomatis* serovars A, B, D, G, H, I, J, K and L2. The minimum level of identity was 94.9%, with eight of the ten serovars having at least 98% identity.

For each of the three proteins Ct-089, Ct-858 and Ct-875, the percentage of HLA DRB1 predicted epitopes (for serovar E) which are fully conserved across all of the serovars tested is very high and estimated at 77%, 95% and 80%, respectively.

For comparative purposes, Figures 12, 13 and 14 show the sequence alignment for Ct-089, Ct-858 and Ct-875 from serovar E respectively with their equivalents from other *Chlamydia trachomatis* serovars and other *Chlamydia* species. Cpn indicates the corresponding sequence

from *Chlamydia pneumoniae*, MoPn indicates the corresponding sequence from *Chlamydia muridarum*.

Ct-089 (Serovar E) amino acid identity

Ct-089 (Serovar D)	99.8%
<i>C. pneumoniae</i> - CpN (SEQ ID No 78)	47.4%
<i>C. muridarum</i> - MoPn (SEQ ID No 74)	73.7%

5

Ct-858 (Serovar E) amino acid identity

Ct-858 (Serovar D)	99.8%
Ct-858 (Serovar L2)	99.8%
<i>C. pneumoniae</i> - CpN (SEQ ID No 40)	44.2%
<i>C. muridarum</i> - MoPn (SEQ ID No 36)	82.2%

Ct-875 (Serovar E) amino acid identity

Ct-875 (Serovar D)	98.5%
<i>C. muridarum</i> - MoPn (SEQ ID No 24)	52.3%

10 **Conclusion**

In summary, each of the three proteins Ct-089, Ct-858 and Ct-875 have highly conserved sequences across all of the *Chlamydia trachomatis* serovars tested.

Furthermore, the data indicates that there is no link between the degree of sequence variation and disease state associated with a particular serovar. For example, in the case of Ct-089, the oculogenital serovar E shows the highest homology to the ocular serovars A and B, while in the case of Ct-858, serovar E shows the highest homology to the oculogenital serovar J and LGV serovar L2.

15

Sequence homology of Ct-089, Ct-858 and Ct-875 with the equivalent proteins in other *Chlamydia* species is relatively low.

The antigenic properties of Ct-089, Ct-858 and Ct-875 have already been described in the prior art. However, contrary to the expectation of one skilled in the art, as a result of the low sequence variation, vaccines containing Ct-089, Ct-858 and Ct-875, immunogenic fragments thereof or polynucleotides encoding them, and which are derived from a first *Chlamydia trachomatis* serovar may be expected to be of use in the treatment or prevention of Chlamydial infection by a second *Chlamydia trachomatis* serovar.

Example 5 – Purification of *Chlamydia trachomatis* elementary bodies from servars D, E, J and K.

Purified elementary bodies were required for challenge of vaccine test subjects and for the preparation of UV irradiated elementary bodies (UVEB) which are used as a positive control vaccine in later examples.

Method

EB from each of the *Chlamydia trachomatis* serovars were prepared. Briefly, all serovars were grown separately in confluent McCoy cell monolayers and cultured in RPMI medium (75cm² culture flasks) that was supplemented with 1µg/ml of cycloheximide immediately before inoculation. Flasks were inoculated with non-purified lysates from infected cells containing ~10⁶ to 10⁷ Infectious Forming Units (IFU) in Sucrose Phosphate Glutamic Acid (SPG). Flasks were spun at 2000 rpm for 1 hour in a table-top cell culture centrifuge and then incubated for 48 or 72 hours at 37°C in a CO₂ atmosphere. This process was repeated until there were at least 20 flasks of highly infected cell populations (> 80% of cells were infected) ready for purification. *Chlamydia* elementary bodies were purified by ultracentrifugation over a series of Hypaque gradients (30%, 52%, 44% and 40%) with intervening washes in SPG.

Results

The titer of the purified EB for each *Chlamydia trachomatis* serovar was assessed using the *Chlamydia* titration infectivity assay and immunofluorescence microscopy (using FITC-conjugated anti-*C. trachomatis* antibody and Evan's Blue in PBS) to calculate the number of IFU per ml. Titers for the resulting purified EB were found to range from 1.2 x 10⁸ to 2.6 x 10⁹ IFU/ml

Example 6 – Expression and purification of Ct-089, Ct-858 and Ct-875 proteins

To prepare the test vaccines, stocks of purified *Chlamydia trachomatis* serovar E for use in later examples Ct-089, Ct-858 and Ct-875 proteins were prepared by expressing their genes in *E. coli*.

Method

- 5 Competent *E. coli* strains BL21 plys E, Tuner (DE3) and BL21 plys S were transformed with Ct-089, Ct-858 and Ct-875 expression plasmids respectively and grown on the appropriate antibiotic selection medium. The resulting expression clones were used in a mini-induction protocol, and protein yields analyzed by SDS-PAGE. If cells grew well during this process and proteins were induced by isopropyl-beta-D-thiogalactopyranoside (IPTG) in sufficient quantities
10 to be detected on Coomassie blue-stained SDS gels, the clones were used in a large-scale induction experiment (IPTG, 1 mM).

- Following lysis of cells in a CHAPS solution and centrifugation, aliquots of the soluble and pellet fractions were analyzed by SDS-PAGE to determine whether the majority of the protein of interest was in the pellet or soluble fraction. The fraction containing the majority of each antigen
15 was subjected to Ni-NTA column purification (after appropriate solubilisation of proteins). Aliquots of the preparations, including material from before Ni-NTA binding, column flow-through, column washes, and column elution fractions, were analyzed by SDS-PAGE. Fractions containing the eluted protein were combined, dialyzed against 10 mM Tris pH 8 or pH 10, filtered sterilized, and concentrated. The BCA protein assay was used on the concentrated
20 CT protein fractions, and purity was assessed by SDS-PAGE.

Example 7 – Evaluation of the protection induced by a vaccine containing Ct-089, Ct-858 and Ct-875 from *Chlamydia trachomatis* serovar E against challenge with *Chlamydia trachomatis* serovars D, K and J.

- The protection provided by a vaccine containing Ct-089, Ct-858 and Ct-875 *Chlamydia trachomatis* serovar E antigens was tested in vaginal challenge experiments with EB from
25 heterologous (i.e. non-serovar E) *Chlamydia trachomatis* serovars.

Method

- The study was conducted with 63 six-week old female C57Bl/6 mice. These mice were split into three groups of twenty-one mice, each group to be challenged by a different serovar
30 (*Chlamydia trachomatis* serovar D, K, or J). The groups were then further separated into sub-groups of seven mice each. These three sub-groups were immunised intramuscularly with 50

ul of different vaccine preparations injected into each anterior tibialis (100 ul total), and repeated three weeks later. Mice were further treated with progesterone, 1.25 mg given in a volume of 100 ul by subcutaneous injection ten and three days before challenge to synchronise their cycles. The three test preparations were:

5 (i) Adjuvant control (AS01B)

The adjuvant utilised was based upon a liposomal formulation containing 3D-MPL, QS21 and cholesterol. The final composition of the adjuvant solution being:

	3D-MPL	100 ug/ml
	QS21	100 ug/ml
10	DOPC	2 mg/ml
	Cholesterol	0.5 mg/ml

Phosphate buffered saline was prepared from 9 mM Na₂HPO₄, 48 mM KH₂PO₄ and 100 mM NaCl at pH 6.1.

15 A mixture of lipid, cholesterol and 3D-MPL was prepared in organic solvent, this was then dried under vacuum. PBS was then added and the vessel agitated until a suspension formed. This suspension was then microfluidised until a liposome size of around 100 nm was obtained (referred to as small unilamellar vesicles or SUV). Subsequently, the SUV were sterilized by passage through a 0.2 um filter.

20 Sterile SUV were mixed with the appropriate quantity of aqueous QS21 (at a concentration of 2 mg/ml) with the addition of phosphate buffered saline to obtain the final desired concentrations. The pH was then adjusted to 6.1 (+/- 0.1) as necessary using sodium hydroxide or hydrochloric acid.

(ii) UV attenuated *Chlamydia trachomatis* elementary bodies with AS01B adjuvant

25 A preparation containing 10 ug of UV treated *Chlamydia trachomatis* elementary bodies (UVEB) from serovar E with adjuvant (as described above).

(iii) Ct-089, Ct-858 and Ct-875 with AS01B adjuvant

A preparation containing Ct-089 (5 ug), Ct-858 (5ug) and Ct-875 (5ug) from *Chlamydia trachomatis* serovar E with adjuvant (as described above).

Mice were challenged, under anaesthetic (1:1 Ketaject and Xylaject), four weeks after final boost with 1×10^8 IFU of serovar D, K or J suspended in 20 μ l of sucrose phosphate glutamic acid (SPG).

5 The infection was allowed to proceed for 10 days, with genital swabs were taken under anaesthetic on Day 4 and Day 7. Mice were euthanized on Day 10 and the uterine horns harvested for histopathology and titration. For titration, one-half of the UGT was homogenized, and IFU was determined using McCoy cells.

10 Samples (vaginal swabs) collected from days 4, 7, and 10 post-challenge were thawed at 37°C. A small amount of glass beads (Sigma) was added to each sample and vortexed for five minutes in 1 ml of SPG. 100 μ l of each sample was inoculated onto a monolayer of McCoy cells in medium containing 1 μ g/ml cyclohexamide in a 24-well plate. Plates were spun at 2000 rpm for one hour before being transferred to a 37°C incubator. Time of incubation is 48-72 hours before fixation.

15 After incubation, methanol that had been pre-chilled at -20°C was used to fix the cells. Each well was filled with methanol and left at -20°C for at least 10 minutes. Plates were then washed with PBS three times before staining with Goat anti-chlamydia trachomatis FITC conjugated polyclonal antibody (Chemicon). The stain solution consisted of Evan's Blue Stain (Sigma), FITC-conjugated anti-C.trachomatis antibody, and PBS. Evan's Blue stain was diluted 1:200 in PBS, and FITC-conjugated anti-C.trachomatis antibody was diluted at 1:100. 500 μ l of the stain
20 solution was added to each well. Plates were then incubated at 37°C for 1.5 – 2 hours.

After the incubation period, the stain was aspirated and the plates were washed with PBS five times on a rocking platform, each time for at least 5 minutes. After the final wash, 1ml of PBS was added to each well, and the plates were ready to be titrated.

25 There were three methods used for calculating the number of IFU per swab. The primary way consisted of counting 10 random fields under a fluorescence microscope and then using the following formula(s):

$n \times 10 \times 190$ (using objective lens 10X)

$n \times 10 \times 283$ (using objective lens 20X)

$n \times 10 \times 1180$ (using objective lens 40X)

30 where n = mean of inclusion bodies counted in 10 random fields, 10 is the dilution factor, and 190, 283 and 1180 are the respective focal conversion factors.

The following method was used when low numbers of inclusion bodies were seen in an entire well:

$$s \times 10$$

where s = number of inclusion bodies counted in a well and 10 is the dilution factor.

- 5 Finally, when no inclusion bodies were seen, an arbitrary value of 7 was chosen to represent IFU/swab. This was based on the assumption that although no inclusion bodies were detected in a tenth of the swab, that did not necessarily mean that there were no inclusion bodies in the entire swab.

Results

- 10 Figures 15 to 17 illustrate the results of Example 7.

Figure 15 indicates that four days after challenge, mice immunised with Ct-089, Ct-858 and Ct-875 according to the present invention show lower levels of shedding compared to the adjuvant control. Furthermore, levels of shedding are generally comparable to those achieved with immunisation by UVEB (lower levels are achieved in the case of serovar K challenge, and
15 higher levels in the case of serovar D challenge).

Seven days after challenge mice receiving the adjuvant control show higher levels of shedding than those immunised with UVEB or with Ct-089, Ct-858 and Ct-875 (see Figure 16). Both UVEB and Ct-089, Ct-858 and Ct-875 immunised mice show very low levels of shedding.

- 20 Figure 17 shows that ten days after challenge the UGT of mice receiving the adjuvant control is highly colonised by bacteria. Both UVEB and Ct-089, Ct-858 and Ct-875 immunised mice show low levels of UGT colonisation, with treatment according to the invention generally showing a slightly lower level than UVEB treatment.

- 25 Statistical analysis indicates that treatment using the Ct-089, Ct-858 and Ct-875 antigens from *Chlamydia trachomatis* serovar E results in significant protection in mice challenged with *Chlamydia trachomatis* serovar J when compared to the negative control (adjuvant only) with $p < 0.01$ by Dunnett's multiple comparison test. No significant difference is seen between antigen treatment and UVEB treatment ($p > 0.05$).

Treatment using the Ct-089, Ct-858 and Ct-875 antigens from *Chlamydia trachomatis* serovar E results in significant protection in mice challenged with *Chlamydia trachomatis* serovar D on Day 4 and Day 7 when compared to the negative control (adjuvant only) with $p < 0.05$. No significant difference is seen between antigen treatment and UVEB treatment ($p > 0.05$).

- 5 Treatment using the Ct-089, Ct-858 and Ct-875 antigens from *Chlamydia trachomatis* serovar E results in significant protection in mice challenged with *Chlamydia trachomatis* serovar K on Day 4 and Day 10 when compared to the negative control (adjuvant only) with $p < 0.05$ and $p < 0.01$ respectively. No significant difference is seen between antigen treatment and UVEB treatment ($p > 0.05$).

10 Conclusions

The experiments performed in Example 7 confirm that the combination of the three proteins, Ct-089, Ct-858 and Ct-875 from *Chlamydia trachomatis* serovar E is capable of eliciting a substantial protective response, which has been shown to be statistically significant. This protective response is one which can provide general protection against challenge by other
15 serovars. In particular, it should be noted that serovars E and K are the most genetically diverse *Chlamydia trachomatis* serovars and the cross-protection observed between these two *Chlamydia trachomatis* serovars suggests that a combination of Ct-089, Ct-858 and Ct-875 antigens may be expected to have wide use in the treatment or prevention of *Chlamydia* infection.

- 20 The level of protection afforded by the vaccine formulation containing Ct-089, Ct-858 and Ct-875 was found to be comparable to the use of UVEB, although clearly the use of purified proteins is desirable in light of the risks involved with the use of the whole elementary bodies.

25 **Example 8 – Evaluation of the protection induced by a vaccine containing Ct-089, Ct-858 and Ct-875 from *Chlamydia trachomatis* serovar E against challenge with serovars K and J, in the highly susceptible mouse strain C3H/HeN**

The protection provided by a vaccine containing Ct-089, Ct-858 and Ct-875 serovar E antigens was tested in vaginal challenge experiments with EB from heterologous (i.e. non-serovar E) *Chlamydia trachomatis* serovars K and J.

Method

The study was conducted with 41 fifteen-week old female C3H/HeN mice, a strain known for their susceptibility to chlamydial infection. These mice were split into two groups, one of which was challenged by *Chlamydia trachomatis* serovar K and the other by serovar J. The groups were then further separated into three sub-groups, these sub-groups were immunised intramuscularly with 50 ul of different vaccine preparations injected into each anterior tibialis (100 ul total), and repeated four weeks later. Each sub-group contained seven mice, save for the group immunised with adjuvant control and challenged with serovar K which contained 6 mice. Mice were further treated with progesterone, 1.25 mg given in a volume of 100 ul by subcutaneous injection ten and three days before challenge to synchronise their cycles. The three test preparations were:

(i) Adjuvant control (AS01B)

The adjuvant utilised was based upon a liposomal formulation containing 3D-MPL, QS21 and cholesterol. The final composition of the adjuvant solution being:

3D-MPL	100 ug/ml
QS21	100 ug/ml
DOPC	2 mg/ml
Cholesterol	0.5 mg/ml

Adjuvant was prepared as described above in Example 7.

(ii) UV attenuated *Chlamydia trachomatis* elementary bodies with AS01B adjuvant

A preparation containing 10 ug of UV treated *Chlamydia trachomatis* elementary bodies (UVEB) from serovar E with adjuvant (as described above).

(iii) Ct-089, Ct-858 and Ct-875 with AS01B adjuvant

A preparation containing Ct-089 (5 ug), Ct-858 (5ug) and Ct-875 (5ug) from *Chlamydia trachomatis* serovar E with adjuvant (as described above).

Mice were challenged, under anaesthetic (1:1 Ketaject and Xylaject, 30 ul per mouse IP, 20 ul into each thigh), four weeks after final boost with 1×10^6 IFU of serovar K or J suspended in 20 ul of sucrose phosphate glutamic acid (SPG).

The infection was allowed to proceed for 10 days, with genital swabs were taken under anaesthetic on Day 4 and Day 7. Mice were euthanized on Day 10 and the uterine horns harvested for histopathology and titration. For titration, one-half of the UGT was homogenized, and IFU was then determined using McCoy cells as described in Example 7.

- 5 The detection limit for titering is 10 IFU, thus one inclusion per well is plotted as 10 IFU. An arbitrary number of 7 IFU was allocated where the number of inclusions observed was less than one.

Results

Figures 18 to 20 illustrate the results of Example 8.

- 10 Figure 18 indicates that four days after challenge with either *Chlamydia trachomatis* serovar K or J, mice immunised with Ct-089, Ct-858 and Ct-875 from *Chlamydia trachomatis* serovar E show lower levels of shedding compared to the adjuvant control. Furthermore, levels of shedding are comparable to those achieved with immunisation by UVEB.

- 15 Seven days after challenge mice receiving the adjuvant control show higher levels of shedding than those immunised with UVEB or with Ct-089, Ct-858 and Ct-875 (see Figure 19). Both UVEB and Ct-089, Ct-858 and Ct-875 immunised mice show very low levels of shedding.

Figure 20 shows that ten days after challenge with either *Chlamydia trachomatis* serovar K or J the UGT of mice receiving the adjuvant control is highly colonised by bacteria. Both UVEB and Ct-089, Ct-858 and Ct-875 immunised mice show low levels of UGT colonisation.

- 20 Statistical analysis indicates that treatment using the Ct-089, Ct-858 and Ct-875 antigens from *Chlamydia trachomatis* serovar E results in significant protection in mice challenged with serovar J when compared to the negative control (adjuvant only) with $p < 0.01$. No significant difference is seen between antigen treatment and UVEB treatment ($p > 0.05$).

- 25 Treatment using the Ct-089, Ct-858 and Ct-875 antigens from *Chlamydia trachomatis* serovar E results in significant protection in mice challenged with serovar K on Day 7 and Day 10 when compared to the negative control (adjuvant only) with $p < 0.05$ and $p < 0.01$ respectively. No significant difference is seen between antigen treatment and UVEB treatment ($p > 0.05$).

Conclusions

The experiments performed in Example 8 confirm that the three proteins, Ct-089, Ct-858 and Ct-875 from *Chlamydia trachomatis* serovar E are capable of eliciting a substantial protective immune response, which has been shown to be statistically significant. The protection elicited is one which provides general protection against challenge by other serovars.

- 5 The level of protection afforded by the vaccine formulation containing Ct-089, Ct-858 and Ct-875 was found to be comparable to the use of UVEB, although clearly the use of purified proteins is desirable in light of the risks involved with the use of the whole elementary bodies.

Example 9 – Response of seropositive individuals to stimulation by Chlamydial antigens.

- 10 The response of seropositive subjects to a number of Chlamydial antigens was examined to investigate which *Chlamydia trachomatis* antigens may be of particular importance in the normal immune response of humans to *Chlamydia trachomatis* infection.

Method

Three subject groups from different locations were involved in the study:

- 15 (i) 25 pregnant women who were IgG positive for *Chlamydia trachomatis* (referred to as BR)
- (ii) 19 women who were IgG or PCR positive for *Chlamydia trachomatis* (referred to as AN)
- (iii) 16 individuals of mixed sex (referred to as CR) -
 - 20 (a) seven patients who were treated for genital *Chlamydia trachomatis* infection, identified by Ligase chain reaction and serum titer
 - (b) nine non-shedding donors with no history of chlamydial disease, identified by T-cell responses to chlamydial antigens and were not shedding at the time of recruitment to the study. *Chlamydia trachomatis* IFN-gamma and *Chlamydia pneumoniae* IFN-gamma response was determined by stimulating 0.3×10^6
25 PBMC with 1 ug/ml of the respective chlamydial elementary body. Supernatants were taken after 72h and analysed by IFN-gamma specific ELISA.

Serology was performed using IgG and IgM complement binding tests supplied by Virion-Serion for subjects in the BR and group, and subjects referred as AN were screened using either the same test or using PCR-techniques (Cobas Amplicor®) on urine samples.

An *in vitro* assay was performed to evaluate the subjects' T-cell response to various *Chlamydia trachomatis* antigens and combinations thereof. Peripheral blood mononuclear cell (PBMC) samples were obtained from heparinised whole blood by Ficoll-Hypaque density gradient centrifugation following standard procedures. The cells are washed and cryopreserved in liquid nitrogen until testing (for further details see Lalvani A, Moris P et al. *J. Infect. Dis.* 1999 180:1656-1664).

For subjects in the CR group, the specific immune response to each *Chlamydia trachomatis* antigen was characterised by performing lymphocyte proliferation analysis using the tritiated thymidine. This technique assessed the cellular expansion upon *in vitro* stimulation to an antigen. In practice, cell proliferation is determined by estimating incorporation of tritiated-thymidine into DNA, a process closely related to underlying changes in cell number.

For subjects in the AN and BR groups, the specific immune response to each *Chlamydia trachomatis* antigen was characterised by performing lymphocyte proliferation analysis using the succinimidyl ester of carboxyfluorescein diacetate (CFSE). CFSE spontaneously and irreversibly couples to both intracellular and cell surface proteins by reaction with lysine side chains and other available amine groups. When lymphocyte cells divide, CFSE labeling is distributed equally between the daughter cells, which are therefore half as fluorescent as the parents. As a result, halving of cellular fluorescence intensity marks each successive generation in a population of proliferating cells and is readily followed by flow cytometry (for further details see Hodgkins, PD et al *J. Exp. Med.* 1996 184:277-281).

Practically, after thawing, PMBC were washed and stained with CFSE before being cultivated (2×10^5 cells) for 72 hrs with 10 ug/ml of antigen in culture media (RPMI-1640 supplemented with glutamine, non essential amino acid, pyruvate and heat inactivated human AB serum). Cells were then harvested and their phenotype was characterized using surface staining to identify memory CD8 and CD4+ T-Cells. Subsequently, flow cytometry analysis indicated the extent of lymphocyte proliferation in response to each antigen (proportion of cells with decreased CFSE intensity upon *in vitro* stimulation).

Results

Figure 21 shows the CD4 response of test subjects to specific antigens, responders in this case from BR and AN groups are defined as having a signal to noise ratio of at least 2:1. Responders in the CR group are defined as those demonstrating a proliferative S/N>10 and IFN-gamma response of 500ug/ml from T-cells generated from the donor subjects. The

proportion of responders can be seen to vary depending upon both the particular antigen being tested and subject group. The AN group generally shows the greatest number of responders (in five out of eight cases), with the CR group generally showing the fewest number of responders (in six out of eight cases) but the specific cellular response was evaluated in another technical setting. Subjects in the BR and AN groups both show their greatest response to the Ct-875 antigen. Figure 22 shows the CD4 response plotted at a signal to noise ratio of at least 3:1 for BR and AN groups.

Figure 23 shows the CD4 response of test subjects to certain antigens, and also to combinations of those antigens (response to the combinations was not examined for the CR subject group, indicated by the notation NE). Compared to the response observed for individual antigens, the combination of Ct-875+Ct-858 or Ct-858+Ct-089 result in a higher proportion of responders in both subject groups. It may be noted that the combination of Ct-875+Ct-089 does not result in any improvement in the number of responders compared to Ct-875 alone, and neither does the combination of Ct-875+ Ct-858+Ct-089 result in any improvement in the number of responders compared to the combination of Ct-875+Ct-858. The four antigen combination of Ct-875+ Ct-858+Ct-089+PmpD results in the greatest number of responders in the BR subject group (100% response already being observed in the AN group for both the Ct-875+Ct-858 and Ct-875+ Ct-858+Ct-089 combinations).

Conclusions

Although the frequency of responders was not consistent between the three subject groups, possibly as a result of the sample size or population differences, Ct-858 and Ct-875 were well recognized for all three groups.

In the human seropositive subjects tested, the optimal response for a two antigen combination is provided by Ct-875+Ct-858. Ct-089 only seems to result in improved response where Ct-875 is not already present, although Ct-089 may have benefit over and above Ct-875+Ct-858 in other population groups. The greatest response was observed for the four antigen combination of Ct-875+Ct-858+Ct-089+PmpD.

In light of the results of Example 9, it can reasonably be expected that the antigen combinations of the present invention, whether in the form of whole proteins, immunogenic fragments thereof or polynucleotides encoding either of these, will be of particular value in human Chlamydial vaccines and in related diagnostic methods.

SEQUENCE LISTING

<110> Probst, Peter
Skeiky, Yasir
Barth, Brenda
Alderson, Mark R
Bhatia, Ajay
Maisonneuve, Jean-Francois
Nozay, Florence
Lobet, Yves
Marchand, Martine
Mettens, Pascal

<120> VACCINES AGAINST CHLAMYDIAL INFECTION

<130> VB61508PCT

<150> US 60/667,331

<151> 2005-03-31

<160> 126

<170> PatentIn version 3.1

<210> 1

<211> 261

<212> DNA

<213> Chlamydia trachomatis

<400> 1

atgagtc	aaa	ataaga	aactc	tgcttt	catg	cagcct	gtga	acgtat	ccgc	tgattt	tagct	60
gccatc	ggttg	gtgcagg	acc	tatgcct	cgc	acagaga	tca	ttaagaa	aat	gtggg	attac	120
attaagg	aga	atagtct	tca	agatcct	taca	aacaaac	gta	atatcaa	tcc	cgatg	ataaa	180
ttggcta	aaag	tttttg	gaac	tgaaaa	acct	atcgata	tgt	tccaaat	gac	aaaaat	gggtt	240
tctcaac	acaca	tcattaa	aata	a								261

<210> 2

<211> 86

<212> PRT

<213> Chlamydia trachomatis

<400> 2

Met	Ser	Gln	Asn	Lys	Asn	Ser	Ala	Phe	Met	Gln	Pro	Val	Asn	Val	Ser
1			5						10				15		
Ala	Asp	Leu	Ala	Ala	Ile	Val	Gly	Ala	Gly	Pro	Met	Pro	Arg	Thr	Glu
		20						25					30		
Ile	Ile	Lys	Lys	Met	Trp	Asp	Tyr	Ile	Lys	Glu	Asn	Ser	Leu	Gln	Asp
		35					40					45			
Pro	Thr	Asn	Lys	Arg	Asn	Ile	Asn	Pro	Asp	Asp	Lys	Leu	Ala	Lys	Val
		50				55					60				
Phe	Gly	Thr	Glu	Lys	Pro	Ile	Asp	Met	Phe	Gln	Met	Thr	Lys	Met	Val
65					70				75					80	
Ser	Gln	His	Ile	Ile	Lys										
					85										

<210> 3

<211> 1122

<212> DNA

<213> Chlamydia trachomatis

<400> 3

```

ctgcctgtgg ggaatcctgc tgaaccaagc cttatgatcg acggaattct gtgggaaggt      60
ttcggcggag atccttgcca tccttgcacc acttggtgtg acgctatcag catgcgtatg      120
ggttactatg gtgactttgt tttcgaccgt gttttgaaaa cagatgtgaa taaagagttt      180
gaaatgggag aggcttttagc cggagcttct gggaatacga cctctactct ttcaaaattg      240
gtagaacgaa cgaaccctgc atatggcaag catatgcaag acgcagagat gtttaccaat      300
gccgcttgca tgacattgaa tatttgggat cgttttgatg tattctgtac attaggagcc      360
accagtggat atcttaaagg aaattcagca tctttcaact tagttgggtt attcggcgat      420
ggtgtaaacy ccacgaaacc tgctgcagat agtattccta acgtgcagtt aaatcagtct      480
gtggtggaac tgtatacaga tactactttt gcttggagtg ttggagctcg tgcagctttg      540
tggaatgtg gatgtgcaac tttaggagct tctttccaat atgctcaatc taaacctaaa      600
atcgaagaat taaacgttct ctgtaacgca gcagagttaa ctattaataa acctaaaggg      660
tatgtaggta aggagtttcc tcttgatctt acagcaggaa cagatgcagc gacgggcact      720
aaagatgcct ctattgatta ccatgagtg gcaagcaagt tatctcttct ttacagactc      780
aatatgttca ctccctacat tggagttaaa tggctctcgt caagctttga ttctgataca      840
attcgtatag cccagcogag gttggttaaca cctggtgtag atattacaac ccttaaccca      900
actattgcag gatgcggcag tgtagctgga gctaacacgg aaggacagat atctgatata      960
atgcaaacyg tctccttgca attgaacaag atgaaatcta gaaaatcttg cggtattgca    1020
gtaggaacaa ctattgtgga tgcagacaaa tacgcagtta cagttgagac tcgcttgatc    1080
gatgagagag ctgctcacgt aaatgcacaa ttccgcttct ag                               1122

```

<210> 4

<211> 373

<212> PRT

<213> Chlamydia trachomatis

<400> 4

```

Leu Pro Val Gly Asn Pro Ala Glu Pro Ser Leu Met Ile Asp Gly Ile
1          5          10          15
Leu Trp Glu Gly Phe Gly Gly Asp Pro Cys Asp Pro Cys Thr Thr Trp
          20          25          30
Cys Asp Ala Ile Ser Met Arg Met Gly Tyr Tyr Gly Asp Phe Val Phe
          35          40          45
Asp Arg Val Leu Lys Thr Asp Val Asn Lys Glu Phe Glu Met Gly Glu
          50          55          60
Ala Leu Ala Gly Ala Ser Gly Asn Thr Thr Ser Thr Leu Ser Lys Leu
          65          70          75          80
Val Glu Arg Thr Asn Pro Ala Tyr Gly Lys His Met Gln Asp Ala Glu
          85          90          95
Met Phe Thr Asn Ala Ala Cys Met Thr Leu Asn Ile Trp Asp Arg Phe
          100          105          110
Asp Val Phe Cys Thr Leu Gly Ala Thr Ser Gly Tyr Leu Lys Gly Asn
          115          120          125
Ser Ala Ser Phe Asn Leu Val Gly Leu Phe Gly Asp Gly Val Asn Ala
          130          135          140
Thr Lys Pro Ala Ala Asp Ser Ile Pro Asn Val Gln Leu Asn Gln Ser
          145          150          155          160
Val Val Glu Leu Tyr Thr Asp Thr Thr Phe Ala Trp Ser Val Gly Ala
          165          170          175
Arg Ala Ala Leu Trp Glu Cys Gly Cys Ala Thr Leu Gly Ala Ser Phe
          180          185          190
Gln Tyr Ala Gln Ser Lys Pro Lys Ile Glu Glu Leu Asn Val Leu Cys
          195          200          205
Asn Ala Ala Glu Phe Thr Ile Asn Lys Pro Lys Gly Tyr Val Gly Lys
          210          215          220
Glu Phe Pro Leu Asp Leu Thr Ala Gly Thr Asp Ala Ala Thr Gly Thr
          225          230          235          240

```


<400> 6

Val	Arg	Gly	Glu	Ser	Leu	Val	Cys	Lys	Asn	Ala	Leu	Gln	Asp	Leu	Ser	1	5	10	15
Phe	Leu	Glu	His	Leu	Leu	Gln	Val	Lys	Tyr	Ala	Pro	Lys	Thr	Trp	Lys	20	25	30	
Glu	Gln	Tyr	Leu	Gly	Trp	Asp	Leu	Val	Gln	Ser	Ser	Val	Ser	Ala	Gln	35	40	45	
Gln	Lys	Leu	Arg	Thr	Gln	Glu	Asn	Pro	Ser	Thr	Ser	Phe	Cys	Gln	Gln	50	55	60	
Val	Leu	Ala	Asp	Phe	Ile	Gly	Gly	Leu	Asn	Asp	Phe	His	Ala	Gly	Val	65	70	75	80
Thr	Phe	Phe	Ala	Ile	Glu	Ser	Ala	Tyr	Leu	Pro	Tyr	Thr	Val	Gln	Lys	85	90	95	
Ser	Ser	Asp	Gly	Arg	Phe	Tyr	Phe	Val	Asp	Ile	Met	Thr	Phe	Ser	Ser	100	105	110	
Glu	Ile	Arg	Val	Gly	Asp	Glu	Leu	Leu	Glu	Val	Asp	Gly	Ala	Pro	Val	115	120	125	
Gln	Asp	Val	Leu	Ala	Thr	Leu	Tyr	Gly	Ser	Asn	His	Lys	Gly	Thr	Ala	130	135	140	
Ala	Glu	Glu	Ser	Ala	Ala	Leu	Arg	Thr	Leu	Phe	Ser	Arg	Met	Ala	Ser	145	150	155	160
Leu	Gly	His	Lys	Val	Pro	Ser	Gly	Arg	Thr	Thr	Leu	Lys	Ile	Arg	Arg	165	170	175	
Pro	Phe	Gly	Thr	Thr	Arg	Glu	Val	Arg	Val	Lys	Trp	Arg	Tyr	Val	Pro	180	185	190	
Glu	Gly	Val	Gly	Asp	Leu	Ala	Thr	Ile	Ala	Pro	Ser	Ile	Arg	Ala	Pro	195	200	205	
Gln	Leu	Gln	Lys	Ser	Met	Arg	Ser	Phe	Phe	Pro	Lys	Lys	Asp	Asp	Ala	210	215	220	
Phe	His	Arg	Ser	Ser	Ser	Leu	Phe	Tyr	Ser	Pro	Met	Val	Pro	His	Phe	225	230	235	240
Trp	Ala	Glu	Leu	Arg	Asn	His	Tyr	Ala	Thr	Ser	Gly	Leu	Lys	Ser	Gly	245	250	255	
Tyr	Asn	Ile	Gly	Ser	Thr	Asp	Gly	Phe	Leu	Pro	Val	Ile	Gly	Pro	Val	260	265	270	
Ile	Trp	Glu	Ser	Glu	Gly	Leu	Phe	Arg	Ala	Tyr	Ile	Ser	Ser	Val	Thr	275	280	285	
Asp	Gly	Asp	Gly	Lys	Ser	His	Lys	Val	Gly	Phe	Leu	Arg	Ile	Pro	Thr	290	295	300	
Tyr	Ser	Trp	Gln	Asp	Met	Glu	Asp	Phe	Asp	Pro	Ser	Gly	Pro	Pro	Pro	305	310	315	320
Trp	Glu	Glu	Phe	Ala	Lys	Ile	Ile	Gln	Val	Phe	Ser	Ser	Asn	Thr	Glu	325	330	335	
Ala	Leu	Ile	Ile	Asp	Gln	Thr	Asn	Asn	Pro	Gly	Gly	Ser	Val	Leu	Tyr	340	345	350	
Leu	Tyr	Ala	Leu	Leu	Ser	Met	Leu	Thr	Asp	Arg	Pro	Leu	Glu	Leu	Pro	355	360	365	
Lys	His	Arg	Met	Ile	Leu	Thr	Gln	Asp	Glu	Val	Val	Asp	Ala	Leu	Asp	370	375	380	
Trp	Leu	Thr	Leu	Leu	Glu	Asn	Val	Asp	Thr	Asn	Val	Glu	Ser	Arg	Leu	385	390	395	400
Ala	Leu	Gly	Asp	Asn	Met	Glu	Gly	Tyr	Thr	Val	Asp	Leu	Gln	Val	Ala	405	410	415	
Glu	Tyr	Leu	Lys	Ser	Phe	Gly	Arg	Gln	Val	Leu	Asn	Cys	Trp	Ser	Lys	420	425	430	
Gly	Asp	Ile	Glu	Leu	Ser	Thr	Pro	Ile	Pro	Leu	Phe	Gly	Phe	Glu	Lys	435	440	445	
Ile	His	Pro	His	Pro	Arg	Val	Gln	Tyr	Ser	Lys	Pro	Ile	Cys	Val	Leu				

450
 Ile Asn Glu Gln Asp Phe Ser Cys Ala Asp Phe Phe Pro Val Val Leu
 465 470 475 480
 Lys Asp Asn Asp Arg Ala Leu Ile Val Gly Thr Arg Thr Ala Gly Ala
 485 490 495
 Gly Gly Phe Val Phe Asn Val Gln Phe Pro Asn Arg Thr Gly Ile Lys
 500 505 510
 Thr Cys Ser Leu Thr Gly Ser Leu Ala Val Arg Glu His Gly Ala Phe
 515 520 525
 Ile Glu Asn Ile Gly Val Glu Pro His Ile Asp Leu Pro Phe Thr Ala
 530 535 540
 Asn Asp Ile Arg Tyr Lys Gly Tyr Ser Glu Tyr Leu Asp Lys Val Lys
 545 550 555 560
 Lys Leu Val Cys Gln Leu Ile Asn Asn Asp Gly Thr Ile Ile Leu Ala
 565 570 575
 Glu Asp Gly Ser Phe
 580

<210> 7
 <211> 1776
 <212> DNA
 <213> Chlamydia trachomatis

<400> 7

atgagcatca	ggggagtagg	aggcaacggg	aatagtcgaa	tcccttctca	taatggggat	60
ggatcgaatc	gcagaagtca	aaatacgaag	ggtaataata	aagttgaaga	tcgagtttgt	120
tctctatatt	catctcgtag	taacgaaaat	agagaatctc	cttatgcagt	agtagacgtc	180
agctctatga	tcgagagcac	cccaacgagt	ggagagacga	caagagcttc	gcgtgggagt	240
ctcagtcgtt	tccaaagagg	tttagtacga	atagctgaca	aagtaagacg	agctgttcag	300
tgtgcgtgga	gttcagtcctc	tacaagcaga	tcgtctgcaa	caagagccgc	agaatccgga	360
tcaagtagtc	gtactgctcg	tgggtgcaagt	tctgggtata	gggagtattc	tccttcagca	420
gctagagggc	tgcgtcttat	gttcacagat	ttctggagaa	ctcgggtttt	acgccagacc	480
tctcctatgg	ctggagtttt	tgggaatctt	gatgtgaacg	aggctcgttt	gatggctgcg	540
tacacaagtg	agtgcgcgga	tcatttagaa	gcgaaggagt	tggctggccc	tgacggggta	600
gcggccgccc	gggaaattgc	taaaagatgg	gagaaaagag	ttagagatct	acaagataaa	660
ggtgctgcac	gaaaattatt	aaatgatcct	ttaggccgac	gaacacctaa	ttatcagagc	720
aaaaatccag	gtgagtatac	tgtagggaat	tccatgtttt	acgatgggtcc	tcaggtagcg	780
aatctccaga	acgtcgacac	tggtttttgg	ctggacatga	gcaatctctc	agacgttgta	840
ttatccagag	agattcaaac	aggacttcga	gcacgagcta	ctttggaaga	atccatgccg	900
atgttagaga	atttagaaga	gcgtttttaga	cgtttgcaag	aaacttggtga	tgccgctcgt	960
actgagatag	aagaatcggg	atggactcga	gagtcgcgat	caagaatgga	aggcgatgag	1020
gcgcaaggac	cttctagagt	acaacaagct	tttcagagct	ttgtaaatga	atgtaacagc	1080
atcgagttct	catttgggag	ctttggagag	catgtgcgag	ttctctgcgc	tagagtatca	1140
cgaggattag	ctgccgcagg	agaggcgatt	cgccgttgct	tctcttgttg	taaaggatcg	1200
acgcacgcct	acgctcctcg	cgatgaccta	tctcctgaag	gtgcatcggt	agcagagact	1260
ttggctagat	tcgcagatga	tatgggaata	gagcgagggtg	ctgatggaac	ctacgatatt	1320
cctttggtag	atgattggag	aagagggggt	cctagtattg	aaggagaagg	atctgactcg	1380
atctatgaaa	tcatgatgcc	tatctatgaa	gttatgaata	tggatctaga	aacacgaaga	1440
tcttttgctg	tacagcaagg	gcactatcag	gacccaagag	cttcagatta	tgacctcca	1500
cgtgctagcg	actatgattt	gcctagaagc	ccatattccta	ctccaccttt	gcctcctaga	1560
tatcagctac	agaatatgga	tgtagaagca	gggttccgtg	aggcagttta	tgcttctttt	1620
gtagcaggaa	tgtacaatta	tgtagtgaca	cagccgcaag	agcgtattcc	caatagtcag	1680
cagggtggaag	ggattctgcg	tgatatgctt	accaacgggt	cacagacatt	tagagacctg	1740
atgaagcggt	ggaatagaga	agtcgatagg	gaataa			1776

<210> 8
 <211> 591
 <212> PRT
 <213> Chlamydia trachomatis

<400> 8

Met	Ser	Ile	Arg	Gly	Val	Gly	Gly	Asn	Gly	Asn	Ser	Arg	Ile	Pro	Ser		
1				5					10					15			
His	Asn	Gly	Asp	Gly	Ser	Asn	Arg	Arg	Ser	Gln	Asn	Thr	Lys	Gly	Asn		
			20					25					30				
Asn	Lys	Val	Glu	Asp	Arg	Val	Cys	Ser	Leu	Tyr	Ser	Ser	Arg	Ser	Asn		
		35					40					45					
Glu	Asn	Arg	Glu	Ser	Pro	Tyr	Ala	Val	Val	Asp	Val	Ser	Ser	Met	Ile		
	50					55					60						
Glu	Ser	Thr	Pro	Thr	Ser	Gly	Glu	Thr	Thr	Arg	Ala	Ser	Arg	Gly	Val		
65					70					75					80		
Leu	Ser	Arg	Phe	Gln	Arg	Gly	Leu	Val	Arg	Ile	Ala	Asp	Lys	Val	Arg		
				85					90					95			
Arg	Ala	Val	Gln	Cys	Ala	Trp	Ser	Ser	Val	Ser	Thr	Ser	Arg	Ser	Ser		
			100					105					110				
Ala	Thr	Arg	Ala	Ala	Glu	Ser	Gly	Ser	Ser	Ser	Arg	Thr	Ala	Arg	Gly		
	115						120					125					
Ala	Ser	Ser	Gly	Tyr	Arg	Glu	Tyr	Ser	Pro	Ser	Ala	Ala	Arg	Gly	Leu		
	130						135				140						
Arg	Leu	Met	Phe	Thr	Asp	Phe	Trp	Arg	Thr	Arg	Val	Leu	Arg	Gln	Thr		
145					150					155					160		
Ser	Pro	Met	Ala	Gly	Val	Phe	Gly	Asn	Leu	Asp	Val	Asn	Glu	Ala	Arg		
				165					170					175			
Leu	Met	Ala	Ala	Tyr	Thr	Ser	Glu	Cys	Ala	Asp	His	Leu	Glu	Ala	Lys		
			180					185					190				
Glu	Leu	Ala	Gly	Pro	Asp	Gly	Val	Ala	Ala	Ala	Arg	Glu	Ile	Ala	Lys		
	195						200					205					
Arg	Trp	Glu	Lys	Arg	Val	Arg	Asp	Leu	Gln	Asp	Lys	Gly	Ala	Ala	Arg		
	210					215					220						
Lys	Leu	Leu	Asn	Asp	Pro	Leu	Gly	Arg	Arg	Thr	Pro	Asn	Tyr	Gln	Ser		
225					230					235					240		
				245					250					255			
Pro	Gln	Val	Ala	Asn	Leu	Gln	Asn	Val	Asp	Thr	Gly	Phe	Trp	Leu	Asp		
			260					265					270				
Met	Ser	Asn	Leu	Ser	Asp	Val	Val	Leu	Ser	Arg	Glu	Ile	Gln	Thr	Gly		
		275						280					285				
Leu	Arg	Ala	Arg	Ala	Thr	Leu	Glu	Glu	Ser	Met	Pro	Met	Leu	Glu	Asn		
		290					295					300					
Leu	Glu	Glu	Arg	Phe	Arg	Arg	Leu	Gln	Glu	Thr	Cys	Asp	Ala	Ala	Arg		
305					310					315					320		
Thr	Glu	Ile	Glu	Glu	Ser	Gly	Trp	Thr	Arg	Glu	Ser	Ala	Ser	Arg	Met		
				325					330					335			
Glu	Gly	Asp	Glu	Ala	Gln	Gly	Pro	Ser	Arg	Val	Gln	Gln	Ala	Phe	Gln		
			340					345					350				
Ser	Phe	Val	Asn	Glu	Cys	Asn	Ser	Ile	Glu	Phe	Ser	Phe	Gly	Ser	Phe		
		355					360					365					
Gly	Glu	His	Val	Arg	Val	Leu	Cys	Ala	Arg	Val	Ser	Arg	Gly	Leu	Ala		
		370				375					380						
Ala	Ala	Gly	Glu	Ala	Ile	Arg	Arg	Cys	Phe	Ser	Cys	Cys	Lys	Gly	Ser		
385					390					395					400		
Thr	His	Arg	Tyr	Ala	Pro	Arg	Asp	Asp	Leu	Ser	Pro	Glu	Gly	Ala	Ser		
				405					410					415			
Leu	Ala	Glu	Thr	Leu	Ala	Arg	Phe	Ala	Asp	Asp	Met	Gly	Ile	Glu	Arg		
		420						425					430				
Gly	Ala	Asp	Gly	Thr	Tyr	Asp	Ile	Pro	Leu	Val	Asp	Asp	Trp	Arg	Arg		
		435				440						445					
Gly	Val	Pro	Ser	Ile	Glu	Gly	Glu	Gly	Ser	Asp	Ser	Ile	Tyr	Glu	Ile		

450		455		460
Met Met Pro Ile Tyr	Glu Val Met Asn Met Asp	Leu Glu Thr Arg Arg		
465	470	475	480	
Ser Phe Ala Val	Gln Gly His Tyr Gln Asp	Pro Arg Ala Ser Asp		
	485	490	495	
Tyr Asp Leu Pro	Arg Ala Ser Asp Tyr Asp Leu	Pro Arg Ser Pro Tyr		
	500	505	510	
Pro Thr Pro Pro	Leu Pro Pro Arg Tyr Gln Leu	Gln Asn Met Asp Val		
	515	520	525	
Glu Ala Gly Phe	Arg Glu Ala Val Tyr Ala Ser	Phe Val Ala Gly Met		
	530	535	540	
Tyr Asn Tyr Val	Val Thr Gln Pro Gln Glu Arg	Ile Pro Asn Ser Gln		
545	550	555	560	
Gln Val Glu Gly	Ile Leu Arg Asp Met Leu Thr	Asn Gly Ser Gln Thr		
	565	570	575	
Phe Arg Asp Leu	Met Lys Arg Trp Asn Arg Glu	Val Asp Arg Glu		
	580	585	590	

<210> 9
 <211> 1962
 <212> DNA
 <213> Chlamydia trachomatis

<400> 9

atggaatcag	gaccagaatc	agtttcttct	aatcagagct	cgatgaatcc	aattattaat	60
gggcaaatcg	cttctaattc	ggagaccaa	gagtcacga	aggcgtccga	agcgagtcct	120
tcagcatcgt	cctctgtaag	cagctggagt	tttttatcct	cagcaaagaa	tgcatthaatc	180
tctcttcgtg	atgccatctt	gaataaaaa	tccagtccaa	cagactctct	ctctcaatta	240
gaggcctcta	cttctacctc	tacggttaca	cgtgtagcgg	caaaagatta	tgatgaggct	300
aaatcgaatt	ttgatacggc	gaaaagtggg	ttagagaacg	ctaagacact	tgctgaatac	360
gaaacgaaaa	tggctgattt	gatggcagct	ctccaagata	tggagcgttt	agctaattca	420
gatoctagta	acaatcatac	cgaagaagta	aataatatta	agaaagcgct	cgaagcacia	480
aaagatacta	ttgataagct	gaataaactc	gttacgctgc	aaaatcagaa	taaatcttta	540
acagaagtgt	tgaaaacaac	tgactctgca	gatcagattc	cagcgattaa	tagtcagtta	600
gagatcaaca	aaaattctgc	agatcaaatt	atcaaagatc	tggaaagaca	aaacataagt	660
tatgaagctg	ttctcactaa	cgcaggagag	gttatcaaag	cttcttctga	agcgggaatt	720
aagttaggac	aagcttttgca	gtctattgtg	gatgctgggg	accaaagtca	ggctgcagtt	780
ctgcaagcac	agcaaaaata	tagcccagat	aatattgcag	ccacgaagga	attaattgat	840
gctgctgaaa	cgaaggtaaa	cgagttaaaa	caagagcata	caggggtaac	ggactcgctt	900
ttagtgaana	aagctgagga	gcagattagt	caagcacaaa	aagatattca	agagatcaaa	960
cctagtgggt	cggtatattc	tatcgttggt	ccgagtgggt	cagctgcttc	cgcaggaagt	1020
gcggcaggag	cgttgaaatc	ctctaacaat	tcaggaagaa	tttcttgggt	gcttgatgat	1080
gtagacaatg	aaatggcagc	gattgcaact	caagggtttc	gatctatgat	cgaacaattt	1140
aatgtaaaaca	atcctgcaac	agctaaagag	ctacaagcta	tggaggctca	gctgactgcy	1200
atgtcagatc	aactgggttg	tgcggtatgg	gagctcccag	ccgaaatata	agcaatcaaa	1260
gatgctcttg	cgcaagcttt	gaaacaacca	tcagcagatg	gtttggctac	agctatggga	1320
caagtggctt	ttgcagctgc	caaggttgga	ggaggctccg	caggaacagc	tggtcactgtc	1380
cagatgaatg	taaaacagct	ttacaagaca	gcgttttctt	cgacttcttc	cagctcttat	1440
gcagcagcac	tttccgatgg	atattctgct	tacaaaacac	tgaactcttt	atattccgaa	1500
agcagaagcg	gcgtgcagtc	agctattagt	caaactgcaa	atcccgcgct	ttccagaagc	1560
gtttctcggt	ctggcataga	aagtcaagga	cgcagtgcag	atgctagcca	aagagcagca	1620
gaaactattg	tcagagatag	ccaaacgtta	ggtgatgtat	atagccgctt	acaggttctg	1680
gattcttttg	tgtctacgat	tgtgagcaat	ccgcaagcaa	atcaagaaga	gattatgcag	1740
aagctcacgg	catctattag	caaagctcca	caatttgggt	atcctgctgt	tcagaattct	1800
gcggatagct	tgcaagaagt	tgctgcgcaa	ttggaaagag	agtttgttga	tggggaacgt	1860
agtctcgag	aatctcaaga	gaatgcgttt	agaaaacagc	ccgctttcat	tcaacaggtg	1920
ttggtaaaaca	ttgcttctct	attctctggt	tatctttctt	aa		1962

<210> 10

<211> 653
 <212> PRT
 <213> Chlamydia trachomatis

<400> 10

Met	Glu	Ser	Gly	Pro	Glu	Ser	Val	Ser	Ser	Asn	Gln	Ser	Ser	Met	Asn
1				5					10					15	
Pro	Ile	Ile	Asn	Gly	Gln	Ile	Ala	Ser	Asn	Ser	Glu	Thr	Lys	Glu	Ser
			20					25					30		
Thr	Lys	Ala	Ser	Glu	Ala	Ser	Pro	Ser	Ala	Ser	Ser	Ser	Val	Ser	Ser
		35					40					45			
Trp	Ser	Phe	Leu	Ser	Ser	Ala	Lys	Asn	Ala	Leu	Ile	Ser	Leu	Arg	Asp
	50					55					60				
Ala	Ile	Leu	Asn	Lys	Asn	Ser	Ser	Pro	Thr	Asp	Ser	Leu	Ser	Gln	Leu
65					70					75					80
Glu	Ala	Ser	Thr	Ser	Thr	Ser	Thr	Val	Thr	Arg	Val	Ala	Ala	Lys	Asp
				85					90					95	
Tyr	Asp	Glu	Ala	Lys	Ser	Asn	Phe	Asp	Thr	Ala	Lys	Ser	Gly	Leu	Glu
			100					105					110		
Asn	Ala	Lys	Thr	Leu	Ala	Glu	Tyr	Glu	Thr	Lys	Met	Ala	Asp	Leu	Met
		115					120				125				
Ala	Ala	Leu	Gln	Asp	Met	Glu	Arg	Leu	Ala	Asn	Ser	Asp	Pro	Ser	Asn
		130				135					140				
Asn	His	Thr	Glu	Glu	Val	Asn	Asn	Ile	Lys	Lys	Ala	Leu	Glu	Ala	Gln
145					150					155					160
Lys	Asp	Thr	Ile	Asp	Lys	Leu	Asn	Lys	Leu	Val	Thr	Leu	Gln	Asn	Gln
				165					170					175	
Asn	Lys	Ser	Leu	Thr	Glu	Val	Leu	Lys	Thr	Thr	Asp	Ser	Ala	Asp	Gln
			180					185				190			
Ile	Pro	Ala	Ile	Asn	Ser	Gln	Leu	Glu	Ile	Asn	Lys	Asn	Ser	Ala	Asp
		195					200					205			
Gln	Ile	Ile	Lys	Asp	Leu	Glu	Arg	Gln	Asn	Ile	Ser	Tyr	Glu	Ala	Val
	210					215					220				
Leu	Thr	Asn	Ala	Gly	Glu	Val	Ile	Lys	Ala	Ser	Ser	Glu	Ala	Gly	Ile
225					230					235					240
Lys	Leu	Gly	Gln	Ala	Leu	Gln	Ser	Ile	Val	Asp	Ala	Gly	Asp	Gln	Ser
				245						250				255	
Gln	Ala	Ala	Val	Leu	Gln	Ala	Gln	Gln	Asn	Asn	Ser	Pro	Asp	Asn	Ile
			260					265					270		
Ala	Ala	Thr	Lys	Glu	Leu	Ile	Asp	Ala	Ala	Glu	Thr	Lys	Val	Asn	Glu
		275					280					285			
Leu	Lys	Gln	Glu	His	Thr	Gly	Leu	Thr	Asp	Ser	Pro	Leu	Val	Lys	Lys
	290					295				300					
Ala	Glu	Glu	Gln	Ile	Ser	Gln	Ala	Gln	Lys	Asp	Ile	Gln	Glu	Ile	Lys
305					310					315					320
Pro	Ser	Gly	Ser	Asp	Ile	Pro	Ile	Val	Gly	Pro	Ser	Gly	Ser	Ala	Ala
				325						330				335	
Ser	Ala	Gly	Ser	Ala	Ala	Gly	Ala	Leu	Lys	Ser	Ser	Asn	Asn	Ser	Gly
			340					345					350		
Arg	Ile	Ser	Leu	Leu	Leu	Asp	Asp	Val	Asp	Asn	Glu	Met	Ala	Ala	Ile
		355					360					365			
Ala	Leu	Gln	Gly	Phe	Arg	Ser	Met	Ile	Glu	Gln	Phe	Asn	Val	Asn	Asn
						375					380				
Pro	Ala	Thr	Ala	Lys	Glu	Leu	Gln	Ala	Met	Glu	Ala	Gln	Leu	Thr	Ala
385					390					395					400
Met	Ser	Asp	Gln	Leu	Val	Gly	Ala	Asp	Gly	Glu	Leu	Pro	Ala	Glu	Ile
				405					410					415	
Gln	Ala	Ile	Lys	Asp	Ala	Leu	Ala	Gln	Ala	Leu	Lys	Gln	Pro	Ser	Ala
			420					425					430		

Asp Gly Leu Ala Thr Ala Met Gly Gln Val Ala Phe Ala Ala Ala Lys
 435 440 445
 Val Gly Gly Gly Ser Ala Gly Thr Ala Gly Thr Val Gln Met Asn Val
 450 455 460
 Lys Gln Leu Tyr Lys Thr Ala Phe Ser Ser Thr Ser Ser Ser Ser Tyr
 465 470 475 480
 Ala Ala Ala Leu Ser Asp Gly Tyr Ser Ala Tyr Lys Thr Leu Asn Ser
 485 490 495
 Leu Tyr Ser Glu Ser Arg Ser Gly Val Gln Ser Ala Ile Ser Gln Thr
 500 505 510
 Ala Asn Pro Ala Leu Ser Arg Ser Val Ser Arg Ser Gly Ile Glu Ser
 515 520 525
 Gln Gly Arg Ser Ala Asp Ala Ser Gln Arg Ala Ala Glu Thr Ile Val
 530 535 540
 Arg Asp Ser Gln Thr Leu Gly Asp Val Tyr Ser Arg Leu Gln Val Leu
 545 550 555 560
 Asp Ser Leu Met Ser Thr Ile Val Ser Asn Pro Gln Ala Asn Gln Glu
 565 570 575
 Glu Ile Met Gln Lys Leu Thr Ala Ser Ile Ser Lys Ala Pro Gln Phe
 580 585 590
 Gly Tyr Pro Ala Val Gln Asn Ser Ala Asp Ser Leu Gln Lys Phe Ala
 595 600 605
 Ala Gln Leu Glu Arg Glu Phe Val Asp Gly Glu Arg Ser Leu Ala Glu
 610 615 620
 Ser Gln Glu Asn Ala Phe Arg Lys Gln Pro Ala Phe Ile Gln Gln Val
 625 630 635 640
 Leu Val Asn Ile Ala Ser Leu Phe Ser Gly Tyr Leu Ser
 645 650

<210> 11
 <211> 2010
 <212> DNA
 <213> Chlamydia trachomatis

<400> 11

gcagaaatca	tgattcctca	aggaatttac	gatggggaga	cgtaactgt	atcatttccc	60
tatactgtta	taggagatcc	gagtgggact	actgtttttt	ctgcaggaga	gttaacatta	120
aaaaatcttg	acaattctat	tgcagctttg	cctttaagtt	gttttgggaa	cttattaggg	180
agttttactg	ttttaggagg	aggacactcg	ttgactttcg	agaacatacg	gacttctaca	240
aatggggcag	ctctaagtaa	tagcgtctgt	gatggactgt	ttactattga	gggttttaaa	300
gaattatcct	tttccaattg	caattcatta	cttgccgtac	tgcctgctgc	aacgactaat	360
aagggtagcc	agactccgac	gacaacatct	acaccgtcta	atgggtactat	ttattctaaa	420
acagatcttt	tgttactcaa	taatgagaag	ttctcattct	atagtaattt	agtctctgga	480
gatgggggag	ctatagatgc	taagagctta	acggttcaag	gaattagcaa	gctttgtgtc	540
ttccaagaaa	atactgctca	agctgatggg	ggagcttgct	aagtagtcac	cagtttctct	600
gctatggcta	acgaggctcc	tattgccttt	gtagcgaatg	ttgcaggagt	aagaggggga	660
gggattgctg	ctgttcagga	tgggcagcag	ggagtgtcat	catctacttc	aacagaagat	720
ccagtagtaa	gtttttccag	aaatactgct	gtagagtgtg	atgggaacgt	agcccagta	780
ggaggaggga	tttactccta	cgggaacggt	gctttcctga	ataatggaaa	aaccttggtt	840
ctcaacaatg	ttgcttctcc	tgtttacatt	gctgctaagc	aaccaacaag	tggaacaggc	900
tctaatacga	gtaataatta	cggagatgga	ggagctatct	tctgtaagaa	tggtgcgcaa	960
gcaggatcca	ataactctgg	atcagtttcc	tttgatggag	agggagtagt	tttctttagt	1020
agcaatgtag	ctgctgggaa	agggggagct	atttatgcca	aaaagctctc	ggttgctaac	1080
tgtggccctg	tacaattttt	aaggaatata	gctaattgat	gtggagcgat	ttatttagga	1140
gaatctggag	agctcagttt	atctgctgat	tatggagata	ttattttcga	tgggaatctt	1200
aaaagaacag	ccaaagagaa	tgctgccgat	gttaatggcg	taactgtgtc	ctcacaagcc	1260
atttcgatgg	gatcggggag	gaaaataacg	acattaagag	ctaaagcagg	gcatacagatt	1320
ctctttaatg	atcccatcga	gatggcaaac	ggaaataacc	agccagcgca	gtcttccaaa	1380
cttctaaaaa	ttaacgatgg	tgaaggatac	acaggggata	ttgtttttgc	taatggaagc	1440

```

agtactttgt accaaaatgt tacgatagag caaggaagga ttgttcttcg tgaaaaggca 1500
aaattatcag tgaattctct aagtcagaca ggtgggagtc tgtatatgga agctgggagt 1560
acattggatt ttgtaactcc acaaccacca caacagcctc ctgccgctaa tcagttgatc 1620
acgctttcca atctgcattt gtctctttct tctttgttag caaacaatgc agttacgaat 1680
cctcctacca atcctccagc gcaagattct catcctgcag tcattggtag cacaactgct 1740
ggttctgtta caattagtgg gcctatcttt tttgaggatt tggatgatac agcttatgat 1800
aggtatgatt ggctaggttc taatcaaaaa atcaatgtcc tgaaattaca gttagggact 1860
aagccccag ctaatgcccc atcagatttg actctaggga atgagatgcc taagtatggc 1920
tatcaaggaa gctggaagct tgcgtgggat cctaatacag caaataatgg tccttatact 1980
ctgaaagcta catggactaa aactgggtaa 2010

```

<210> 12
 <211> 669
 <212> PRT
 <213> Chlamydia trachomatis

<400> 12

```

Ala Glu Ile Met Ile Pro Gln Gly Ile Tyr Asp Gly Glu Thr Leu Thr
1      5      10      15
Val Ser Phe Pro Tyr Thr Val Ile Gly Asp Pro Ser Gly Thr Thr Val
20     25     30
Phe Ser Ala Gly Glu Leu Thr Leu Lys Asn Leu Asp Asn Ser Ile Ala
35     40     45
Ala Leu Pro Leu Ser Cys Phe Gly Asn Leu Leu Gly Ser Phe Thr Val
50     55     60
Leu Gly Arg Gly His Ser Leu Thr Phe Glu Asn Ile Arg Thr Ser Thr
65     70     75     80
Asn Gly Ala Ala Leu Ser Asn Ser Ala Ala Asp Gly Leu Phe Thr Ile
85     90     95
Glu Gly Phe Lys Glu Leu Ser Phe Ser Asn Cys Asn Ser Leu Leu Ala
100    105    110
Val Leu Pro Ala Ala Thr Thr Asn Lys Gly Ser Gln Thr Pro Thr Thr
115    120    125
Thr Ser Thr Pro Ser Asn Gly Thr Ile Tyr Ser Lys Thr Asp Leu Leu
130    135    140
Leu Leu Asn Asn Glu Lys Phe Ser Phe Tyr Ser Asn Leu Val Ser Gly
145    150    155    160
Asp Gly Gly Ala Ile Asp Ala Lys Ser Leu Thr Val Gln Gly Ile Ser
165    170    175
Lys Leu Cys Val Phe Gln Glu Asn Thr Ala Gln Ala Asp Gly Gly Ala
180    185    190
Cys Gln Val Val Thr Ser Phe Ser Ala Met Ala Asn Glu Ala Pro Ile
195    200    205
Ala Phe Val Ala Asn Val Ala Gly Val Arg Gly Gly Ile Ala Ala
210    215    220
Val Gln Asp Gly Gln Gln Gly Val Ser Ser Ser Thr Ser Thr Glu Asp
225    230    235    240
Pro Val Val Ser Phe Ser Arg Asn Thr Ala Val Glu Phe Asp Gly Asn
245    250    255
Val Ala Arg Val Gly Gly Gly Ile Tyr Ser Tyr Gly Asn Val Ala Phe
260    265    270
Leu Asn Asn Gly Lys Thr Leu Phe Leu Asn Asn Val Ala Ser Pro Val
275    280    285
Tyr Ile Ala Ala Lys Gln Pro Thr Ser Gly Gln Ala Ser Asn Thr Ser
290    295    300
Asn Asn Tyr Gly Asp Gly Gly Ala Ile Phe Cys Lys Asn Gly Ala Gln
305    310    315    320
Ala Gly Ser Asn Asn Ser Gly Ser Val Ser Phe Asp Gly Glu Gly Val
325    330    335

```

Val Phe Phe Ser Ser Asn Val Ala Ala Gly Lys Gly Gly Ala Ile Tyr
 340 345 350
 Ala Lys Lys Leu Ser Val Ala Asn Cys Gly Pro Val Gln Phe Leu Arg
 355 360 365
 Asn Ile Ala Asn Asp Gly Gly Ala Ile Tyr Leu Gly Glu Ser Gly Glu
 370 375 380
 Leu Ser Leu Ser Ala Asp Tyr Gly Asp Ile Ile Phe Asp Gly Asn Leu
 385 390 395 400
 Lys Arg Thr Ala Lys Glu Asn Ala Ala Asp Val Asn Gly Val Thr Val
 405 410 415
 Ser Ser Gln Ala Ile Ser Met Gly Ser Gly Gly Lys Ile Thr Thr Leu
 420 425 430
 Arg Ala Lys Ala Gly His Gln Ile Leu Phe Asn Asp Pro Ile Glu Met
 435 440 445
 Ala Asn Gly Asn Asn Gln Pro Ala Gln Ser Ser Lys Leu Leu Lys Ile
 450 455 460
 Asn Asp Gly Glu Gly Tyr Thr Gly Asp Ile Val Phe Ala Asn Gly Ser
 465 470 475 480
 Ser Thr Leu Tyr Gln Asn Val Thr Ile Glu Gln Gly Arg Ile Val Leu
 485 490 495
 Arg Glu Lys Ala Lys Leu Ser Val Asn Ser Leu Ser Gln Thr Gly Gly
 500 505 510
 Ser Leu Tyr Met Glu Ala Gly Ser Thr Leu Asp Phe Val Thr Pro Gln
 515 520 525
 Pro Pro Gln Gln Pro Pro Ala Ala Asn Gln Leu Ile Thr Leu Ser Asn
 530 535 540
 Leu His Leu Ser Leu Ser Ser Leu Leu Ala Asn Asn Ala Val Thr Asn
 545 550 555 560
 Pro Pro Thr Asn Pro Pro Ala Gln Asp Ser His Pro Ala Val Ile Gly
 565 570 575
 Ser Thr Thr Ala Gly Ser Val Thr Ile Ser Gly Pro Ile Phe Phe Glu
 580 585 590
 Asp Leu Asp Asp Thr Ala Tyr Asp Arg Tyr Asp Trp Leu Gly Ser Asn
 595 600 605
 Gln Lys Ile Asn Val Leu Lys Leu Gln Leu Gly Thr Lys Pro Pro Ala
 610 615 620
 Asn Ala Pro Ser Asp Leu Thr Leu Gly Asn Glu Met Pro Lys Tyr Gly
 625 630 635 640
 Tyr Gln Gly Ser Trp Lys Leu Ala Trp Asp Pro Asn Thr Ala Asn Asn
 645 650 655
 Gly Pro Tyr Thr Leu Lys Ala Thr Trp Thr Lys Thr Gly
 660 665

<210> 13
 <211> 3519
 <212> DNA
 <213> Chlamydia trachomatis

<400> 13

agttgcgtag	atcttcatgc	tggaggacag	tctgtaaatg	agctggtata	tgtaggccct	60
caagcggttt	tattgttaga	ccaaattcga	gatctattcg	ttgggtctaa	agatagtcag	120
gctgaaggac	agtatagggt	aattgtagga	gatccaagtt	ctttccaaga	gaaagatgca	180
gatactcttc	ccgggaaggt	agagcaaagt	actttgttct	cagtaaccaa	tcccggtggt	240
ttccaaggtg	tggaccaaca	ggatcaagtc	tcttcccaag	ggttaatttg	tagttttacg	300
agcagcaacc	ttgattctcc	ccgtgacgga	gaatcttttt	taggtattgc	ttttgttggg	360
gatagtagta	aggctggaat	cacattaact	gacgtgaaag	cttctttgtc	tggagcggct	420
ttatattcta	cagaagatct	tatctttgaa	aagattaagg	gtggattgga	atttgcacat	480
tggtcttctc	tagaacaggg	gggagcttgt	gcagctcaaa	gtattttgat	tcattgattgt	540
caaggattgc	aggttaaaca	ctgtactaca	gccgtgaatg	ctgaggggtc	tagtgcggaat	600

gatcatcttg	gatttggagg	aggecgctt	tttgttacgg	gttctctt	tggagagaaa	660
agtctctata	tgcctgcagg	agatatggta	gttgcgaatt	gtgatggggc	tatatctttt	720
gaaggaaaca	gcgcgaactt	tgctaattga	ggagcgattg	ctgcctctgg	gaaagtgcct	780
tttgtcgcta	atgataaaaa	gacttctttt	atagagaacc	gagctttgtc	tggaggagcg	840
attgcagcct	cttctgatat	tgcttttcaa	aactgcgcag	aactagtttt	caaaggcaat	900
tgtgcaattg	gaacagagga	taaaggttct	ttaggtggag	gggctatata	ttctctaggc	960
accgttcttt	tgcaagggaa	tcacgggata	acttgtgata	agaatgagtc	tgcttcgcaa	1020
ggaggcgcca	tttttggcaa	aaattgtcag	atttctgaca	acgagggggc	agtgggtttt	1080
agagatagta	cagcttgctt	aggaggagcg	gctattgcag	ctcaagaaat	tgtttctatt	1140
cagaacaatc	aggctgggat	ttccttcgag	ggaggtaagg	ctagtttcgg	aggaggtatt	1200
gcgtgtggat	ctttttcttc	cgcaggcggt	gcttctgttt	tagggactat	tgatatttct	1260
aagaatttag	gcgcgatttc	gttctctcgt	actttatgta	cgacctcaga	tttaggacaa	1320
atggagtacc	agggaggagg	agctctat	ggtgaaaata	tttctctt	tgagaatgct	1380
ggtgtgctca	cctttaaaga	caacattgtg	aagacttttg	cttcgaatgg	gaaaattctg	1440
ggaggaggag	cgatttttag	tactggtaag	gtggaaatta	ccaataattc	cggaggaatt	1500
tcttttacag	gaaatgcgag	agctccacaa	gctcttccaa	ctcaagagga	gtttccttta	1560
ttcagcaaaa	aagaagggcg	accactctct	tcaggatatt	ctgggggagg	agcgatttta	1620
ggaagagaag	tagctattct	ccacaacgct	gcagtagtat	ttgagcaaaa	tcgtttgcag	1680
tgacgcgaag	aagaagcgac	attattaggt	tggtgtggag	gagggcgctg	tcattgggatg	1740
gatagcactt	cgattgttgg	caactcttca	gtaagatttg	gtaataatta	cgcaatggga	1800
caaggagtct	caggaggagc	tcttttatct	aaaacagtgc	agttagctgg	aaatggaagc	1860
gtcgattttt	ctcgaaatat	tgctagtgtg	ggaggaggag	ctcttcaagc	ttctgaagga	1920
aattgtgagc	tagttgataa	cggctatgtg	ctattcagag	ataatcgagg	gagggtttat	1980
gggggtgcta	tttcttgctt	acgtggagat	gtagtcat	ctggaaacaa	gggtagagtt	2040
gaatttaaag	acaacatagc	aacacgtctt	tatgtggaag	aaactgtaga	aaagggttgaa	2100
gaggtagagc	cagctcctga	gcaaaaagac	aataatgagc	tttctttctt	agggagtgtg	2160
gaacagagtt	ttattactgc	agctaataca	gctcttttcg	catctgaaga	tggggattta	2220
tcacctgagt	catccatttc	ttctgaagaa	cttgcgaaaa	gaagagagtg	tgctggagga	2280
gctatttttg	caaaacgggt	tcgtattgta	gataaccaag	aggccgttgt	attctcgaat	2340
aacttctctg	atatttatgg	cggcgccatt	tttacagggt	ctcttcgaga	agaggataag	2400
ttagatgggc	aaatccctga	agtcttgatc	tcaggcaatg	caggggatgt	tgtttttctc	2460
ggaaattcct	cgaagcgtga	tgagcatctt	cctcatagag	gtgggggagc	catttgact	2520
caaaatttga	cgatttctca	gaatacaggg	aatgttctgt	tttataacaa	cgtggcctgt	2580
tcggggaggag	ctgttcgtat	agaggatcat	ggtaatgttc	ttttagaagc	ttttggagga	2640
gatattgttt	ttaaaggaaa	ttcttctt	agagcacaa	gatccgatgc	tatctatttt	2700
gcaggtaaa	aatcgcatat	tacagccctg	aatgctacgg	aaggacatgc	tattgttttc	2760
cacgacgcac	tagtttttga	aaatctaaaa	gaaaggaaat	ctgctgaagt	attgttaatc	2820
aatagtcgag	aaaatccagg	ttacactgga	tctattcgat	ttttagaagc	agaaagttaa	2880
gttcctcaat	gtattcatgt	acaacaagga	agccttgagt	tgctaaatgg	agctacatta	2940
tgtagttatg	gttttaaa	agatgctgga	gctaagttgg	tattggctgc	tggaatctaa	3000
ctgaagattt	tagattcagg	aactcctgta	caagggcatg	ctatcagtaa	acctgaagca	3060
gaaatcgagt	catcttctga	accagagggt	gcacattctc	tttggattgc	gaagaatgct	3120
caaacaacag	ttcctatgg	tgatatccat	actatttctg	tagatttagc	ctccttctct	3180
tctagtcaac	aggaggggac	agtagaagct	cctcaggtta	ttgttcctgg	aggaagtatt	3240
gttcgatctg	gagagcttaa	tttggagtta	gttaacacaa	caggtactgg	ttatgaaaat	3300
catgctttgt	tgaagaatga	ggctaaaagt	ccattgatgt	ctttcgttgc	ttctagtgat	3360
gaagcttcag	ccgaaatcag	taacttgcg	gtttctgatt	tacagattca	tgtagcaact	3420
ccagagattg	aagaagacac	atacggccat	atgggagatt	ggtctgaggc	taaaattcaa	3480
gatggaactc	ttgtcattag	ttggaatcct	actggataa			3519

<210> 14
 <211> 1172
 <212> PRT
 <213> Chlamydia trachomatis

<400> 14

Ser Cys Val Asp Leu His Ala Gly Gly Gln Ser Val Asn Glu Leu Val
 1 5 10 15
 Tyr Val Gly Pro Gln Ala Val Leu Leu Leu Asp Gln Ile Arg Asp Leu

	980		985		990
Leu Val	Leu Ala Ala Gly Ser Lys	Leu Lys Ile Leu Asp Ser Gly Thr			
	995	1000		1005	
Pro Val	Gln Gly His Ala Ile	Ser Lys Pro Glu Ala	Glu Ile Glu		
1010		1015		1020	
Ser Ser	Ser Glu Pro Glu Gly	Ala His Ser Leu Trp	Ile Ala Lys		
1025		1030		1035	
Asn Ala	Gln Thr Thr Val Pro	Met Val Asp Ile His	Thr Ile Ser		
1040		1045		1050	
Val Asp	Leu Ala Ser Phe Ser	Ser Ser Gln Gln Glu	Gly Thr Val		
1055		1060		1065	
Glu Ala	Pro Gln Val Ile Val	Pro Gly Gly Ser Tyr	Val Arg Ser		
1070		1075		1080	
Gly Glu	Leu Asn Leu Glu Leu	Val Asn Thr Thr Gly	Thr Gly Tyr		
1085		1090		1095	
Glu Asn	His Ala Leu Leu Lys	Asn Glu Ala Lys Val	Pro Leu Met		
1100		1105		1110	
Ser Phe	Val Ala Ser Ser Asp	Glu Ala Ser Ala Glu	Ile Ser Asn		
1115		1120		1125	
Leu Ser	Val Ser Asp Leu Gln	Ile His Val Ala Thr	Pro Glu Ile		
1130		1135		1140	
Glu Glu	Asp Thr Tyr Gly His	Met Gly Asp Trp Ser	Glu Ala Lys		
1145		1150		1155	
Ile Gln	Asp Gly Thr Leu Val	Ile Ser Trp Asn Pro	Thr Gly		
1160		1165		1170	

<210> 15
 <211> 1266
 <212> DNA
 <213> Chlamydia trachomatis

<400> 15

atgactgcat	caggaggagc	tggaggggcta	ggcagcaccc	aaacagtaga	cgttgcgcga	60
gcacaagctg	ctgcagctac	tcaagatgca	caagagggtta	tcggctctca	ggaagcttct	120
gaggcaagta	tgctcaaagg	atgtgaggat	ctcataaatc	ctgcagctgc	aaccggaatc	180
aaaaaaaaag	aagagaagtt	tgaatcatta	gaagctcgtc	gcaaaccaac	agcggataaa	240
gcagaaaaga	aatccgagag	cacagaggaa	aaaggcgata	ctcctcttga	agatcgtttc	300
acagaagatc	tttccgaagt	ctccggagaa	gattttcgag	gattgaaaaa	ttcgttcgat	360
gatgattctt	ctcctgaaga	aattctcgat	gcgctcacia	gtaaattttc	tgatcccaca	420
ataaaggatc	tagctcttga	ttatctaatt	caaacagctc	cctctgatag	gaaacttaag	480
tccgctctca	ttcaggcaaa	gcatcaactg	atgagccaga	atcctcaggc	gattgttgga	540
ggacgcaatg	ttctgttagc	ttcagaaacc	tttgettcca	gagcaaatac	atctccttca	600
tcgcttcgct	ccttatatct	ccaagtaacc	tcatccccct	ctaattgtga	taatttacgt	660
caaatgcttg	cttcttaact	gccatcagag	aaaaccgctg	ttatggagtt	tctagtaaatt	720
ggcatggtag	cagatttaaa	atcggagggc	ccttcatttc	ctcctgcaaa	attgcaagta	780
tatatgacgg	aactaagcaa	tctccaagcc	ttacactctg	tagatagctt	ttttgataga	840
aatattggga	acttggaaaa	tagcttaaac	catgaaggac	atgcccctat	tccatcctta	900
acgacaggaa	atttaactaa	aaccttctta	caattagtag	aagataaatt	cccttcctct	960
tccaaagctc	aaaaggcatt	aatgaactg	gtaggcccag	atactggtcc	tcaaactgaa	1020
gttttaaaact	tattcttccg	cgctcttaat	ggctgttcgc	ctagaatatt	ctctggagct	1080
gaaaaaaaaac	agcagctggc	atcggttatc	acaaatacgc	tagatgcat	aatgaggat	1140
aatgaggatt	atcctaaacc	aggtgacttc	ccacgatctt	ccttctctag	tacgcctcct	1200
catgctccag	tacotcaatc	tgagattcca	acgtcaccta	cctcaacaca	gcctccatca	1260
ccctaa						1266

<210> 16
 <211> 421
 <212> PRT
 <213> Chlamydia trachomatis

<400> 16

Met	Thr	Ala	Ser	Gly	Gly	Ala	Gly	Gly	Leu	Gly	Ser	Thr	Gln	Thr	Val
1			5					10					15		
Asp	Val	Ala	Arg	Ala	Gln	Ala	Ala	Ala	Thr	Gln	Asp	Ala	Gln	Glu	
		20					25					30			
Val	Ile	Gly	Ser	Gln	Glu	Ala	Ser	Glu	Ala	Ser	Met	Leu	Lys	Gly	Cys
	35					40					45				
Glu	Asp	Leu	Ile	Asn	Pro	Ala	Ala	Ala	Thr	Arg	Ile	Lys	Lys	Lys	Glu
	50					55					60				
Glu	Lys	Phe	Glu	Ser	Leu	Glu	Ala	Arg	Arg	Lys	Pro	Thr	Ala	Asp	Lys
65					70					75					80
Ala	Glu	Lys	Lys	Ser	Glu	Ser	Thr	Glu	Glu	Lys	Gly	Asp	Thr	Pro	Leu
				85					90					95	
Glu	Asp	Arg	Phe	Thr	Glu	Asp	Leu	Ser	Glu	Val	Ser	Gly	Glu	Asp	Phe
		100						105					110		
Arg	Gly	Leu	Lys	Asn	Ser	Phe	Asp	Asp	Asp	Ser	Ser	Pro	Glu	Glu	Ile
	115						120					125			
Leu	Asp	Ala	Leu	Thr	Ser	Lys	Phe	Ser	Asp	Pro	Thr	Ile	Lys	Asp	Leu
	130					135					140				
Ala	Leu	Asp	Tyr	Leu	Ile	Gln	Thr	Ala	Pro	Ser	Asp	Arg	Lys	Leu	Lys
145					150					155					160
Ser	Ala	Leu	Ile	Gln	Ala	Lys	His	Gln	Leu	Met	Ser	Gln	Asn	Pro	Gln
			165						170						175
Ala	Ile	Val	Gly	Arg	Asn	Val	Leu	Leu	Ala	Ser	Glu	Thr	Phe	Ala	
	180						185					190			
Ser	Arg	Ala	Asn	Thr	Ser	Pro	Ser	Ser	Leu	Arg	Ser	Leu	Tyr	Leu	Gln
	195						200					205			
Val	Thr	Ser	Ser	Pro	Ser	Asn	Cys	Asp	Asn	Leu	Arg	Gln	Met	Leu	Ala
	210					215					220				
Ser	Tyr	Leu	Pro	Ser	Glu	Lys	Thr	Ala	Val	Met	Glu	Phe	Leu	Val	Asn
225					230					235					240
Gly	Met	Val	Ala	Asp	Leu	Lys	Ser	Glu	Gly	Pro	Ser	Ile	Pro	Pro	Ala
			245						250					255	
Lys	Leu	Gln	Val	Tyr	Met	Thr	Glu	Leu	Ser	Asn	Leu	Gln	Ala	Leu	His
	260							265					270		
Ser	Val	Asp	Ser	Phe	Phe	Asp	Arg	Asn	Ile	Gly	Asn	Leu	Glu	Asn	Ser
	275						280					285			
Leu	Lys	His	Glu	Gly	His	Ala	Pro	Ile	Pro	Ser	Leu	Thr	Thr	Gly	Asn
	290					295					300				
Leu	Thr	Lys	Thr	Phe	Leu	Gln	Leu	Val	Glu	Asp	Lys	Phe	Pro	Ser	Ser
305					310					315					320
Ser	Lys	Ala	Gln	Lys	Ala	Leu	Asn	Glu	Leu	Val	Gly	Pro	Asp	Thr	Gly
			325						330					335	
Pro	Gln	Thr	Glu	Val	Leu	Asn	Leu	Phe	Phe	Arg	Ala	Leu	Asn	Gly	Cys
		340						345					350		
Ser	Pro	Arg	Ile	Phe	Ser	Gly	Ala	Glu	Lys	Lys	Gln	Gln	Leu	Ala	Ser
	355						360						365		
Val	Ile	Thr	Asn	Thr	Leu	Asp	Ala	Ile	Asn	Ala	Asp	Asn	Glu	Asp	Tyr
	370					375					380				
Pro	Lys	Pro	Gly	Asp	Phe	Pro	Arg	Ser	Ser	Phe	Ser	Ser	Thr	Pro	Pro
385					390					395					400
His	Ala	Pro	Val	Pro	Gln	Ser	Glu	Ile	Pro	Thr	Ser	Pro	Thr	Ser	Thr
			405						410						415
Gln	Pro	Pro	Ser	Pro											
			420												

<210> 17

<211> 1170

<212> DNA
 <213> Chlamydia psitacii

<400> 17

atgaaaaaac	tcttgaaatc	ggcattattg	tttgccacta	cgggttccgc	tctctcctta	60
caagccttgc	ctgtagggaa	tccagctgaa	ccaagtttat	taattgatgg	cactatgtgg	120
gaaggcgctt	caggcgatcc	ttgtgatcct	tgctctactt	ggtgtgatgc	tatcagcatc	180
cgcgcagggg	actacggaga	ttatgttttc	gatcgcatct	taaaagttga	tgtaataaaa	240
actatcagca	tggggacagc	tccaactggg	aatgcagctg	ctgactttaa	aaccgttgca	300
gacaggaata	acatagccta	cggcaaacat	atgcaagatg	cagaatgggc	cacaaacgcg	360
gctttcttag	cattaaacat	ttgggatcgt	tttgatgtct	tctgcacatt	aggggcatct	420
aacggctatc	tcaaagcaaa	tgctgcagct	ttcaatctag	tcggcttact	tggggtaaca	480
ggaacagatc	ttcaaggcca	atatccaaac	gtagccatct	ctcaaggcct	tgtagagcct	540
tatactgaca	caaccttctc	ttggagcggt	ggtgcgcgtg	gagctttatg	ggaatgtggg	600
tgcgcaactt	taggagcaga	gttccaatat	gcgcagtcta	atcctaagat	cgaaatgctt	660
aatgtaattt	ctagcccaac	acaatttgtg	attcataagc	ctagaggata	taaagggaca	720
gcggccaact	tccctctgcc	tttaaccgct	ggaacagaga	gcgctactga	tactaaatca	780
gctacaatta	agtatcatga	atggcaaat	ggtttagctc	tttcttatag	attgaacatg	840
cttggttccat	atattggagt	aaactgggtc	agagctacat	ttgatgctga	ctctatccgc	900
attgctcagc	ctaaattacc	tacggccatt	ttaaacctaa	ctacatggaa	ccctacttta	960
ttagggggagg	ctactactat	aaacactgga	gcaaaatag	ctgaccagtt	acaaattgct	1020
tcgcttcaaa	tcaacaaaat	gaagtctaga	aaagcttgtg	gtattgctgt	tgggtgcaacc	1080
ttaattgatg	ctgacaaatg	gtcgatcact	ggtgaagctc	gcttaatcaa	cgaaagagct	1140
gctcacgtaa	acgctcaatt	cagattotaa				1170

<210> 18
 <211> 389
 <212> PRT
 <213> Chlamydia psitacii

<400> 18

Met	Lys	Lys	Leu	Leu	Lys	Ser	Ala	Leu	Leu	Phe	Ala	Thr	Thr	Gly	Ser
1				5					10					15	
Ala	Leu	Ser	Leu	Gln	Ala	Leu	Pro	Val	Gly	Asn	Pro	Ala	Glu	Pro	Ser
			20					25					30		
Leu	Leu	Ile	Asp	Gly	Thr	Met	Trp	Glu	Gly	Ala	Ser	Gly	Asp	Pro	Cys
		35					40					45			
Asp	Pro	Cys	Ser	Thr	Trp	Cys	Asp	Ala	Ile	Ser	Ile	Arg	Ala	Gly	Tyr
	50					55					60				
Tyr	Gly	Asp	Tyr	Val	Phe	Asp	Arg	Ile	Leu	Lys	Val	Asp	Val	Asn	Lys
65					70				75					80	
Thr	Ile	Ser	Met	Gly	Thr	Ala	Pro	Thr	Gly	Asn	Ala	Ala	Ala	Asp	Phe
			85					90						95	
Lys	Thr	Val	Ala	Asp	Arg	Asn	Asn	Ile	Ala	Tyr	Gly	Lys	His	Met	Gln
			100				105						110		
Asp	Ala	Glu	Trp	Ser	Thr	Asn	Ala	Ala	Phe	Leu	Ala	Leu	Asn	Ile	Trp
		115					120					125			
Asp	Arg	Phe	Asp	Val	Phe	Cys	Thr	Leu	Gly	Ala	Ser	Asn	Gly	Tyr	Leu
	130					135					140				
Lys	Ala	Asn	Ala	Ala	Ala	Phe	Asn	Leu	Val	Gly	Leu	Leu	Gly	Val	Thr
145					150					155				160	
Gly	Thr	Asp	Leu	Gln	Gly	Gln	Tyr	Pro	Asn	Val	Ala	Ile	Ser	Gln	Gly
			165					170						175	
Leu	Val	Glu	Leu	Tyr	Thr	Asp	Thr	Thr	Phe	Ser	Trp	Ser	Val	Gly	Ala
		180					185						190		
Arg	Gly	Ala	Leu	Trp	Glu	Cys	Gly	Cys	Ala	Thr	Leu	Gly	Ala	Glu	Phe
	195					200						205			
Gln	Tyr	Ala	Gln	Ser	Asn	Pro	Lys	Ile	Glu	Met	Leu	Asn	Val	Ile	Ser

210	215	220
Ser Pro Thr Gln Phe Val Ile His Lys Pro Arg Gly Tyr Lys Gly Thr		
225	230	235
Ala Ala Asn Phe Pro Leu Pro Leu Thr Ala Gly Thr Glu Ser Ala Thr		240
	245	250
Asp Thr Lys Ser Ala Thr Ile Lys Tyr His Glu Trp Gln Ile Gly Leu		255
	260	265
Ala Leu Ser Tyr Arg Leu Asn Met Leu Val Pro Tyr Ile Gly Val Asn		270
	275	280
Trp Ser Arg Ala Thr Phe Asp Ala Asp Ser Ile Arg Ile Ala Gln Pro		285
	290	295
Lys Leu Pro Thr Ala Ile Leu Asn Leu Thr Thr Trp Asn Pro Thr Leu		300
305	310	315
Leu Gly Glu Ala Thr Thr Ile Asn Thr Gly Ala Lys Tyr Ala Asp Gln		320
	325	330
Leu Gln Ile Ala Ser Leu Gln Ile Asn Lys Met Lys Ser Arg Lys Ala		335
	340	345
Cys Gly Ile Ala Val Gly Ala Thr Leu Ile Asp Ala Asp Lys Trp Ser		350
	355	360
Ile Thr Gly Glu Ala Arg Leu Ile Asn Glu Arg Ala Ala His Val Asn		365
	370	375
Ala Gln Phe Arg Phe		380
385		

<210> 19
 <211> 1170
 <212> DNA
 <213> Chlamydia pneumoniae

<400> 19

atgaaaaaac	tcttaaagtc	ggcgttatta	tccgccgcat	ttgctgggttc	tggttggtcc	60
ttacaagcct	tgccgttagg	gaacccttct	gatccaagct	tattaattga	tggtacaata	120
tgggaagggtg	ctgcaggaga	tccttgcgat	ccttgcgcta	cttggtgcga	cgctattagc	180
ttacgtgctg	gattttacgg	agactatggt	ttcgaccgta	tcttaaaagt	agatgcacct	240
aaaacatttt	ctatgggagc	caagcctact	ggatccgctg	ctgcaaacta	tactactgcc	300
gtagatagac	ctaaccgggc	ctacaataag	catttacacg	atgcagagtg	gttactaat	360
gcaggcttca	ttgccttaaa	catttgggat	cgctttgatg	ttttctgtac	tttaggagct	420
tctaattggt	acattagagg	aaactctaca	gcgttcaatc	tcgttggttt	attcggagtt	480
aaagggtacta	ctgtaaatgc	aaatgaacta	ccaaacgttt	ctttaagtaa	cggagttggt	540
gaactttaca	cagacacctc	tttctcttgg	agcgtaggcg	ctcgtggagc	cttatgggaa	600
tgcggttggtg	caactttggg	agctgaattc	caatatgcac	agtccaaacc	taaagttgaa	660
gaacttaatg	tgatctgtaa	cgtatcgcaa	ttctctgtaa	acaaacccaa	gggctataaa	720
ggcggttgctt	tccccttgcc	aacagacgct	ggcgtagcaa	cagctactgg	aacaaagtct	780
gcgaccatca	attatcatga	atggcaagta	ggagcctctc	tatcttacag	actaaactct	840
ttagtgccat	acattggagt	acaatggtct	cgagcaactt	ttgatgctga	taacatccgc	900
attgctcagc	caaaactacc	tacagctggt	ttaaacttaa	ctgcatggaa	cccttcttta	960
ctaggaaatg	ccacagcatt	gtctactact	gattcggtct	cagacttcat	gcaaattggt	1020
tcctgtcaga	tcaacaagtt	taaatctaga	aaagcttggtg	gagttactgt	aggagctact	1080
ttagttgatg	ctgataaatg	gtcacttact	gcagaagctc	gtttaattaa	cgagagagct	1140
gtcacgatat	ctggtcagtt	cagattctaa				1170

<210> 20
 <211> 389
 <212> PRT
 <213> Chlamydia pneumoniae

<400> 20

Met Lys Lys Leu Leu Lys Ser Ala Leu Leu Ser Ala Ala Phe Ala Gly

1	5	10	15
Ser Val Gly Ser Leu Gln Ala Leu Pro Val Gly Asn Pro Ser Asp Pro			
20	25	30	
Ser Leu Leu Ile Asp Gly Thr Ile Trp Glu Gly Ala Ala Gly Asp Pro			
35	40	45	
Cys Asp Pro Cys Ala Thr Trp Cys Asp Ala Ile Ser Leu Arg Ala Gly			
50	55	60	
Phe Tyr Gly Asp Tyr Val Phe Asp Arg Ile Leu Lys Val Asp Ala Pro			
65	70	75	80
Lys Thr Phe Ser Met Gly Ala Lys Pro Thr Gly Ser Ala Ala Ala Asn			
85	90	95	
Tyr Thr Thr Ala Val Asp Arg Pro Asn Pro Ala Tyr Asn Lys His Leu			
100	105	110	
His Asp Ala Glu Trp Phe Thr Asn Ala Gly Phe Ile Ala Leu Asn Ile			
115	120	125	
Trp Asp Arg Phe Asp Val Phe Cys Thr Leu Gly Ala Ser Asn Gly Tyr			
130	135	140	
Ile Arg Gly Asn Ser Thr Ala Phe Asn Leu Val Gly Leu Phe Gly Val			
145	150	155	160
Lys Gly Thr Thr Val Asn Ala Asn Glu Leu Pro Asn Val Ser Leu Ser			
165	170	175	
Asn Gly Val Val Glu Leu Tyr Thr Asp Thr Ser Phe Ser Trp Ser Val			
180	185	190	
Gly Ala Arg Gly Ala Leu Trp Glu Cys Gly Cys Ala Thr Leu Gly Ala			
195	200	205	
Glu Phe Gln Tyr Ala Gln Ser Lys Pro Lys Val Glu Glu Leu Asn Val			
210	215	220	
Ile Cys Asn Val Ser Gln Phe Ser Val Asn Lys Pro Lys Gly Tyr Lys			
225	230	235	240
Gly Val Ala Phe Pro Leu Pro Thr Asp Ala Gly Val Ala Thr Ala Thr			
245	250	255	
Gly Thr Lys Ser Ala Thr Ile Asn Tyr His Glu Trp Gln Val Gly Ala			
260	265	270	
Ser Leu Ser Tyr Arg Leu Asn Ser Leu Val Pro Tyr Ile Gly Val Gln			
275	280	285	
Trp Ser Arg Ala Thr Phe Asp Ala Asp Asn Ile Arg Ile Ala Gln Pro			
290	295	300	
Lys Leu Pro Thr Ala Val Leu Asn Leu Thr Ala Trp Asn Pro Ser Leu			
305	310	315	320
Leu Gly Asn Ala Thr Ala Leu Ser Thr Thr Asp Ser Phe Ser Asp Phe			
325	330	335	
Met Gln Ile Val Ser Cys Gln Ile Asn Lys Phe Lys Ser Arg Lys Ala			
340	345	350	
Cys Gly Val Thr Val Gly Ala Thr Leu Val Asp Ala Asp Lys Trp Ser			
355	360	365	
Leu Thr Ala Glu Ala Arg Leu Ile Asn Glu Arg Ala Ala His Val Ser			
370	375	380	
Gly Gln Phe Arg Phe			
385			

<210> 21
 <211> 1776
 <212> DNA
 <213> Chlamydia trachomatis

<400> 21

atgagcatca	ggggagtagg	aggcaacggg	aatagtcgaa	tcccttctca	taatggggat	60
ggatcgaatc	gcagaagtca	aaatacgaag	ggtaataata	aagttgaaga	tcgagtttgt	120
tctctatatt	catctcgtag	taacgaaaat	agagaatctc	cttatgcagt	agtagacgtc	180

agctctatga tcgagagcac cccaacgagt ggagagacga caagagcttc gcgtggagtg 240
 ttcagtcggt tccaaagagg tttagtacga gtagctgaca aagtaagacg agctgttcag 300

tcaagtagtc gtactgctcg tgggtgcaagt tctgggtata gggagtattc tccttcagca 420
 gctagagggc tgcgtcttat gttcacagat ttctggagaa ctctgggtttt acgccagacc 480
 tctcctatgg ctggagtttt tgggaatctt gatgtgaacg aggctcgttt gatggctgcg 540
 tacacaagtg agtgccgcca tcatttagaa gcgaacaagt tggctggccc tgacggggtta 600
 gcggccgccc gggaaattgc taaaagatgg gagcaaagag ttagagatct acaagataaa 660
 ggtgctgcac gaaaattatt aaatgatcct ttaggcccgc gaacaccta ttatcagagc 720
 aaaaatccag gtgagtatac tgtagggaat tccatgtttt acgatgggtc tcaggtagcg 780
 aatctccaga acgtcgacac tggtttttgg ctggacatga gcaatctctc agacgttgta 840
 ttatccagag agattcaaac aggacttcga gcacgagcta ctttgggaaga atccatgccg 900
 atgttagaga atttagaaga gcgtttttaga cgtttgcaag aaacttgtga tgccggtcgt 960
 actgagatag aagaatcggg atggactcga ggtccgcga caagaatgga aggcgatgag 1020
 gcgcaaggac cttctagagc acaacaagct tttcagagct ttgtaaata atgtaacagc 1080
 atcgagttct catttgggag ctttggagag catgtgcgag ttctctgcgc tagagtatca 1140
 cgaggattag ctgccgcagg agaggcgatt cgcgttgct tctcttggtg taaaggatcg 1200
 acgcatcgct acgctcctcg cgatgacctt tctcctgaag gtgcatcggt agcagagact 1260
 ttggctagat tcgcagatga tatgggaata gagcgaggtg ctgatggaac ctacgatatt 1320
 cctttggtag atgattggag aagaggggtt cctagtattg aaggagaagg atctgactcg 1380
 atctatgaaa tcatgatgcc tatctatgaa gttatggata tggatctaga aacacgaaga 1440
 tcttttgcgg tacagcaagg gcactatcag gaccgaagag cttcagatta tgacctcca 1500
 cgtgctagcg actatgattt gcctagaagc ccatatccta ctccaccttt gcctcctaga 1560
 tatcagctac agaatatgga tgtagaagca gggttccgtg aggcagttta tgcttctttt 1620
 gtagcaggaa tgtacaatta tgtagtgaac cagccgcaag agcgtattcc caatagtcag 1680
 caggtggaag ggattctgcg tgatatgctt accaacgggt cacagacatt tagagacctg 1740
 atgaggcggt ggaatagaga agtcgatagg gaataa 1776

<210> 22

<211> 591

<212> PRT

<213> Chlamydia trachomatis

<400> 22

Met Ser Ile Arg Gly Val Gly Gly Asn Gly Asn Ser Arg Ile Pro Ser
 1 5 10 15
 His Asn Gly Asp Gly Ser Asn Arg Arg Ser Gln Asn Thr Lys Gly Asn
 20 25 30
 Asn Lys Val Glu Asp Arg Val Cys Ser Leu Tyr Ser Ser Arg Ser Asn
 35 40 45
 Glu Asn Arg Glu Ser Pro Tyr Ala Val Val Asp Val Ser Ser Met Ile
 50 55 60
 Glu Ser Thr Pro Thr Ser Gly Glu Thr Thr Arg Ala Ser Arg Gly Val
 65 70 75 80
 Phe Ser Arg Phe Gln Arg Gly Leu Val Arg Val Ala Asp Lys Val Arg
 85 90 95
 Arg Ala Val Gln Cys Ala Trp Ser Ser Val Ser Thr Arg Arg Ser Ser
 100 105 110
 Ala Thr Arg Ala Ala Glu Ser Gly Ser Ser Ser Arg Thr Ala Arg Gly
 115 120 125
 Ala Ser Ser Gly Tyr Arg Glu Tyr Ser Pro Ser Ala Ala Arg Gly Leu
 130 135 140
 Arg Leu Met Phe Thr Asp Phe Trp Arg Thr Arg Val Leu Arg Gln Thr
 145 150 155 160
 Ser Pro Met Ala Gly Val Phe Gly Asn Leu Asp Val Asn Glu Ala Arg
 165 170 175
 Leu Met Ala Ala Tyr Thr Ser Glu Cys Ala Asp His Leu Glu Ala Asn
 180 185 190
 Lys Leu Ala Gly Pro Asp Gly Val Ala Ala Ala Arg Glu Ile Ala Lys

aatgatgaaa	attcagtttc	cccttattct	gtggtggatg	tcactgattt	aatagagagc	240
ggagagtctt	ctaggcatgt	aataaagaaa	tctatagaaa	cagaagaagc	tgctcatcga	300
gaatctagt	tagagggggc	tgggcattct	tctcgcgaa	tatttgagc	gttgcaagca	360
ggattaggac	gtctggctag	aagagtggg	gaagctgtca	gaaatactgt	aggctctatc	420
ttccacaaa	gagctgggtc	tgagcaaa	acaggcaaa	ctcggacaaa	atattccct	480
tcagcatcaa	gaggattacg	cctcatgttc	acagacttct	ggcgatatcg	agttttgcat	540
cggaaatcct	ctatggatgg	actttttgca	aagcttgatg	ccgatgaggc	tgaagatatg	600
gcagcttaca	cgaagagta	tgtagcaat	ctagaaaaac	gaggagcagc	tgatcgagaa	660
actatagaac	actgtcaa	gtagctaaa	aattgggaaa	aaagagctag	agatttgcca	720
gacatggggg	cgcacaaaa	atttttacgc	gacctttttg	gtaagagtga	tcctaagtat	780
aaggggacac	tgcttgga	atacactgtc	ggaaatacca	tgttttacga	tggaaccaggt	840
gtgagcaaac	tatcagaggt	tgatacaggt	ttttgggttg	acatggagaa	gctctcggat	900
gctgtcttgt	ctgcaaatat	tcaaaaagg	cttcgagctc	gatttgtttt	aaatcagctc	960
attccacagt	tagagagtct	agaagagcgt	tttagaaaac	tgagagagtgc	ttgcgatgag	1020
gctcgtgctt	cgtaaaggga	agcaggttgg	ataaagaag	gcaaggaacc	taacaaagcg	1080
caacgagctt	ttcggcgatt	tgtagaagaa	agccggaatc	tagagctttc	ttttggtagt	1140
tttgagaaaa	gtgctcgtcg	tctttccgct	cgtgtttccc	aagggttagc	tgctgcaggg	1200
gaggcaattc	gccgctgctt	tgattgtcgc	aaaggcaaat	attcccttaa	aaaggacttg	1260
tcttctgaag	aattaaattt	ggcagaagag	ttaattaggt	ttactgatga	gatggggata	1320
gagagagacc	cagatggaaa	ttacaatatt	ccttggttag	aaaactggag	aacaggagtt	1380
cctgttattg	aaggagaagg	ggcagaacat	atztatgaaa	cgatgatgcc	tgtccaggaa	1440
tcttttgagc	aggttatga	agttatggat	atgggattgg	aagagcgtag	ggattttgct	1500
gtgagtcaac	aacactatca	agttcctcct	agatcttcgt	tgaattacga	gactccgcga	1560
ttcagagaat	atgacgttcc	acgtaattcc	gctcgttctt	attacgatgt	tccaagagta	1620
cctcccaaaa	atgaggtaga	agagatgcat	gtgactaaag	gaatgaggag	ttctgtgtat	1680
gcttggtttg	tagcaggaat	gcgcaactac	attgtttcac	agccacaaga	acagattcca	1740
aattctgaac	aggtggagca	gcttttccaa	gagcttatta	acgatgggga	tcagataatt	1800
caagagctta	tgaagatatg	gaatgaggaa	ctagataatc	aataa		1845

<210> 24

<211> 614

<212> PRT

<213> Chlamydia muridarum

<400> 24

Met	Phe	Tyr	Phe	Leu	Gly	Trp	Phe	Val	Met	Gly	Ile	Lys	Gly	Val	Gly
1			5						10					15	
Gly	Ser	Gly	His	Ser	Asp	Tyr	Pro	Ile	Pro	Ser	His	Asn	Gly	Asp	Gly
			20					25					30		
Glu	Ser	Glu	Lys	Asn	Ser	Ser	Asp	Ser	Thr	Ser	Ser	Lys	Val	Asn	Ala
			35				40					45			
Lys	Val	Thr	Ser	Ser	Leu	Gln	Gly	Ala	Pro	Ser	Thr	Asn	Asp	Glu	Asn
			50			55					60				
Ser	Val	Ser	Pro	Tyr	Ser	Val	Val	Asp	Val	Thr	Asp	Leu	Ile	Glu	Ser
65				70					75					80	
Gly	Glu	Ser	Ser	Arg	His	Val	Ile	Lys	Lys	Ser	Ile	Glu	Thr	Glu	Glu
				85				90						95	
Ala	Ala	His	Arg	Glu	Ser	Ser	Val	Glu	Gly	Ala	Gly	His	Ser	Ser	Arg
			100					105					110		
Gly	Ile	Phe	Gly	Arg	Leu	Gln	Ala	Gly	Leu	Gly	Arg	Leu	Ala	Arg	Arg
			115				120					125			
Val	Gly	Glu	Ala	Val	Arg	Asn	Thr	Val	Gly	Ser	Ile	Phe	Pro	Gln	Arg
			130			135					140				
Ala	Gly	Ala	Glu	Gln	Arg	Thr	Gly	Lys	Ala	Arg	Thr	Lys	Tyr	Ser	Pro
145				150					155					160	
Ser	Ala	Ser	Arg	Gly	Leu	Arg	Leu	Met	Phe	Thr	Asp	Phe	Trp	Arg	Tyr
				165				170						175	
Arg	Val	Leu	His	Arg	Asn	Pro	Pro	Met	Asp	Gly	Leu	Phe	Ala	Lys	Leu
			180					185					190		

Asp	Ala	Asp	Glu	Ala	Glu	Asp	Met	Ala	Ala	Tyr	Thr	Lys	Glu	Tyr	Val
	195						200					205			
Ser	Asn	Leu	Glu	Lys	Arg	Gly	Ala	Ala	Asp	Arg	Glu	Thr	Ile	Glu	His
	210					215					220				
Cys	Gln	Met	Val	Ala	Lys	Asn	Trp	Glu	Lys	Arg	Ala	Arg	Asp	Leu	Arg
	225				230					235				240	
Asp	Met	Gly	Ala	Ala	Lys	Lys	Phe	Leu	Arg	Asp	Pro	Phe	Gly	Lys	Ser
				245					250					255	
Asp	Pro	Lys	Tyr	Lys	Gly	Thr	Leu	Pro	Gly	Glu	Tyr	Thr	Val	Gly	Asn
			260				265						270		
Thr	Met	Phe	Tyr	Asp	Gly	Pro	Gly	Val	Ser	Lys	Leu	Ser	Glu	Val	Asp
	275					280						285			
Thr	Gly	Phe	Trp	Leu	Asp	Met	Glu	Lys	Leu	Ser	Asp	Ala	Val	Leu	Ser
	290				295					300					
Ala	Asn	Ile	Gln	Lys	Gly	Leu	Arg	Ala	Arg	Phe	Val	Leu	Asn	Gln	Ser
	305				310					315				320	
Ile	Pro	Gln	Leu	Glu	Ser	Leu	Glu	Glu	Arg	Phe	Arg	Lys	Leu	Glu	Ser
			325						330					335	
Ala	Cys	Asp	Glu	Ala	Arg	Ala	Ser	Leu	Lys	Glu	Ala	Gly	Trp	Ile	Lys
		340					345						350		
Glu	Gly	Lys	Glu	Pro	Asn	Lys	Ala	Gln	Arg	Ala	Phe	Arg	Arg	Phe	Val
	355					360						365			
Glu	Glu	Ser	Arg	Asn	Leu	Glu	Leu	Ser	Phe	Gly	Ser	Phe	Gly	Glu	Ser
	370				375						380				
Ala	Arg	Arg	Leu	Ser	Ala	Arg	Val	Ser	Gln	Gly	Leu	Ala	Ala	Ala	Gly
	385				390					395					400
Glu	Ala	Ile	Arg	Arg	Cys	Phe	Asp	Cys	Arg	Lys	Gly	Lys	Tyr	Ser	Leu
			405					410						415	
Lys	Lys	Asp	Leu	Ser	Ser	Glu	Glu	Leu	Asn	Leu	Ala	Glu	Glu	Leu	Ile
		420						425						430	
Arg	Phe	Thr	Asp	Glu	Met	Gly	Ile	Glu	Arg	Asp	Pro	Asp	Gly	Asn	Tyr
	435					440						445			
Asn	Ile	Pro	Trp	Val	Glu	Asn	Trp	Arg	Thr	Gly	Val	Pro	Val	Ile	Glu
	450					455					460				
Gly	Glu	Gly	Ala	Glu	His	Ile	Tyr	Glu	Thr	Met	Met	Pro	Val	Gln	Glu
	465				470					475					480
Ser	Phe	Glu	Gln	Val	Tyr	Glu	Val	Met	Asp	Met	Gly	Leu	Glu	Glu	Arg
			485						490					495	
Arg	Asp	Phe	Ala	Val	Ser	Gln	Gln	His	Tyr	Gln	Val	Pro	Pro	Arg	Ser
		500						505					510		
Ser	Leu	Asn	Tyr	Glu	Thr	Pro	Arg	Phe	Arg	Glu	Tyr	Asp	Val	Pro	Arg
	515					520						525			
Asn	Ser	Ala	Arg	Ser	Tyr	Tyr	Asp	Val	Pro	Arg	Val	Pro	Pro	Gln	Asn
	530					535					540				
Glu	Val	Glu	Glu	Met	His	Val	Thr	Lys	Gly	Met	Arg	Ser	Ser	Val	Tyr
	545				550					555					560
Ala	Cys	Phe	Val	Ala	Gly	Met	Arg	Asn	Tyr	Ile	Val	Ser	Gln	Pro	Gln
			565						570					575	
Glu	Gln	Ile	Pro	Asn	Ser	Glu	Gln	Val	Glu	Gln	Leu	Phe	Gln	Glu	Leu
			580					585					590		
Ile	Asn	Asp	Gly	Asp	Gln	Ile	Ile	Gln	Glu	Leu	Met	Lys	Ile	Trp	Asn
	595					600						605			
Glu	Glu	Leu	Asp	Asn	Gln										
	610														

<210> 25
 <211> 2346
 <212> DNA
 <213> Chlamydia psittaci

<400> 25

atggctgggg	taagcgggaat	tggaggtggc	ggtggggccag	ggaaactccc	tcctcatgga	60
aatgatgatg	ataaacaatc	taaatcagcc	agtttcggag	gccatgatat	agtttttggg	120
gatggggagc	gctctagatc	cggtagtgtg	agtagtgaac	actcaataga	ggagagaacc	180
cggacgttaa	tggaggaggg	ttttcaagta	cgcactcctg	aagaggtaga	ggaaactcga	240
agagcgtcta	tttccccaga	ggaagcatct	aacccaggat	tcttttctcg	tatatggtca	300
tctgttaagg	gaatattcac	aggtgggaaa	aagagtgata	gagctcaagg	accagaaaatt	360
tcctctccta	tcattgctgg	atataaacgt	catggcgtgc	gtcttctctg	tgcgcgcgt	420
atgcaggcac	atgtgcaaag	tcaaagctct	caagagattt	ctgcatcaga	cgtttcagaa	480
ataggagatt	tagattcttg	ggatacagat	atcacggata	tttctgatga	aagttcgtca	540
cagtcgatag	atgttgatac	agacgataga	gccgaagctt	ctacatcttc	agggagaggt	600
gttggtggat	tggcggctcg	tggtcgtggt	ttgtgggatt	ttgctactag	gcagcaagaa	660
actcctgttg	atggattttac	ggggatgact	ttttctgagt	tggctgatac	gggtccaattg	720
tatgatcaga	tgatttttaga	tgcggacaat	gagactgagc	ggcaggaact	cttaaagtat	780
cgcgatatgt	atcaaagcta	tgtaatacgt	atgttaggtg	agggcaatac	ctcacctaca	840
gatcagttcg	atgtgagtgc	ttctgctggt	atcccagggg	cttcttctag	aagatatagc	900
gatggcgttg	gagaagcgag	atgttttagac	atagatgacg	atztatccag	tgtgtcggaa	960
agtgcgtttt	tagatgctat	agaaagtggg	gagtatgccg	atcatgtctt	agaagagatc	1020
agccctgaag	taagaagagt	tttagatgaa	gctaataact	tgcgtttaca	gtttgatatg	1080
gaagtttctg	caagtgtaac	accttcatta	agagagcgta	ttcaatttgc	tcttgtgagg	1140
ttggaaagag	ggattatccg	tatacttact	ttgattagac	gtaacctagt	cgctctagca	1200
cgtttagtaa	gaagaggtct	togatccctt	ggggagcttg	taagacgttg	ttgctgtcgt	1260
gagagaggtg	tttacagatt	tcttggtaga	gatcgggctt	atgctagggg	ggccgaaaga	1320
tttattcaaa	ggcataccaa	ctcagagaat	ttttacagtc	caggaaactct	tacggttccc	1380
tatgaggttg	taaacgcttg	ggtaaatgga	agacctgatg	ttgtctatgt	ttctgatgtt	1440
agaggtatgt	ttggtcatga	agttgtgaga	cttcacgttg	atgatcgtga	gggtacatat	1500
gagataattg	gctctagctg	gattccttat	gaaagtgatg	gtggggatac	acccccacct	1560
ttaccgggaa	atcatcctag	tttagattac	gcagatatta	acgatgactc	tgaagatctt	1620
cccacaacag	gggatagggg	tgetgagccg	ctatatgctc	agatgagacc	ccgcccctcg	1680
ggaagagatg	agggaccgat	ttacgatgtc	ccaagtcctc	aaagtagaag	gcccagagca	1740
ggtgatgata	gggatacacc	tccgccttta	cggggaatc	atcccggttt	agattctaca	1800
gatcttccca	caacaggggg	tagagatcct	gagctactat	atgctcagat	gagacgtcgc	1860
cctcgtggaa	gagatgaggg	aacgatattac	gatgttccaa	gttctcaaaa	tagaaggccc	1920
ggaacaggtg	atgctagggg	ttctatttac	gacacgccaa	gacctgtctc	tgatgggtatt	1980
tacgacgtcc	ccagatctcc	ttccgaagat	atttataatg	tgccaagatc	tggccctcaa	2040
ctattttactg	tgcttctctg	ggatgggtat	aggcttccaa	atctatcagg	atctgctctt	2100
ggagtgcactc	caggattttg	aaatgggtgt	ggggcagctt	ctatggcaga	agaaattgat	2160
aggtttattg	aagaaaccca	tgaagaaga	gagtcggcag	cggcagcgcg	tcgtccttta	2220
ccccctcttc	ctccgttgca	aactcctccg	gaaagtcctt	atggaagtaa	tcggatgatg	2280
cgggtgttga	gactcatgaa	cgatagggta	caggagtaca	aagagcgtcg	taaggataag	2340
caataa						2346

<210> 26

<211> 781

<212> PRT

<213> Chlamydia psitacii

<400> 26

Met	Ala	Gly	Val	Ser	Gly	Ile	Gly	Gly	Gly	Gly	Pro	Gly	Lys	Leu
1				5					10				15	
Pro	Pro	His	Gly	Asn	Asp	Asp	Asp	Lys	Gln	Ser	Lys	Ser	Ala	Ser
			20					25					30	Phe
Gly	Gly	His	Asp	Ile	Val	Phe	Gly	Asp	Gly	Glu	Arg	Ser	Arg	Ser
		35				40					45			Gly
Ser	Val	Ser	Ser	Glu	His	Ser	Ile	Glu	Glu	Arg	Thr	Arg	Thr	Leu
	50					55				60				Met
Glu	Glu	Gly	Phe	Gln	Val	Arg	Thr	Pro	Glu	Glu	Val	Glu	Glu	Thr
65				70					75					80

Arg	Ala	Ser	Ile	Ser	Pro	Glu	Glu	Ala	Ser	Asn	Pro	Gly	Phe	Phe	Ser	85	90	95
Arg	Ile	Trp	Ser	Ser	Val	Lys	Gly	Ile	Phe	Thr	Gly	Gly	Lys	Lys	Ser	100	105	110
Asp	Arg	Ala	Gln	Gly	Pro	Glu	Ile	Ser	Ser	Pro	Ile	Ile	Ala	Gly	Tyr	115	120	125
Lys	Arg	His	Gly	Val	Arg	Leu	Pro	Asp	Ala	Arg	Ala	Met	Gln	Ala	His	130	135	140
Leu	Gln	Ser	Gln	Ser	Leu	Gln	Glu	Ile	Ser	Ala	Ser	Asp	Val	Ser	Glu	145	150	155
Ile	Gly	Asp	Leu	Asp	Ser	Gly	Asp	Thr	Asp	Ile	Thr	Asp	Ile	Ser	Asp	165	170	175
Glu	Ser	Ser	Leu	Gln	Ser	Ile	Asp	Leu	Asp	Thr	Asp	Asp	Arg	Ala	Glu	180	185	190
Ala	Ser	Thr	Ser	Ser	Gly	Arg	Gly	Val	Gly	Gly	Leu	Ala	Ala	Arg	Val	195	200	205
Arg	Gly	Leu	Trp	Asp	Phe	Ala	Thr	Arg	Gln	Gln	Glu	Thr	Pro	Val	Asp	210	215	220
Gly	Phe	Thr	Gly	Met	Thr	Phe	Ser	Glu	Leu	Val	Asp	Thr	Val	Gln	Leu	225	230	235
Tyr	Asp	Gln	Met	Ile	Leu	Asp	Ala	Asp	Asn	Glu	Thr	Glu	Arg	Gln	Glu	245	250	255
Leu	Leu	Lys	Tyr	Arg	Asp	Met	Tyr	Gln	Ser	Tyr	Val	Asn	Thr	Met	Leu	260	265	270
Gly	Glu	Gly	Asn	Thr	Ser	Pro	Thr	Asp	Gln	Phe	Asp	Val	Ser	Ala	Ser	275	280	285
Ala	Gly	Ile	Pro	Gly	Ala	Ser	Ser	Arg	Arg	Tyr	Ser	Asp	Gly	Val	Gly	290	295	300
Glu	Ala	Arg	Phe	Leu	Asp	Ile	Asp	Asp	Asp	Leu	Ser	Ser	Val	Ser	Glu	305	310	315
Ser	Glu	Leu	Leu	Asp	Ala	Ile	Glu	Ser	Gly	Glu	Tyr	Ala	Asp	His	Val	325	330	335
Leu	Glu	Glu	Ile	Ser	Pro	Glu	Val	Arg	Arg	Val	Leu	Asp	Glu	Ala	Asn	340	345	350
Asn	Leu	Arg	Leu	Gln	Phe	Asp	Met	Glu	Val	Ser	Ala	Ser	Val	Thr	Pro	355	360	365
Ser	Leu	Arg	Glu	Arg	Ile	Gln	Phe	Ala	Leu	Val	Arg	Leu	Glu	Arg	Gly	370	375	380
Ile	Ile	Arg	Ile	Leu	Thr	Leu	Ile	Arg	Arg	Asn	Leu	Val	Ala	Leu	Ala	385	390	395
Arg	Leu	Val	Arg	Arg	Gly	Leu	Arg	Ser	Leu	Gly	Glu	Leu	Val	Arg	Arg	405	410	415
Cys	Cys	Val	Arg	Glu	Arg	Gly	Val	Tyr	Arg	Phe	Leu	Gly	Arg	Asp	Arg	420	425	430
Ala	Tyr	Ala	Arg	Glu	Ala	Glu	Arg	Phe	Ile	Gln	Arg	His	Thr	Asn	Ser	435	440	445
Glu	Asn	Phe	Tyr	Ser	Pro	Gly	Thr	Leu	Thr	Val	Pro	Tyr	Glu	Val	Val	450	455	460
Asn	Ala	Trp	Val	Asn	Gly	Arg	Pro	Asp	Val	Val	Tyr	Val	Ser	Asp	Val	465	470	475
Arg	Gly	Met	Phe	Gly	His	Glu	Val	Val	Arg	Leu	His	Val	Asp	Asp	Arg	485	490	495
Glu	Gly	Thr	Tyr	Glu	Ile	Ile	Gly	Ser	Ser	Trp	Ile	Pro	Tyr	Glu	Ser	500	505	510
Asp	Gly	Gly	Asp	Thr	Pro	Pro	Pro	Leu	Pro	Gly	Asn	His	Pro	Ser	Leu	515	520	525
Asp	Tyr	Ala	Asp	Ile	Asn	Asp	Asp	Ser	Glu	Asp	Leu	Pro	Thr	Thr	Gly	530	535	540
Asp	Arg	Asp	Ala	Glu	Pro	Leu	Tyr	Ala	Gln	Met	Arg	Pro	Arg	Pro	Arg	545	550	555

Gly	Arg	Asp	Glu	Gly	Pro	Ile	Tyr	Asp	Val	Pro	Ser	Pro	Gln	Ser	Arg
			565						570					575	
Arg	Pro	Arg	Ala	Gly	Asp	Asp	Arg	Asp	Thr	Pro	Pro	Pro	Leu	Pro	Gly
			580					585					590		
Asn	His	Pro	Gly	Leu	Asp	Ser	Thr	Asp	Leu	Pro	Thr	Thr	Gly	Gly	Arg
		595				600						605			
Asp	Pro	Glu	Leu	Leu	Tyr	Ala	Gln	Met	Arg	Arg	Arg	Pro	Arg	Gly	Arg
	610					615					620				
Asp	Glu	Gly	Thr	Ile	Tyr	Asp	Val	Pro	Ser	Ser	Gln	Asn	Arg	Arg	Pro
625					630					635					640
Gly	Thr	Gly	Asp	Ala	Arg	Asp	Ser	Ile	Tyr	Asp	Thr	Pro	Arg	Pro	Val
			645						650					655	
Ser	Asp	Gly	Ile	Tyr	Asp	Val	Pro	Arg	Ser	Pro	Ser	Glu	Asp	Ile	Tyr
			660					665					670		
Asn	Val	Pro	Arg	Ser	Gly	Pro	Gln	Leu	Phe	Thr	Val	Leu	Pro	Glu	Asp
	675					680						685			
Gly	Tyr	Arg	Leu	Pro	Asn	Leu	Ser	Gly	Ser	Ala	Leu	Gly	Val	Thr	Pro
	690				695						700				
Gly	Phe	Gly	Asn	Gly	Val	Gly	Ala	Ala	Ser	Met	Ala	Glu	Glu	Ile	Asp
705					710					715					720
Arg	Phe	Ile	Glu	Glu	Thr	His	Glu	Arg	Arg	Glu	Ser	Ala	Ala	Ala	Ala
			725						730					735	
Arg	Arg	Pro	Leu	Pro	Pro	Leu	Pro	Pro	Leu	Gln	Thr	Pro	Pro	Glu	Ser
		740						745					750		
Pro	Tyr	Gly	Ser	Asn	Arg	Met	Met	Arg	Leu	Leu	Arg	Leu	Met	Asn	Asp
	755					760						765			
Arg	Val	Gln	Glu	Tyr	Lys	Glu	Arg	Arg	Lys	Asp	Lys	Gln			
	770					775						780			

<210> 27
 <211> 3042
 <212> DNA
 <213> Chlamydia trachomatis

<400> 27

atgcaaacgt	ctttccataa	gttcttttctt	tcaatgattc	tagcttattc	ttgctgctct	60
ttaagtgggg	gggggtatgc	agcagaaatc	atgattcctc	aaggaattta	cgatggggag	120
acgttaactg	tatcatttcc	ctatactgtt	ataggagatc	cgagtgggac	tactgttttt	180
tctgcaggag	agttaacgtt	aaaaaatctt	gacaattcta	ttgcagcttt	gcctttaagt	240
tgttttggga	acttattagg	gagttttact	gttttaggga	gaggacactc	gttgactttc	300
gagaacatac	ggactttctac	aaatggagct	gcactaagtg	acagcgctaa	tagcgggtta	360
tttactattg	agggttttaa	agaattatct	ttttccaatt	gcaactcatt	acttgccgta	420
ctgcctgctg	caacgactaa	taatggtagc	cagactccga	cgacaacatc	tacaccgtct	480
aatgggtacta	tttattctaa	aacagatctt	ttgttactca	ataatgagaa	gttctcattc	540
tatagtaatt	tagtctctgg	agatggggga	gctatagatg	ctaagagctt	aacggttcaa	600
ggaattagca	agcttttgtg	cttccaagaa	aatactgctc	aagctgatgg	gggagcttgt	660
caagtagtca	ccagttttctc	tgctatggct	aacgaggctc	ctattgcctt	tatagcgaat	720
gttgcaggag	taagaggggg	agggattgct	gctgttcagg	atgggcagca	gggagtgtca	780
tcatctactt	caacagaaga	tccagtagta	agtttttcca	gaaatactgc	ggtagagttt	840
gatgggaacg	tagccccgag	aggaggagg	atttactcct	acgggaacgt	tgctttcctg	900
aataatggaa	aaaccttggt	tctcaacaat	gttgcttctc	ctgtttacat	tgctgctgag	960
caaccaacaa	atggacaggc	ttctaatacg	agtataaatt	acggagatgg	aggagctatc	1020
ttctgtaaga	atgggtgcga	agcagcagga	tccaataact	ctggatcagt	ttcctttgat	1080
ggagagggag	tagttttctt	tagtagcaat	gtagctgctg	ggaaaggggg	agctatttat	1140
gccaaaaagc	tctcggttgc	taactgtggc	cctgtacaat	tcttagggaa	tatcgctaatt	1200
gatggtggag	cgattttatt	aggagaatct	ggagagctca	gtttatctgc	tgattatgga	1260
gatattatct	tccgatggga	tcttaaaaga	acagccaaag	agaatgctgc	cgatgttaatt	1320
ggcgtaactg	tgctctcaca	agccatttcg	atgggatcgg	gagggaaaat	aacgacatta	1380
agagctaaag	cagggcacat	gattctcttt	aatgatccca	tcgagatggc	aaacggaaat	1440

aaccagccag	cgcagtccttc	cgaacctcta	aaaattaacg	atgggtgaagg	atacacaggg	1500
gatattgttt	ttgctaattg	aaacagtact	ttgtacaaaa	atgttacgat	agagcaagga	1560
aggattgttc	ttcgtgaaaa	ggcaaaaatta	tcagtgaatt	ctctaagtca	gacaggtggg	1620
agtctgtata	tggaagctgg	gagtacattg	gattttgtaa	ctccacaacc	accacaacag	1680
cctcctgccg	ctaatacagtt	gatcacgctt	tccaatctgc	atgtgtctct	ttcttctttg	1740
ttagcaaaaca	atgcagttac	gaatcctcct	accaatcctc	cagcgcaaga	ttctcatcct	1800
gcaatcattg	gtagcacaaac	tgctggttct	gttacaatta	gtgggcctat	cttttttgag	1860
gatttggtatg	atacagctta	tgataggtat	gattggctag	gttctaataca	aaaaatcgat	1920
gtcctgaaat	tacagttagg	gactcagccc	tcagctaata	ccccatcaga	tttgactcta	1980
gggaatgaga	tgccaaagta	tggtatcaaa	ggaagctgga	agcttgcggtg	ggatccctaata	2040
acagcaaata	atggtcctta	tactctgaaa	gctacatgga	ctaaaactgg	gtataatcct	2100
gggcctgagc	gagtagcttc	tttggttcca	aatagtttat	ggggatccat	tttagatata	2160
cgatctgcgc	attcagcaat	tcaagcaagt	gtggatgggc	gctcttattg	tcgaggatta	2220
tgggtttctg	gagtttcgaa	tttcttctat	catgaccgcg	atgctttagg	tcagggatat	2280
cggtatatatta	gtgggggtta	ttccttagga	gcaaaactcct	actttggatc	atcgatgttt	2340
ggtctagcat	ttaccgaagt	atttggtaga	tctaaagatt	atgtagtgtg	tcgttccaat	2400
catcatgctt	gcataggatc	cgtttatcta	tctaccaaac	aagctttatg	tggtatcctat	2460
ttgttcggag	atgcgtttat	ccgtgctagc	tacgggtttg	ggaaccagca	tatgaaaacc	2520
tcatacacat	ttgcagagga	gagcgatggt	cgttgggata	ataactgtct	ggttgggagag	2580
attggagtgg	gattaccgat	tgtgattact	ccatctaagc	tctatttgaa	tgagttgcgt	2640
cctttcgtgc	aagctgagtt	ttcttatgcc	gatcatgaat	cttttacaga	ggaaggcgat	2700
caagctcggy	cattcaggag	tggacatctc	atgaatctat	cagttcctgt	tggagtaaaa	2760
tttgatcgat	gttctagtac	acaccctaata	aaatatagct	ttatgggggc	ttatatctgt	2820
gatgcttatac	gcaccatctc	tgggactcag	acaacactcc	tatcccatca	agagacatgg	2880
acaacagatg	ccttttcattt	ggcaagacat	ggagtcatag	ttagagggtc	tatgtatgct	2940
tctctaacaa	gcaatataga	agtatatggc	catggaagat	atgagtatcg	agatacttct	3000
cgagggttatg	gtttgagtgc	aggaaagtaaa	gtccggttct	aa		3042

<210> 28

<211> 1013

<212> PRT

<213> Chlamydia trachomatis

<400> 28

Met	Gln	Thr	Ser	Phe	His	Lys	Phe	Phe	Leu	Ser	Met	Ile	Leu	Ala	Tyr
1				5					10					15	
Ser	Cys	Cys	Ser	Leu	Ser	Gly	Gly	Gly	Tyr	Ala	Ala	Glu	Ile	Met	Ile
			20						25				30		
Pro	Gln	Gly	Ile	Tyr	Asp	Gly	Glu	Thr	Leu	Thr	Val	Ser	Phe	Pro	Tyr
		35					40					45			
Thr	Val	Ile	Gly	Asp	Pro	Ser	Gly	Thr	Thr	Val	Phe	Ser	Ala	Gly	Glu
	50					55					60				
Leu	Thr	Leu	Lys	Asn	Leu	Asp	Asn	Ser	Ile	Ala	Ala	Leu	Pro	Leu	Ser
65				70					75					80	
Cys	Phe	Gly	Asn	Leu	Leu	Gly	Ser	Phe	Thr	Val	Leu	Gly	Arg	Gly	His
			85					90					95		
Ser	Leu	Thr	Phe	Glu	Asn	Ile	Arg	Thr	Ser	Thr	Asn	Gly	Ala	Ala	Leu
			100					105					110		
Ser	Asp	Ser	Ala	Asn	Ser	Gly	Leu	Phe	Thr	Ile	Glu	Gly	Phe	Lys	Glu
	115						120					125			
Leu	Ser	Phe	Ser	Asn	Cys	Asn	Ser	Leu	Leu	Ala	Val	Leu	Pro	Ala	Ala
	130					135					140				
Thr	Thr	Asn	Asn	Gly	Ser	Gln	Thr	Pro	Thr	Thr	Thr	Ser	Thr	Pro	Ser
145					150					155				160	
Asn	Gly	Thr	Ile	Tyr	Ser	Lys	Thr	Asp	Leu	Leu	Leu	Leu	Asn	Asn	Glu
			165					170					175		
Lys	Phe	Ser	Phe	Tyr	Ser	Asn	Leu	Val	Ser	Gly	Asp	Gly	Gly	Ala	Ile
			180				185						190		
Asp	Ala	Lys	Ser	Leu	Thr	Val	Gln	Gly	Ile	Ser	Lys	Leu	Cys	Val	Phe

675	680	685
Leu Lys Ala Thr Trp Thr	Lys Thr Gly Tyr Asn	Pro Gly Pro Glu Arg
690	695	700
Val Ala Ser Leu Val	Pro Asn Ser Leu Trp Gly	Ser Ile Leu Asp Ile
705	710	715
Arg Ser Ala His Ser Ala Ile	Gln Ala Ser Val Asp Gly	Arg Ser Tyr
725	730	735
Cys Arg Gly Leu Trp Val Ser	Gly Val Ser Asn Phe Phe	Tyr His Asp
740	745	750
Arg Asp Ala Leu Gly Gln Gly	Tyr Arg Tyr Ile Ser Gly	Gly Tyr Ser
755	760	765
Leu Gly Ala Asn Ser Tyr Phe	Gly Ser Ser Met Phe Gly	Leu Ala Phe
770	775	780
Thr Glu Val Phe Gly Arg Ser	Lys Asp Tyr Val Val	Cys Arg Ser Asn
785	790	795
His His Ala Cys Ile Gly Ser	Val Tyr Leu Ser Thr	Lys Gln Ala Leu
805	810	815
Cys Gly Ser Tyr Leu Phe Gly	Asp Ala Phe Ile Arg	Ala Ser Tyr Gly
820	825	830
Phe Gly Asn Gln His Met Lys	Thr Ser Tyr Thr Phe	Ala Glu Glu Ser
835	840	845
Asp Val Arg Trp Asp Asn Asn	Cys Leu Val Gly Glu	Ile Gly Val Gly
850	855	860
Leu Pro Ile Val Ile Thr Pro	Ser Lys Leu Tyr Leu	Asn Glu Leu Arg
865	870	875
Pro Phe Val Gln Ala Glu Phe	Ser Tyr Ala Asp His	Glu Ser Phe Thr
885	890	895
Glu Glu Gly Asp Gln Ala Arg	Ala Phe Arg Ser Gly	His Leu Met Asn
900	905	910
Leu Ser Val Pro Val Gly Val	Lys Phe Asp Arg Cys	Ser Ser Thr His
915	920	925
Pro Asn Lys Tyr Ser Phe Met	Gly Ala Tyr Ile Cys	Asp Ala Tyr Arg
930	935	940
Thr Ile Ser Gly Thr Gln Thr	Thr Leu Leu Ser His	Gln Glu Thr Trp
945	950	955
Thr Thr Asp Ala Phe His Leu	Ala Arg His Gly	Val Ile Val Arg Gly
965	970	975
Ser Met Tyr Ala Ser Leu Thr	Ser Asn Ile Glu	Val Tyr Gly His Gly
980	985	990
Arg Tyr Glu Tyr Arg Asp Thr	Ser Arg Gly Tyr Gly	Leu Ser Ala Gly
995	1000	1005
Ser Lys Val Arg Phe		
1010		

<210> 29
 <211> 2964
 <212> DNA
 <213> Chlamydia muridarum

<400> 29

gtgatgcaaa cgccttttca taagttcttt cttctagcaa tgctatctta ctctttattg	60
caaggagggc atgcggcaga tatttccatg cctccgggaa tttatgatgg gacaacattg	120
acggcgccat ttccctacac tgtgatcgga gatcccagag ggacaaaggt tacttcatcg	180
ggatcgctag agttgaaaaa cctggacaat tccattgcga ctttacctct aagttgtttt	240
ggtaatttgt tggggaattt cactattgca ggaagagggc attcgttagt atttgagaat	300
atacgaacat ctacaaatgg ggcggcattg agtaatcatg ctccttctgg actgtttgta	360
attgaagctt ttgatgaact ctctcttttg aattgtaatt cattggatc tgtagttcct	420
caaacagggg gtacgactac ttctgttcct tctaattggga cgatctattc tagaacagat	480
cttgttctaa gagatatcaa gaaggtttct ttctatagta acttagtttc tggagatggg	540

ggagctatag	atgcacaaag	tttaatgggt	aacggaattg	aaaaactttg	taccttccaa	600
gaaaatgtag	cgcagtcgga	tgggggagcg	tgctcaggtaa	caaagacctt	ctctgctgtg	660
ggcaataagg	ttcctttgtc	tttttttaggc	aatggttgctg	gtaataaggg	gggaggaggt	720
gctgctgtca	aagatgggtca	gggggcagga	ggggcgactg	atctatcggt	taattttgcc	780
aataaactctg	ctgtagaatt	tgagggaatt	agtgctcgaa	taggtggagg	gatctactcg	840
gacggaaata	tttccttttt	agggatgca	aagacagttt	tcctaagtaa	cgtagcttcg	900
cctattttatg	ttgaccctgc	tgctgcagga	ggacagcccc	ctgcagataa	agataactat	960
ggagatggag	gagccatctt	ctgcaaaaat	gatactaaca	taggtgaagt	ctctttcaaa	1020
gacgaggggtg	ttgttttctt	tagtaaaaat	attgccgcag	gaaagggggg	cgctatttat	1080
gctaagaaac	tgacaatttc	tgactgtggt	ccgggtccagt	ttcttggtaa	tgctcggaat	1140
gacggggggcg	ctatttatct	agtagatcag	ggggaaactta	gtctatctgc	tgatcgcgga	1200
gatattattt	ttgatggaaa	tttaaagaga	atgggtacgc	aaggcgctgc	caccgtccat	1260
gatgtaatgg	ttgcctcgaa	tgctatctct	atgggtacag	gggggcaaat	cacaacatta	1320
agggtctaagg	aaggctcgccg	aattcttttt	aatgacccta	ttgaaatggc	gaatggacaa	1380
cctgtaatac	aaactcttac	agtaaaccag	ggcgaaggat	atacggggga	cattgttttt	1440
gctaaagggtg	ataatgtttt	gtactcaagt	attgagctga	gtcaggggaag	aattattctc	1500
cgagagcaaa	caaaattatt	ggtaaactcc	ctgactcaga	ctggaggggag	tgtacatatg	1560
gaagggggga	gtacactaga	ctttgcagta	acaacgccac	cagctgctaa	ttcgatggct	1620
cttactaatg	tacacttctc	cttagcttct	ttactaaaaa	ataatggggt	tacaaatcct	1680
ccaacgaatc	ctccagtaga	ggtttctagt	ccagctgtaa	ttggtaatac	agctgctggt	1740
actgttacga	tttctgggtcc	gatctttttt	gaagatttag	atgaaactgc	ttacgataat	1800
aatcagtggt	taggtgcgga	tcaaaactatt	gatgtgctgc	agttgcattt	aggagcgaat	1860
cctccggcta	acgtcccaac	tgatttgact	ttagggaacg	aaagttctaa	atatgggtat	1920
caagggaagt	ggacaacttca	atgggaacca	gatcctgcga	atcctccaca	gaacaatagc	1980
tacatgttga	aggcaagctg	gactaaaaca	ggttataatc	ctgggtccgga	gcgcgtagct	2040
tctctggtct	ctaatagtct	ttggggatcc	attttagatg	tgcgttccgc	gcattctgcg	2100
attcaagcaa	gtatagatgg	acgagcttat	tgctggggta	tttggtattc	tgggatttcg	2160
aactttttct	atcatgatca	ggatgcttta	ggacaggggt	atcgatcatat	tagtggggga	2220
tattcgatag	gagcaaactc	ttatttcggg	tcttctatgt	ttggacttgc	ttttactgaa	2280
acttttggtg	ggtccaaaga	ttatgtggtc	tgctgatcta	acgatcacac	ttgtgtaggc	2340
tctgtttact	tatccactag	acaagcggtt	tgcggtacct	gtttattttg	agatgctttt	2400
gttcggggcga	gttacggatt	tggaatcag	catatgaaga	cctcttatac	atttgctgaa	2460
gagagtaatg	tgcgttggga	taataactgt	gtagtgggag	aagttggagc	tgggctccct	2520
atcatgctcg	ctgcatctaa	gctttatcta	aatgagttgc	gtcccttcgt	gcaagcagag	2580
tttgcttatg	cagagcatga	atcttttaca	gagagagggg	atcaggctag	ggagtttaag	2640
agtgggcatc	ttatgaatct	atctattcca	gttgggggtga	agtttgatcg	atgctctagt	2700
aaacatccta	acaagtatag	ttttatggga	gcttatatct	gtgatgctta	ccgggtccatt	2760
tctggaacgg	agacaacact	cctgtctcat	aaagagactt	ggacaacaga	tgctttccat	2820
ttagcaaggc	atggagttat	ggtcagagga	tctatgtatg	cttctttaac	aggtaatata	2880
gaagtctatg	gccatggaaa	atatgaatac	agggatgcct	ctcgagggta	tggtttaagt	2940
attggaagta	aaatccgatt	ctaa				2964

<210> 30

<211> 987

<212> PRT

<213> Chlamydia muridarum

<400> 30

Met	Met	Gln	Thr	Pro	Phe	His	Lys	Phe	Phe	Leu	Leu	Ala	Met	Leu	Ser
1				5				10						15	
Tyr	Ser	Leu	Leu	Gln	Gly	Gly	His	Ala	Ala	Asp	Ile	Ser	Met	Pro	Pro
				20				25						30	
Gly	Ile	Tyr	Asp	Gly	Thr	Thr	Leu	Thr	Ala	Pro	Phe	Pro	Tyr	Thr	Val
				35				40						45	
Ile	Gly	Asp	Pro	Arg	Gly	Thr	Lys	Val	Thr	Ser	Ser	Gly	Ser	Leu	Glu
				50				55						60	
Leu	Lys	Asn	Leu	Asp	Asn	Ser	Ile	Ala	Thr	Leu	Pro	Leu	Ser	Cys	Phe
				65				70						80	
Gly	Asn	Leu	Leu	Gly	Asn	Phe	Thr	Ile	Ala	Gly	Arg	Gly	His	Ser	Leu

atgaaagcgt	ctcttcgtaa	gtttcttaatt	tcaacaacgc	taacacttcc	atactcattc	60
caagcctttt	ctttggaagt	cgtagtcctt	aatggaactt	atgatgggaa	ccttagagaa	120
acgttccctt	atacgattac	atccaatcct	gaaggaaaca	cggcaatact	gtcaggaaat	180
ttaaattcttt	taaatcttga	taactccatg	gtagcaacgc	cttcaagttg	ctttttcaac	240
tctgcaggat	ccatgacaat	tgtggggaga	aaccacaatc	taacctttac	aaaccttcgc	300
acgtcggcaa	acgggtgctg	cctaagctct	attcctacaa	caactcctga	atcgttccct	360
tatacgatta	aaggagttaa	caccctctcc	ttttctaaat	gcctagccct	aatggcccg	420
acaacaacgc	cgccaataac	gacaactcct	gtaaatacaa	acggaggggc	gttctactcc	480
aaagctcctg	tattttctaga	gaatattcag	aattgtctat	ttaaaaataa	cagggctgct	540
gatagcggcg	gtggcctatg	ggtagaaaca	gctgggatta	gcaatatcaa	aaaatccatg	600
cagttcctta	gcaacgtcgg	agccaacggg	ggcgctatca	acgcgtctaa	aagcctagat	660
gttacgcaat	gtccttcgat	tctcttcaga	tctaactctg	ctgagaaact	cggaggagct	720
atccaagctg	ttgatcctgc	aacaacaaat	caagtaaata	ctgccgtcag	attctccgaa	780
aatggctcag	tacaatttga	tgccaataat	gcgaaatctg	gcggagcgat	ttattcgaaa	840
gggaacgtcg	attttctcaa	taatgcgcaa	ttgctgatac	agaataactc	cgcattctct	900
gaagtcgcta	ataactaatga	agtattagga	caaggtgggg	cgattttctg	tgtacaacag	960
actcctactc	aaccgcgcgc	gccaccacca	cctacaacga	atcctgtctt	ctcaggatta	1020
actataacca	atcaaaaaga	tatcctcttt	gcaataaact	ttgccgcaac	tgcaggcgga	1080
gcgattttatg	gagaaaagggt	cagcattacc	tcctcaggga	aaacgatggt	tacaaacaac	1140
atcgctaaag	atggcgggag	tatctacatt	cctgaaaatg	gagagctcac	cttatctgct	1200
gactacggcg	atatgatctt	ctatgaaaat	ctaaaaaag	atgacgctac	tgtcacaaga	1260
aaagctgtta	ccttagcaaa	aggagcaacg	attaagttac	tagcagcttc	tggggatcat	1320
aaactctggt	tctacgatcc	tattgtgact	acacttccag	aaacagctcc	tactaatgac	1380
aagactctaa	cgatcaacca	agataaaaca	tcctccaccc	cttttactaa	ctatatggga	1440
accctcctat	tttcaggagc	ttatgtagat	agccaaagcg	ctagcactac	agcgaatttt	1500
gaatccacta	tctatcaaaa	agtcattctt	ggtggcgggg	agcttggtct	agcagataaa	1560
gccagcctat	ctgtagcttc	ctttactcag	gaaacagatt	ctattctttt	aatggataat	1620
ggaactactc	tagcaattac	agagcattcc	catcaaacac	cagcagctgg	tgggggtggc	1680
ggaggcggag	gaaccccccac	tcaggaagcc	aatactgatg	gagttatttc	cttaacaaat	1740
cttcatgtca	atatcagctc	gottacggaa	caaggtgagg	ggcgaaact	tgaacaaaaa	1800
aatacagatg	ggacgataac	tttaactggg	catgtatcct	tagacgatgt	ttcagggaact	1860
gcttacgaga	atcacgatct	tttcaataaa	gataccgtca	cgataaatct	gctttctctt	1920
tctacagcag	gagatagtaa	aacgacgac	aattggtttg	acctcactct	tagaggagac	1980
gcagaacctc	aatacggtta	ccaaggatca	tggcaactgg	cttgggaaaa	tggagctgat	2040
gccaataaac	agaaaatcct	aaaagctaca	tggacaaaaa	caggattcac	tcctaatacct	2100
gagcgtcaag	catcttttagt	tcctaataag	ttatggggag	cattcatcga	cctacgttct	2160
atgaatgcct	tagcgacagc	aagctgtgac	ggcttcgggt	atggtaaggg	attgtgggta	2220
gctgggattt	ccaatatctt	ccaccatgat	cgcaatagcg	tatcccatgg	tttcgcgtcg	2280
attagcgggtg	gttatgttat	tggagccaat	tcacaaacag	taacggattc	tgtatttggg	2340
gtggccttct	cccagatatt	tgctaagtct	aaagactatg	ttgtctcttc	agcaaaaatca	2400
caagctatag	caggtagcgc	ttacctatcg	gtaaaacgtc	agttaagcaa	cacgatattc	2460
tcattccttcg	ctgcaagaat	taactacagc	catactaacg	aggatatgaa	aacacgctat	2520
accttcattc	ctgaaaaaga	tggcaattgg	gataataact	gctggttagg	agaaataggg	2580
ggaagcttac	ctattgtttt	acaaattact	aaattacatc	taaatcaaat	cattcctttt	2640
atgaatgttc	agcttggcta	tgctgagcat	ggatcggtta	aagaaaaact	tgcagaagca	2700
cgctccttct	gttcttctcg	tttgattaac	ttagcgggtc	ctgttggatt	taaaattgat	2760
aggcgttccc	actcccaccc	ggattttttac	agcctagcta	tatcctacat	tcccgatgta	2820
tggcgaaagga	atccaggatg	taacacttta	ttgctcgcaa	atggagtccg	ttggaaaaacg	2880
ccagcaacta	atctaaatag	acatgggtta	ttgatcgcaag	gatccacaca	tacagctgtg	2940
ctcagtaata	ttgagatctt	tagccatggg	agttgcgaat	tacgtagctc	ctcacgcaac	3000
tacaatataa	atgtaggaag	taaaattcga	ttctaa			3036

<210> 32
 <211> 1011
 <212> PRT
 <213> Chlamydia psitacci

<400> 32

Met	Lys	Ala	Ser	Leu	Arg	Lys	Phe	Leu	Ile	Ser	Thr	Thr	Leu	Thr	Leu
1				5					10					15	
Pro	Tyr	Ser	Phe	Gln	Ala	Phe	Ser	Leu	Glu	Val	Val	Val	Pro	Asn	Gly
			20					25					30		
Thr	Tyr	Asp	Gly	Asn	Leu	Arg	Glu	Thr	Phe	Pro	Tyr	Thr	Ile	Thr	Ser
		35					40					45			
Asn	Pro	Glu	Gly	Thr	Thr	Ala	Ile	Leu	Ser	Gly	Asn	Leu	Asn	Leu	Leu
	50					55					60				
Asn	Leu	Asp	Asn	Ser	Met	Val	Ala	Thr	Pro	Ser	Ser	Cys	Phe	Phe	Asn
65					70					75					80
Ser	Ala	Gly	Ser	Met	Thr	Ile	Val	Gly	Arg	Asn	His	Asn	Leu	Thr	Phe
				85				90					95		
Thr	Asn	Leu	Arg	Thr	Ser	Ala	Asn	Gly	Ala	Ala	Leu	Ser	Ser	Ile	Pro
			100					105					110		
Thr	Thr	Thr	Pro	Glu	Ser	Phe	Pro	Tyr	Thr	Ile	Lys	Gly	Val	Asn	Thr
			115				120					125			
Leu	Ser	Phe	Ser	Asn	Cys	Leu	Ala	Leu	Met	Ala	Arg	Thr	Thr	Thr	Ala
	130					135					140				
Pro	Asn	Thr	Thr	Thr	Pro	Val	Asn	Pro	Asn	Gly	Gly	Ala	Phe	Tyr	Ser
145					150					155					160
Lys	Ala	Pro	Val	Phe	Leu	Glu	Asn	Ile	Gln	Asn	Val	Leu	Phe	Lys	Asn
				165				170						175	
Asn	Arg	Ala	Ala	Asp	Ser	Gly	Gly	Gly	Leu	Trp	Val	Glu	Thr	Ala	Gly
			180					185					190		
Ile	Ser	Asn	Ile	Lys	Lys	Ser	Met	Gln	Phe	Leu	Ser	Asn	Val	Gly	Ala
		195					200					205			
Asn	Gly	Gly	Ala	Ile	Asn	Ala	Ser	Lys	Ser	Leu	Asp	Val	Thr	Gln	Cys
	210				215						220				
Pro	Ser	Ile	Leu	Phe	Arg	Ser	Asn	Ser	Ala	Glu	Lys	Leu	Gly	Gly	Ala
225					230					235					240
Ile	Gln	Ala	Val	Asp	Pro	Ala	Thr	Thr	Asn	Gln	Val	Asn	Thr	Ala	Val
			245					250						255	
Arg	Phe	Ser	Glu	Asn	Gly	Ser	Val	Gln	Phe	Asp	Ala	Asn	Asn	Ala	Lys
			260					265					270		
Ser	Gly	Gly	Ala	Ile	Tyr	Ser	Lys	Gly	Asn	Val	Asp	Phe	Ser	Asn	Asn
		275					280					285			
Ala	Gln	Leu	Leu	Ile	Gln	Asn	Asn	Ser	Ala	Ser	Pro	Glu	Val	Ala	Asn
	290					295					300				
Thr	Asn	Glu	Val	Leu	Gly	Gln	Gly	Gly	Ala	Ile	Phe	Cys	Val	Gln	Gln
305					310					315					320
Thr	Pro	Thr	Gln	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Thr	Thr	Asn	Pro	Val
			325					330						335	
Phe	Ser	Gly	Leu	Thr	Ile	Thr	Asn	Gln	Lys	Asp	Ile	Leu	Phe	Ala	Asn
			340					345					350		
Asn	Phe	Ala	Ala	Thr	Ala	Gly	Gly	Ala	Ile	Tyr	Gly	Glu	Lys	Val	Ser
		355				360						365			
Ile	Thr	Ser	Ser	Gly	Lys	Thr	Met	Phe	Thr	Asn	Asn	Ile	Ala	Lys	Asp
		370				375					380				
Gly	Gly	Ala	Ile	Tyr	Ile	Pro	Glu	Asn	Gly	Glu	Leu	Thr	Leu	Ser	Ala
385					390					395					400
Asp	Tyr	Gly	Asp	Met	Ile	Phe	Tyr	Glu	Asn	Leu	Lys	Lys	Asp	Asp	Ala
			405					410						415	
Thr	Val	Thr	Arg	Asn	Ala	Val	Thr	Leu	Ala	Lys	Gly	Ala	Thr	Ile	Lys
			420					425					430		
Leu	Leu	Ala	Ala	Ser	Gly	Asp	His	Lys	Leu	Cys	Phe	Tyr	Asp	Pro	Ile
		435				440						445			
Val	Thr	Thr	Leu	Pro	Glu	Thr	Ala	Pro	Thr	Asn	Asp	Lys	Thr	Leu	Thr
		450				455					460				
Ile	Asn	Gln	Asp	Lys	Thr	Ser	Ser	Thr	Pro	Phe	Thr	Asn	Tyr	Ile	Gly
465					470					475					480

515 520 525
 Thr Gly Ile Lys Thr Cys Ser Leu Thr Gly Ser Leu Ala Val Arg Glu
 530 535 540
 His Gly Ala Phe Ile Glu Asn Ile Gly Val Glu Pro His Ile Asp Leu
 545 550 555 560
 Pro Phe Thr Ala Asn Asp Ile Arg Tyr Lys Gly Tyr Ser Glu Tyr Leu
 565 570 575
 Asp Lys Val Lys Lys Leu Val Cys Gln Leu Ile Asn Asn Asp Gly Thr
 580 585 590
 Ile Ile Leu Ala Glu Asp Gly Ser Phe
 595 600

<210> 35
 <211> 1806
 <212> DNA
 <213> Chlamydia muridarum

<400> 35

atgaaaatga	ataggattttt	gctactgctg	ctaacctttt	cttcgcgtat	acattctcct	60
ttgcatgggg	aaagttttagt	ctgtcagaat	gctctgaaag	atttgagttt	tttggagcat	120
ttgctgcaag	tcaagtatgc	ccctaaaact	tggaaagaac	agtatttagg	ttgggatctt	180
tctaaaagct	ctgtttttgc	agagcagaaa	ttgcgttccg	aggacaaccc	ttcaacaagc	240
ttttgtcagc	aagtaattgc	ggactttatt	ggagcggtga	gtgattttca	tgccggggtc	300
tctttctttg	ctgtagagag	tgccctacct	ccctactctg	tacaaaaaag	tagcgatgga	360
cgcttctatt	tcgttgatgt	aatgaccttt	tcttctgata	ttcgcgtcgg	ggatgagtta	420
cttgaggtag	acgggcagcc	tggtgcagaa	gcacttgcta	ccctatatgg	aaccaatcac	480
aaggggactc	tcgctgaaga	atctgctgct	ttaagaacgt	tattttctcg	tatggcttct	540
ttaggcacata	aagtccttc	cgggagaatc	accctcaaag	ttcgtcgttc	ttctgggtct	600
gtgaaagatg	tgcgagcaaa	atggcggttat	actccagaaa	gtgtagggga	tttagctacg	660
atagctcctt	ccataaaagc	tccacagctg	cagaagtcta	tgagaggggc	ctttcctaaa	720
aaagaaagtg	tatttcatca	gtcgagcact	ctgtttttatt	ctccaatggg	tcctcatttt	780
tggtcggagt	ttcgtaatca	ctacgcaacg	agtggtttta	aaagtgggta	caatattggg	840
gataccgatg	gatttttccc	agtcattgga	cccgttattt	gggagtcgga	cgggaattttt	900
catgcttata	ttttccctct	ggttgatgaa	aatggttaga	gccataacgt	aggattttatc	960
agaattccta	cgtatggttg	gcaagagatg	gaagatttag	attctatagg	gacacctcct	1020
tggaagaggt	ttggttaagat	cattacgcta	ttttctgaaa	aaacagaggc	tttgcattct	1080
gaccaaacga	ataatcctgg	ggggagcggt	atgtatttat	acggattgct	ctctatggtg	1140
acggataaac	ctttagatct	tcctaaacat	agaatgattc	taactcagga	cgaagtagtt	1200
gatgcttttag	attggttgaa	tttattggaa	aatgtggata	caaacgcaga	ggctcggatt	1260
gctttgggag	ataatatgga	aggatatccc	attgacttgc	aggctgctga	atatctgaaa	1320
agctttgctc	atcaggtatt	ggcatgttgg	agaatggag	atatcgaatt	atctacaccg	1380
attcctcttt	ttgggtttga	gaaaattcat	ccacatcctc	gagtcctaata	tactaagcct	1440
atgtgtgttt	tgattaatga	acaggatttt	tcttgtgcgg	atttcttccc	tgctattctg	1500
aaagacaatg	acagagccct	tgctgttgga	actcgaacag	cgggagctgg	gggatttgtc	1560
ttcaatgtac	aattccctaa	cagaacggga	attaaaagtt	gctctttaac	aggatcttta	1620
gcagttagag	agcatgggga	tttgattgaa	aatgttgggg	ttgaacctca	tattgaaatt	1680
cctttcacag	ctaattgat	tcgttataga	gggtattctg	aatatattca	gaaagtacaa	1740
aaattgggtg	ctcagcta	caataatgac	agtgtaat	ttctctcaga	ggatggaagt	1800
ttttaa						1806

<210> 36
 <211> 601
 <212> PRT
 <213> Chlamydia muridarum

<400> 36

Met Lys Met Asn Arg Ile Leu Leu Leu Leu Leu Thr Phe Ser Ser Ala
 1 5 10 15

Ile	His	Ser	Pro	Leu	His	Gly	Glu	Ser	Leu	Val	Cys	Gln	Asn	Ala	Leu	
			20					25					30			
Lys	Asp	Leu	Ser	Phe	Leu	Glu	His	Leu	Leu	Gln	Val	Lys	Tyr	Ala	Pro	
		35					40					45				
Lys	Thr	Trp	Lys	Glu	Gln	Tyr	Leu	Gly	Trp	Asp	Leu	Ser	Lys	Ser	Ser	
		50				55					60					
Val	Phe	Ala	Glu	Gln	Lys	Leu	Arg	Ser	Glu	Asp	Asn	Pro	Ser	Thr	Ser	
65					70					75					80	
Phe	Cys	Gln	Gln	Val	Ile	Ala	Asp	Phe	Ile	Gly	Ala	Leu	Ser	Asp	Phe	
				85					90					95		
His	Ala	Gly	Val	Ser	Phe	Phe	Ala	Val	Glu	Ser	Ala	Tyr	Leu	Pro	Tyr	
			100					105					110			
Ser	Val	Gln	Lys	Ser	Ser	Asp	Gly	Arg	Phe	Tyr	Phe	Val	Asp	Val	Met	
		115					120					125				
Thr	Phe	Ser	Ser	Asp	Ile	Arg	Val	Gly	Asp	Glu	Leu	Leu	Glu	Val	Asp	
		130				135					140					
Gly	Gln	Pro	Val	Ala	Glu	Ala	Leu	Ala	Thr	Leu	Tyr	Gly	Thr	Asn	His	
145					150					155					160	
Lys	Gly	Thr	Leu	Ala	Glu	Glu	Ser	Ala	Ala	Leu	Arg	Thr	Leu	Phe	Ser	
				165					170					175		
Arg	Met	Ala	Ser	Leu	Gly	His	Lys	Val	Pro	Ser	Gly	Arg	Ile	Thr	Leu	
			180					185					190			
Lys	Val	Arg	Arg	Ser	Ser	Gly	Ser	Val	Lys	Asp	Val	Arg	Ala	Lys	Trp	
		195					200					205				
Arg	Tyr	Thr	Pro	Glu	Ser	Val	Gly	Asp	Leu	Ala	Thr	Ile	Ala	Pro	Ser	
		210				215					220					
Ile	Lys	Ala	Pro	Gln	Leu	Gln	Lys	Ser	Met	Arg	Gly	Ala	Phe	Pro	Lys	
225				230						235					240	
Lys	Glu	Ser	Val	Phe	His	Gln	Ser	Ser	Thr	Leu	Phe	Tyr	Ser	Pro	Met	
				245					250					255		
Val	Pro	His	Phe	Trp	Ser	Glu	Phe	Arg	Asn	His	Tyr	Ala	Thr	Ser	Gly	
			260					265					270			
Leu	Lys	Ser	Gly	Tyr	Asn	Ile	Gly	Asp	Thr	Asp	Gly	Phe	Phe	Pro	Val	
		275				280					285					
Met	Gly	Pro	Val	Ile	Trp	Glu	Ser	Asp	Gly	Ile	Phe	His	Ala	Tyr	Ile	
		290				295					300					
Phe	Pro	Leu	Val	Asp	Glu	Asn	Gly	Arg	Ser	His	Asn	Val	Gly	Phe	Ile	
305				310						315					320	
Arg	Ile	Pro	Thr	Tyr	Gly	Trp	Gln	Glu	Met	Glu	Asp	Leu	Asp	Ser	Ile	
				325					330					335		
Gly	Thr	Pro	Pro	Trp	Glu	Glu	Phe	Gly	Lys	Ile	Ile	Thr	Leu	Phe	Ser	
			340					345					350			
Glu	Lys	Thr	Glu	Ala	Leu	Ile	Ile	Asp	Gln	Thr	Asn	Asn	Pro	Gly	Gly	
		355				360					365					
Ser	Val	Met	Tyr	Leu	Tyr	Gly	Leu	Leu	Ser	Met	Leu	Thr	Asp	Lys	Pro	
		370				375					380					
Leu	Asp	Leu	Pro	Lys	His	Arg	Met	Ile	Leu	Thr	Gln	Asp	Glu	Val	Val	
385				390						395					400	
Asp	Ala	Leu	Asp	Trp	Leu	Asn	Leu	Leu	Glu	Asn	Val	Asp	Thr	Asn	Ala	
				405					410					415		
Glu	Ala	Arg	Ile	Ala	Leu	Gly	Asp	Asn	Met	Glu	Gly	Tyr	Pro	Ile	Asp	
			420					425					430			
Leu	Gln	Ala	Ala	Glu	Tyr	Leu	Lys	Ser	Phe	Ala	His	Gln	Val	Leu	Ala	
		435					440					445				
Cys	Trp	Lys	Asn	Gly	Asp	Ile	Glu	Leu	Ser	Thr	Pro	Ile	Pro	Leu	Phe	
		450				455					460					
Gly	Phe	Glu	Lys	Ile	His	Pro	His	Pro	Arg	Val	Gln	Tyr	Thr	Lys	Pro	
465				470						475					480	
Ile	Cys	Val	Leu	Ile	Asn	Glu	Gln	Asp	Phe	Ser	Cys	Ala	Asp	Phe	Phe	
				485				490						495		

Pro Ala Ile Leu Lys Asp Asn Asp Arg Ala Leu Val Val Gly Thr Arg
500 505 510
Thr Ala Gly Ala Gly Gly Phe Val Phe Asn Val Gln Phe Pro Asn Arg
515 520 525
Thr Gly Ile Lys Ser Cys Ser Leu Thr Gly Ser Leu Ala Val Arg Glu
530 535 540
His Gly Asp Leu Ile Glu Asn Val Gly Val Glu Pro His Ile Glu Ile
545 550 555 560
Pro Phe Thr Ala Asn Asp Ile Arg Tyr Arg Gly Tyr Ser Glu Tyr Ile
565 570 575
Gln Lys Val Gln Lys Leu Val Ala Gln Leu Ile Asn Asn Asp Ser Val
580 585 590
Ile Ile Leu Ser Glu Asp Gly Ser Phe
595 600

<210> 37
<211> 1782
<212> DNA
<213> Chlamydia psitacii

<400> 37

atgaaagtga	aacaaattac	agccttgatt	tgctccttag	tattagggtt	tcaaatttca	60
ggttccgcta	agacttttagt	tcaaaaaaat	gcatgttctg	acttggattt	tttggaacac	120
ttacttgatg	ttaaataatgc	tcctaaagag	tggaacata	agctttttca	ttgggatttg	180
aaagatgcaa	cggatcaagc	acgtttaaaa	ttgtgtattg	aggaaaatcc	ttcaacaagc	240
tactgccaa	gagttcctgc	agaatatatc	tctgatttaa	aagattttca	tgccgggatt	300
actttcttcc	gcacagagaa	ttctcatcta	ccttatacgg	ttaagttaag	caattctcgc	360
agatgcttta	ttgttgatgt	gcatacgtat	aactctgaaa	tttctgtagg	tgatgaaatt	420
ttagagatgg	acggtatgcc	gattatggag	gtaatcgaga	gtatacgtac	tggtagagga	480
gctctttctg	attacgctgc	agctgcacga	acactctttt	ctcgttctgc	tgcccttaggc	540
catcaaattc	ctatgggagt	ggcaacatta	aaaattcgtc	gtcctagcgg	tttaacgcgt	600
acggtaaaa	ctaaatggcg	ccatacgcct	gaatatattc	aagatctatc	tttaatatct	660
cctttagtaa	aagatcctat	catccagatg	agatctagcc	gtgcttgccc	tttattatct	720
agtgcctctg	aaaattgttt	attcacaaac	gaaatggttc	cttatttctg	gaaggaatta	780
cgtcagcaat	ataaacgtgg	tttaagtagt	gattacaata	tcggaagtaa	aagaggtttc	840
ttacctgatt	ttggacatgt	gacatggaaa	gctaaaagtg	gtccttacca	tgcttatgtg	900
ttcacctgca	cggataatca	tggaacagtc	cacagtatgt	gattccttag	gatttctaca	960
tattcttggg	cagatatgga	agatcgtact	gctatgaata	tggaatcccc	atgggatgac	1020
ttcagcgaga	tcattagtgt	tttacaagag	aaaaccgaag	ctttgattat	cgatcagaca	1080
aacaatcctg	gtggtagtgt	cttctatctt	tatgcattga	tttctagatt	aacagacaga	1140
cctttagaaa	cacctaaaca	tagaatgatt	ctcactcaaa	gtgaagtaca	atctgcagta	1200
caatggttga	accttcttga	aggagttgaa	accgatgagc	aagcaagaaa	tgctctcggt	1260
gaggatatgg	aaggttatcc	tatcgatatg	aatgcggcag	gatattctaca	gacattttct	1320
aatactgttt	taaaatgttg	ggcaaatggg	gatattaatc	tctctacacc	tatgcctttg	1380
ttaggatttg	ctaaagtaca	tcacatcct	gaacatcggt	atacacgtcc	tatctgcgtc	1440
ttaatcaatc	aggaagattt	ctcctgcgga	gattttattcc	ctgcgattat	gaaggatagc	1500
ggtcgagctc	ttattgttagg	aacggccaca	gcaggagccg	gagggtttgt	ctttaacgta	1560
gagttcccta	atagaacagg	cattaaaagt	tggtctttta	caggatctct	agcagtaaga	1620
cctgacggtt	cttacataga	gaatttaggg	gtctctcctc	atatattctt	agattttaca	1680
gatacggatg	tacaaacagg	aaaatattct	gattacatta	gcactgtgaa	aagtttagtt	1740
cttgatctta	ttgaaagaga	agctgataac	aaagcttctt	aa		1782

<210> 38
<211> 593
<212> PRT
<213> Chlamydia psitacii

<400> 38

Met	Lys	Val	Lys	Gln	Ile	Thr	Ala	Leu	Ile	Cys	Ser	Leu	Val	Leu	Gly
1				5					10					15	
Phe	Gln	Ile	Ser	Gly	Ser	Ala	Lys	Thr	Leu	Val	Gln	Lys	Asn	Ala	Cys
			20					25					30		
Ser	Asp	Leu	Asp	Phe	Leu	Glu	His	Leu	Leu	Asp	Val	Lys	Tyr	Ala	Pro
		35					40					45			
Lys	Glu	Trp	Lys	His	Lys	Leu	Phe	His	Trp	Asp	Leu	Lys	Asp	Ala	Thr
	50					55					60				
Asp	Gln	Ala	Arg	Leu	Lys	Leu	Cys	Ile	Glu	Glu	Asn	Pro	Ser	Thr	Ser
65					70					75					80
Tyr	Cys	Gln	Gly	Val	Leu	Ala	Glu	Tyr	Ile	Ser	Asp	Leu	Lys	Asp	Phe
			85						90					95	
His	Ala	Gly	Ile	Thr	Phe	Phe	Arg	Thr	Glu	Asn	Ser	His	Leu	Pro	Tyr
			100					105					110		
Thr	Val	Lys	Leu	Ser	Asn	Ser	Arg	Arg	Cys	Phe	Ile	Val	Asp	Val	His
		115					120						125		
Thr	Tyr	Asn	Ser	Glu	Ile	Ser	Val	Gly	Asp	Glu	Ile	Leu	Glu	Met	Asp
	130					135						140			
Gly	Met	Pro	Ile	Met	Glu	Val	Ile	Glu	Ser	Ile	Arg	Thr	Gly	Arg	Gly
145					150					155					160
Ala	Leu	Ser	Asp	Tyr	Ala	Ala	Ala	Ala	Arg	Thr	Leu	Phe	Ser	Arg	Ser
			165						170					175	
Ala	Ala	Leu	Gly	His	Gln	Ile	Pro	Met	Gly	Val	Ala	Thr	Leu	Lys	Ile
			180					185					190		
Arg	Arg	Pro	Ser	Gly	Leu	Thr	Arg	Thr	Val	Lys	Ala	Lys	Trp	Arg	His
		195					200						205		
Thr	Pro	Glu	Tyr	Ile	Gln	Asp	Leu	Ser	Leu	Ile	Ser	Pro	Leu	Val	Lys
		210				215					220				
Asp	Pro	Ile	Ile	Gln	Met	Arg	Ser	Ser	Arg	Ala	Cys	Pro	Leu	Leu	Ser
225					230					235					240
Ser	Ala	Ser	Glu	Asn	Cys	Leu	Phe	Thr	Asn	Glu	Met	Val	Pro	Tyr	Phe
			245						250					255	
Trp	Lys	Glu	Leu	Arg	Gln	Gln	Tyr	Lys	Arg	Gly	Leu	Ser	Ser	Asp	Tyr
		260						265					270		
Asn	Ile	Gly	Ser	Lys	Arg	Gly	Phe	Leu	Pro	Asp	Phe	Gly	His	Val	Thr
		275					280					285			
Trp	Lys	Ala	Lys	Ser	Gly	Pro	Tyr	His	Ala	Tyr	Val	Phe	Thr	Cys	Thr
		290				295					300				
Asp	Asn	His	Gly	Gln	Ser	His	Ser	Ile	Gly	Phe	Leu	Arg	Ile	Ser	Thr
305					310					315					320
Tyr	Ser	Trp	Thr	Asp	Met	Glu	Asp	Arg	Thr	Ala	Met	Asn	Met	Glu	Ser
			325						330					335	
Pro	Trp	Asp	Asp	Phe	Ser	Glu	Ile	Ile	Ser	Val	Leu	Gln	Glu	Lys	Thr
		340						345					350		
Glu	Ala	Leu	Ile	Ile	Asp	Gln	Thr	Asn	Asn	Pro	Gly	Gly	Ser	Val	Phe
		355					360					365			
Tyr	Leu	Tyr	Ala	Leu	Ile	Ser	Arg	Leu	Thr	Asp	Arg	Pro	Leu	Glu	Thr
	370					375					380				
Pro	Lys	His	Arg	Met	Ile	Leu	Thr	Gln	Ser	Glu	Val	Gln	Ser	Ala	Val
385					390					395					400
Gln	Trp	Leu	Asn	Leu	Glu	Gly	Val	Glu	Thr	Asp	Glu	Gln	Ala	Arg	
			405					410					415		
Asn	Ala	Leu	Gly	Glu	Asp	Met	Glu	Gly	Tyr	Pro	Ile	Asp	Met	Asn	Ala
		420						425					430		
Ala	Gly	Tyr	Leu	Gln	Thr	Phe	Ser	Asn	Thr	Val	Leu	Lys	Cys	Trp	Ala
		435					440					445			
Asn	Gly	Asp	Ile	Asn	Leu	Ser	Thr	Pro	Met	Pro	Leu	Leu	Gly	Phe	Ala
	450					455					460				
Lys	Val	His	Pro	His	Pro	Glu	His	Arg	Tyr	Thr	Arg	Pro	Ile	Cys	Val
465					470					475					480

<400> 40

Met	Lys	Lys	Gly	Lys	Leu	Gly	Ala	Ile	Val	Phe	Gly	Leu	Leu	Phe	Thr	
1				5					10					15		
Ser	Ser	Val	Ala	Gly	Phe	Ser	Lys	Asp	Leu	Thr	Lys	Asp	Asn	Ala	Tyr	
			20					25					30			
Gln	Asp	Leu	Asn	Val	Ile	Glu	His	Leu	Ile	Ser	Leu	Lys	Tyr	Ala	Pro	
		35					40					45				
Leu	Pro	Trp	Lys	Glu	Leu	Leu	Phe	Gly	Trp	Asp	Leu	Ser	Gln	Gln	Thr	
	50					55					60					
Gln	Gln	Ala	Arg	Leu	Gln	Leu	Val	Leu	Glu	Glu	Lys	Pro	Thr	Thr	Asn	
65					70					75					80	
Tyr	Cys	Gln	Lys	Val	Leu	Ser	Asn	Tyr	Val	Arg	Ser	Leu	Asn	Asp	Tyr	
				85					90					95		
His	Ala	Gly	Ile	Thr	Phe	Tyr	Arg	Thr	Glu	Ser	Ala	Tyr	Ile	Pro	Tyr	
			100					105					110			
Val	Leu	Lys	Leu	Ser	Glu	Asp	Gly	His	Val	Phe	Val	Val	Asp	Val	Gln	
	115						120					125				
Thr	Ser	Gln	Gly	Asp	Ile	Tyr	Leu	Gly	Asp	Glu	Ile	Leu	Glu	Val	Asp	
	130					135					140					
Gly	Met	Gly	Ile	Arg	Glu	Ala	Ile	Glu	Ser	Leu	Arg	Phe	Gly	Arg	Gly	
145					150					155					160	
Ser	Ala	Thr	Asp	Tyr	Ser	Ala	Ala	Val	Arg	Ser	Leu	Thr	Ser	Arg	Ser	
				165					170					175		
Ala	Ala	Phe	Gly	Asp	Ala	Val	Pro	Ser	Gly	Ile	Ala	Met	Leu	Lys	Leu	
			180					185					190			
Arg	Arg	Pro	Ser	Gly	Leu	Ile	Arg	Ser	Thr	Pro	Val	Arg	Trp	Arg	Tyr	
	195						200					205				
Thr	Pro	Glu	His	Ile	Gly	Asp	Phe	Ser	Leu	Val	Ala	Pro	Leu	Ile	Pro	
	210				215						220					
Glu	His	Lys	Pro	Gln	Leu	Pro	Thr	Gln	Ser	Cys	Val	Leu	Phe	Arg	Ser	
225					230					235					240	
Gly	Val	Asn	Ser	Gln	Ser	Ser	Ser	Ser	Ser	Leu	Phe	Ser	Ser	Tyr	Met	
				245					250					255		
Val	Pro	Tyr	Phe	Trp	Glu	Glu	Leu	Arg	Val	Gln	Asn	Lys	Gln	Arg	Phe	
			260					265					270			
Asp	Ser	Asn	His	His	Ile	Gly	Ser	Arg	Asn	Gly	Phe	Leu	Pro	Thr	Phe	
		275					280					285				
Gly	Pro	Ile	Leu	Trp	Glu	Gln	Asp	Lys	Gly	Pro	Tyr	Arg	Ser	Tyr	Ile	
	290					295					300					
Phe	Lys	Ala	Lys	Asp	Ser	Gln	Gly	Asn	Pro	His	Arg	Ile	Gly	Phe	Leu	
305					310					315					320	
Arg	Ile	Ser	Ser	Tyr	Val	Trp	Thr	Asp	Leu	Glu	Gly	Leu	Glu	Glu	Asp	
				325					330					335		
His	Lys	Asp	Ser	Pro	Trp	Glu	Leu	Phe	Gly	Glu	Ile	Ile	Asp	His	Leu	
			340					345					350			
Glu	Lys	Glu	Thr	Asp	Ala	Leu	Ile	Ile	Asp	Gln	Thr	His	Asn	Pro	Gly	
	355						360					365				
Gly	Ser	Val	Phe	Tyr	Leu	Tyr	Ser	Leu	Leu	Ser	Met	Leu	Thr	Asp	His	
	370					375					380					
Pro	Leu	Asp	Thr	Pro	Lys	His	Arg	Met	Ile	Phe	Thr	Gln	Asp	Glu	Val	
385					390					395					400	
Ser	Ser	Ala	Leu	His	Trp	Gln	Asp	Leu	Leu	Glu	Asp	Val	Phe	Thr	Asp	
				405					410					415		
Glu	Gln	Ala	Val	Ala	Val	Leu	Gly	Glu	Thr	Met	Glu	Gly	Tyr	Cys	Met	
		420					425						430			
Asp	Met	His	Ala	Val	Ala	Ser	Leu	Gln	Asn	Phe	Ser	Gln	Ser	Val	Leu	
	435						440					445				
Ser	Ser	Trp	Val	Ser	Gly	Asp	Ile	Asn	Leu	Ser	Lys	Pro	Met	Pro	Leu	
	450					455					460					

Leu Gly Phe Ala Gln Val Arg Pro His Pro Lys His Gln Tyr Thr Lys
 465 470 475 480
 Pro Leu Phe Met Leu Ile Asp Glu Asp Asp Phe Ser Cys Gly Asp Leu
 485 490 495
 Ala Pro Ala Ile Leu Lys Asp Asn Gly Arg Ala Thr Leu Ile Gly Lys
 500 505 510
 Pro Thr Ala Gly Ala Gly Gly Phe Val Phe Gln Val Thr Phe Pro Asn
 515 520 525
 Arg Ser Gly Ile Lys Gly Leu Ser Leu Thr Gly Ser Leu Ala Val Arg
 530 535 540
 Lys Asp Gly Glu Phe Ile Glu Asn Leu Gly Val Ala Pro His Ile Asp
 545 550 555 560
 Leu Gly Phe Thr Ser Arg Asp Leu Gln Thr Ser Arg Phe Thr Asp Tyr
 565 570 575
 Val Glu Ala Val Lys Thr Ile Val Leu Thr Ser Leu Ser Glu Asn Ala
 580 585 590
 Lys Lys Ser Glu Glu Gln Thr Ser Pro Gln Glu Thr Pro Glu Val Ile
 595 600 605
 Arg Val Ser Tyr Pro Thr Thr Ser Ala Ser
 610 615

<210> 41
 <211> 4596
 <212> DNA
 <213> Chlamydia trachomatis

<400> 41

atgagttcog	agaaagatat	aaaaagcacc	tgttctaagt	tttctttgtc	tgtagtagca	60
gctatccttg	cctctgttag	cgggttagct	agttgcgtag	atcttcacgc	tggaggacag	120
tctgtaaagt	agctgggtata	tgtaggccct	caagcgggtt	tattgttaga	ccaaattcga	180
gatctattcg	ttgggtctaa	agatagtcag	gctgaaggac	agtatagggt	aattgtagga	240
gatccaagtt	ctttccaaga	gaaagatgcg	gatactcttc	ccgggaaggt	agagcaaagt	300
actttgttct	cagtaaccaa	tcccgtgggt	ttccaagggt	tggaccaaca	ggatcaagtc	360
tcttcccaag	ggttaatttg	tagttttacg	agcagcaacc	ttgattctcc	tcgtgacgga	420
gaatcttttt	taggtattgc	ttttgttggg	gatagtagta	aggctggaat	cacattaact	480
gacgtgaaag	cttctttgtc	tggagcggct	ttatattcta	cagaagatct	tatctttgaa	540
aagattaagg	gtggattgga	atttgcacat	tggtctttct	tagaacaggg	gggagcttgt	600
gcagctcaaa	gtattttgat	tcattgattgt	caaggattgc	agggttaaaca	ctgtactaca	660
gccgtgaatg	ctgaggggtc	tagtgcgaaat	gatcatcttg	gatttggagg	aggcgctttc	720
tttgttacgg	gttctctttc	tggagagaaa	agtctctata	tgcctgcagg	agatatggta	780
gttgcgaaatt	gtgatggggc	tatatctttt	gaaggaaaca	gcgcgaactt	tgctaattgga	840
ggagcgattg	ctgcctctgg	gaaagtgcct	tttgtcgcta	atgataaaaa	gacttctttt	900
atagagaacc	gagctttgtc	tggaggagcg	attgcagcct	cttctgatat	tgcctttcaa	960
aactgcgcag	aactagtttt	caaaggcaat	tgtgcaattg	gaacagagga	taaagggtct	1020
ttaggtggag	gggctatata	ttctctaggc	accgttcttt	tgcaagggaa	tcacgggata	1080
acttgtgata	agaatgagtc	tgcttcgcaa	ggaggcgcca	tttttggcaa	aaattgtcag	1140
atttctgaca	acgagggggc	agtgtttttc	agagatagta	cagcttgctt	aggaggaggc	1200
gctattgcag	ctcaagaaat	tgtttctatt	cagaacaatc	aggctgggat	ttccttcgag	1260
ggaggttaagg	ctagtttcgg	aggaggtatt	gcgtgtggat	ctttttcttc	cgcaggtgggt	1320
gcttctgttt	tagggaccat	tgatatttcg	aagaattttag	gcgcgatttc	gttctctcgt	1380
actttatgta	cgacctcaga	tttaggacaa	atggagtacc	agggaggagg	agctctattt	1440
ggtgaaaata	tttctctttc	tgagaatgct	ggtgtgctca	ccttttaaaga	caacattgtg	1500
aagacttttg	cttcgaatgg	gaaaattctg	ggaggaggag	cgatttttagc	tactggtaag	1560
gtggaaaatta	ctaataattc	cgaaggaatt	tcttttacag	gaaatgcgag	agctccacaa	1620
gctcttccaa	ctcaagagga	gtttccttta	ttcagcaaaa	aagaagggcg	accactctct	1680
tcaggatatt	ctggggggagg	agcgatttta	ggaagagaag	tagctattct	ccacaacgct	1740
gcagtagtat	ttgagcaaaa	tcgtttgcag	tgacgcgaag	aagaagcgac	attattaggt	1800
tgttgtggag	gaggcgctgt	tcattgggatg	gatagcactt	cgattgttgg	caactcttca	1860
gtaagatttg	gtaataatta	cgcaatggga	caaggagctc	caggaggagc	tcttttatct	1920

aaaacagtgc	agtttagctgg	gaatggaagc	gtcgaattttt	ctcgaaatat	tgctagtttg	1980
ggaggaggag	ctcttcaagc	ttctgaagga	aattgtgagc	tagttgataa	cggctatgtg	2040
ctattcagag	ataatcgagg	gagggtttat	gggggtgcta	tttcttgctt	acgtggagat	2100
gtagtcattt	ctggaaacaa	gggtagagtt	gaatttaaag	acaacatagc	aacacgtcct	2160
tatgtggaag	aaactgtaga	aaaggttgaa	gaggttagagc	cagctcctga	gcaaaaagac	2220
aataatgagc	tttctttcct	agggagagca	gaacagagtt	ttattactgc	agctaataca	2280
gctcttttcg	catctgaaga	tggggattta	tcacctgagt	catccatttc	ttctgaagaa	2340
cttgcgaaaa	gaagagagtg	tgctggagga	gctatttttg	caaaacgggt	tcgtattgta	2400
gataaccaag	aggccgttgt	attctcgaat	aacttctctg	atatttatgg	cggcgccatt	2460
tttacagggt	ctcttcgaga	agaggataag	ttagatgggc	aaatccctga	agtcttgatc	2520
tcaggcaatg	caggggatgt	tgttttttcc	ggaaattcct	cgaagcgtga	tgagcatcct	2580
cctcatacag	gtgggggagc	catttggtact	caaaatttga	cgatttctca	gaatacaggg	2640
aatgttctgt	tttataacaa	cgtggcctgt	tcgggaggag	ctgttcgtat	agaggatcat	2700
ggtaatgttc	ttttagaagc	ttttggagga	gatattgttt	ttaaaggaaa	ttcttctttc	2760
agagcacaag	gatccgatgc	tatctatttt	gcaggtaaag	aatcgcatat	tacagccctg	2820
aatgctacgg	aaggacatgc	tattgttttc	cacgacgcat	tagtttttga	aaatctagaa	2880
gaaaggaaat	ctgctgaagt	attgttaatc	aatagtcgag	aaaatccagg	ttacactgga	2940
tctattcgat	ttttagaagc	agaaagtaaa	gttcctcaat	gtattcatgt	acaacaagga	3000
agccttgagt	tgctaaatgg	agccacatta	tgtagttagt	gtttttaaca	agatgctgga	3060
gctaagttgg	tattggctgc	tggaagctaaa	ctgaagattt	tagattcagg	aactcctgta	3120
caacaagggc	atgctatcac	taaacctgaa	gcagaaatcg	agtcactctc	tgaaccagag	3180
gggtgcacatt	ctctttggat	tgccaagaat	gctcaaacaa	cagttcctat	ggttgatata	3240
catactattt	ctgtagattt	agcctccttc	tcttctagtc	aacaggaggg	gacagtagaa	3300
gctcctcagg	ttattgttcc	tggaaggaag	tatgttcgat	ctggagagct	taatttggag	3360
ttagttaaca	caacagggtac	tggttatgaa	aatcatgctt	tattgaagaa	tgaggctaaa	3420
gttccattga	tgtctttcgt	tgcttctggt	gatgaagctt	cagccgaaat	cagtaacttg	3480
tcggtttctg	atttacagat	tcagttagta	actccagaga	ttgaagaaga	cacatacggc	3540
catatgggag	attggtctga	ggctaaaatt	caagatggaa	ctcttgatcat	tagttggaat	3600
cctactggat	atcgattaga	tcttcaaaaa	gcaggggctt	tagtatttaa	tgcatatatg	3660
gaagaagggg	ctgtcttgtc	tgctctgaaa	aatgcacgct	ttgctcataa	tctcactgct	3720
cagcgtatgg	aattcgatta	ttctacaaat	gtgtggggat	tcgccttttg	tggtttccga	3780
actctatctg	cagagaatct	ggttgctatt	gatggataca	aaggagctta	tggtggtgct	3840
tctgctggag	tcgatattca	attgatggaa	gattttgttc	taggagttag	tggaagctgct	3900
ttcctaggta	aaatggatag	tcagaagttt	gatgcggagg	tttctcggaa	gggagttggt	3960
ggttctgtat	atacaggatt	tttagctgga	tcctggttct	tcaaaggaca	atatagcctt	4020
ggagaaacac	agaacgatat	gaaaacgcgt	tatggagtac	taggagagtc	gagtgccttc	4080
tggaacatct	gaggagtact	ggcagatgct	ttagttgaat	accgaagttt	agttggtcct	4140
gtgagaccta	cttttttatgc	tttgcatctt	aatccttatg	tcgaagtatc	ttatgcttct	4200
atgaaattcc	ctggcttttac	agaacaagga	agagaagcgc	gttcttttga	agacgcttcc	4260
cttaccaata	tcaccattcc	tttagggatg	aagtttgaat	tggcgttcat	aaaaggacag	4320
ttttcagagg	tgaactcttt	gggaataagt	tatgcatggg	aagcttatcg	aaaagtagaa	4380
ggaggcgagg	tgcaagctttt	agaagctggg	tttgattggg	agggagctcc	aatggatcct	4440
cctagacagg	agctgcgtgt	cgctctggaa	aataatacgg	aatggagttc	ttacttcagc	4500
acagtcttag	gattaacagc	tttttgtgga	ggatttactt	ctacagatag	taaactagga	4560
tatgaggcga	atactggatt	gcgattgata	tttttaa			4596

<210> 42
 <211> 1531
 <212> PRT

<400> 42

Met	Ser	Ser	Glu	Lys	Asp	Ile	Lys	Ser	Thr	Cys	Ser	Lys	Phe	Ser	Leu
1			5					10					15		
Ser	Val	Val	Ala	Ala	Ile	Leu	Ala	Ser	Val	Ser	Gly	Leu	Ala	Ser	Cys
			20					25					30		
Val	Asp	Leu	His	Ala	Gly	Gly	Gln	Ser	Val	Asn	Glu	Leu	Val	Tyr	Val
			35				40					45			
Gly	Pro	Gln	Ala	Val	Leu	Leu	Leu	Asp	Gln	Ile	Arg	Asp	Leu	Phe	Val

50	55	60
Gly Ser Lys Asp Ser Gln Ala Glu Gly Gln Tyr Arg Leu Ile Val Gly		
65	70	75
Asp Pro Ser Ser Phe Gln Glu Lys Asp Ala Asp Thr Leu Pro Gly Lys		80
	85	90
Val Glu Gln Ser Thr Leu Phe Ser Val Thr Asn Pro Val Val Phe Gln		95
	100	105
Gly Val Asp Gln Gln Asp Gln Val Ser Ser Gln Gly Leu Ile Cys Ser		110
	115	120
Phe Thr Ser Ser Asn Leu Asp Ser Pro Arg Asp Gly Glu Ser Phe Leu		125
	130	135
Gly Ile Ala Phe Val Gly Asp Ser Ser Lys Ala Gly Ile Thr Leu Thr		140
	145	150
Asp Val Lys Ala Ser Leu Ser Gly Ala Ala Leu Tyr Ser Thr Glu Asp		155
	165	170
Leu Ile Phe Glu Lys Ile Lys Gly Gly Leu Glu Phe Ala Ser Cys Ser		175
	180	185
Ser Leu Glu Gln Gly Gly Ala Cys Ala Ala Gln Ser Ile Leu Ile His		190
	195	200
Asp Cys Gln Gly Leu Gln Val Lys His Cys Thr Thr Ala Val Asn Ala		205
	210	215
Glu Gly Ser Ser Ala Asn Asp His Leu Gly Phe Gly Gly Gly Ala Phe		220
	225	230
Phe Val Thr Gly Ser Leu Ser Gly Glu Lys Ser Leu Tyr Met Pro Ala		235
	245	250
Gly Asp Met Val Val Ala Asn Cys Asp Gly Ala Ile Ser Phe Glu Gly		255
	260	265
Asn Ser Ala Asn Phe Ala Asn Gly Gly Ala Ile Ala Ala Ser Gly Lys		270
	275	280
Val Leu Phe Val Ala Asn Asp Lys Lys Thr Ser Phe Ile Glu Asn Arg		285
	290	295
Ala Leu Ser Gly Gly Ala Ile Ala Ala Ser Ser Asp Ile Ala Phe Gln		300
	305	310
Asn Cys Ala Glu Leu Val Phe Lys Gly Asn Cys Ala Ile Gly Thr Glu		315
	325	330
Asp Lys Gly Ser Leu Gly Gly Gly Ala Ile Ser Ser Leu Gly Thr Val		335
	340	345
Leu Leu Gln Gly Asn His Gly Ile Thr Cys Asp Lys Asn Glu Ser Ala		350
	355	360
Ser Gln Gly Gly Ala Ile Phe Gly Lys Asn Cys Gln Ile Ser Asp Asn		365
	370	375
Glu Gly Pro Val Val Phe Arg Asp Ser Thr Ala Cys Leu Gly Gly Gly		380
	385	390
Ala Ile Ala Ala Gln Glu Ile Val Ser Ile Gln Asn Asn Gln Ala Gly		395
	405	410
Ile Ser Phe Glu Gly Gly Lys Ala Ser Phe Gly Gly Gly Ile Ala Cys		415
	420	425
Gly Ser Phe Ser Ser Ala Gly Gly Ala Ser Val Leu Gly Thr Ile Asp		430
	435	440
Ile Ser Lys Asn Leu Gly Ala Ile Ser Phe Ser Arg Thr Leu Cys Thr		445
	450	455
Thr Ser Asp Leu Gly Gln Met Glu Tyr Gln Gly Gly Gly Ala Leu Phe		460
	465	470
Gly Glu Asn Ile Ser Leu Ser Glu Asn Ala Gly Val Leu Thr Phe Lys		475
	485	490
Asp Asn Ile Val Lys Thr Phe Ala Ser Asn Gly Lys Ile Leu Gly Gly		495
	500	505
Gly Ala Ile Leu Ala Thr Gly Lys Val Glu Ile Thr Asn Asn Ser Glu		510
	515	520
Gly Ile Ser Phe Thr Gly Asn Ala Arg Ala Pro Gln Ala Leu Pro Thr		525

530		535		540
Gln Glu Glu Phe Pro Leu Phe Ser Lys Lys Glu Gly Arg Pro Leu Ser				
545		550		555
Ser Gly Tyr Ser Gly Gly Ala Ile Leu Gly Arg Glu Val Ala Ile				
	565		570	575
Leu His Asn Ala Ala Val Val Phe Glu Gln Asn Arg Leu Gln Cys Ser				
	580		585	590
Glu Glu Glu Ala Thr Leu Leu Gly Cys Cys Gly Gly Gly Ala Val His				
	595		600	605
Gly Met Asp Ser Thr Ser Ile Val Gly Asn Ser Ser Val Arg Phe Gly				
	610		615	620
Asn Asn Tyr Ala Met Gly Gln Gly Val Ser Gly Gly Ala Leu Leu Ser				
625		630		635
Lys Thr Val Gln Leu Ala Gly Asn Gly Ser Val Asp Phe Ser Arg Asn				
	645		650	655
Ile Ala Ser Leu Gly Gly Gly Ala Leu Gln Ala Ser Glu Gly Asn Cys				
	660		665	670
Glu Leu Val Asp Asn Gly Tyr Val Leu Phe Arg Asp Asn Arg Gly Arg				
	675		680	685
Val Tyr Gly Gly Ala Ile Ser Cys Leu Arg Gly Asp Val Val Ile Ser				
	690		695	700
Gly Asn Lys Gly Arg Val Glu Phe Lys Asp Asn Ile Ala Thr Arg Leu				
705		710		715
Tyr Val Glu Glu Thr Val Glu Lys Val Glu Glu Val Glu Pro Ala Pro				
	725		730	735
Glu Gln Lys Asp Asn Asn Glu Leu Ser Phe Leu Gly Arg Ala Glu Gln				
	740		745	750
Ser Phe Ile Thr Ala Ala Asn Gln Ala Leu Phe Ala Ser Glu Asp Gly				
	755		760	765
Asp Leu Ser Pro Glu Ser Ser Ile Ser Ser Glu Glu Leu Ala Lys Arg				
	770		775	780
Arg Glu Cys Ala Gly Gly Ala Ile Phe Ala Lys Arg Val Arg Ile Val				
785		790		795
Asp Asn Gln Glu Ala Val Val Phe Ser Asn Asn Phe Ser Asp Ile Tyr				
	805		810	815
Gly Gly Ala Ile Phe Thr Gly Ser Leu Arg Glu Glu Asp Lys Leu Asp				
	820		825	830
Gly Gln Ile Pro Glu Val Leu Ile Ser Gly Asn Ala Gly Asp Val Val				
	835		840	845
Phe Ser Gly Asn Ser Ser Lys Arg Asp Glu His Leu Pro His Thr Gly				
	850		855	860
Gly Gly Ala Ile Cys Thr Gln Asn Leu Thr Ile Ser Gln Asn Thr Gly				
865		870		875
Asn Val Leu Phe Tyr Asn Asn Val Ala Cys Ser Gly Gly Ala Val Arg				
	885		890	895
Ile Glu Asp His Gly Asn Val Leu Leu Glu Ala Phe Gly Gly Asp Ile				
	900		905	910
Val Phe Lys Gly Asn Ser Ser Phe Arg Ala Gln Gly Ser Asp Ala Ile				
	915		920	925
Tyr Phe Ala Gly Lys Glu Ser His Ile Thr Ala Leu Asn Ala Thr Glu				
	930		935	940
Gly His Ala Ile Val Phe His Asp Ala Leu Val Phe Glu Asn Leu Glu				
945		950		955
Glu Arg Lys Ser Ala Glu Val Leu Leu Ile Asn Ser Arg Glu Asn Pro				
	965		970	975
Gly Tyr Thr Gly Ser Ile Arg Phe Leu Glu Ala Glu Ser Lys Val Pro				
	980		985	990
Gln Cys Ile His Val Gln Gln Gly Ser Leu Glu Leu Leu Asn Gly Ala				
	995		1000	1005
Thr Leu Cys Ser Tyr Gly Phe Lys Gln Asp Ala Gly Ala Lys Leu				

1010	1015	1020
Val Leu Ala Ala Gly Ala Lys	Leu Lys Ile Leu Asp	Ser Gly Thr
1025	1030	1035
Pro Val Gln Gln Gly His Ala	Ile Ser Lys Pro Glu	Ala Glu Ile
1040	1045	1050
Glu Ser Ser Ser Glu Pro Glu	Gly Ala His Ser Leu	Trp Ile Ala
1055	1060	1065
Lys Asn Ala Gln Thr Thr Val	Pro Met Val Asp Ile	His Thr Ile
1070	1075	1080
Ser Val Asp Leu Ala Ser Phe	Ser Ser Ser Gln Gln	Glu Gly Thr
1085	1090	1095
Val Glu Ala Pro Gln Val Ile	Val Pro Gly Gly Ser	Tyr Val Arg
1100	1105	1110
Ser Gly Glu Leu Asn Leu Glu	Leu Val Asn Thr Thr	Gly Thr Gly
1115	1120	1125
Tyr Glu Asn His Ala Leu Leu	Lys Asn Glu Ala Lys	Val Pro Leu
1130	1135	1140
Met Ser Phe Val Ala Ser Gly	Asp Glu Ala Ser Ala	Glu Ile Ser
1145	1150	1155
Asn Leu Ser Val Ser Asp Leu	Gln Ile His Val Val	Thr Pro Glu
1160	1165	1170
Ile Glu Glu Asp Thr Tyr Gly	His Met Gly Asp Trp	Ser Glu Ala
1175	1180	1185
Lys Ile Gln Asp Gly Thr Leu	Val Ile Ser Trp Asn	Pro Thr Gly
1190	1195	1200
Tyr Arg Leu Asp Pro Gln Lys	Ala Gly Ala Leu Val	Phe Asn Ala
1205	1210	1215
Leu Trp Glu Glu Gly Ala Val	Leu Ser Ala Leu Lys	Asn Ala Arg
1220	1225	1230
Phe Ala His Asn Leu Thr Ala	Gln Arg Met Glu Phe	Asp Tyr Ser
1235	1240	1245
Thr Asn Val Trp Gly Phe Ala	Phe Gly Gly Phe Arg	Thr Leu Ser
1250	1255	1260
Ala Glu Asn Leu Val Ala Ile	Asp Gly Tyr Lys Gly	Ala Tyr Gly
1265	1270	1275
Gly Ala Ser Ala Gly Val Asp	Ile Gln Leu Met Glu	Asp Phe Val
1280	1285	1290
Leu Gly Val Ser Gly Ala Ala	Phe Leu Gly Lys Met	Asp Ser Gln
1295	1300	1305
Lys Phe Asp Ala Glu Val Ser	Arg Lys Gly Val Val	Gly Ser Val
1310	1315	1320
Tyr Thr Gly Phe Leu Ala Gly	Ser Trp Phe Phe Lys	Gly Gln Tyr
1325	1330	1335
Ser Leu Gly Glu Thr Gln Asn	Asp Met Lys Thr Arg	Tyr Gly Val
1340	1345	1350
Leu Gly Glu Ser Ser Ala Ser	Trp Thr Ser Arg Gly	Val Leu Ala
1355	1360	1365
Asp Ala Leu Val Glu Tyr Arg	Ser Leu Val Gly Pro	Val Arg Pro
1370	1375	1380
Thr Phe Tyr Ala Leu His Phe	Asn Pro Tyr Val Glu	Val Ser Tyr
1385	1390	1395
Ala Ser Met Lys Phe Pro Gly	Phe Thr Glu Gln Gly	Arg Glu Ala
1400	1405	1410
Arg Ser Phe Glu Asp Ala Ser	Leu Thr Asn Ile Thr	Ile Pro Leu
1415	1420	1425
Gly Met Lys Phe Glu Leu Ala	Phe Ile Lys Gly Gln	Phe Ser Glu
1430	1435	1440
Val Asn Ser Leu Gly Ile Ser	Tyr Ala Trp Glu Ala	Tyr Arg Lys
1445	1450	1455
Val Glu Gly Gly Ala Val Gln	Leu Leu Glu Ala Gly	Phe Asp Trp

1460	1465	1470
Glu Gly Ala Pro Met Asp Leu Pro Arg Gln Glu Leu Arg Val Ala		
1475	1480	1485
Leu Glu Asn Asn Thr Glu Trp Ser Ser Tyr Phe Ser Thr Val Leu		
1490	1495	1500
Gly Leu Thr Ala Phe Cys Gly Gly Phe Thr Ser Thr Asp Ser Lys		
1505	1510	1515
Leu Gly Tyr Glu Ala Asn Thr Gly Leu Arg Leu Ile Phe		
1520	1525	1530

<210> 43
 <211> 4563
 <212> DNA
 <213> Chlamydia muridarum

<400> 43

atgagttccg	agaaagataa	aaaaaactcc	tgttctaagt	tttccttata	ggtagtagca	60
gctattctcg	cttctatgag	tggtttatcg	aattgttccg	atctttatgc	cgtaggaagt	120
tctgcagacc	atcctgccta	cttgattcct	caagcggggt	tattattgga	tcatattaag	180
gatatattca	ttggccctaa	agatagtcag	gataaggggc	agtataagtt	gattattggt	240
gaggctggct	ctttccaaga	tagtaatgca	gagactcttc	ctcaaaaggt	agagcacagc	300
actttgtttt	cagttacaac	acctataatt	gtgcaaggaa	tagatcaaca	agatcaggtc	360
tcttcgcagg	gattggctctg	taatttttca	ggagatcatt	cagaggagat	ttttgagaga	420
gaatcctttt	tagggatcgc	tttcctaggg	aatggtagca	aggatggaat	cacgttaaca	480
gatataaaat	cttcgtttatc	tgggtgctgcc	ttgtattctt	cagatgatct	tatttttgaa	540
agaattaagg	gagatataga	gctttcttct	tgttcattct	tagaaagagg	aggagcttgt	600
tcagctcaaa	gtattttaat	tcatgattgt	caaggattaa	cggtaaaaca	ttgtgccgca	660
ggggtgaatg	ttgaaggagt	tagtgctagc	gaccatctcg	gatttggggg	cggggccttc	720
tctactacaa	gttctctttc	tggagagaag	agtttgtata	tgcttcgagg	cgatattgtg	780
gtggctacct	gcgatggctc	tgtgtgtttc	gaaggaaata	gtgctcagtt	agcaaagtgt	840
ggcgctattg	ccgcttctgg	taaagttctt	ttttagctca	acgaaaaaaa	gatttctctt	900
acagacaacc	aagctttgtc	tggaggagct	atctctgcat	cttctagtat	ttctttccaa	960
aattgtgctg	agcttgtgtt	caagagtaat	cttgcaaaag	gagttaaaga	taaatgttct	1020
ttgggaggag	gtgcttttag	ctcttttaga	tccgtagttt	tgaaagataa	tctcgggtatt	1080
acttatgaaa	aaaatcagtc	ctattcggaa	ggaggggcta	tttttgggaa	ggattgtgag	1140
atttttgaaa	acagggggcc	tgttgtattc	agagataata	cagctgcttt	aggaggcgga	1200
gctatttttg	cgcaacaaac	tgtggcgatt	tgtggtaata	agtctggaat	atcttttgaa	1260
ggaagtaagt	ctagtttttg	agggggccatt	gcttgtggaa	atctctcttc	tgagaataat	1320
tcttcagctt	tgggatcaat	tgatatctct	aacaatctag	gagatatctc	ttttcttcgg	1380
actctgtgta	ctacttcgga	tttagggcaa	acggattacc	aagggggagg	ggccttattc	1440
gctgaaaata	tttctctttc	tgagaatgct	ggtgcaattta	ctttcaaaga	caatattgtg	1500
aagacatttg	cctcaaattg	aaaaatgttg	ggtggagggg	caatttttag	ttcaggaaat	1560
gttttgatta	gcaaaaactc	tggagagatt	tctttttag	ggaatgctcg	agctcctcag	1620
gctattccga	ctcgttcata	tgacgaattg	tcttttggcg	cacaattaac	tcaaaactact	1680
tcaggatggt	ctggaggagg	agctcttttt	ggtaaaagagg	ttgccattgt	tcaaaatgcc	1740
actgttggtat	tcgagcaaaa	tcgcttacag	tgtggcgagc	aggaaacaca	tgggtggaggc	1800
ggtgctgttt	atggtatgga	gagtgcctct	attattggaa	actcttttgt	gagattcggga	1860
aataattacg	ctgtagggaa	tcagatttct	ggaggagctc	ttttatccaa	gaaggctcgt	1920
ttagctgaaa	atacaagggt	agatttttct	cgaaatatcg	ctactttctg	cggcggggct	1980
gttcaagttt	ctgatggaag	ttgcgaattg	atcaacaatg	ggtatgtgct	attcagagat	2040
aaccgagggc	agacattttg	tggggctatt	tcttgcttga	aaggagatgt	gatcatttcc	2100
ggaaataaag	ataggggttg	gttttagagat	aacattgtga	cgcggcctta	ttttgaagaa	2160
aatgaagaaa	aagttgagac	agcagatatt	aattcagata	agcaagaagc	agaagagcgc	2220
tctttattag	agaacattga	gcagagcttt	attactgcaa	ctaatacagac	ctttttctta	2280
gaggaagaga	aactcccatc	agaagctttt	atctctgctg	aagaactttc	aaagagaaga	2340
gaatgtgctg	gtggggcgat	ttttgcaaaa	cgggtctaca	ttacggataa	taaagaacct	2400
atcttgtttt	cgcataattt	ttctgatgtt	tatgggggag	ctattttttac	gggttctcta	2460
caggaaaactg	ataaacaaga	tgttgtaact	cctgaagtgt	tgatatcagg	caacgatggg	2520
gatgtcattt	tttctggaaa	tgcagctaaa	catgataagc	atttacctga	tacaggtggt	2580

ggagccattt	gtacacagaa	tttgacgatt	tcccaaaaca	atgggaatgt	cttggttcttg	2640
aacaattttg	cttggttctgg	tggagcagtt	cgcatagagg	atcatggaga	agttcttttta	2700
gaggcttttg	ggggagatat	tattttcaat	ggaaactctt	ctttcagagc	tcaaggatcg	2760
gatgcgatct	attttgctgg	taaggactct	agaattaaag	ctttaaatgc	tactgaagga	2820
catgcgattg	tgttccaaga	tgcattggtg	tttgaaaata	tagaagaaag	aaagtcttcg	2880
ggactattgg	tgattaactc	tcaggaaaat	gaggggtata	cgggatccgt	ccgatttttta	2940
ggatctgaaa	gtaaggttcc	tcaatggatt	catgtgcaac	agggaggtct	tgagttgcta	3000
catggagcta	ttttatgtag	ttatgggggt	aaacaagatc	ctagagctaa	aatagtatta	3060
tctgctggat	ctaaattgaa	gattctagat	tcagagcaag	aaaataacgc	agaaattgga	3120
gatcttgaag	attctgttaa	ttcagaaaaa	acaccatctc	tttggattgg	gaagaacgct	3180
caagcaaaag	tccctctggt	tgatatccat	actattttcta	ttgatttagc	atcattttct	3240
tctaaagctc	aggaaacccc	tgaggaagct	ccacaagtca	tcgtccctaa	gggaagttgt	3300
gtccactcgg	gagagttaag	tttggagttg	gttaatacaa	caggaaaagg	ttatgagaat	3360
catgcgttgt	taaaaaatga	tactcaggtt	tctctcatgt	ctttcaaaga	ggaaaatgat	3420
ggatcttttag	aagatttgag	taagttgtct	gttttcggatt	tacgcattaa	agttttctact	3480
ccagatatgg	tagaagaaac	ttatggccat	atgggggatt	ggtctgaagc	tacaattcaa	3540
gatggggctc	ttgtcattaa	ttggcatcct	actggatata	aattagatcc	gcaaaaagct	3600
ggttcttttg	tattcaatgc	attatggggag	gaagaggctg	tattgtctac	tctaaaaaat	3660
gctcggattg	cccataacct	taccattcag	agaatggaat	ttgattattc	tacaaatgct	3720
tgggggattag	cttttagtag	cttttagagag	ctatcttcag	agaagcttgt	ttctgttgat	3780
ggatatagag	gctcttatat	aggggcttct	gcaggcattg	atactcagtt	gatggaagat	3840
tttgtttttg	gaatcagcac	ggcttccttc	ttcgggaaaa	tgcatagtca	gaattttgat	3900
gcagagattt	ctcgacatgg	ttttgttggt	tcggtctata	caggcttctc	agctggggcc	3960
tggttcttca	aggggacagta	cagtcttggc	gaaacacata	acgatatgac	aactcggttac	4020
gggggttttg	gagaatctaa	tgctacttgg	aagtctcgag	gagtactagc	agatgcttta	4080
gttgaatatc	gtagtttagt	cgggtccagca	cgacctaaat	tttatgcttt	gcattttaat	4140
ccttatgtcg	aggtatctta	tgcatctcgg	aagttcccta	gttttgtaga	acaaggagga	4200
gaagctcgtg	cttttgaaga	aacctcttta	acaaacatta	ccgttccctt	tggtatgaaa	4260
tttgaactat	cttttacaaa	aggacagttt	tcagagacta	attctcttgg	aataggttgt	4320
gcattgggaaa	tgtatcgga	agtcgaagga	agatctgtag	agctactaga	agctgggttt	4380
gattgggaag	gatctcctat	agatctccct	aaacaagagc	tgagagtggc	tttagaaaac	4440
aatacgggaat	ggagttcgta	tttttagtaca	gctctaggag	taacagcatt	ttgtggagga	4500
ttttcttcta	tggataataa	actaggatac	gaagcgaatg	ctggaatgcg	tttgattttc	4560
tag						4563

<210> 44
 <211> 1520
 <212> PRT
 <213> Chlamydia muridarum

<400> 44

Met	Ser	Ser	Glu	Lys	Asp	Lys	Lys	Asn	Ser	Cys	Ser	Lys	Phe	Ser	Leu
1			5					10						15	
Ser	Val	Val	Ala	Ala	Ile	Leu	Ala	Ser	Met	Ser	Gly	Leu	Ser	Asn	Cys
			20					25						30	
Ser	Asp	Leu	Tyr	Ala	Val	Gly	Ser	Ser	Ala	Asp	His	Pro	Ala	Tyr	Leu
			35					40						45	
Ile	Pro	Gln	Ala	Gly	Leu	Leu	Leu	Asp	His	Ile	Lys	Asp	Ile	Phe	Ile
			50					55						60	
Gly	Pro	Lys	Asp	Ser	Gln	Asp	Lys	Gly	Gln	Tyr	Lys	Leu	Ile	Ile	Gly
65								70						80	
Glu	Ala	Gly	Ser	Phe	Gln	Asp	Ser	Asn	Ala	Glu	Thr	Leu	Pro	Gln	Lys
Val	Glu	His	Ser	Thr	Leu	Phe	Ser	Val	Thr	Thr	Pro	Ile	Ile	Val	Gln
Gly	Ile	Asp	Gln	Gln	Asp	Gln	Val	Ser	Ser	Gln	Gly	Leu	Val	Cys	Asn
Phe	Ser	Gly	Asp	His	Ser	Glu	Ile	Phe	Glu	Arg	Glu	Ser	Phe	Leu	
130								135						140	

Gly	Ile	Ala	Phe	Leu	Gly	Asn	Gly	Ser	Lys	Asp	Gly	Ile	Thr	Leu	Thr
145					150					155					160
Asp	Ile	Lys	Ser	Ser	Leu	Ser	Gly	Ala	Ala	Leu	Tyr	Ser	Ser	Asp	Asp
				165						170					175
Leu	Ile	Phe	Glu	Arg	Ile	Lys	Gly	Asp	Ile	Glu	Leu	Ser	Ser	Cys	Ser
			180					185						190	
Ser	Leu	Glu	Arg	Gly	Gly	Ala	Cys	Ser	Ala	Gln	Ser	Ile	Leu	Ile	His
		195					200						205		
Asp	Cys	Gln	Gly	Leu	Thr	Val	Lys	His	Cys	Ala	Ala	Gly	Val	Asn	Val
	210					215						220			
Glu	Gly	Val	Ser	Ala	Ser	Asp	His	Leu	Gly	Phe	Gly	Gly	Gly	Ala	Phe
225						230				235					240
Ser	Thr	Thr	Ser	Ser	Leu	Ser	Gly	Glu	Lys	Ser	Leu	Tyr	Met	Pro	Ala
				245					250						255
Gly	Asp	Ile	Val	Val	Ala	Thr	Cys	Asp	Gly	Pro	Val	Cys	Phe	Glu	Gly
			260					265						270	
Asn	Ser	Ala	Gln	Leu	Ala	Asn	Gly	Gly	Ala	Ile	Ala	Ala	Ser	Gly	Lys
		275					280						285		
Val	Leu	Phe	Val	Ala	Asn	Glu	Lys	Lys	Ile	Ser	Phe	Thr	Asp	Asn	Gln
	290					295						300			
Ala	Leu	Ser	Gly	Gly	Ala	Ile	Ser	Ala	Ser	Ser	Ser	Ile	Ser	Phe	Gln
305					310						315				320
Asn	Cys	Ala	Glu	Leu	Val	Phe	Lys	Ser	Asn	Leu	Ala	Lys	Gly	Val	Lys
				325					330					335	
Asp	Lys	Cys	Ser	Leu	Gly	Gly	Gly	Ala	Leu	Ala	Ser	Leu	Glu	Ser	Val
			340					345						350	
Val	Leu	Lys	Asp	Asn	Leu	Gly	Ile	Thr	Tyr	Glu	Lys	Asn	Gln	Ser	Tyr
		355					360						365		
Ser	Glu	Gly	Gly	Ala	Ile	Phe	Gly	Lys	Asp	Cys	Glu	Ile	Phe	Glu	Asn
	370					375						380			
Arg	Gly	Pro	Val	Val	Phe	Arg	Asp	Asn	Thr	Ala	Ala	Leu	Gly	Gly	Gly
385					390						395				400
Ala	Ile	Leu	Ala	Gln	Gln	Thr	Val	Ala	Ile	Cys	Gly	Asn	Lys	Ser	Gly
				405					410					415	
Ile	Ser	Phe	Glu	Gly	Ser	Lys	Ser	Ser	Phe	Gly	Gly	Ala	Ile	Ala	Cys
			420					425						430	
Gly	Asn	Phe	Ser	Ser	Glu	Asn	Asn	Ser	Ser	Ala	Leu	Gly	Ser	Ile	Asp
		435					440						445		
Ile	Ser	Asn	Asn	Leu	Gly	Asp	Ile	Ser	Phe	Leu	Arg	Thr	Leu	Cys	Thr
	450					455						460			
Thr	Ser	Asp	Leu	Gly	Gln	Thr	Asp	Tyr	Gln	Gly	Gly	Gly	Ala	Leu	Phe
465					470						475				480
Ala	Glu	Asn	Ile	Ser	Leu	Ser	Glu	Asn	Ala	Gly	Ala	Ile	Thr	Phe	Lys
				485					490					495	
Asp	Asn	Ile	Val	Lys	Thr	Phe	Ala	Ser	Asn	Gly	Lys	Met	Leu	Gly	Gly
			500					505						510	
Gly	Ala	Ile	Leu	Ala	Ser	Gly	Asn	Val	Leu	Ile	Ser	Lys	Asn	Ser	Gly
		515					520						525		
Glu	Ile	Ser	Phe	Val	Gly	Asn	Ala	Arg	Ala	Pro	Gln	Ala	Ile	Pro	Thr
	530					535						540			
Arg	Ser	Ser	Asp	Glu	Leu	Ser	Phe	Gly	Ala	Gln	Leu	Thr	Gln	Thr	Thr
545					550					555					560
Ser	Gly	Cys	Ser	Gly	Gly	Gly	Ala	Leu	Phe	Gly	Lys	Glu	Val	Ala	Ile
				565					570					575	
Val	Gln	Asn	Ala	Thr	Val	Val	Phe	Glu	Gln	Asn	Arg	Leu	Gln	Cys	Gly
			580					585						590	
Glu	Gln	Glu	Thr	His	Gly	Gly	Gly	Gly	Ala	Val	Tyr	Gly	Met	Glu	Ser
		595					600					605			
Ala	Ser	Ile	Ile	Gly	Asn	Ser	Phe	Val	Arg	Phe	Gly	Asn	Asn	Tyr	Ala
	610					615					620				

Val	Gly	Asn	Gln	Ile	Ser	Gly	Gly	Ala	Leu	Leu	Ser	Lys	Lys	Val	Arg
625					630					635					640
Leu	Ala	Glu	Asn	Thr	Arg	Val	Asp	Phe	Ser	Arg	Asn	Ile	Ala	Thr	Phe
			645						650						655
Cys	Gly	Gly	Ala	Val	Gln	Val	Ser	Asp	Gly	Ser	Cys	Glu	Leu	Ile	Asn
			660					665						670	
Asn	Gly	Tyr	Val	Leu	Phe	Arg	Asp	Asn	Arg	Gly	Gln	Thr	Phe	Gly	Gly
	675						680					685			
Ala	Ile	Ser	Cys	Leu	Lys	Gly	Asp	Val	Ile	Ile	Ser	Gly	Asn	Lys	Asp
	690					695						700			
Arg	Val	Glu	Phe	Arg	Asp	Asn	Ile	Val	Thr	Arg	Pro	Tyr	Phe	Glu	Glu
705					710					715					720
Asn	Glu	Glu	Lys	Val	Glu	Thr	Ala	Asp	Ile	Asn	Ser	Asp	Lys	Gln	Glu
			725						730						735
Ala	Glu	Glu	Arg	Ser	Leu	Leu	Glu	Asn	Ile	Glu	Gln	Ser	Phe	Ile	Thr
			740					745						750	
Ala	Thr	Asn	Gln	Thr	Phe	Phe	Leu	Glu	Glu	Glu	Lys	Leu	Pro	Ser	Glu
	755						760							765	
Ala	Phe	Ile	Ser	Ala	Glu	Glu	Leu	Ser	Lys	Arg	Arg	Glu	Cys	Ala	Gly
	770					775						780			
Gly	Ala	Ile	Phe	Ala	Lys	Arg	Val	Tyr	Ile	Thr	Asp	Asn	Lys	Glu	Pro
785					790					795					800
Ile	Leu	Phe	Ser	His	Asn	Phe	Ser	Asp	Val	Tyr	Gly	Gly	Ala	Ile	Phe
				805					810						815
Thr	Gly	Ser	Leu	Gln	Glu	Thr	Asp	Lys	Gln	Asp	Val	Val	Thr	Pro	Glu
			820					825						830	
Val	Val	Ile	Ser	Gly	Asn	Asp	Gly	Asp	Val	Ile	Phe	Ser	Gly	Asn	Ala
		835					840							845	
Ala	Lys	His	Asp	Lys	His	Leu	Pro	Asp	Thr	Gly	Gly	Gly	Ala	Ile	Cys
	850					855								860	
Thr	Gln	Asn	Leu	Thr	Ile	Ser	Gln	Asn	Asn	Gly	Asn	Val	Leu	Phe	Leu
865					870					875					880
Asn	Asn	Phe	Ala	Cys	Ser	Gly	Gly	Ala	Val	Arg	Ile	Glu	Asp	His	Gly
			885						890						895
Glu	Val	Leu	Leu	Glu	Ala	Phe	Gly	Gly	Asp	Ile	Ile	Phe	Asn	Gly	Asn
			900					905						910	
Ser	Ser	Phe	Arg	Ala	Gln	Gly	Ser	Asp	Ala	Ile	Tyr	Phe	Ala	Gly	Lys
			915					920						925	
Asp	Ser	Arg	Ile	Lys	Ala	Leu	Asn	Ala	Thr	Glu	Gly	His	Ala	Ile	Val
	930					935						940			
Phe	Gln	Asp	Ala	Leu	Val	Phe	Glu	Asn	Ile	Glu	Glu	Arg	Lys	Ser	Ser
945					950					955					960
Gly	Leu	Leu	Val	Ile	Asn	Ser	Gln	Glu	Asn	Glu	Gly	Tyr	Thr	Gly	Ser
			965						970						975
Val	Arg	Phe	Leu	Gly	Ser	Glu	Ser	Lys	Val	Pro	Gln	Trp	Ile	His	Val
			980					985						990	
Gln	Gln	Gly	Gly	Leu	Glu	Leu	Leu	His	Gly	Ala	Ile	Leu	Cys	Ser	Tyr
		995						1000							1005
Gly	Val	Lys	Gln	Asp	Pro	Arg	Ala	Lys	Ile	Val	Leu	Ser	Ala	Gly	
	1010					1015									
Ser	Lys	Leu	Lys	Ile	Leu	Asp	Ser	Glu	Gln	Glu	Asn	Asn	Ala	Glu	
	1025					1030									
Ile	Gly	Asp	Leu	Glu	Asp	Ser	Val	Asn	Ser	Glu	Lys	Thr	Pro	Ser	
	1040					1045									
Leu	Trp	Ile	Gly	Lys	Asn	Ala	Gln	Ala	Lys	Val	Pro	Leu	Val	Asp	
	1055					1060									
Ile	His	Thr	Ile	Ser	Ile	Asp	Leu	Ala	Ser	Phe	Ser	Ser	Lys	Ala	
	1070					1075									
Gln	Glu	Thr	Pro	Glu	Glu	Ala	Pro	Gln	Val	Ile	Val	Pro	Lys	Gly	
	1085					1090									
															1095

Ser	Cys	Val	His	Ser	Gly	Glu	Leu	Ser	Leu	Glu	Leu	Val	Asn	Thr
1100						1105					1110			
Thr	Gly	Lys	Gly	Tyr	Glu	Asn	His	Ala	Leu	Leu	Lys	Asn	Asp	Thr
1115						1120					1125			
Gln	Val	Ser	Leu	Met	Ser	Phe	Lys	Glu	Glu	Asn	Asp	Gly	Ser	Leu
1130						1135					1140			
Glu	Asp	Leu	Ser	Lys	Leu	Ser	Val	Ser	Asp	Leu	Arg	Ile	Lys	Val
1145						1150					1155			
Ser	Thr	Pro	Asp	Ile	Val	Glu	Glu	Thr	Tyr	Gly	His	Met	Gly	Asp
1160						1165					1170			
Trp	Ser	Glu	Ala	Thr	Ile	Gln	Asp	Gly	Ala	Leu	Val	Ile	Asn	Trp
1175						1180					1185			
His	Pro	Thr	Gly	Tyr	Lys	Leu	Asp	Pro	Gln	Lys	Ala	Gly	Ser	Leu
1190						1195					1200			
Val	Phe	Asn	Ala	Leu	Trp	Glu	Glu	Glu	Ala	Val	Leu	Ser	Thr	Leu
1205						1210					1215			
Lys	Asn	Ala	Arg	Ile	Ala	His	Asn	Leu	Thr	Ile	Gln	Arg	Met	Glu
1220						1225					1230			
Phe	Asp	Tyr	Ser	Thr	Asn	Ala	Trp	Gly	Leu	Ala	Phe	Ser	Ser	Phe
1235						1240					1245			
Arg	Glu	Leu	Ser	Ser	Glu	Lys	Leu	Val	Ser	Val	Asp	Gly	Tyr	Arg
1250						1255					1260			
Gly	Ser	Tyr	Ile	Gly	Ala	Ser	Ala	Gly	Ile	Asp	Thr	Gln	Leu	Met
1265						1270					1275			
Glu	Asp	Phe	Val	Leu	Gly	Ile	Ser	Thr	Ala	Ser	Phe	Phe	Gly	Lys
1280						1285					1290			
Met	His	Ser	Gln	Asn	Phe	Asp	Ala	Glu	Ile	Ser	Arg	His	Gly	Phe
1295						1300					1305			
Val	Gly	Ser	Val	Tyr	Thr	Gly	Phe	Leu	Ala	Gly	Ala	Trp	Phe	Phe
1310						1315					1320			
Lys	Gly	Gln	Tyr	Ser	Leu	Gly	Glu	Thr	His	Asn	Asp	Met	Thr	Thr
1325						1330					1335			
Arg	Tyr	Gly	Val	Leu	Gly	Glu	Ser	Asn	Ala	Thr	Trp	Lys	Ser	Arg
1340						1345					1350			
Gly	Val	Leu	Ala	Asp	Ala	Leu	Val	Glu	Tyr	Arg	Ser	Leu	Val	Gly
1355						1360					1365			
Pro	Ala	Arg	Pro	Lys	Phe	Tyr	Ala	Leu	His	Phe	Asn	Pro	Tyr	Val
1370						1375					1380			
Glu	Val	Ser	Tyr	Ala	Ser	Ala	Lys	Phe	Pro	Ser	Phe	Val	Glu	Gln
1385						1390					1395			
Gly	Gly	Glu	Ala	Arg	Ala	Phe	Glu	Glu	Thr	Ser	Leu	Thr	Asn	Ile
1400						1405					1410			
Thr	Val	Pro	Phe	Gly	Met	Lys	Phe	Glu	Leu	Ser	Phe	Thr	Lys	Gly
1415						1420					1425			
Gln	Phe	Ser	Glu	Thr	Asn	Ser	Leu	Gly	Ile	Gly	Cys	Ala	Trp	Glu
1430						1435					1440			
Met	Tyr	Arg	Lys	Val	Glu	Gly	Arg	Ser	Val	Glu	Leu	Leu	Glu	Ala
1445						1450					1455			
Gly	Phe	Asp	Trp	Glu	Gly	Ser	Pro	Ile	Asp	Leu	Pro	Lys	Gln	Glu
1460						1465					1470			
Leu	Arg	Val	Ala	Leu	Glu	Asn	Asn	Thr	Glu	Trp	Ser	Ser	Tyr	Phe
1475						1480					1485			
Ser	Thr	Ala	Leu	Gly	Val	Thr	Ala	Phe	Cys	Gly	Gly	Phe	Ser	Ser
1490						1495					1500			
Met	Asp	Asn	Lys	Leu	Gly	Tyr	Glu	Ala	Asn	Ala	Gly	Met	Arg	Leu
1505						1510					1515			
Ile	Phe													
1520														

<211> 4614
 <212> DNA
 <213> Chlamydia psitacii

<400> 45

atgggtcgcaa	aaaaggtatc	aagattttcca	aaatctacat	tttcccatto	cgtagtttta	60
gcaatattag	tttctactgg	gatgactgct	aataatcata	gattatatgg	ttatgagaca	120
gtttcagagg	cgtttttgag	tgattcttct	ttgaaaaccc	aattagaaac	gacttctgcg	180
ggtgttttta	gaaaagtaaa	atctactgat	acacaagagg	ttcagaaaga	aaataaagaa	240
gaaaatacgc	ctgtagagac	ttcttttata	gagaatgctt	cttcatgttc	tgttgctatt	300
ttaggctcag	aatgcggtca	aagacagcat	ttagtcaatg	ccagtacttt	gtttgagata	360
tcggattctt	tatcatggaa	gagtatagat	ggcaggttgt	ctaaaagctc	caagaagtct	420
gctacagccg	aagatgcaga	gagaaaatat	cttgtggatg	attccagtca	aggttttagct	480
ttttgttata	aaaacccatc	agatttgtgt	gtggatgaaa	ctacgcctgg	attccttaggt	540
gttgctcttg	taggagtggg	atctacatca	ggactatctt	tttctaattt	aaagtcgctc	600
tcagcaggat	ctgcggtcta	ttctgatgaa	gatgttgttt	ttgaacacct	taaagaaaaa	660
ctgttttttg	aaggttgtga	gtctcaagca	ggtgggtggag	ctgttttcagg	acgtagtatt	720
gctataaatg	gttgccatga	cgtttctgca	gtgtcttgta	agaccgattt	agatcttgca	780
tcttctgaag	tcgtagatth	ttccaaaggt	ggaggtgctt	ttaacgcgca	taaggtgcat	840
ggtgaagcac	ataaatccag	atthttttact	ggagaaatca	tctttacagc	caattctggg	900
aatgttttgc	tagatggtaa	tcatgcagac	aaggcgaacg	gtggagtgtg	agcctgtgga	960
gcatttgttt	gttctgtaaa	tcgtggagat	atccgctaca	caagtaaccg	cgctctatct	1020
ggaggcgctg	tatctgcttt	taagtctatt	gattttgttg	gaaacgtagg	attgatagag	1080
ttttagagata	accaggcttt	aatttctcct	gaaagtctct	tatttttagg	tggtggggcc	1140
ttagcttctg	gagagagaat	tagtttctta	aacaatggag	gcatccattg	ttgcaaaaac	1200
acctctaaat	cctctggagg	agctctttta	tctagggatg	taagaattgt	agagaacatc	1260
ggaaattctt	tgtttaagga	aaactctgct	caagtcgtag	gtggagccat	tagttctcaa	1320
aatcaagtag	aggttgggtca	gaatttttga	aatatcactt	ttgaaggtaa	tacttccaag	1380
atgggtgggtg	gagctattca	ctgtttatct	gctcagcaac	cttatacgag	ttctgaagaa	1440
gctctggaag	gatctgggga	tatcaagatt	gttgataatt	cgggggctgt	aaattttgca	1500
tctaattaga	acctatttga	atctcaagag	acacatagtc	atattgggtg	tggtgctcta	1560
tacggatcaa	atgttttagt	ttcaggcaat	attggagagg	ttactttttc	taagaatacc	1620
gctggtcaat	gtgaatccga	cagtacctgt	ataggtgggtg	gagcggtttt	tgctaattag	1680
gctgttagaa	tagtagataa	ctcaggagcg	attactttct	cttataataa	agggacaatt	1740
cttccatttc	ctaaagttgc	tgcaagttct	gaaggggaaa	gtgctccaga	agctcctaaa	1800
gagtcattct	ctgtagatth	aggggttcgc	ggcgttgagg	caatttttgc	caagcgata	1860
gagatagcag	ataactctgg	tgtactatct	ttctcagata	atttcatgaa	aattagagat	1920
aataaggcac	aaaaagagaa	tcctctaggg	ggtggtgctt	tatttgggat	agatgaagtc	1980
ggtttgaaaa	ataataaaga	acttgcattc	actaataacc	atgtctctgg	tgagaatagt	2040
agcgggtggtg	ctgtcctatc	taaagttggt	actattgctg	ataatggaaa	agtacaattt	2100
ttccgcaatt	attogaattt	ccttgggtgg	gccgtttgtt	ctctaggaga	tgctctaaac	2160
attaaaaata	atgaatcttc	agtatctttt	attggcaaca	gaactgtgac	tgctgggtga	2220
gcgcttgcta	gtgctgcagg	tgatgtttct	atttctaaaa	accttgggaa	agtagaattt	2280
aaggataatt	tagtttttgg	cgattctcgt	gtagataatc	ttgaagaagg	tcaactcaac	2340
actacaggac	atcatagtgg	cggcggtgcc	atttttgcta	aagcttcagt	ggttattcgt	2400
gaaaataaag	atcagggtgt	tttctcaggg	aattcttcag	gatgtttcgg	tggtgcgatt	2460
ttaacagggt	ctttaacccc	agaagatcaa	gagcgttttg	cttctaaggt	agtgaatgat	2520
aataactaaag	tcggttattac	agagaacatt	ggagacgtag	tatttttcagg	aaatagcact	2580
acggcttcaa	aacatcctga	gcataatttg	ttcgggtggg	gtgctatcta	taccaagac	2640
ttaattatca	ataaaaaatgc	aggttctgta	gctttttata	ataactacgc	tcctacagggt	2700
ggtgctgtcc	gtatttagtga	aaagggaaact	gtgatttttag	aggctctagg	aggagatatt	2760
gttttccaag	gaaatagaaa	ttctgaagat	atctctaatg	gattatattt	tgccggaaaa	2820
gagtcgaaat	tagttgaggt	atctgcttct	ggggaaaaaaa	cggttaattt	ttcagatgcc	2880
attatctttg	aagattttaac	cttaagacaa	ggcctagaag	gtcgtgagga	tatttttaaat	2940
gatcctacat	tagtattgaa	ttctaaggct	aaagatgatt	ctgaagtttc	tcattctgga	3000
aacattcgct	ttgcctatgc	gacatctaag	attcctcaag	tcgctgtatt	agaatcagga	3060
actcttattt	tatctgataa	tgctgagttg	tggttgtgtg	gcttaaaaca	agagaaaggt	3120
agtggatctt	tgctctcagc	aggaactgta	ttacgtatth	tcgatcceta	tgctaagcct	3180
gaagaaaagc	ctgaaagtcc	ttctgcaaga	tcttactata	gtgcttatga	ttctgctaga	3240

aatcctgaag	agaagacttt	ggcagacatc	agtgttattg	gtgtagatct	agcttctttt	3300
gttgctagt	aggatgaagc	tgctccttta	cctccacaga	ttatcgttcc	taagggcaca	3360
acaatcggtt	cgggatcttt	agacttgaat	cttggtgatt	ctgcaggtgt	tgggttatgaa	3420
aaccatgcct	tattaaataa	agagactgat	atcacattgc	tttcatttag	gagtgcctca	3480
gcagtctcgg	atgttctctga	tttagaccat	gcttttgaag	agttacgtat	taacgtttct	3540
gttcctaaaa	ttacggacga	cacttatggg	catatgggaa	aatggtcaga	tcctcaggtt	3600
gttaacggta	aattaacgat	caactggaag	cctaccagct	ataagttaa	tcctgaaaaa	3660
ggaggctcta	tcgtattgaa	cactttatgg	ggacaatgcg	gagatttgcg	cgcttataaaa	3720
caacagcatt	tatctcataa	tattactgca	caaagaatgg	aattagattt	ctcaacaaac	3780
atttggggat	ctggaatggg	aacattctcc	aattgtgcaa	cgattgctgg	agtggacggc	3840
tttactcatc	gtgctggcgg	ctatgcttta	ggttttagata	cacagttgat	agaagatttc	3900
ttgataggag	gaagctttgc	gcagttcttt	ggttacactg	atagtcagtc	atcttcatca	3960
cgtagtgacc	aaagtgttta	cttaggtacg	ggatatgtcg	gtatctttgc	gggttcttgg	4020
ttattcaagg	ggatgtttat	ctatagtgat	attcaaaacg	acttgaatac	aacatatact	4080
acaccaaaca	ttggtagatc	taaaggatcg	tggaaatagcc	gcggtatctt	agcagatgct	4140
catgtggatt	atcgctatat	tgtgaattca	cgtaggttta	tctcatcgat	tgtttcggct	4200
gtgggtacct	tcgtagaagc	tgaatatggt	tacattgatc	ttcctacatt	tgcggaagta	4260
ggtagtgaag	tgagaacatt	tgctgaaggg	catttacaaa	atatagcgat	tccttttggg	4320
attacttttg	agcataacta	ttctcgaggg	cagcggttcag	aagtgaatag	cttaagtttc	4380
tcctatgctt	tagatgtcta	tcgtaaagca	cctacagtgc	ttatcaattt	gcctgcagct	4440
tcttattctt	gggagggggg	aggttctgat	ctttctagaa	agtttatgaa	agcacagttt	4500
agtaatgata	cggagtggag	ttcctacttc	tctactttct	tagggtttac	ctatgaatgg	4560
agagaacaca	cggtatctta	tgatgtgaat	ggagggtatac	gtttgatatt	ctag	4614

<210> 46
 <211> 1537
 <212> PRT
 <213> Chlamydia psitacci

<400> 46

Met	Val	Ala	Lys	Lys	Val	Ser	Arg	Phe	Pro	Lys	Ser	Thr	Phe	Ser	His
1			5						10					15	
Ser	Val	Val	Leu	Ala	Ile	Leu	Val	Ser	Thr	Gly	Met	Thr	Ala	Asn	Asn
		20						25					30		
His	Arg	Leu	Tyr	Gly	Tyr	Glu	Thr	Val	Ser	Glu	Ala	Phe	Leu	Ser	Asp
		35				40						45			
Ser	Ser	Leu	Lys	Thr	Gln	Leu	Glu	Thr	Thr	Ser	Ala	Gly	Val	Phe	Arg
	50				55						60				
Lys	Val	Lys	Ser	Thr	Asp	Thr	Gln	Glu	Val	Gln	Lys	Glu	Asn	Lys	Glu
65					70					75				80	
Glu	Asn	Thr	Pro	Val	Glu	Thr	Ser	Phe	Ile	Glu	Asn	Ala	Ser	Ser	Cys
			85					90						95	
Ser	Val	Ala	Ile	Leu	Gly	Ser	Glu	Cys	Gly	Gln	Arg	Gln	His	Leu	Val
		100					105						110		
Asn	Ala	Ser	Thr	Leu	Phe	Glu	Ile	Ser	Asp	Ser	Leu	Ser	Trp	Lys	Ser
		115				120							125		
Ile	Asp	Gly	Glu	Leu	Ser	Lys	Ser	Ser	Lys	Lys	Ser	Ala	Thr	Ala	Glu
	130					135						140			
Asp	Ala	Glu	Arg	Lys	Tyr	Leu	Val	Asp	Asp	Ser	Ser	Gln	Gly	Leu	Ala
145					150					155				160	
Phe	Cys	Tyr	Lys	Asn	Pro	Ser	Asp	Cys	Val	Val	Asp	Glu	Thr	Thr	Pro
			165					170						175	
Gly	Phe	Leu	Gly	Val	Ala	Leu	Val	Gly	Val	Gly	Ser	Thr	Ser	Gly	Leu
		180						185					190		
Ser	Phe	Ser	Asn	Leu	Lys	Ser	Leu	Ser	Ala	Gly	Ser	Ala	Val	Tyr	Ser
		195					200					205			
Asp	Glu	Asp	Val	Val	Phe	Glu	His	Leu	Lys	Glu	Lys	Leu	Phe	Phe	Glu
	210					215					220				
Gly	Cys	Glu	Ser	Gln	Ala	Gly	Gly	Gly	Ala	Val	Ser	Gly	Arg	Ser	Ile

225					230					235				240
Ala	Ile	Asn	Gly	Cys	His	Asp	Val	Ser	Ala	Val	Ser	Cys	Lys	Thr
				245					250					255
Leu	Asp	Leu	Ala	Ser	Ser	Glu	Val	Val	Asp	Phe	Ser	Lys	Gly	Gly
			260						265					270
Ala	Phe	Asn	Ala	His	Lys	Val	His	Gly	Glu	Ala	His	Lys	Ser	Arg
		275						280				285		
Phe	Thr	Gly	Glu	Ile	Ile	Phe	Thr	Ala	Asn	Ser	Gly	Asn	Val	Leu
	290					295					300			
Asp	Gly	Asn	His	Ala	Asp	Lys	Ala	Asn	Gly	Gly	Val	Val	Ala	Cys
305					310					315				320
Ala	Phe	Val	Cys	Ser	Val	Asn	Arg	Gly	Asp	Ile	Arg	Tyr	Thr	Ser
				325					330					335
Arg	Ala	Leu	Ser	Gly	Gly	Ala	Val	Ser	Ala	Phe	Lys	Ser	Ile	Asp
			340					345						350
Val	Gly	Asn	Val	Gly	Leu	Ile	Glu	Phe	Val	Asp	Asn	Gln	Ala	Leu
		355					360							365
Ser	Pro	Glu	Ser	Ser	Leu	Phe	Leu	Gly	Gly	Gly	Ala	Leu	Ala	Ser
	370					375					380			
Glu	Arg	Ile	Ser	Phe	Leu	Asn	Asn	Gly	Gly	Ile	His	Cys	Cys	Lys
385					390					395				400
Thr	Ser	Lys	Ser	Ser	Gly	Gly	Ala	Leu	Leu	Ser	Arg	Asp	Val	Arg
				405					410					415
Val	Glu	Asn	Ile	Gly	Asn	Ser	Leu	Phe	Lys	Glu	Asn	Ser	Ala	Gln
			420					425						430
Val	Gly	Gly	Ala	Ile	Ser	Ser	Gln	Asn	Gln	Val	Glu	Val	Gly	Gln
		435					440					445		Asn
Phe	Gly	Asn	Ile	Thr	Phe	Glu	Gly	Asn	Thr	Ser	Lys	Met	Gly	Gly
	450					455					460			
Ala	Ile	His	Cys	Leu	Ser	Ala	Gln	Gln	Pro	Tyr	Thr	Ser	Ser	Glu
465						470				475				480
Ala	Leu	Glu	Gly	Ser	Gly	Asp	Ile	Lys	Ile	Val	Asp	Asn	Ser	Gly
				485					490					495
Val	Asn	Phe	Ala	Ser	Asn	Glu	Asn	Leu	Leu	Glu	Ser	Gln	Glu	Thr
			500					505						510
Ser	His	Ile	Gly	Gly	Gly	Ala	Leu	Tyr	Gly	Ser	Asn	Val	Leu	Val
		515					520					525		Ser
Gly	Asn	Ile	Gly	Glu	Val	Thr	Phe	Ser	Lys	Asn	Thr	Ala	Gly	Gln
	530					535					540			Cys
Glu	Ser	Asp	Ser	Thr	Cys	Ile	Gly	Gly	Gly	Ala	Val	Phe	Ala	Asn
545					550					555				560
Ala	Val	Arg	Ile	Val	Asp	Asn	Ser	Gly	Ala	Ile	Thr	Phe	Ser	Tyr
				565					570					575
Lys	Gly	Thr	Ile	Leu	Pro	Phe	Pro	Lys	Val	Ala	Ala	Ser	Ser	Glu
			580					585						590
Glu	Ser	Ala	Pro	Glu	Ala	Pro	Lys	Glu	Ser	Ser	Pro	Val	Asp	Leu
		595				600					605			Gly
Val	Arg	Gly	Gly	Gly	Ala	Ile	Phe	Ala	Lys	Arg	Ile	Glu	Ile	Ala
	610					615					620			Asp
Asn	Ser	Gly	Val	Leu	Ser	Phe	Ser	Asp	Asn	Phe	Met	Lys	Ile	Arg
625					630					635				640
Asn	Lys	Ala	Gln	Lys	Glu	Asn	Pro	Leu	Gly	Gly	Gly	Ala	Leu	Phe
				645					650					655
Ile	Asp	Glu	Val	Gly	Leu	Lys	Asn	Asn	Lys	Glu	Leu	Ala	Phe	Thr
			660					665					670	Asn
Asn	His	Val	Ser	Gly	Glu	Asn	Ser	Ser	Gly	Gly	Ala	Val	Leu	Ser
		675					680				685			Lys
Val	Val	Thr	Ile	Ala	Asp	Asn	Gly	Lys	Val	Gln	Phe	Phe	Arg	Asn
	690					695					700			Tyr
Ser	Asn	Phe	Leu	Gly	Gly	Ala	Val	Cys	Ser	Leu	Gly	Asp	Ala	Leu
														Asn

705					710					715			720		
Ile	Lys	Asn	Asn	Glu	Ser	Ser	Val	Ser	Phe	Ile	Gly	Asn	Arg	Thr	Val
				725					730				735		
Thr	Ala	Gly	Gly	Ala	Leu	Ala	Ser	Ala	Ala	Gly	Asp	Val	Ser	Ile	Ser
				740					745				750		
Lys	Asn	Leu	Gly	Lys	Val	Glu	Phe	Lys	Asp	Asn	Leu	Val	Phe	Gly	Asp
				755					760				765		
Ser	Arg	Val	Asp	Asn	Leu	Glu	Glu	Gly	Gln	Leu	Asn	Thr	Thr	Gly	His
				770					775				780		
His	Ser	Gly	Gly	Gly	Ala	Ile	Phe	Ala	Lys	Ala	Ser	Val	Val	Ile	Arg
					790					795					800
Glu	Asn	Lys	Asp	Gln	Val	Leu	Phe	Ser	Gly	Asn	Ser	Ser	Gly	Cys	Phe
				805					810						815
Gly	Gly	Ala	Ile	Leu	Thr	Gly	Ser	Leu	Thr	Pro	Glu	Asp	Gln	Glu	Arg
				820					825				830		
Phe	Ala	Ser	Lys	Val	Val	Asn	Asp	Asn	Thr	Lys	Val	Val	Ile	Thr	Glu
				835					840				845		
Asn	Ile	Gly	Asp	Val	Val	Phe	Ser	Gly	Asn	Ser	Thr	Thr	Ala	Ser	Lys
				850					855				860		
His	Pro	Glu	His	Asn	Leu	Phe	Gly	Gly	Gly	Ala	Ile	Tyr	Thr	Gln	Asp
				865					870						880
Leu	Ile	Ile	Asn	Lys	Asn	Ala	Gly	Ser	Val	Ala	Phe	Tyr	Asn	Asn	Tyr
				885					890						895
Ala	Pro	Thr	Gly	Gly	Ala	Val	Arg	Ile	Ser	Glu	Lys	Gly	Thr	Val	Ile
				900					905				910		
Leu	Glu	Ala	Leu	Gly	Gly	Asp	Ile	Val	Phe	Gln	Gly	Asn	Arg	Asn	Ser
				915					920				925		
Glu	Asp	Ile	Ser	Asn	Gly	Leu	Tyr	Phe	Ala	Gly	Lys	Glu	Ser	Lys	Leu
				930					935				940		
Val	Glu	Val	Ser	Ala	Ser	Gly	Glu	Lys	Thr	Val	Asn	Phe	Ser	Asp	Ala
				945					950						960
Ile	Ile	Phe	Glu	Asp	Leu	Thr	Leu	Arg	Gln	Gly	Leu	Glu	Gly	Arg	Glu
				965					970						975
Asp	Ile	Leu	Asn	Asp	Pro	Thr	Leu	Val	Leu	Asn	Ser	Lys	Ala	Lys	Asp
				980					985				990		
Asp	Ser	Glu	Val	Ser	His	Ser	Gly	Asn	Ile	Arg	Phe	Ala	Tyr	Ala	Thr
				995					1000				1005		
Ser	Lys	Ile	Pro	Gln	Val	Ala	Val	Leu	Glu	Ser	Gly	Thr	Leu	Ile	
				1010					1015				1020		
Leu	Ser	Asp	Asn	Ala	Glu	Leu	Trp	Leu	Cys	Gly	Leu	Lys	Gln	Glu	
				1025					1030				1035		
Lys	Gly	Ser	Glu	Ile	Leu	Leu	Ser	Ala	Gly	Thr	Val	Leu	Arg	Ile	
				1040					1045				1050		
Phe	Asp	Pro	Asn	Ala	Lys	Pro	Glu	Glu	Lys	Pro	Glu	Ser	Pro	Ser	
				1055					1060				1065		
Ala	Arg	Ser	Tyr	Tyr	Ser	Ala	Tyr	Asp	Ser	Ala	Arg	Asn	Pro	Glu	
				1070					1075				1080		
Glu	Lys	Thr	Leu	Ala	Asp	Ile	Ser	Val	Ile	Gly	Val	Asp	Leu	Ala	
				1085					1090				1095		
Ser	Phe	Val	Ala	Ser	Glu	Asp	Glu	Ala	Ala	Pro	Leu	Pro	Pro	Gln	
				1100					1105				1110		
Ile	Ile	Val	Pro	Lys	Gly	Thr	Thr	Ile	Gly	Ser	Gly	Ser	Leu	Asp	
				1115					1120				1125		
Leu	Asn	Leu	Val	Asp	Ser	Ala	Gly	Val	Gly	Tyr	Glu	Asn	His	Ala	
				1130					1135				1140		
Leu	Leu	Asn	Lys	Glu	Thr	Asp	Ile	Thr	Leu	Leu	Ser	Phe	Arg	Ser	
				1145					1150				1155		
Ala	Ser	Ala	Val	Ser	Asp	Val	Pro	Asp	Leu	Asp	His	Ala	Leu	Glu	
				1160					1165				1170		
Glu	Leu	Arg	Ile	Asn	Val	Ser	Val	Pro	Lys	Ile	Thr	Asp	Asp	Thr	

1175	Tyr Gly His Met Gly Lys	1180	Trp Ser Asp Pro Gln	1185	Val Val Asn Gly
1190	Lys Leu Thr Ile Asn Trp	1195	Lys Pro Thr Ser Tyr	1200	Lys Leu Asn Pro
1205	Glu Lys Gly Gly Ser Ile	1210	Val Leu Asn Thr Leu	1215	Trp Gly Gln Cys
1220	Gly Asp Leu Arg Ala Leu	1225	Lys Gln Gln His Leu	1230	Ser His Asn Ile
1235	Thr Ala Gln Arg Met Glu	1240	Leu Asp Phe Ser Thr	1245	Asn Ile Trp Gly
1250	Ser Gly Met Gly Thr Phe	1255	Ser Asn Cys Ala Thr	1260	Ile Ala Gly Val
1265	Asp Gly Phe Thr His Arg	1270	Ala Gly Gly Tyr Ala	1275	Leu Gly Leu Asp
1280	Thr Gln Leu Ile Glu Asp	1285	Phe Leu Ile Gly Gly	1290	Ser Phe Ala Gln
1295	Phe Phe Gly Tyr Thr Asp	1300	Ser Gln Ser Phe Ser	1305	Ser Arg Ser Asp
1310	Gln Ser Gly Tyr Leu Gly	1315	Thr Gly Tyr Val Gly	1320	Ile Phe Ala Gly
1325	Ser Trp Leu Phe Lys Gly	1330	Met Phe Ile Tyr Ser	1335	Asp Ile Gln Asn
1340	Asp Leu Asn Thr Thr Tyr	1345	Pro Thr Pro Asn Ile	1350	Gly Arg Ser Lys
1355	Gly Ser Trp Asn Ser Arg	1360	Gly Ile Leu Ala Asp	1365	Ala His Val Asp
1370	Tyr Arg Tyr Ile Val Asn	1375	Ser Arg Arg Phe Ile	1380	Ser Ser Ile Val
1385	Ser Ala Val Val Pro Phe	1390	Val Glu Ala Glu Tyr	1395	Val Tyr Ile Asp
1400	Leu Pro Thr Phe Ala Glu	1405	Val Gly Ser Glu Val	1410	Arg Thr Phe Ala
1415	Glu Gly His Leu Gln Asn	1420	Ile Ala Ile Pro Phe	1425	Gly Ile Thr Leu
1430	Glu His Asn Tyr Ser Arg	1435	Gly Gln Arg Ser Glu	1440	Val Asn Ser Leu
1445	Ser Phe Ser Tyr Ala Leu	1450	Asp Val Tyr Arg Lys	1455	Ala Pro Thr Val
1460	Leu Ile Asn Leu Pro Ala	1465	Ala Ser Tyr Ser Trp	1470	Glu Gly Val Gly
1475	Ser Asp Leu Ser Arg Lys	1480	Phe Met Lys Ala Gln	1485	Phe Ser Asn Asp
1490	Thr Glu Trp Ser Ser Tyr	1495	Phe Ser Thr Phe Leu	1500	Gly Phe Thr Tyr
1505	Glu Trp Arg Glu His Thr	1510	Val Ser Tyr Asp Val	1515	Asn Gly Gly Ile
1520	Arg Leu Ile Phe	1525		1530	
1535					

<210> 47
 <211> 1185
 <212> DNA
 <213> Chlamydia trachomatis

<400> 47

atgaaaaaac tcttgaaatc ggtattagtg tttgccgctt tgagttctgc ttcctccttg	60
caagctctgc ctgtggggaa tctgtctgaa ccaagcctta tgatcgacgg aattctatgg	120
gaaggtttcg gcggagatcc ttgcgatcct tgcaccactt ggtgtgacgc tatcagcatg	180

cgtatggggtt	actatgggtga	ctttgttttc	gaccgtggtt	tgcaaacaga	tgtgaataaa	240
gaattccaaa	tggtgtccaa	gocctacaact	gctacaggca	atgctgcagc	tccatccact	300
tgtacagcaa	gagagaatcc	tgcttacggc	cgacatatgc	aggatgctga	gatgtttaca	360
aatgctgctt	acatggcatt	gaatatttgg	gategttttg	atgtattctg	tacattagga	420
gccaccagtg	gatatcttaa	aggaaattca	gcacctttca	acttagttgg	cttattcgga	480
gataatgaga	accatgctac	agtttcagat	agtaagcttg	taccaaatat	gagcttagat	540
caatctgttg	ttgagttgta	tacagatact	acttttgctt	ggagtgctgg	agctcgtgca	600
gctttgtggg	aatgtgggatg	cgcgacttta	ggcgcttctt	tccaatacgc	tcaatccaag	660
cctaaagtcg	aagaattaaa	cgttctctgt	aacgcagctg	agtttactat	caataagcct	720
aaaggatatg	tagggcaaga	attccctctt	gactttaaag	caggaacaga	tggtgtgaca	780
ggaactaagg	atgcctctat	tgattaccat	gaatggcaag	caagtttagc	tctctcttac	840
agactgaata	tgttcactcc	ctacattgga	gttaaattggt	ctcgagcaag	ttttgatgca	900
gacacgattc	gtattgctca	gocgaagtca	gctacaactg	tctttgatgt	taccactctg	960
aacccaacta	ttgctggagc	tggcgatgtg	aaagctagcg	cagagggtca	gctcggagat	1020
accatgcaaa	tcgtttcctt	gcaattgaac	aagatgaaat	ctagaaaatc	ttgcggtatt	1080
gcagtaggaa	caactattgt	ggatgcagac	aaatacgag	ttacagttga	gactcgcttg	1140
atcgatgaga	gagctgctca	cgtaaattgca	caattccgct	tctaa		1185

<210> 48
 <211> 394
 <212> PRT
 <213> Chlamydia trachomatis

<400> 48

Met	Lys	Lys	Leu	Leu	Lys	Ser	Val	Leu	Val	Phe	Ala	Ala	Leu	Ser	Ser
1			5					10					15		
Ala	Ser	Ser	Leu	Gln	Ala	Leu	Pro	Val	Gly	Asn	Pro	Ala	Glu	Pro	Ser
			20					25					30		
Leu	Met	Ile	Asp	Gly	Ile	Leu	Trp	Glu	Gly	Phe	Gly	Gly	Asp	Pro	Cys
			35				40						45		
Asp	Pro	Cys	Thr	Thr	Trp	Cys	Asp	Ala	Ile	Ser	Met	Arg	Met	Gly	Tyr
			50				55					60			
Tyr	Gly	Asp	Phe	Val	Phe	Asp	Arg	Val	Leu	Gln	Thr	Asp	Val	Asn	Lys
							70					75			80
Glu	Phe	Gln	Met	Gly	Ala	Lys	Pro	Thr	Thr	Ala	Thr	Gly	Asn	Ala	Ala
														95	
Ala	Pro	Ser	Thr	Cys	Thr	Ala	Arg	Glu	Asn	Pro	Ala	Tyr	Gly	Arg	His
			100					105					110		
Met	Gln	Asp	Ala	Glu	Met	Phe	Thr	Asn	Ala	Ala	Tyr	Met	Ala	Leu	Asn
			115				120						125		
Ile	Trp	Asp	Arg	Phe	Asp	Val	Phe	Cys	Thr	Leu	Gly	Ala	Thr	Ser	Gly
			130				135						140		
Tyr	Leu	Lys	Gly	Asn	Ser	Ala	Ser	Phe	Asn	Leu	Val	Gly	Leu	Phe	Gly
							150					155			160
Asp	Asn	Glu	Asn	His	Ala	Thr	Val	Ser	Asp	Ser	Lys	Leu	Val	Pro	Asn
							165					170			175
Met	Ser	Leu	Asp	Gln	Ser	Val	Val	Glu	Leu	Tyr	Thr	Asp	Thr	Thr	Phe
			180					185					190		
Ala	Trp	Ser	Ala	Gly	Ala	Arg	Ala	Ala	Leu	Trp	Glu	Cys	Gly	Cys	Ala
			195				200						205		
Thr	Leu	Gly	Ala	Ser	Phe	Gln	Tyr	Ala	Gln	Ser	Lys	Pro	Lys	Val	Glu
			210				215						220		
Glu	Leu	Asn	Val	Leu	Cys	Asn	Ala	Ala	Glu	Phe	Thr	Ile	Asn	Lys	Pro
							230					235			240
Lys	Gly	Tyr	Val	Gly	Gln	Glu	Phe	Pro	Leu	Asp	Leu	Lys	Ala	Gly	Thr
							245							255	
Asp	Gly	Val	Thr	Gly	Thr	Lys	Asp	Ala	Ser	Ile	Asp	Tyr	His	Glu	Trp
			260					265					270		
Gln	Ala	Ser	Leu	Ala	Leu	Ser	Tyr	Arg	Leu	Asn	Met	Phe	Thr	Pro	Tyr

275 280 285
 Ile Gly Val Lys Trp Ser Arg Ala Ser Phe Asp Ala Asp Thr Ile Arg
 290 295 300
 Ile Ala Gln Pro Lys Ser Ala Thr Thr Val Phe Asp Val Thr Thr Leu
 305 310 315 320
 Asn Pro Thr Ile Ala Gly Ala Gly Asp Val Lys Ala Ser Ala Glu Gly
 325 330 335
 Gln Leu Gly Asp Thr Met Gln Ile Val Ser Leu Gln Leu Asn Lys Met
 340 345 350
 Lys Ser Arg Lys Ser Cys Gly Ile Ala Val Gly Thr Thr Ile Val Asp
 355 360 365
 Ala Asp Lys Tyr Ala Val Thr Val Glu Thr Arg Leu Ile Asp Glu Arg
 370 375 380

Ala Ala His Val Asn Ala Gln Phe Arg Phe
 385 390

<210> 49
 <211> 1194
 <212> DNA
 <213> Chlamydia trachomatis

<400> 49

atgaaaaaac	tcttgaaatc	ggtattagta	tttgccgctt	tgagttctgc	ttcctccttg	60
caagctctgc	ctgtggggaa	tcctgctgaa	ccaagcctta	tgatcgacgg	aattctgtgg	120
gaaggtttcg	gtggagatcc	ttgcgatcct	tgaccactt	ggtgtgacgc	tatcagcatg	180
cgtatgggtt	actatgggtga	ctttgttttc	gaccgtgttt	tgaaaacaga	tgtgaataaa	240
gaatttcaga	tgggagcggc	gcctactacc	agcgatgtag	caggcttaca	aaacgatecca	300
acaacaaatg	ttgctcgtcc	aaatcccgtc	tatggcaaac	acatgcaaga	tgctgaaatg	360
tttacgaacg	ctgcttacat	ggcattaaat	atctgggatc	gttttgatgt	attttgtaca	420
ttgggagcaa	ctaccgggta	tttaaaagga	aactccgctt	ccttcaactt	agttggatta	480
ttcgggaacaa	aaacacaagc	ttctagcttt	aatacagcga	atctttttcc	taacactgct	540
ttgaatcaag	ctgtgggtga	gctttataca	gacactacct	ttgcttgagg	cgtaggtgct	600
cgtgcagctc	tctgggaatg	tgggtgtgca	acgttaggag	cttctttcca	atatgctcaa	660
tctaaacctta	aagtagaaga	gttaaagtgt	ctttgtaatg	catccgaatt	tactattaat	720
aagccgaaag	gatagtgttg	ggcggaaatt	ccacttgata	ttaccgcagg	aacagaagct	780
gcgacaggga	ctaaggatgc	ctctattgac	taccatgagt	ggcaagcaag	tttagccctt	840
tottacagat	taaataatgt	cactcccttac	attggagtta	aatggtctag	agtaagtgtt	900
gatgccgaca	cgatccgtat	cgctcagcct	aaattggctg	aagcaatctt	ggatgtcact	960
actctaaacc	cgaccatcgc	tggtaaagga	actgtggctg	cttccggaag	cgaaaacgac	1020
ctggctgata	caatgcaaat	cgtttccttg	cagttgaaca	agatgaaatc	tagaaaatct	1080
tgcggtattg	cagtaggaac	gactattgta	gatgcagaca	aatacgcaat	tacagttgag	1140
actcgttga	tcgatgagag	agcagctcac	gtaaatgcac	aattccgctt	ctaa	1194

<210> 50
 <211> 397
 <212> PRT
 <213> Chlamydia trachomatis

<400> 50

Met Lys Lys Leu Leu Lys Ser Val Leu Val Phe Ala Ala Leu Ser Ser
 1 5 10 15
 Ala Ser Ser Leu Gln Ala Leu Pro Val Gly Asn Pro Ala Glu Pro Ser
 20 25 30
 Leu Met Ile Asp Gly Ile Leu Trp Glu Gly Phe Gly Gly Asp Pro Cys
 35 40 45
 Asp Pro Cys Thr Thr Trp Cys Asp Ala Ile Ser Met Arg Met Gly Tyr
 50 55 60

Tyr	Gly	Asp	Phe	Val	Phe	Asp	Arg	Val	Leu	Lys	Thr	Asp	Val	Asn	Lys
65					70					75				80	
Glu	Phe	Gln	Met	Gly	Ala	Ala	Pro	Thr	Thr	Ser	Asp	Val	Ala	Gly	Leu
				85					90					95	
Gln	Asn	Asp	Pro	Thr	Thr	Asn	Val	Ala	Arg	Pro	Asn	Pro	Ala	Tyr	Gly
			100					105					110		
Lys	His	Met	Gln	Asp	Ala	Glu	Met	Phe	Thr	Asn	Ala	Ala	Tyr	Met	Ala
		115				120						125			
Leu	Asn	Ile	Trp	Asp	Arg	Phe	Asp	Val	Phe	Cys	Thr	Leu	Gly	Ala	Thr
	130					135					140				
Thr	Gly	Tyr	Leu	Lys	Gly	Asn	Ser	Ala	Ser	Phe	Asn	Leu	Val	Gly	Leu
145					150					155				160	
Phe	Gly	Thr	Lys	Thr	Gln	Ala	Ser	Ser	Phe	Asn	Thr	Ala	Asn	Leu	Phe
				165					170					175	
Pro	Asn	Thr	Ala	Leu	Asn	Gln	Ala	Val	Val	Glu	Leu	Tyr	Thr	Asp	Thr
			180					185						190	
Thr	Phe	Ala	Trp	Ser	Val	Gly	Ala	Arg	Ala	Ala	Leu	Trp	Glu	Cys	Gly
	195					200						205			
Cys	Ala	Thr	Leu	Gly	Ala	Ser	Phe	Gln	Tyr	Ala	Gln	Ser	Lys	Pro	Lys
	210					215					220				
Val	Glu	Glu	Leu	Asn	Val	Leu	Cys	Asn	Ala	Ser	Glu	Phe	Thr	Ile	Asn
225					230					235				240	
Lys	Pro	Lys	Gly	Tyr	Val	Gly	Ala	Glu	Phe	Pro	Leu	Asp	Ile	Thr	Ala
				245					250					255	
Gly	Thr	Glu	Ala	Ala	Thr	Gly	Thr	Lys	Asp	Ala	Ser	Ile	Asp	Tyr	His
		260						265						270	
Glu	Trp	Gln	Ala	Ser	Leu	Ala	Leu	Ser	Tyr	Arg	Leu	Asn	Met	Phe	Thr
	275					280						285			
Pro	Tyr	Ile	Gly	Val	Lys	Trp	Ser	Arg	Val	Ser	Phe	Asp	Ala	Asp	Thr
	290					295					300				
Ile	Arg	Ile	Ala	Gln	Pro	Lys	Leu	Ala	Glu	Ala	Ile	Leu	Asp	Val	Thr
305					310					315				320	
Thr	Leu	Asn	Pro	Thr	Ile	Ala	Gly	Lys	Gly	Thr	Val	Val	Ala	Ser	Gly
				325					330					335	
Ser	Glu	Asn	Asp	Leu	Ala	Asp	Thr	Met	Gln	Ile	Val	Ser	Leu	Gln	Leu
		340						345					350		
Asn	Lys	Met	Lys	Ser	Arg	Lys	Ser	Cys	Gly	Ile	Ala	Val	Gly	Thr	Thr
		355					360					365			
Ile	Val	Asp	Ala	Asp	Lys	Tyr	Ala	Val	Thr	Val	Glu	Thr	Arg	Leu	Ile
	370					375					380				
Asp	Glu	Arg	Ala	Ala	His	Val	Asn	Ala	Gln	Phe	Arg	Phe			
385					390					395					

<210> 51
 <211> 1194
 <212> DNA
 <213> Chlamydia trachomatis

<400> 51

atgaaaaaac	tcttgaaatc	ggtattagta	tttgccgctt	tgagttctgc	ttcctccttg	60
caagctctgc	ctgtggggaa	tcctgctgaa	ccaagcctta	tgatcgacgg	aattctgtgg	120
gaagggtttg	gcggagatcc	ttgcgatcct	tgccgcactt	ggtgtgacgc	tatcagcatg	180
cgtgtttggt	actacggaga	ctttgttttc	gaccgtgttt	tgaaaactga	tgtgaataaa	240
gaatttcaga	tgggagcggc	gcctactacc	aacgatgcag	cagacttaca	aaacgatcca	300
aaaacaaatg	ttgctcgtcc	aaatcccgct	tatggcaaac	acatgcaaga	tgctgaaatg	360
tttacgaacg	ctgcttacat	ggcattaaat	atctgggata	gttttgatgt	attttgtaca	420
ttggggagcaa	ctaccggtta	tttaaaagga	aactccgctt	ccttcaactt	agttggatta	480
ttcggaacaa	aaacaaaatc	ttctgatttt	aatacagcga	agcttggttc	taacattgct	540
ttgaatcgag	ctgtggttga	gctttatata	gacactacct	ttgcttgag	cgtaggtgct	600

cgtgcagctc	tctgggaatg	tgggtgtgca	acgttaggag	cttctttcca	atatgctcaa	660
tctaaaccta	aagtagaaga	gttaaagtgt	ctttgtaatg	catccgaatt	tactattaat	720
aagccgaaag	gatattgttg	ggcggaatgt	ccacttgata	ttaccgcagg	aacagaagct	780
gcgacagggg	ctaaggatgc	ctctattgac	taccatgagt	ggcaagcaag	tttagccctt	840
tcttacagac	taaataatgt	cactccttac	attggagtta	aatggcttag	agtaagtttt	900
gatgccgaca	cgatccgtat	cgctcagcct	aaattggctg	aagcaatctt	ggatgtcact	960
actctaaacc	cgaccatcgc	tggtaaagga	actgtggctg	cttcgggaag	cgataacgac	1020
ctggctgata	caatgcaaat	cgtttccttg	cagttgaaca	agatgaaatc	tagaaaatct	1080
tgcgggtattg	cagtaggaac	gactattgta	gatgcagaca	aatacgcagt	tacagttgag	1140
actcgcttga	tcgatgagag	agcagctcac	gtaaatgcac	aattccgctt	ctaa	1194

<210> 52
 <211> 397
 <212> PRT
 <213> Chlamydia trachomatis

<400> 52

Met	Lys	Lys	Leu	Leu	Lys	Ser	Val	Leu	Val	Phe	Ala	Ala	Leu	Ser	Ser	
1			5					10					15			
Ala	Ser	Ser	Leu	Gln	Ala	Leu	Pro	Val	Gly	Asn	Pro	Ala	Glu	Pro	Ser	
			20				25						30			
Leu	Met	Ile	Asp	Gly	Ile	Leu	Trp	Glu	Gly	Phe	Gly	Gly	Asp	Pro	Cys	
		35				40						45				
Asp	Pro	Cys	Ala	Thr	Trp	Cys	Asp	Ala	Ile	Ser	Met	Arg	Val	Gly	Tyr	
	50				55					60						
Tyr	Gly	Asp	Phe	Val	Phe	Asp	Arg	Val	Leu	Lys	Thr	Asp	Val	Asn	Lys	
65				70					75					80		
Glu	Phe	Gln	Met	Gly	Ala	Ala	Pro	Thr	Thr	Asn	Asp	Ala	Ala	Asp	Leu	
				85				90						95		
Gln	Asn	Asp	Pro	Lys	Thr	Asn	Val	Ala	Arg	Pro	Asn	Pro	Ala	Tyr	Gly	
			100				105						110			
Lys	His	Met	Gln	Asp	Ala	Glu	Met	Phe	Thr	Asn	Ala	Ala	Tyr	Met	Ala	
	115					120						125				
Leu	Asn	Ile	Trp	Asp	Arg	Phe	Asp	Val	Phe	Cys	Thr	Leu	Gly	Ala	Thr	
	130					135					140					
Thr	Gly	Tyr	Leu	Lys	Gly	Asn	Ser	Ala	Ser	Phe	Asn	Leu	Val	Gly	Leu	
145				150					155					160		
Phe	Gly	Thr	Lys	Thr	Lys	Ser	Ser	Asp	Phe	Asn	Thr	Ala	Lys	Leu	Val	
			165					170					175			
Pro	Asn	Ile	Ala	Leu	Asn	Arg	Ala	Val	Val	Glu	Leu	Tyr	Thr	Asp	Thr	
		180					185						190			
Thr	Phe	Ala	Trp	Ser	Val	Gly	Ala	Arg	Ala	Ala	Leu	Trp	Glu	Cys	Gly	
	195					200						205				
Cys	Ala	Thr	Leu	Gly	Ala	Ser	Phe	Gln	Tyr	Ala	Gln	Ser	Lys	Pro	Lys	
	210					215					220					
Val	Glu	Glu	Leu	Asn	Val	Leu	Cys	Asn	Ala	Ser	Glu	Phe	Thr	Ile	Asn	
225				230					235					240		
Lys	Pro	Lys	Gly	Tyr	Val	Gly	Ala	Glu	Phe	Pro	Leu	Asp	Ile	Thr	Ala	
			245					250					255			
Gly	Thr	Glu	Ala	Ala	Thr	Gly	Thr	Lys	Asp	Ala	Ser	Ile	Asp	Tyr	His	
		260				265							270			
Glu	Trp	Gln	Ala	Ser	Leu	Ala	Leu	Ser	Tyr	Arg	Leu	Asn	Met	Phe	Thr	
	275					280						285				
Pro	Tyr	Ile	Gly	Val	Lys	Trp	Ser	Arg	Val	Ser	Phe	Asp	Ala	Asp	Thr	
	290					295					300					
Ile	Arg	Ile	Ala	Gln	Pro	Lys	Leu	Ala	Glu	Ala	Ile	Leu	Asp	Val	Thr	
305				310					315					320		
Thr	Leu	Asn	Pro	Thr	Ile	Ala	Gly	Lys	Gly	Thr	Val	Val	Ala	Ser	Gly	
			325					330						335		

Ser Asp Asn Asp Leu Ala Asp Thr Met Gln Ile Val Ser Leu Gln Leu
 340 345 350
 Asn Lys Met Lys Ser Arg Lys Ser Cys Gly Ile Ala Val Gly Thr Thr
 355 360 365
 Ile Val Asp Ala Asp Lys Tyr Ala Val Thr Val Glu Thr Arg Leu Ile
 370 375 380
 Asp Glu Arg Ala Ala His Val Asn Ala Gln Phe Arg Phe
 385 390 395

<210> 53
 <211> 1182
 <212> DNA
 <213> Chlamydia trachomatis

<400> 53

atgaaaaaac tcttgaaatc ggtattagta tttgccgctt tgagttctgc ttcctccttg 60
 caagctctgc ctgtggggaa tcctgctgaa ccaagcctta tgatcgacgc aattctgtgg 120
 gaagggtttcg gcggagatcc ttgcgatcct tgcaccactt ggtgtgacgc tatcagcatg 180
 cgtatggggtt actatgggtga ctttgttttc gaccgtgttt tgaaaacaga tgtgaataaa 240
 gaattccaaa tgggtgacaa gcctacaagt actacaggca atgctacagc tccaaccact 300
 cttacagcaa gagagaatcc tgcttacggc cgacatatgc aggatgctga gatgtttaca 360
 aatgccgctt gcatggcatt gaatatgttg gatcgctttg atgtattctg tacactagga 420
 gcctctagcg gataccttaa aggaaactct gcttctttca atttagttgg attgtttgga 480
 gataatgaaa atcaaagcac ggtcaaaacg aattctgtac caaatatgag cttagatcaa 540
 tctgttgttg aactttacac agatactgcc ttctcttgga gcgtgggccc tcgagcagct 600
 ttgtgggagt gcggatgtgc gactttaggg gcttctttcc aatacgtca atctaaacct 660
 aaagtcgaag aattaaacgt tctctgtaac gcagctgagt ttactatcaa taagcctaaa 720
 ggatatgtag ggcaagaatt ccctcttgca ctcatagcag gaactgatgc agcgacgggc 780
 actaaagatg cctctattga ttaccatgag tggcaagcaa gtttagctct ctcttacaga 840
 ttgaatatgt tcaactcccta cattggagtt aaatgggtctc gagcaagttt tgatgccgat 900
 acgattcgta tagcccagcc aaaatcagct acagctatct ttgatactac cacgcttaac 960
 ccaactattg ctggagctgg cgatgtgaaa gctagcgcag agggtcagct cggagatacc 1020
 atgcaaatcg tctccttgca attgaacaag atgaaatcta gaaaatcttg cggatttgca 1080
 gtaggaacga ctattgtaga tgcagacaaa tacgcagtta cagttgagac tcgcttgatc 1140
 gatgagagag ctgctcacgt aaatgcacaa ttccgcttct aa 1182

<210> 54
 <211> 393
 <212> PRT
 <213> Chlamydia trachomatis

<400> 54

Met Lys Lys Leu Leu Lys Ser Val Leu Val Phe Ala Ala Leu Ser Ser
 1 5 10 15
 Ala Ser Ser Leu Gln Ala Leu Pro Val Gly Asn Pro Ala Glu Pro Ser
 20 25 30
 Leu Met Ile Asp Gly Ile Leu Trp Glu Gly Phe Gly Gly Asp Pro Cys
 35 40 45
 Asp Pro Cys Thr Thr Trp Cys Asp Ala Ile Ser Met Arg Met Gly Tyr
 50 55 60
 Tyr Gly Asp Phe Val Phe Asp Arg Val Leu Lys Thr Asp Val Asn Lys
 65 70 75 80
 Glu Phe Gln Met Gly Asp Lys Pro Thr Ser Thr Thr Gly Asn Ala Thr
 85 90 95
 Ala Pro Thr Thr Leu Thr Ala Arg Glu Asn Pro Ala Tyr Gly Arg His
 100 105 110
 Met Gln Asp Ala Glu Met Phe Thr Asn Ala Ala Cys Met Ala Leu Asn
 115 120 125

Ile	Trp	Asp	Arg	Phe	Asp	Val	Phe	Cys	Thr	Leu	Gly	Ala	Ser	Ser	Gly
130						135					140				
Tyr	Leu	Lys	Gly	Asn	Ser	Ala	Ser	Phe	Asn	Leu	Val	Gly	Leu	Phe	Gly
145						150				155					160
Asp	Asn	Glu	Asn	Gln	Ser	Thr	Val	Lys	Thr	Asn	Ser	Val	Pro	Asn	Met
			165						170						175
Ser	Leu	Asp	Gln	Ser	Val	Val	Glu	Leu	Tyr	Thr	Asp	Thr	Ala	Phe	Ser
			180						185						190
Trp	Ser	Val	Gly	Ala	Arg	Ala	Ala	Leu	Trp	Glu	Cys	Gly	Cys	Ala	Thr
		195					200					205			
Leu	Gly	Ala	Ser	Phe	Gln	Tyr	Ala	Gln	Ser	Lys	Pro	Lys	Val	Glu	Glu
		210				215					220				
Leu	Asn	Val	Leu	Cys	Asn	Ala	Ala	Glu	Phe	Thr	Ile	Asn	Lys	Pro	Lys
225					230					235					240
Gly	Tyr	Val	Gly	Gln	Glu	Phe	Pro	Leu	Ala	Leu	Ile	Ala	Gly	Thr	Asp
			245						250						255
Ala	Ala	Thr	Gly	Thr	Lys	Asp	Ala	Ser	Ile	Asp	Tyr	His	Glu	Trp	Gln
			260				265								270
Ala	Ser	Leu	Ala	Leu	Ser	Tyr	Arg	Leu	Asn	Met	Phe	Thr	Pro	Tyr	Ile
		275					280					285			
Gly	Val	Lys	Trp	Ser	Arg	Ala	Ser	Phe	Asp	Ala	Asp	Thr	Ile	Arg	Ile
		290				295					300				
Ala	Gln	Pro	Lys	Ser	Ala	Thr	Ala	Ile	Phe	Asp	Thr	Thr	Thr	Leu	Asn
305					310					315					320
Pro	Thr	Ile	Ala	Gly	Ala	Gly	Asp	Val	Lys	Ala	Ser	Ala	Glu	Gly	Gln
			325						330						335
Leu	Gly	Asp	Thr	Met	Gln	Ile	Val	Ser	Leu	Gln	Leu	Asn	Lys	Met	Lys
		340					345						350		
Ser	Arg	Lys	Ser	Cys	Gly	Ile	Ala	Val	Gly	Thr	Thr	Ile	Val	Asp	Ala
		355					360					365			
Asp	Lys	Tyr	Ala	Val	Thr	Val	Glu	Thr	Arg	Leu	Ile	Asp	Glu	Arg	Ala
		370				375					380				
Ala	His	Val	Asn	Ala	Gln	Phe	Arg	Phe							
385					390										

<210> 55
 <211> 1179
 <212> DNA
 <213> Chlamydia trachomatis

<400> 55

atgaaaaaac	tcttgaaatc	ggtattagta	tttgccgctt	tgagttctgc	ttcctccttg	60
caagctctgc	ctgtggggaa	tcctgctgaa	ccaagcctta	tgatcgacgg	aattctgtgg	120
gaaggtttcg	gcggagatcc	ttgcgatcct	tgccgacctt	ggtgtgacgc	tatcagcatg	180
cgtgttggtt	actacggaga	ctttgttttc	gaccgtgttt	tgaaaactga	tgtgaataaa	240
gaatttcaga	tgggtgccaa	gcctacaact	gatacaggca	atagtgcagc	tccatccact	300
cttacagcaa	gagagaatcc	tgcttacggc	cgacatatgc	aggatgctga	gatgtttaca	360
aatgccgctt	gcatggcatt	gaatatttgg	gatcgttttg	atgtattctg	tacattagga	420
gccaccagtg	gatatcttaa	aggaaaactct	gcttctttca	atttagttgg	attgtttgga	480
gataatgaaa	atcaaaaaaac	ggtcaaagcg	gagtctgtac	caaatatgag	ctttgatcaa	540
tctgttggtg	agttgtatac	agatactact	tttgcgtgga	gcgtcggcgc	tcgcgcagct	600
ttgtgggaat	gtggatgtgc	aacttttagga	gcttcattcc	aatatgetca	atctaaacct	660
aaagtagaag	aattaaacgt	tctctgcaat	gcagcagagt	ttactattaa	taaacctaaa	720
gggtatgtag	gtaaggagtt	tcctcttgat	cttacagcag	gaacagatgc	tgcgacagga	780
actaaggatg	cctctattga	ttaccatgaa	tggcaagcaa	gtttagctct	ctcttacaga	840
ctgaatatgt	tcactcccta	cattggagtt	aatgggtctc	gagcaagctt	tgatgccgat	900
acgattcgta	tagcccagcc	aaaatcagct	acagctatct	ttgatactac	cacgcttaac	960
ccaactattg	ctggagctgg	cgatgtgaaa	actggcgcag	agggtcagct	cggagacaca	1020
atgcaaatcg	tttcccttgca	attgaacaag	atgaaatcta	gaaaatcttg	cggatttgca	1080

gtaggaacaa otattgtgga tgcagacaaa tacgcagtta cagttgagac tcgcttgatc 1140
 gatgagagag cagctcacgt aaatgcacaa ttccgcttc 1179

<210> 56
 <211> 393
 <212> PRT
 <213> Chlamydia trachomatis

<400> 56

Met Lys Lys Leu Leu Lys Ser Val Leu Val Phe Ala Ala Leu Ser Ser
 1 5 10 15
 Ala Ser Ser Leu Gln Ala Leu Pro Val Gly Asn Pro Ala Glu Pro Ser
 20 25 30
 Leu Met Ile Asp Gly Ile Leu Trp Glu Gly Phe Gly Gly Asp Pro Cys
 35 40 45
 Asp Pro Cys Ala Thr Trp Cys Asp Ala Ile Ser Met Arg Val Gly Tyr
 50 55 60
 Tyr Gly Asp Phe Val Phe Asp Arg Val Leu Lys Thr Asp Val Asn Lys
 65 70 75 80
 Glu Phe Gln Met Gly Ala Lys Pro Thr Thr Asp Thr Gly Asn Ser Ala
 85 90 95
 Ala Pro Ser Thr Leu Thr Ala Arg Glu Asn Pro Ala Tyr Gly Arg His
 100 105 110
 Met Gln Asp Ala Glu Met Phe Thr Asn Ala Ala Cys Met Ala Leu Asn
 115 120 125
 Ile Trp Asp Arg Phe Asp Val Phe Cys Thr Leu Gly Ala Thr Ser Gly
 130 135 140
 Tyr Leu Lys Gly Asn Ser Ala Ser Phe Asn Leu Val Gly Leu Phe Gly
 145 150 155 160
 Asp Asn Glu Asn Gln Lys Thr Val Lys Ala Glu Ser Val Pro Asn Met
 165 170 175
 Ser Phe Asp Gln Ser Val Val Glu Leu Tyr Thr Asp Thr Thr Phe Ala
 180 185 190
 Trp Ser Val Gly Ala Arg Ala Ala Leu Trp Glu Cys Gly Cys Ala Thr
 195 200 205
 Leu Gly Ala Ser Phe Gln Tyr Ala Gln Ser Lys Pro Lys Val Glu Glu
 210 215 220
 Leu Asn Val Leu Cys Asn Ala Ala Glu Phe Thr Ile Asn Lys Pro Lys
 225 230 235 240
 Gly Tyr Val Gly Lys Glu Phe Pro Leu Asp Leu Thr Ala Gly Thr Asp
 245 250 255
 Ala Ala Thr Gly Thr Lys Asp Ala Ser Ile Asp Tyr His Glu Trp Gln
 260 265 270
 Ala Ser Leu Ala Leu Ser Tyr Arg Leu Asn Met Phe Thr Pro Tyr Ile
 275 280 285
 Gly Val Lys Trp Ser Arg Ala Ser Phe Asp Ala Asp Thr Ile Arg Ile
 290 295 300
 Ala Gln Pro Lys Ser Ala Thr Ala Ile Phe Asp Thr Thr Thr Leu Asn
 305 310 315 320
 Pro Thr Ile Ala Gly Ala Gly Asp Val Lys Thr Gly Ala Glu Gly Gln
 325 330 335
 Leu Gly Asp Thr Met Gln Ile Val Ser Leu Gln Leu Asn Lys Met Lys
 340 345 350
 Ser Arg Lys Ser Cys Gly Ile Ala Val Gly Thr Thr Ile Val Asp Ala
 355 360 365
 Asp Lys Tyr Ala Val Thr Val Glu Thr Arg Leu Ile Asp Glu Arg Ala
 370 375 380
 Ala His Val Asn Ala Gln Phe Arg Phe
 385 390

<210> 57
 <211> 1944
 <212> DNA
 <213> Chlamydia trachomatis

<400> 57

atggaatcag	gaccagaatc	agtttcttct	aatcagagct	cgatgaatcc	aattattaat	60
gggcaaatcg	cttctaattc	ggagaccaaa	gagtcacga	aggagtcaga	agcgagtcct	120
tcagcatcgt	cctctgtaag	cagctggagt	tttttatcct	cagcaaagca	tgcattaatc	180
tctcttcgtg	atgccatctt	gaataaaaat	tctagtccaa	cagactctct	ctctcaatta	240
gaggcctcta	cttctacctc	tacggttaca	cgtgtagctg	cgcgagatta	taatgaggct	300
aaatcgaatt	ttgatacggc	gaaaagtggg	ttagagaacg	ctacgacact	tgctgaatac	360
gagacgaaaa	tggctgattt	aatggcagct	ctccaagata	tggagcgttt	ggctaaacag	420
aaggctgaag	ttacaagaat	taaagaagct	cttcaagaga	aacaagaggt	tattgataag	480
ctcaatcagt	tagttaaact	tgaaaaacag	aatcagactt	taaaggaaac	tttaacaacc	540
acagactctg	cagatcagat	tccagcgatt	aatagtcagt	tagagatcaa	caaaaattct	600
gcagatcaaa	ttatcaaaga	tctggaagga	caaaacataa	gttatgaagc	tgttctcact	660
aacgcaggag	aggttatcaa	agcttcttct	gaagcgggaa	ttaagttagg	acaagctttg	720
cagtctattg	tggatgctgg	ggatcaaagc	caggctgcag	ttcttcaagc	acagcaaaat	780
aatagcccag	ataatatcgc	agccacgaag	aaattaattg	atgctgctga	aacgaaggta	840
aacgagttaa	aacaagagca	tacagggcta	acggactcgc	ctttagttaa	aaaagctgag	900
gagcagatta	gtcaagcaca	aaaagatatt	caagagatca	aacctagtgg	ttcggatatt	960
cctatcgttg	gtccgagtg	gtcagctgct	tccgcaggaa	gtgcggtagg	agcgttgaaa	1020
tcctctaaca	attcaggaag	aatttccttg	ttgcttgatg	atgtagacaa	tgaaatggca	1080
gcgattgcaa	tgcaagggtt	tcgatctatg	atcgaacaat	ttaatgtaaa	caatcctgca	1140
acagctaaag	agctacaagc	tatggaggct	cagctgactg	cgatgtcaga	tcaactgggt	1200
ggtgcggtg	gcgagctccc	agccgaaata	caagcaatca	aagatgctct	tgcgcaagct	1260
ttgaaacaac	catcaacaga	tggtttagct	acagctatgg	gacaagtggc	ttttgcagct	1320
gccaagggtg	gaggaggctc	cgcaggaaca	gctggcactg	tccagatgaa	tgtaaaacag	1380
ctttacaaga	cagcggtttt	ttcgacttct	tccagctctt	atgcagcagc	actttccgat	1440
ggatattctg	cttacaaaac	actgaactct	ttatattccg	aaagcagaag	cggcggtgcag	1500
tcagctatta	gtcaaaactgc	aaatcccgcg	ctttccagaa	gcgtttctcg	tcttggcata	1560
gaaagtcaag	gacgcagtgc	agatgctagc	caaagagcag	cagaaactat	tgctcagagat	1620
agccaaacgt	taggtgatgt	atatagccgc	ttacagggtc	tggattcttt	gatgtctacg	1680
attgtgagca	atccgcaagt	aaatcaagaa	gagattatgc	agaagctcac	ggcatctatt	1740
agcaaagctc	cacaatttgg	gtatcctgct	gttcagaatt	ctgcccgatag	cttgacagaag	1800
tttgctgcgc	aattggaaag	agagtttggt	gatggggaac	gtagtctcgc	agaatctcga	1860
gagaatgcgt	ttagaaaaca	gcccgttttc	attcaacag	tgttggtaaa	cattgcttct	1920
ctattctctg	gttatctttc	ttaa				1944

<210> 58
 <211> 647
 <212> PRT
 <213> Chlamydia trachomatis

<400> 58

Met	Glu	Ser	Gly	Pro	Glu	Ser	Val	Ser	Ser	Asn	Gln	Ser	Ser	Met	Asn
1			5					10						15	
Pro	Ile	Ile	Asn	Gly	Gln	Ile	Ala	Ser	Asn	Ser	Glu	Thr	Lys	Glu	Ser
			20					25					30		
Thr	Lys	Glu	Ser	Glu	Ala	Ser	Pro	Ser	Ala	Ser	Ser	Ser	Val	Ser	Ser
		35				40						45			
Trp	Ser	Phe	Leu	Ser	Ser	Ala	Lys	His	Ala	Leu	Ile	Ser	Leu	Arg	Asp
	50				55						60				
Ala	Ile	Leu	Asn	Lys	Asn	Ser	Ser	Pro	Thr	Asp	Ser	Leu	Ser	Gln	Leu
65				70					75					80	
Glu	Ala	Ser	Thr	Ser	Thr	Ser	Thr	Val	Thr	Arg	Val	Ala	Ala	Arg	Asp

85										90					95				
Tyr	Asn	Glu	Ala	Lys	Ser	Asn	Phe	Asp	Thr	Ala	Lys	Ser	Gly	Leu	Glu				
			100					105					110						
Asn	Ala	Thr	Thr	Leu	Ala	Glu	Tyr	Glu	Thr	Lys	Met	Ala	Asp	Leu	Met				
		115					120					125							
Ala	Ala	Leu	Gln	Asp	Met	Glu	Arg	Leu	Ala	Lys	Gln	Lys	Ala	Glu	Val				
	130					135					140								
Thr	Arg	Ile	Lys	Glu	Ala	Leu	Gln	Glu	Lys	Gln	Glu	Val	Ile	Asp	Lys				
145				150					155					160					
Leu	Asn	Gln	Leu	Val	Lys	Leu	Glu	Lys	Gln	Asn	Gln	Thr	Leu	Lys	Glu				
			165						170					175					
Thr	Leu	Thr	Thr	Thr	Asp	Ser	Ala	Asp	Gln	Ile	Pro	Ala	Ile	Asn	Ser				
		180						185					190						
Gln	Leu	Glu	Ile	Asn	Lys	Asn	Ser	Ala	Asp	Gln	Ile	Ile	Lys	Asp	Leu				
	195					200					205								
Glu	Gly	Gln	Asn	Ile	Ser	Tyr	Glu	Ala	Val	Leu	Thr	Asn	Ala	Gly	Glu				
	210					215					220								
Val	Ile	Lys	Ala	Ser	Ser	Glu	Ala	Gly	Ile	Lys	Leu	Gly	Gln	Ala	Leu				
225				230					235					240					
Gln	Ser	Ile	Val	Asp	Ala	Gly	Asp	Gln	Ser	Gln	Ala	Ala	Val	Leu	Gln				
			245						250					255					
Ala	Gln	Gln	Asn	Asn	Ser	Pro	Asp	Asn	Ile	Ala	Ala	Thr	Lys	Lys	Leu				
		260						265					270						
Ile	Asp	Ala	Ala	Glu	Thr	Lys	Val	Asn	Glu	Leu	Lys	Gln	Glu	His	Thr				
	275						280					285							
Gly	Leu	Thr	Asp	Ser	Pro	Leu	Val	Lys	Lys	Ala	Glu	Glu	Gln	Ile	Ser				
	290					295					300								
Gln	Ala	Gln	Lys	Asp	Ile	Gln	Glu	Ile	Lys	Pro	Ser	Gly	Ser	Asp	Ile				
305				310					315					320					
Pro	Ile	Val	Gly	Pro	Ser	Gly	Ser	Ala	Ala	Ser	Ala	Gly	Ser	Ala	Val				
			325						330					335					
Gly	Ala	Leu	Lys	Ser	Ser	Asn	Asn	Ser	Gly	Arg	Ile	Ser	Leu	Leu	Leu				
		340						345				350							
Asp	Asp	Val	Asp	Asn	Glu	Met	Ala	Ala	Ile	Ala	Met	Gln	Gly	Phe	Arg				
	355						360					365							
Ser	Met	Ile	Glu	Gln	Phe	Asn	Val	Asn	Asn	Pro	Ala	Thr	Ala	Lys	Glu				
	370					375					380								
Leu	Gln	Ala	Met	Glu	Ala	Gln	Leu	Thr	Ala	Met	Ser	Asp	Gln	Leu	Val				
385				390					395					400					
Gly	Ala	Asp	Gly	Glu	Leu	Pro	Ala	Glu	Ile	Gln	Ala	Ile	Lys	Asp	Ala				
			405						410					415					
Leu	Ala	Gln	Ala	Leu	Lys	Gln	Pro	Ser	Thr	Asp	Gly	Leu	Ala	Thr	Ala				
		420						425				430							
Met	Gly	Gln	Val	Ala	Phe	Ala	Ala	Ala	Lys	Val	Gly	Gly	Gly	Ser	Ala				
	435					440						445							
Gly	Thr	Ala	Gly	Thr	Val	Gln	Met	Asn	Val	Lys	Gln	Leu	Tyr	Lys	Thr				
	450					455					460								
Ala	Phe	Ser	Ser	Thr	Ser	Ser	Ser	Tyr	Ala	Ala	Ala	Leu	Ser	Asp					
465				470					475					480					
Gly	Tyr	Ser	Ala	Tyr	Lys	Thr	Leu	Asn	Ser	Leu	Tyr	Ser	Glu	Ser	Arg				
			485						490					495					
Ser	Gly	Val	Gln	Ser	Ala	Ile	Ser	Gln	Thr	Ala	Asn	Pro	Ala	Leu	Ser				
		500						505					510						
Arg	Ser	Val	Ser	Arg	Ser	Gly	Ile	Glu	Ser	Gln	Gly	Arg	Ser	Ala	Asp				
	515						520					525							
Ala	Ser	Gln	Arg	Ala	Ala	Glu	Thr	Ile	Val	Arg	Asp	Ser	Gln	Thr	Leu				
	530					535					540								
Gly	Asp	Val	Tyr	Ser	Arg	Leu	Gln	Val	Leu	Asp	Ser	Leu	Met	Ser	Thr				
545				550							555				560				
Ile	Val	Ser	Asn	Pro	Gln	Val	Asn	Gln	Glu	Ile	Met	Gln	Lys	Leu					

<210> 62
 <211> 651
 <212> PRT
 <213> Chlamydia pneumoniae

<400> 62

Met	Val	Asn	Pro	Ile	Gly	Pro	Gly	Pro	Ile	Asp	Glu	Thr	Glu	Arg	Thr
1				5					10					15	
Pro	Pro	Ala	Asp	Leu	Ser	Ala	Gln	Gly	Leu	Glu	Ala	Ser	Ala	Ala	Asn
		20						25					30		
Lys	Ser	Ala	Glu	Ala	Gln	Arg	Ile	Ala	Gly	Ala	Glu	Ala	Lys	Pro	Lys
		35					40					45			
Glu	Ser	Lys	Thr	Asp	Ser	Val	Glu	Arg	Trp	Ser	Ile	Leu	Arg	Ser	Ala
	50					55					60				
Val	Asn	Ala	Leu	Met	Ser	Leu	Ala	Asp	Lys	Leu	Gly	Ile	Ala	Ser	Ser
65				70						75					80
Asn	Ser	Ser	Ser	Ser	Thr	Ser	Arg	Ser	Ala	Asp	Val	Asp	Ser	Thr	Thr
				85					90					95	
Ala	Thr	Ala	Pro	Thr	Pro	Pro	Pro	Pro	Thr	Phe	Asp	Asp	Tyr	Lys	Thr
			100					105					110		
Gln	Ala	Gln	Thr	Ala	Tyr	Asp	Thr	Ile	Phe	Thr	Ser	Thr	Ser	Leu	Ala
		115					120					125			
Asp	Ile	Gln	Ala	Ala	Leu	Val	Ser	Leu	Gln	Asp	Ala	Val	Thr	Asn	Ile
	130					135					140				
Lys	Asp	Thr	Ala	Ala	Thr	Asp	Glu	Glu	Thr	Ala	Ile	Ala	Ala	Glu	Trp
145					150					155					160
Glu	Thr	Lys	Asn	Ala	Asp	Ala	Val	Lys	Val	Gly	Ala	Gln	Ile	Thr	Glu
			165					170						175	
Leu	Ala	Lys	Tyr	Ala	Ser	Asp	Asn	Gln	Ala	Ile	Leu	Asp	Ser	Leu	Gly
		180					185						190		
Lys	Leu	Thr	Ser	Phe	Asp	Leu	Leu	Gln	Ala	Ala	Leu	Leu	Gln	Ser	Val
	195						200					205			
Ala	Asn	Asn	Asn	Lys	Ala	Ala	Glu	Leu	Leu	Lys	Glu	Met	Gln	Asp	Asn
	210				215						220				
Pro	Val	Val	Pro	Gly	Lys	Thr	Pro	Ala	Ile	Ala	Gln	Ser	Leu	Val	Asp
225					230					235					240
Gln	Thr	Asp	Ala	Thr	Ala	Thr	Gln	Ile	Glu	Lys	Asp	Gly	Asn	Ala	Ile
			245						250					255	
Arg	Asp	Ala	Tyr	Phe	Ala	Gly	Gln	Asn	Ala	Ser	Gly	Ala	Val	Glu	Asn
		260					265						270		
Ala	Lys	Ser	Asn	Asn	Ser	Ile	Ser	Asn	Ile	Asp	Ser	Ala	Lys	Ala	Ala
	275					280						285			
Ile	Ala	Thr	Ala	Lys	Thr	Gln	Ile	Ala	Glu	Ala	Gln	Lys	Lys	Phe	Pro
	290					295					300				
Asp	Ser	Pro	Ile	Leu	Gln	Glu	Ala	Glu	Gln	Met	Val	Ile	Gln	Ala	Glu
305				310						315					320
Lys	Asp	Leu	Lys	Asn	Ile	Lys	Pro	Ala	Asp	Gly	Ser	Asp	Val	Pro	Asn
			325						330					335	
Pro	Gly	Thr	Thr	Val	Gly	Gly	Ser	Lys	Gln	Gln	Gly	Ser	Ser	Ile	Gly
		340					345						350		
Ser	Ile	Arg	Val	Ser	Met	Leu	Leu	Asp	Asp	Ala	Glu	Asn	Glu	Thr	Ala
	355					360						365			
Ser	Ile	Leu	Met	Ser	Gly	Phe	Arg	Gln	Met	Ile	His	Met	Phe	Asn	Thr
	370				375					380					
Glu	Asn	Pro	Asp	Ser	Gln	Ala	Ala	Gln	Gln	Glu	Leu	Ala	Ala	Gln	Ala
385				390						395					400
Arg	Ala	Ala	Lys	Ala	Ala	Gly	Asp	Asp	Ser	Ala	Ala	Ala	Ala	Leu	Ala
			405					410						415	

Asp Ala Gln Lys Ala Leu Glu Ala Ala Leu Gly Lys Ala Gly Gln Gln
 420 425 430
 Gln Gly Ile Leu Asn Ala Leu Gly Gln Ile Ala Ser Ala Ala Val Val
 435 440 445
 Ser Ala Gly Val Pro Pro Ala Ala Ala Ser Ser Ile Gly Ser Ser Val
 450 455 460
 Lys Gln Leu Tyr Lys Thr Ser Lys Ser Thr Gly Ser Asp Tyr Lys Thr
 465 470 475 480
 Gln Ile Ser Ala Gly Tyr Asp Ala Tyr Lys Ser Ile Asn Asp Ala Tyr
 485 490 495
 Gly Arg Ala Arg Asn Asp Ala Thr Arg Asp Val Ile Asn Asn Val Ser
 500 505 510
 Thr Pro Ala Leu Thr Arg Ser Val Pro Arg Ala Arg Thr Glu Ala Arg
 515 520 525
 Gly Pro Glu Lys Thr Asp Gln Ala Leu Ala Arg Val Ile Ser Gly Asn
 530 535 540
 Ser Arg Thr Leu Gly Asp Val Tyr Ser Gln Val Ser Ala Leu Gln Ser
 545 550 555 560
 Val Met Gln Ile Ile Gln Ser Asn Pro Gln Ala Asn Asn Glu Glu Ile
 565 570 575
 Arg Gln Lys Leu Thr Ser Ala Val Thr Lys Pro Pro Gln Phe Gly Tyr
 580 585 590
 Pro Tyr Val Gln Leu Ser Asn Asp Ser Thr Gln Lys Phe Ile Ala Lys
 595 600 605
 Leu Glu Ser Leu Phe Ala Glu Gly Ser Arg Thr Ala Ala Glu Ile Lys
 610 615 620
 Ala Leu Ser Phe Glu Thr Asn Ser Leu Phe Ile Gln Gln Val Leu Val
 625 630 635 640
 Asn Ile Gly Ser Leu Tyr Ser Gly Tyr Leu Gln
 645 650

<210> 63
 <211> 261
 <212> DNA
 <213> Chlamydia trachomatis

<400> 63

atgagtc meta ataagaactc tgctttcatg cagcctgtga acgtatccgc tgatttagct	60
gccatcggtg gtgcaggacc tatgcctcgc acagagatca ttaagaaaat gtgggattac	120
attaagaaga atggccttca agatcctaca aacaaacgta atatcaatcc cgatgataaa	180
ttggctaaag tttttggaac tgaaaaacct atcgatatgt tccaaatgac aaaaatgggt	240
tctcaacaca tcattaaata a	261

<210> 64
 <211> 86
 <212> PRT
 <213> Chlamydia trachomatis

<400> 64

Met Ser Gln Asn Lys Asn Ser Ala Phe Met Gln Pro Val Asn Val Ser
 1 5 10 15
 Ala Asp Leu Ala Ala Ile Val Gly Ala Gly Pro Met Pro Arg Thr Glu
 20 25 30
 Ile Ile Lys Lys Met Trp Asp Tyr Ile Lys Lys Asn Gly Leu Gln Asp
 35 40 45
 Pro Thr Asn Lys Arg Asn Ile Asn Pro Asp Asp Lys Leu Ala Lys Val
 50 55 60
 Phe Gly Thr Glu Lys Pro Ile Asp Met Phe Gln Met Thr Lys Met Val

65 70
 Ser Gln His Ile Ile Lys
 85

75

80

<210> 65
 <211> 261
 <212> DNA
 <213> Chlamydia muridarum

<400> 65

atgagtcaaaa	ataagaactc	tgctttcatg	cagcctgtga	acgtatcttc	tgatttagct	60
gccattgttg	gtacagggcc	tatgcctcgc	acagaaatca	ttaagaaaat	ttgggattat	120
attaagcaga	ataaacttca	agatcctact	aacaaacgca	acatcaatcc	tgatgataaa	180
ttagccaagg	tttttggttc	caaagaccct	gtagatatgt	tccaaatgac	aaaaatagtc	240
tctaaacaca	ttgttaaata	a				261

<210> 66
 <211> 86
 <212> PRT
 <213> Chlamydia muridarum

<400> 66

Met	Ser	Gln	Asn	Lys	Asn	Ser	Ala	Phe	Met	Gln	Pro	Val	Asn	Val	Ser
1			5						10				15		
Ser	Asp	Leu	Ala	Ala	Ile	Val	Gly	Thr	Gly	Pro	Met	Pro	Arg	Thr	Glu
			20					25					30		
Ile	Ile	Lys	Lys	Ile	Trp	Asp	Tyr	Ile	Lys	Gln	Asn	Lys	Leu	Gln	Asp
		35				40					45				
Pro	Thr	Asn	Lys	Arg	Asn	Ile	Asn	Pro	Asp	Asp	Lys	Leu	Ala	Lys	Val
	50				55						60				
Phe	Gly	Ser	Lys	Asp	Pro	Val	Asp	Met	Phe	Gln	Met	Thr	Lys	Ile	Val
65					70					75				80	
Ser	Lys	His	Ile	Val	Lys										
					85										

<210> 67
 <211> 264
 <212> DNA
 <213> Chlamydia psitacii

<400> 67

atgagtcaaaa	aaaacaaaaa	ctctgctttt	atgaacccccg	tcaatattac	ccccgattta	60
gcagctatcg	ttggcgaggg	accaatgccc	cgcactgaaa	ttgtcaaaaa	agtatgggag	120
cacattaaaaa	aaaataacct	tcaagaccct	aagaataaaa	gaaatatcct	tcccgatgac	180
gccctagcta	aagtcttttg	ttctaaaaat	ccaatcgata	tgtttcaa	gacgaaagcc	240
ctttccgctc	atatcgtaaa	ataa				264

<210> 68
 <211> 87
 <212> PRT
 <213> Chlamydia psitacii

<400> 68

Met	Ser	Gln	Lys	Asn	Lys	Asn	Ser	Ala	Phe	Met	Asn	Pro	Val	Asn	Ile
1			5						10				15		
Thr	Pro	Asp	Leu	Ala	Ala	Ile	Val	Gly	Glu	Gly	Pro	Met	Pro	Arg	Thr

	20		25		30
Glu Ile Val	Lys Lys Val Trp	Glu His Ile	Lys Lys Asn Asn	Leu Gln	
	35	40	45		
Asp Pro Lys	Asn Lys Arg Asn	Ile Leu Pro	Asp Asp Ala	Leu Ala Lys	
	50	55	60		
Val Phe Gly	Ser Lys Asn Pro	Ile Asp Met	Phe Gln Met	Thr Lys Ala	
	65	70	75	80	
Leu Ser Ala	His Ile Val Lys				
	85				

<210> 69
 <211> 264
 <212> DNA
 <213> Chlamydia pneumoniae

<400> 69

atgagtcaaa	aaaataaaaa	ctctgctttt	atgcatcccg	tgaatatattc	cacagattta	60
gcagtttatag	ttggcaaggg	acctatgccc	agaaccgaaa	ttgtaaagaa	agtttgggaa	120
tacattaaaa	aacacaactg	tcaggatcaa	aaaaataaac	gtaatatcct	tcccgatgcg	180
aatcttgcca	aagtcttttg	ctctagtgat	cctatcgaca	tgttccaaat	gaccaaagcc	240
ctttccaaac	atattgtaaa	ataa				264

<210> 70
 <211> 87
 <212> PRT
 <213> Chlamydia pneumoniae

<400> 70

Met Ser Gln	Lys Asn Lys	Asn Ser Ala	Phe Met His	Pro Val Asn	Ile
1	5	10	15		
Ser Thr Asp	Leu Ala Val	Ile Val Gly	Lys Gly Pro	Met Pro Arg	Thr
	20	25	30		
Glu Ile Val	Lys Lys Val Trp	Glu Tyr Ile	Lys Lys His	Asn Cys Gln	
	35	40	45		
Asp Gln Lys	Asn Lys Arg Asn	Ile Leu Pro	Asp Ala Asn	Leu Ala Lys	
	50	55	60		
Val Phe Gly	Ser Ser Asp	Pro Ile Asp	Met Phe Gln	Met Thr Lys	Ala
	65	70	75	80	
Leu Ser Lys	His Ile Val Lys				
	85				

<210> 71
 <211> 1266
 <212> DNA
 <213> Chlamydia trachomatis

<400> 71

atgactgcat	caggaggagc	tggagggcta	ggcagcaccc	aaacagtaga	cgttgcgcga	60
gcacaagctg	ctgcagctac	tcaagatgca	caagaggtta	tcggctctca	ggaagcttct	120
gaggcaagta	tgctcaaagg	atgtgaggat	ctcataaatc	ctgcagctgc	aaccggaatc	180
aaaaaaaaag	gagagaagtt	tgaatcatta	gaagctcgtc	gcaaaccaac	agcggataaa	240
gcagaaaaga	aatccgagag	cacagaggaa	aaaggcgata	ctcctcttga	agatcgtttc	300
acagaagatc	tttccgaagt	ctccggagaa	gattttcgag	gattgaaaaa	ttcgttcgat	360
gatgattctt	ctcctgacga	aattctcgat	gcgctcacaa	gtaaattttc	tgatcccaca	420
ataaaggatc	tagctcttga	ttatctaatt	caaacagctc	cctctgatgg	gaaacttaag	480
tccactctca	ttcaggcaaa	gcatacaactg	atgagccaga	atcctcaggc	gattggttga	540
ggacgcgaatg	ttctgttagc	ttcagaaacc	tttgcttcca	gagcaaatac	atctccttca	600

tcgcttcgct	ccttatat	ccaagtaacc	tcacccccct	ctaattg	gcgc	taatttacat	660
caaatgcttg	cttcttactt	gccatcagag	aaaacogctg	ttatggagtt	tctagtaa	att	720
ggcatggtag	cagatttaaa	atcggagggc	ccttccattc	ctcctgcaaa	attgcaagta		780
tatatgacgg	aactaagcaa	tctccaagcc	ttacactctg	taaatagctt	ttttgataga		840
aattattggga	acttgga	aaa	tagcttaaa	catgaaggac	atgcccctat	tccatcctta	900
acgacaggaa	atttaactaa	aaccttctta	caattagtag	aagataaatt	cccttcctct		960
tccaaagctc	aaaaggcatt	aaatgaactg	gtaggcccag	atactggtcc	tcaaactgaa		1020
gttttaaaact	tattcttccg	cgctctta	aat	ggctgttcgc	ctagaatatt	ctctggagct	1080
gaaaaaaaac	agcagctggc	atcggttatc	acaaatacgc	tagatgcat	aaatgcggat		1140
aatgaggatt	atcctaaacc	aggtgacttc	ccacgatctt	ccttctctag	tacgcctcct		1200
catgctccag	tacctcaatc	tgagattcca	acgtcaccta	cctcaacaca	gcctccatca		1260
ccctaa							1266

<210> 72
 <211> 421
 <212> PRT
 <213> Chlamydia trachomatis

<400> 72

Met	Thr	Ala	Ser	Gly	Gly	Ala	Gly	Gly	Leu	Gly	Ser	Thr	Gln	Thr	Val	
1				5					10					15		
Asp	Val	Ala	Arg	Ala	Gln	Ala	Ala	Ala	Ala	Thr	Gln	Asp	Ala	Gln	Glu	
			20					25					30			
Val	Ile	Gly	Ser	Gln	Glu	Ala	Ser	Glu	Ala	Ser	Met	Leu	Lys	Gly	Cys	
		35					40					45				
Glu	Asp	Leu	Ile	Asn	Pro	Ala	Ala	Ala	Thr	Arg	Ile	Lys	Lys	Lys	Gly	
	50					55					60					
Glu	Lys	Phe	Glu	Ser	Leu	Glu	Ala	Arg	Arg	Lys	Pro	Thr	Ala	Asp	Lys	
65					70				75						80	
Ala	Glu	Lys	Lys	Ser	Glu	Ser	Thr	Glu	Glu	Lys	Gly	Asp	Thr	Pro	Leu	
			85					90						95		
Glu	Asp	Arg	Phe	Thr	Glu	Asp	Leu	Ser	Glu	Val	Ser	Gly	Glu	Asp	Phe	
			100					105					110			
Arg	Gly	Leu	Lys	Asn	Ser	Phe	Asp	Asp	Asp	Ser	Ser	Pro	Asp	Glu	Ile	
	115						120					125				
Leu	Asp	Ala	Leu	Thr	Ser	Lys	Phe	Ser	Asp	Pro	Thr	Ile	Lys	Asp	Leu	
	130					135					140					
Ala	Leu	Asp	Tyr	Leu	Ile	Gln	Thr	Ala	Pro	Ser	Asp	Gly	Lys	Leu	Lys	
145					150				155						160	
Ser	Thr	Leu	Ile	Gln	Ala	Lys	His	Gln	Leu	Met	Ser	Gln	Asn	Pro	Gln	
			165					170						175		
Ala	Ile	Val	Gly	Gly	Arg	Asn	Val	Leu	Leu	Ala	Ser	Glu	Thr	Phe	Ala	
			180				185						190			
Ser	Arg	Ala	Asn	Thr	Ser	Pro	Ser	Ser	Leu	Arg	Ser	Leu	Tyr	Phe	Gln	
	195					200						205				
Val	Thr	Ser	Ser	Pro	Ser	Asn	Cys	Ala	Asn	Leu	His	Gln	Met	Leu	Ala	
	210					215						220				
Ser	Tyr	Leu	Pro	Ser	Glu	Lys	Thr	Ala	Val	Met	Glu	Phe	Leu	Val	Asn	
	225				230				235					240		
Gly	Met	Val	Ala	Asp	Leu	Lys	Ser	Glu	Gly	Pro	Ser	Ile	Pro	Pro	Ala	
			245					250						255		
Lys	Leu	Gln	Val	Tyr	Met	Thr	Glu	Leu	Ser	Asn	Leu	Gln	Ala	Leu	His	
			260				265						270			
Ser	Val	Asn	Ser	Phe	Phe	Asp	Arg	Asn	Ile	Gly	Asn	Leu	Glu	Asn	Ser	
	275					280						285				
Leu	Lys	His	Glu	Gly	His	Ala	Pro	Ile	Pro	Ser	Leu	Thr	Thr	Gly	Asn	
	290					295						300				
Leu	Thr	Lys	Thr	Phe	Leu	Gln	Leu	Val	Glu	Asp	Lys	Phe	Pro	Ser	Ser	
305					310					315					320	

Ser Lys Ala Gln Lys Ala Leu Asn Glu Leu Val Gly Pro Asp Thr Gly
325 330 335
Pro Gln Thr Glu Val Leu Asn Leu Phe Phe Arg Ala Leu Asn Gly Cys
340 345 350
Ser Pro Arg Ile Phe Ser Gly Ala Glu Lys Lys Gln Gln Leu Ala Ser
355 360 365
Val Ile Thr Asn Thr Leu Asp Ala Ile Asn Ala Asp Asn Glu Asp Tyr
370 375 380
Pro Lys Pro Gly Asp Phe Pro Arg Ser Ser Phe Ser Ser Thr Pro Pro
385 390 395 400
His Ala Pro Val Pro Gln Ser Glu Ile Pro Thr Ser Pro Thr Ser Thr
405 410 415
Gln Pro Pro Ser Pro
420

<210> 73
<211> 1257
<212> DNA
<213> Chlamydia muridarum

<400> 73

atgactgcat	ccggaggagc	tggagggtta	ggcggaaccc	aaacagtaaa	cgtagcacaa	60
gcgcaagctg	cagcagctac	tcaggatgca	caagaaatca	taggctctca	ggaagcttct	120
gaagccagtt	tgattaaagg	aagtgaggat	cttgctaate	ctgctgcagc	gactagaatc	180
aaaaagaaa	aagacaaatt	tcagtcatta	gaagctcgtc	gaaaaacaac	tagtaaatcc	240
gaaaaaaaat	cagaaagtac	agaagagaaa	tcagactctt	ctcttgaaga	gcgcttcaca	300
gaaaatcttt	cggatgtttc	tggagaagat	tttcgagggt	ttaaaggattc	tctgagttaa	360
gattcctctc	ctgaagagat	tcttgagaag	ctgtcaggca	aattttcgga	ccccacaatt	420
aaagatcttg	ctctagactt	tctgattcaa	tcgagtcctc	ctgatgggaa	attaagagcc	480
tctcttattc	aggcaaaaac	gacgcttttt	caacaaaatc	ctcaagcagt	caaaggaggg	540
cgcaacgttc	tttttagcatc	agaagccttt	gcttctaaag	caaacacttc	ccctgcatca	600
ttacgcgcat	tgtataccca	agtaacctca	tctccggcta	attgtgcttc	tctaagtcag	660
atgctatcct	cttattctcc	tacagaaaaa	gcagctgtta	tagatttttt	aacaaatggt	720
atggtgtctg	atctcaaate	aggaggccct	tccatccctg	ctccacaatt	gcaagtgtat	780
atgacggagc	tcagcaatct	acaagccctc	aactctgtag	acagtttttt	tgacaaaaat	840
acaaaaggac	tagaagacaa	tttaaaagcc	gaaggacata	cccttcacc	atccctaact	900
cccagtaate	ttgctcaaac	ttttttaaag	ttagtggaag	ataagttccc	gtcctcccaa	960
aaagctcaaa	aattgttgga	tggccttggt	ggttctgacg	ttactcctca	aactgaagtt	1020
ttaaatctct	tttaccgagc	gctcaatggt	tgttccccac	gaatattcgg	caatgctgag	1080
aaaaaacagc	agctagcaac	agtaattact	aacacattag	ataccgtgaa	tgccgataac	1140
gaagattatc	ctaaacctag	cgatttcccc	aaaccttcc	tccatggcac	tcctcctcat	1200
gctccagtg	ctctatctga	tattccatca	gcaacaacaa	actctgcaga	ccaataa	1257

<210> 74
<211> 418
<212> PRT
<213> Chlamydia muridarum

<400> 74

Met Thr Ala Ser Gly Gly Ala Gly Gly Leu Gly Gly Thr Gln Thr Val
1 5 10 15
Asn Val Ala Gln Ala Gln Ala Ala Ala Thr Gln Asp Ala Gln Glu
20 25 30
Ile Ile Gly Ser Gln Glu Ala Ser Glu Ala Ser Leu Ile Lys Gly Ser
35 40 45
Glu Asp Leu Ala Asn Pro Ala Ala Thr Arg Ile Lys Lys Lys Glu
50 55 60
Asp Lys Phe Gln Ser Leu Glu Ala Arg Arg Lys Thr Thr Ser Lys Ser

65					70					75				80	
Glu	Lys	Lys	Ser	Glu	Ser	Thr	Glu	Glu	Lys	Ser	Asp	Ser	Ser	Leu	Glu
				85					90					95	
Glu	Arg	Phe	Thr	Glu	Asn	Leu	Ser	Asp	Val	Ser	Gly	Glu	Asp	Phe	Arg
			100					105					110		
Gly	Leu	Lys	Asp	Ser	Leu	Ser	Glu	Asp	Ser	Ser	Pro	Glu	Glu	Ile	Leu
		115					120					125			
Glu	Lys	Leu	Ser	Gly	Lys	Phe	Ser	Asp	Pro	Thr	Ile	Lys	Asp	Leu	Ala
	130				135						140				
Leu	Asp	Phe	Leu	Ile	Gln	Ser	Ser	Pro	Pro	Asp	Gly	Lys	Leu	Arg	Ala
145					150					155					160
Ser	Leu	Ile	Gln	Ala	Lys	Gln	Thr	Leu	Phe	Gln	Gln	Asn	Pro	Gln	Ala
			165						170					175	
Val	Lys	Gly	Gly	Arg	Asn	Val	Leu	Leu	Ala	Ser	Glu	Ala	Phe	Ala	Ser
		180						185					190		
Lys	Ala	Asn	Thr	Ser	Pro	Ala	Ser	Leu	Arg	Ala	Leu	Tyr	Thr	Gln	Val
	195						200					205			
Thr	Ser	Ser	Pro	Ala	Asn	Cys	Ala	Ser	Leu	Ser	Gln	Met	Leu	Ser	Ser
	210				215						220				
Tyr	Ser	Pro	Thr	Glu	Lys	Ala	Ala	Val	Ile	Asp	Phe	Leu	Thr	Asn	Gly
225				230						235					240
Met	Val	Ser	Asp	Leu	Lys	Ser	Gly	Gly	Pro	Ser	Ile	Pro	Ala	Pro	Gln
			245						250					255	
Leu	Gln	Val	Tyr	Met	Thr	Glu	Leu	Ser	Asn	Leu	Gln	Ala	Leu	Asn	Ser
		260					265						270		
Val	Asp	Ser	Phe	Phe	Asp	Lys	Asn	Thr	Lys	Gly	Leu	Glu	Asp	Asn	Leu
	275						280					285			
Lys	Ala	Glu	Gly	His	Thr	Leu	Pro	Pro	Ser	Leu	Thr	Pro	Ser	Asn	Leu
	290					295					300				
Ala	Gln	Thr	Phe	Leu	Lys	Leu	Val	Glu	Asp	Lys	Phe	Pro	Ser	Ser	Gln
305				310					315						320
Lys	Ala	Gln	Lys	Leu	Leu	Asp	Gly	Leu	Val	Gly	Ser	Asp	Val	Thr	Pro
			325						330					335	
Gln	Thr	Glu	Val	Leu	Asn	Leu	Phe	Tyr	Arg	Ala	Leu	Asn	Gly	Cys	Ser
		340						345					350		
Pro	Arg	Ile	Phe	Gly	Asn	Ala	Glu	Lys	Lys	Gln	Gln	Leu	Ala	Thr	Val
	355						360					365			
Ile	Thr	Asn	Thr	Leu	Asp	Thr	Val	Asn	Ala	Asp	Asn	Glu	Asp	Tyr	Pro
	370				375						380				
Lys	Pro	Ser	Asp	Phe	Pro	Lys	Pro	Ser	Phe	His	Gly	Thr	Pro	Pro	His
385				390						395					400
Ala	Pro	Val	Ser	Leu	Ser	Asp	Ile	Pro	Ser	Ala	Thr	Thr	Asn	Ser	Ala
			405						410					415	

Asp Gln

<210> 75

<211> 1194

<212> DNA

<213> Chlamydia psitacii

<400> 75

atggctgcac	ctggaggagc	tggtggccta	ggcggttcac	aagctgttga	cgttgcgcaa	60
gtgcaagctg	cagctgcgaa	agctgatgcc	caagaagtta	tcgctagcca	agagcaatcc	120
gacatcagta	tgattaagga	ttctcaggat	ttatcaaadc	ctcaggctgc	gacacgtaca	180
aagaaaaaag	aagaaaaatt	caaactcta	gaatctagaa	ggaaaggcgc	gactcaagca	240
gagaaaaagt	ctgaaagcac	gggagataaa	tccgacgcgg	atcttgcgga	taagtataca	300
gaaaataatg	ctgaaatctc	aggtcaagat	ttacgcagta	tccgagattc	tttgcgatgat	360
ggttcttccg	aagaagatgt	tttagatctt	gtaaaatcta	agttctctga	tcctgcgctt	420
caaagtgttg	ccctagatta	tttagtccag	acaacaccag	cttctaaagg	agctttaaaa	480

gacaccttaa	tcagggcaca	acaaaaccac	atgcaacaaa	atcgacaagc	tggtgttggt	540
ggtaaaaaata	ttctatttgc	ctctcaagag	tatgcattct	tattaaatac	ctctgctcca	600
ggattacgtg	ctctttatct	tgaggtaacg	tctgatttcc	attcttgtga	gcaattacta	660
acatctctcc	agtcacgtta	tagttacgaa	gaaatgggca	ctgtttcctc	tttcatactt	720
aaggggatgg	ctgctgattt	aaaatctgaa	ggatcttcaa	ttccagctcc	gaaactacag	780
gtgatgatga	cagaaactcg	taaccttcaa	gctgtgctta	ctggttatca	tttctttgag	840
acaaagctac	caacacttac	cgcattctta	aaagccgatg	gggtaacagt	tccggatctt	900
aaatttgata	aagtagccga	tactttcttt	aagttaatca	atgataaatt	ccctacggct	960
tcaaaaatgg	agcgcggtgt	ccgtgacctt	attggcgacg	atacagaagc	tggttacaggg	1020
atgctcaacc	tcttctttgt	tgctttaagg	gggacatccc	caagattatt	tgcttcagca	1080
gaaaagcgtc	agcaattagg	cacaatgatg	gctaattgct	tagatgctgt	gaatattaac	1140
aacgaagatt	acccaaaatc	tacagacttc	cccaaactt	atccctggtc	ttaa	1194

<210> 76
 <211> 397
 <212> PRT
 <213> Chlamydia psitacci

<400> 76

Met	Ala	Ala	Ser	Gly	Gly	Ala	Gly	Gly	Leu	Gly	Gly	Ser	Gln	Ala	Val
1				5					10					15	
Asp	Val	Ala	Gln	Val	Gln	Ala	Ala	Ala	Lys	Ala	Asp	Ala	Gln	Glu	
			20					25				30			
Val	Ile	Ala	Ser	Gln	Glu	Gln	Ser	Asp	Ile	Ser	Met	Ile	Lys	Asp	Ser
			35				40					45			
Gln	Asp	Leu	Ser	Asn	Pro	Gln	Ala	Ala	Thr	Arg	Thr	Lys	Lys	Lys	Glu
			50			55					60				
Glu	Lys	Phe	Gln	Thr	Leu	Glu	Ser	Arg	Arg	Lys	Gly	Ala	Thr	Gln	Ala
					70					75				80	
Glu	Lys	Lys	Ser	Glu	Ser	Thr	Gly	Asp	Lys	Ser	Asp	Ala	Asp	Leu	Ala
				85					90					95	
Asp	Lys	Tyr	Thr	Glu	Asn	Asn	Ala	Glu	Ile	Ser	Gly	Gln	Asp	Leu	Arg
			100				105						110		
Ser	Ile	Arg	Asp	Ser	Leu	His	Asp	Gly	Ser	Ser	Glu	Glu	Asp	Val	Leu
			115				120					125			
Asp	Leu	Val	Lys	Ser	Lys	Phe	Ser	Asp	Pro	Ala	Leu	Gln	Ser	Val	Ala
			130			135					140				
Leu	Asp	Tyr	Leu	Val	Gln	Thr	Thr	Pro	Ala	Ser	Lys	Gly	Ala	Leu	Lys
					150					155				160	
Asp	Thr	Leu	Ile	Arg	Ala	Gln	Gln	Asn	His	Met	Gln	Gln	Asn	Arg	Gln
				165				170						175	
Ala	Val	Val	Gly	Gly	Lys	Asn	Ile	Leu	Phe	Ala	Ser	Gln	Glu	Tyr	Ala
			180				185						190		
Ser	Leu	Leu	Asn	Thr	Ser	Ala	Pro	Gly	Leu	Arg	Ala	Leu	Tyr	Leu	Glu
			195				200					205			
Val	Thr	Ser	Asp	Phe	His	Ser	Cys	Glu	Gln	Leu	Leu	Thr	Ser	Leu	Gln
			210			215						220			
Ser	Arg	Tyr	Ser	Tyr	Glu	Glu	Met	Gly	Thr	Val	Ser	Ser	Phe	Ile	Leu
					230					235				240	
Lys	Gly	Met	Ala	Ala	Asp	Leu	Lys	Ser	Glu	Gly	Ser	Ser	Ile	Pro	Ala
			245					250						255	
Pro	Lys	Leu	Gln	Val	Met	Met	Thr	Glu	Thr	Arg	Asn	Leu	Gln	Ala	Val
			260				265						270		
Leu	Thr	Gly	Tyr	His	Phe	Phe	Glu	Thr	Lys	Leu	Pro	Thr	Leu	Thr	Ala
			275				280					285			
Ser	Leu	Lys	Ala	Asp	Gly	Val	Thr	Val	Pro	Asp	Leu	Lys	Phe	Asp	Lys
			290			295				300					
Val	Ala	Asp	Thr	Phe	Phe	Lys	Leu	Ile	Asn	Asp	Lys	Phe	Pro	Thr	Ala
			305			310				315				320	

Ser Lys Met Glu Arg Gly Val Arg Asp Leu Ile Gly Asp Asp Thr Glu
325 330 335
Ala Val Thr Gly Met Leu Asn Leu Phe Phe Val Ala Leu Arg Gly Thr
340 345 350
Ser Pro Arg Leu Phe Ala Ser Ala Glu Lys Arg Gln Gln Leu Gly Thr
355 360 365
Met Met Ala Asn Ala Leu Asp Ala Val Asn Ile Asn Asn Glu Asp Tyr
370 375 380
Pro Lys Ser Thr Asp Phe Pro Lys Pro Tyr Pro Trp Ser
385 390 395

<210> 77
<211> 1200
<212> DNA
<213> Chlamydia pneumoniae

<400> 77

atggcagcat	caggaggcac	aggtgggttta	ggaggcactc	aggggtgtcaa	ccttgcagct	60
gtagaagctg	cagctgcaaa	agcagatgca	gcagaagttg	tagccagcca	agaaggttct	120
gagatgaaca	tgattcaaca	atctcaggac	ctgacaaatc	ccgcagcagc	aacacgcacg	180
aaaaaaaaag	aagagaagtt	tcaaactcta	gaatctcgga	aaaaaggaga	agctggaaag	240
gctgagaaaa	aatctgaatc	tacagaagag	aagcctgaca	cagatcttgc	tgataagtat	300
gcttctggga	attctgaaat	ctctgggtcaa	gaacttcgcg	gcctgcgtga	tgcaatagga	360
gacgatgctt	ctccagaaga	cattcttgct	cttgtacaag	agaaaattaa	agaccagct	420
ctgcaatcca	cagctttgga	ctacctgggt	caaacgactc	caccctccca	aggtaaatta	480
aaagaagcgc	ttatccaagc	aaggaatact	catacggagc	aattcggacg	aactgctatt	540
ggtgcgaaaa	acatcttatt	tgcctctcaa	gaatatgcag	accaactgaa	tgtttctcct	600
tcagggcttc	gctctttgta	cttagaagtg	actggagaca	cacatacctg	tgatcagcta	660
ctttctatgc	ttcaagaccg	ctatacctac	caagatatgg	ctattgtcag	ctcctttcta	720
atgaaaggaa	tggcaacaga	attaaaaagg	cagggtccct	acgtaccag	tgcgcaacta	780
caagttctca	tgacagaaac	togtaacctg	caagcagttc	ttacctcgta	cgattacttt	840
gaaagtcgcg	ttcctatttt	actogatagc	ttaaaagctg	agggaaatcca	aactccttct	900
gatctaaact	ttgtgaaggt	agctgagtc	taccataaaa	tcattaacga	taagttccca	960
acagcatcta	aagtagaacg	agaagtcgcg	aatctcatag	gagacgatgt	tgattctgtg	1020
accggtgtct	tgaacttatt	cttttctgct	ttacgtcaaa	cgtcgtcacg	ccttttctct	1080
tcagcagaca	aacgtcagca	attaggagct	atgattgcta	atgctttaga	tgctgtaaat	1140
ataaacaatg	aagattatcc	caaagcatca	gacttcctca	aaccctatcc	ttggtcatga	1200

<210> 78
<211> 399
<212> PRT
<213> Chlamydia pneumoniae

<400> 78

Met	Ala	Ala	Ser	Gly	Gly	Thr	Gly	Gly	Leu	Gly	Gly	Thr	Gln	Gly	Val
1				5					10					15	
Asn	Leu	Ala	Ala	Val	Glu	Ala	Ala	Ala	Ala	Lys	Ala	Asp	Ala	Ala	Glu
			20						25				30		
Val	Val	Ala	Ser	Gln	Glu	Gly	Ser	Glu	Met	Asn	Met	Ile	Gln	Gln	Ser
			35				40					45			
Gln	Asp	Leu	Thr	Asn	Pro	Ala	Ala	Ala	Thr	Arg	Thr	Lys	Lys	Lys	Glu
	50					55					60				
Glu	Lys	Phe	Gln	Thr	Leu	Glu	Ser	Arg	Lys	Lys	Gly	Glu	Ala	Gly	Lys
	65				70					75				80	
Ala	Glu	Lys	Lys	Ser	Glu	Ser	Thr	Glu	Glu	Lys	Pro	Asp	Thr	Asp	Leu
			85						90					95	
Ala	Asp	Lys	Tyr	Ala	Ser	Gly	Asn	Ser	Glu	Ile	Ser	Gly	Gln	Glu	Leu
			100					105					110		

Arg Gly Leu Arg Asp Ala Ile Gly Asp Asp Ala Ser Pro Glu Asp Ile
 115 120 125
 Leu Ala Leu Val Gln Glu Lys Ile Lys Asp Pro Ala Leu Gln Ser Thr
 130 135 140
 Ala Leu Asp Tyr Leu Val Gln Thr Thr Pro Pro Ser Gln Gly Lys Leu
 145 150 155 160
 Lys Glu Ala Leu Ile Gln Ala Arg Asn Thr His Thr Glu Gln Phe Gly
 165 170 175
 Arg Thr Ala Ile Gly Ala Lys Asn Ile Leu Phe Ala Ser Gln Glu Tyr
 180 185 190
 Ala Asp Gln Leu Asn Val Ser Pro Ser Gly Leu Arg Ser Leu Tyr Leu
 195 200 205
 Glu Val Thr Gly Asp Thr His Thr Cys Asp Gln Leu Leu Ser Met Leu
 210 215 220
 Gln Asp Arg Tyr Thr Tyr Gln Asp Met Ala Ile Val Ser Ser Phe Leu
 225 230 235 240
 Met Lys Gly Met Ala Thr Glu Leu Lys Arg Gln Gly Pro Tyr Val Pro
 245 250 255
 Ser Ala Gln Leu Gln Val Leu Met Thr Glu Thr Arg Asn Leu Gln Ala
 260 265 270
 Val Leu Thr Ser Tyr Asp Tyr Phe Glu Ser Arg Val Pro Ile Leu Leu
 275 280 285
 Asp Ser Leu Lys Ala Glu Gly Ile Gln Thr Pro Ser Asp Leu Asn Phe
 290 295 300
 Val Lys Val Ala Glu Ser Tyr His Lys Ile Ile Asn Asp Lys Phe Pro
 305 310 315 320
 Thr Ala Ser Lys Val Glu Arg Glu Val Arg Asn Leu Ile Gly Asp Asp
 325 330 335
 Val Asp Ser Val Thr Gly Val Leu Asn Leu Phe Phe Ser Ala Leu Arg
 340 345 350
 Gln Thr Ser Ser Arg Leu Phe Ser Ser Ala Asp Lys Arg Gln Gln Leu
 355 360 365
 Gly Ala Met Ile Ala Asn Ala Leu Asp Ala Val Asn Ile Asn Asn Glu
 370 375 380
 Asp Tyr Pro Lys Ala Ser Asp Phe Pro Lys Pro Tyr Pro Trp Ser
 385 390 395

<210> 79
 <211> 1266
 <212> DNA
 <213> Chlamydia trachomatis

<400> 79

atgactgcat	caggaggagc	tggagggcta	ggcagcaccc	aaacagtaga	cgttgcgcga	60
gcacaagctg	ctgcagctac	tcaagatgca	caagagggtta	tgggctctca	ggaagcttct	120
gaggcaagta	tgctcaaagg	atgtgaggat	ctcataaatac	ctgcagctgc	aaccggaatc	180
aaaaaaaaag	aagagaagtt	tgaatcatta	gaagctcgtc	gcaaaccaac	agcggataaa	240
gcagaaaaga	aatccgagag	cacagaggaa	aaaggcgata	ctcctcttga	agatcgtttc	300
acagaagatc	tttccgaagt	ctccggagaa	gattttcgag	gattgaaaaa	ttcgttcgat	360
gatgattctt	ctcctgaaga	aattctcgat	gcgctcacaa	gtaaattttc	tgatcccaca	420
ataaaggatc	tagctottga	ttatctaatt	caaacagctc	cctctgatag	gaaacttaag	480
tccgctctca	ttcaggcaaa	gcatcaactg	atgagccaga	atcctcaggc	gattgttggg	540
ggacgcaatg	ttctgttagc	ttcagaaacc	tttgcttcca	gagcaaatac	atctccttca	600
tcgcttcgct	ccttatattt	ccaagtaacc	tcacccccct	ctaattgtga	taatttacgt	660
caaatgcttg	cttcttactc	gccatcagag	aaaaccgctg	ttatggagtt	tctagtaaata	720
ggcatggtag	cagattttaa	atcggagggc	ccttccattc	ctcctgcaaa	attgcaagta	780
tatatgacgg	aactaagcaa	tctccaagcc	ttacactctg	tagatagctt	ttttgataga	840
aatattggga	acttggaaaa	tagcttaaag	catgaaggac	atgcccctat	tccatcctta	900
acgacaggaa	atttaactaa	aaccttctta	caattagtag	aagataaatt	cccttctctt	960

tccaaagctc aaaaggcatt aaatgaactg gtagggcccag atactgggtcc tcaaactgaa 1020
 gtttttaact tattcttccg cgctcttaat ggctgttcgc ctagaatatt ctctggagct 1080
 gaaaaaaaaac agcagctggc atcgggttacc acaaatacgc tagatgcgat aaatgcggat 1140
 aatgaggatt atcctaaacc aggtgacttc ccacgatctt ccttctctag tacgcctcct 1200
 catgctccag tacctcaatc tgagattcca acgtcaccta cctcaacaca gcctccatca 1260
 ccctaa 1266

<210> 80

<211> 421

<212> PRT

<213> Chlamydia trachomatis

<400> 80

Met	Thr	Ala	Ser	Gly	Gly	Ala	Gly	Gly	Leu	Gly	Ser	Thr	Gln	Thr	Val
1				5					10					15	
Asp	Val	Ala	Arg	Ala	Gln	Ala	Ala	Ala	Ala	Thr	Gln	Asp	Ala	Gln	Glu
			20					25					30		
Val	Ile	Gly	Ser	Gln	Glu	Ala	Ser	Glu	Ala	Ser	Met	Leu	Lys	Gly	Cys
		35					40					45			
Glu	Asp	Leu	Ile	Asn	Pro	Ala	Ala	Ala	Thr	Arg	Ile	Lys	Lys	Lys	Glu
	50					55					60				
Glu	Lys	Phe	Glu	Ser	Leu	Glu	Ala	Arg	Arg	Lys	Pro	Thr	Ala	Asp	Lys
65					70					75					80
Ala	Glu	Lys	Lys	Ser	Glu	Ser	Thr	Glu	Glu	Lys	Gly	Asp	Thr	Pro	Leu
				85					90					95	
Glu	Asp	Arg	Phe	Thr	Glu	Asp	Leu	Ser	Glu	Val	Ser	Gly	Glu	Asp	Phe
		100					105						110		
Arg	Gly	Leu	Lys	Asn	Ser	Phe	Asp	Asp	Asp	Ser	Ser	Pro	Glu	Glu	Ile
	115						120					125			
Leu	Asp	Ala	Leu	Thr	Ser	Lys	Phe	Ser	Asp	Pro	Thr	Ile	Lys	Asp	Leu
	130					135						140			
Ala	Leu	Asp	Tyr	Leu	Ile	Gln	Thr	Ala	Pro	Ser	Asp	Arg	Lys	Leu	Lys
145					150					155					160
Ser	Ala	Leu	Ile	Gln	Ala	Lys	His	Gln	Leu	Met	Ser	Gln	Asn	Pro	Gln
			165					170						175	
Ala	Ile	Val	Gly	Gly	Arg	Asn	Val	Leu	Leu	Ala	Ser	Glu	Thr	Phe	Ala
		180						185					190		
Ser	Arg	Ala	Asn	Thr	Ser	Pro	Ser	Ser	Leu	Arg	Ser	Leu	Tyr	Phe	Gln
	195						200					205			
Val	Thr	Ser	Ser	Pro	Ser	Asn	Cys	Asp	Asn	Leu	Arg	Gln	Met	Leu	Ala
	210					215					220				
Ser	Tyr	Ser	Pro	Ser	Glu	Lys	Thr	Ala	Val	Met	Glu	Phe	Leu	Val	Asn
225					230					235					240
Gly	Met	Val	Ala	Asp	Leu	Lys	Ser	Glu	Gly	Pro	Ser	Ile	Pro	Pro	Ala
			245						250					255	
Lys	Leu	Gln	Val	Tyr	Met	Thr	Glu	Leu	Ser	Asn	Leu	Gln	Ala	Leu	His
		260					265						270		
Ser	Val	Asp	Ser	Phe	Phe	Asp	Arg	Asn	Ile	Gly	Asn	Leu	Glu	Asn	Ser
	275						280					285			
Leu	Lys	His	Glu	Gly	His	Ala	Pro	Ile	Pro	Ser	Leu	Thr	Thr	Gly	Asn
	290					295					300				
Leu	Thr	Lys	Thr	Phe	Leu	Gln	Leu	Val	Glu	Asp	Lys	Phe	Pro	Ser	Ser
305					310					315					320
Ser	Lys	Ala	Gln	Lys	Ala	Leu	Asn	Glu	Leu	Val	Gly	Pro	Asp	Thr	Gly
			325						330					335	
Pro	Gln	Thr	Glu	Val	Leu	Asn	Leu	Phe	Phe	Arg	Ala	Leu	Asn	Gly	Cys
		340						345					350		
Ser	Pro	Arg	Ile	Phe	Ser	Gly	Ala	Glu	Lys	Lys	Gln	Gln	Leu	Ala	Ser
	355						360					365			

Val Ile Thr Asn Thr Leu Asp Ala Ile Asn Ala Asp Asn Glu Asp Tyr
 370 375 380
 Pro Lys Pro Gly Asp Phe Pro Arg Ser Ser Phe Ser Ser Thr Pro Pro
 385 390 395 400
 His Ala Pro Val Pro Gln Ser Glu Ile Pro Thr Ser Pro Thr Ser Thr
 405 410 415
 Gln Pro Pro Ser Pro
 420

<210> 81
 <211> 1266
 <212> DNA
 <213> Chlamydia trachomatis

<400> 81

atgactgcat	caggaggagc	tggaggggcta	ggcagcaccc	aaacagtaga	cgttgcgcga	60
gcacaagctg	ctgcagctac	tcaagatgca	caagagggtta	tcggctctca	ggaagcttct	120
gaggcaagta	tgctcaaagg	atgtgaggat	ctcataaatc	ctgcagctgc	aaccggaatc	180
aaaaaaaaag	aagagaagtt	tgaatcatta	gaagctcgtc	gcaaaccaac	agcggataaa	240
gcagaaaaga	aatccgagag	cacagaggaa	aaaggcgata	ctcctcttga	agatcgtttc	300
acagaagatc	tttccgaagt	ctccggagaa	gattttcgag	gattgaaaaa	ttcgttcgat	360
gatgattctt	ctcctgaaga	aattctcgat	gcgctcaca	gtaaattttc	tgatcccaca	420
ataaaggatc	tagctcttga	ttatctaatt	caaacagctc	cctctgatag	gaaacttaag	480
tccgctctca	ttcaggcaaa	gcatcaactg	atgagccaga	atcctcaggc	gattggttga	540
ggacgcaatg	ttctgttagc	ttcagaaacc	tttgcttcca	gagcaaatac	atctccttca	600
tcgcttcgct	ccttataatc	ccaagtaacc	tcacccccct	ctaattgtga	taatttacgt	660
caaatgcttg	cttcttactc	gccatcagag	aaaaccgctg	ttatggagtt	tctagtaaat	720
ggcatggtag	cagattttaa	atcggagggc	ccttccattc	ctcctgcaaa	attgcaagta	780
tatatgacgg	aactaagcaa	tctccaagcc	ttacactctg	tagatagctt	ttttgataga	840
aattattggga	acttggaaaa	tagcttaaa	catgaaggac	atgcccctat	tccatcctta	900
acgacaggaa	atttaactaa	aaccttctta	caattagtag	aagataaatt	cccttctctc	960
tccaaagctc	aaaaggcatt	aaatgaactg	gtaggcccag	atactgggtc	tcaaactgaa	1020
gttttaaaact	tattcttccg	cgctcttaatt	ggctgttcgc	ctagaatatt	ctctggagct	1080
gaaaaaaaaac	agcagctggc	atcggttatc	acaaatacgc	tagatgcat	aatgcggtat	1140
aatgaggatt	atcctaaacc	aggtgacttc	ccacgatctt	ccttctctag	tacgcctcct	1200
catgctccag	tacctcaatc	tgagattcca	acgtcaccta	cctcaacaca	gcctccatca	1260
ccctaa						1266

<210> 82
 <211> 421
 <212> PRT
 <213> Chlamydia trachomatis

<400> 82

Met	Thr	Ala	Ser	Gly	Gly	Ala	Gly	Gly	Leu	Gly	Ser	Thr	Gln	Thr	Val
1				5					10					15	
Asp	Val	Ala	Arg	Ala	Gln	Ala	Ala	Ala	Thr	Gln	Asp	Ala	Gln	Glu	
		20					25					30			
Val	Ile	Gly	Ser	Gln	Glu	Ala	Ser	Glu	Ala	Ser	Met	Leu	Lys	Gly	Cys
		35					40					45			
Glu	Asp	Leu	Ile	Asn	Pro	Ala	Ala	Ala	Thr	Arg	Ile	Lys	Lys	Lys	Glu
		50				55					60				
Glu	Lys	Phe	Glu	Ser	Leu	Glu	Ala	Arg	Arg	Lys	Pro	Thr	Ala	Asp	Lys
		65				70				75				80	
Ala	Glu	Lys	Lys	Ser	Glu	Ser	Thr	Glu	Glu	Lys	Gly	Asp	Thr	Pro	Leu
				85				90						95	
Glu	Asp	Arg	Phe	Thr	Glu	Asp	Leu	Ser	Glu	Val	Ser	Gly	Glu	Asp	Phe
			100					105					110		

Arg Gly Leu Lys Asn Ser Phe Asp Asp Asp Ser Ser Pro Glu Glu Ile
 115 120 125
 Leu Asp Ala Leu Thr Ser Lys Phe Ser Asp Pro Thr Ile Lys Asp Leu
 130 135 140
 Ala Leu Asp Tyr Leu Ile Gln Thr Ala Pro Ser Asp Arg Lys Leu Lys
 145 150 155 160
 Ser Ala Leu Ile Gln Ala Lys His Gln Leu Met Ser Gln Asn Pro Gln
 165 170 175
 Ala Ile Val Gly Gly Arg Asn Val Leu Leu Ala Ser Glu Thr Phe Ala
 180 185 190
 Ser Arg Ala Asn Thr Ser Pro Ser Ser Leu Arg Ser Leu Tyr Leu Gln
 195 200 205
 Val Thr Ser Ser Pro Ser Asn Cys Asp Asn Leu Arg Gln Met Leu Ala
 210 215 220
 Ser Tyr Ser Pro Ser Glu Lys Thr Ala Val Met Glu Phe Leu Val Asn
 225 230 235 240
 Gly Met Val Ala Asp Leu Lys Ser Glu Gly Pro Ser Ile Pro Pro Ala
 245 250 255
 Lys Leu Gln Val Tyr Met Thr Glu Leu Ser Asn Leu Gln Ala Leu His
 260 265 270
 Ser Val Asp Ser Phe Phe Asp Arg Asn Ile Gly Asn Leu Glu Asn Ser
 275 280 285
 Leu Lys His Glu Gly His Ala Pro Ile Pro Ser Leu Thr Thr Gly Asn
 290 295 300
 Leu Thr Lys Thr Phe Leu Gln Leu Val Glu Asp Lys Phe Pro Ser Ser
 305 310 315 320
 Ser Lys Ala Gln Lys Ala Leu Asn Glu Leu Val Gly Pro Asp Thr Gly
 325 330 335
 Pro Gln Thr Glu Val Leu Asn Leu Phe Phe Arg Ala Leu Asn Gly Cys
 340 345 350
 Ser Pro Arg Ile Phe Ser Gly Ala Glu Lys Lys Gln Gln Leu Ala Ser
 355 360 365
 Val Ile Thr Asn Thr Leu Asp Ala Ile Asn Ala Asp Asn Glu Asp Tyr
 370 375 380
 Pro Lys Pro Gly Asp Phe Pro Arg Ser Ser Phe Ser Ser Thr Pro Pro
 385 390 395 400
 His Ala Pro Val Pro Gln Ser Glu Ile Pro Thr Ser Pro Thr Ser Thr
 405 410 415
 Gln Pro Pro Ser Pro
 420

<210> 83
 <211> 1266
 <212> DNA
 <213> Chlamydia trachomatis

<400> 83

atgactgcat	caggaggagc	tggagggcta	ggcagcaccc	aaacagtaga	cgttgcgcga	60
gcacaagctg	ctgcagctac	tcaagatgca	caagagggtta	tgggtctctca	ggaagcttct	120
gaggcaagta	tgctcaaagg	atgtgaggat	ctcataaatc	ctgcagctgc	aaccggaatc	180
aaaaaaaaag	gagagaagtt	tgaatcatta	gaagctcgtc	gcaaaccaac	agcggataaa	240
gcagaaaaga	aatccgagag	cacagaggaa	aaaggcgata	ctcctcttga	agatcgtttc	300
acagaagatc	tttccgaagt	ctccggagaa	gattttcgag	gattgaaaaa	ttcgttcgat	360
gatgattctt	ctcctgacga	aattctcgat	gcgctcacaa	gtaaattttc	tgatcccaca	420
ataaaggatc	tagctcttga	ttatctaatt	caaacagctc	cctctgatgg	gaaacttaag	480
tccactctca	ttcaggcaaa	gcatacaactg	atgagccaga	atcctcaggc	gattgttgga	540
ggagcgaatg	ttctgttagc	ttcagaaacc	tttgcttcca	gagcaaatac	atctccttca	600
tcgcttcgct	ccttatattt	ccaagtaacc	tcataccccc	ctaattggcg	taattttacat	660
caaatgcttg	ctttcttactt	gccatcagag	aaaaccgctg	ttatggagtt	tctagtaaat	720

```

ggcatggttag cagattttaa atcggaggggc ccttccattc ctcttgcaaa attgcaagta 780
tatatgacgg aactaagcaa tctccaagcc ttacactctg taaatagctt ttttgataga 840
aatattggga acttggaaaa tagcttaaag catgaaggac atgcccctat tccatcctta 900
acgacaggaa atttaactaa aaccttctta caattagtag aagataaaatt ccccttcctct 960
tccaaagctc aaaaggcatt aaatgaactg gtaggcccag atactggtcc tcaaactgaa 1020
gttttaaact tattcttccg cgctcttaat ggctgttcgc ctagaatatt ctctggagct 1080
gaaaaaaaaac agcagctggc atcgggtatc acaaatacgc tagatgcgat aaatgcggtat 1140
aatgaggatt atcctaacc aggtgacttc ccacgatctt ccttctctag tacgcctcct 1200
catgctccag tacctcaatc tgagattcca acgtcaccta cctcaacaca gcctccatca 1260
ccctaa 1266

```

```

<210> 84
<211> 421
<212> PRT
<213> Chlamydia trachomatis

```

```

<400> 84

```

```

Met Thr Ala Ser Gly Gly Ala Gly Gly Leu Gly Ser Thr Gln Thr Val
1      5      10      15
Asp Val Ala Arg Ala Gln Ala Ala Ala Thr Gln Asp Ala Gln Glu
20      25      30
Val Ile Gly Ser Gln Glu Ala Ser Glu Ala Ser Met Leu Lys Gly Cys
35      40      45
Glu Asp Leu Ile Asn Pro Ala Ala Ala Thr Arg Ile Lys Lys Lys Gly
50      55      60
Glu Lys Phe Glu Ser Leu Glu Ala Arg Arg Lys Pro Thr Ala Asp Lys
65      70      75      80
Ala Glu Lys Lys Ser Glu Ser Thr Glu Glu Lys Gly Asp Thr Pro Leu
85      90      95
Glu Asp Arg Phe Thr Glu Asp Leu Ser Glu Val Ser Gly Glu Asp Phe
100     105     110
Arg Gly Leu Lys Asn Ser Phe Asp Asp Ser Ser Pro Asp Glu Ile
115     120     125
Leu Asp Ala Leu Thr Ser Lys Phe Ser Asp Pro Thr Ile Lys Asp Leu
130     135     140
Ala Leu Asp Tyr Leu Ile Gln Thr Ala Pro Ser Asp Gly Lys Leu Lys
145     150     155     160
Ser Thr Leu Ile Gln Ala Lys His Gln Leu Met Ser Gln Asn Pro Gln
165     170     175
Ala Ile Val Gly Gly Arg Asn Val Leu Leu Ala Ser Glu Thr Phe Ala
180     185     190
Ser Arg Ala Asn Thr Ser Pro Ser Ser Leu Arg Ser Leu Tyr Phe Gln
195     200     205
Val Thr Ser Ser Pro Ser Asn Cys Ala Asn Leu His Gln Met Leu Ala
210     215     220
Ser Tyr Leu Pro Ser Glu Lys Thr Ala Val Met Glu Phe Leu Val Asn
225     230     235     240
Gly Met Val Ala Asp Leu Lys Ser Glu Gly Pro Ser Ile Pro Pro Ala
245     250     255
Lys Leu Gln Val Tyr Met Thr Glu Leu Ser Asn Leu Gln Ala Leu His
260     265     270
Ser Val Asn Ser Phe Phe Asp Arg Asn Ile Gly Asn Leu Glu Asn Ser
275     280     285
Leu Lys His Glu Gly His Ala Pro Ile Pro Ser Leu Thr Thr Gly Asn
290     295     300
Leu Thr Lys Thr Phe Leu Gln Leu Val Glu Asp Lys Phe Pro Ser Ser
305     310     315     320
Ser Lys Ala Gln Lys Ala Leu Asn Glu Leu Val Gly Pro Asp Thr Gly
325     330     335

```

Pro Gln Thr Glu Val Leu Asn Leu Phe Phe Arg Ala Leu Asn Gly Cys
340 345 350
Ser Pro Arg Ile Phe Ser Gly Ala Glu Lys Lys Gln Gln Leu Ala Ser
355 360 365
Val Ile Thr Asn Thr Leu Asp Ala Ile Asn Ala Asp Asn Glu Asp Tyr
370 375 380
Pro Lys Pro Gly Asp Phe Pro Arg Ser Ser Phe Ser Ser Thr Pro Pro
385 390 395 400
His Ala Pro Val Pro Gln Ser Glu Ile Pro Thr Ser Pro Thr Ser Thr
405 410 415
Gln Pro Pro Ser Pro
420

<210> 85
<211> 1266
<212> DNA
<213> Chlamydia trachomatis

<400> 85

atgactgcat	caggaggagc	tggagggcta	ggcagcaccc	aaacagtaga	cggtgcgcca	60
gcacaagctg	ctgcagctac	tcaagatgca	caagaggtta	tcggctctca	ggaagcttct	120
gaggcaagta	tgctcaaagg	atgtgaggat	ctcataaatc	ctgcagctgc	aaccggaatc	180
aaaaaaaaag	aagagaagtt	tgaatcatta	gaagctcgtc	gcaaaccaac	agcggataaa	240
gcagaaaaga	aatccgagag	cacagaggaa	aaaggcgata	ctcctcttga	agatcgtttc	300
acagaagatc	tttccgaagt	ctccggagaa	gattttcgag	gattgaaaaa	ttcgttcgat	360
gatgattcct	ctcctgacga	aattctcgat	gcgctcacaa	gtaaattttc	tgatcccaca	420
ataaaggatc	tagctcttga	ttatctaatt	caaacagctc	cctctgatgg	gaaacttaag	480
tccgctctca	ttcaggcaaa	gcatcaactg	atgagccaga	atcctcaggc	gattgttgga	540
ggacgcaatg	ttctgttagc	ttcagaaacc	tttgcttcca	gagcaaatac	atctccttca	600
tcgcttcgct	ccttatattt	ccaagtaacc	tcattccccct	ctaattgcgc	taatttacat	660
caaatgcttg	cttcttactt	gccatcagag	aaaaccgctg	ttatggagtt	tctagtaaatt	720
ggcatggtag	cagattttaa	atcggagggc	ccttccattc	ctcctgcaaa	attgcaagta	780
tatatgacgg	aactaagcaa	tctccaagcc	ttacactctg	taaatagctt	ttttgataga	840
aatattggga	acttggaaaa	tagcttaaag	catgaaggac	atgcccttat	tccatcctta	900
acgacaggaa	atttaactaa	aaccttctta	caattagtag	aagataaatt	cccttctctt	960
tccaaagctc	aaaaggcatt	aaatgaactg	gtaggcccag	atactgggtc	tcaaactgaa	1020
gttttaaaact	tattcttccg	cgctcttaatt	ggctgttcgc	ctagaatatt	ctctggagct	1080
gaaaaaaaaac	agcagctggc	atcgggtatc	acaaatacgc	tagatgcgat	aaatgcggat	1140
aatgaggatt	atcctaaacc	aggtgacttc	ccacgatctt	ccttctctag	tacgcctcct	1200
catgctccag	tacctcaatc	tgagattcca	acgtcaccta	cctcaacaca	gcctccatca	1260
ccctaa						1266

<210> 86
<211> 421
<212> PRT
<213> Chlamydia trachomatis

<400> 86

Met Thr Ala Ser Gly Gly Ala Gly Gly Leu Gly Ser Thr Gln Thr Val
1 5 10 15
Asp Val Ala Arg Ala Gln Ala Ala Ala Thr Gln Asp Ala Gln Glu
20 25 30
Val Ile Gly Ser Gln Glu Ala Ser Glu Ala Ser Met Leu Lys Gly Cys
35 40 45
Glu Asp Leu Ile Asn Pro Ala Ala Ala Thr Arg Ile Lys Lys Lys Glu
50 55 60
Glu Lys Phe Glu Ser Leu Glu Ala Arg Arg Lys Pro Thr Ala Asp Lys
65 70 75 80

Ala Glu Lys Lys Ser Glu Ser Thr Glu Glu Lys Gly Asp Thr Pro Leu
85 90 95
Glu Asp Arg Phe Thr Glu Asp Leu Ser Glu Val Ser Gly Glu Asp Phe
100 105 110
Arg Gly Leu Lys Asn Ser Phe Asp Asp Ser Ser Pro Asp Glu Ile
115 120 125
Leu Asp Ala Leu Thr Ser Lys Phe Ser Asp Pro Thr Ile Lys Asp Leu
130 135 140
Ala Leu Asp Tyr Leu Ile Gln Thr Ala Pro Ser Asp Gly Lys Leu Lys
145 150 155 160
Ser Ala Leu Ile Gln Ala Lys His Gln Leu Met Ser Gln Asn Pro Gln
165 170 175
Ala Ile Val Gly Arg Asn Val Leu Leu Ala Ser Glu Thr Phe Ala
180 185 190
Ser Arg Ala Asn Thr Ser Pro Ser Ser Leu Arg Ser Leu Tyr Phe Gln
195 200 205
Val Thr Ser Ser Pro Ser Asn Cys Ala Asn Leu His Gln Met Leu Ala
210 215 220
Ser Tyr Leu Pro Ser Glu Lys Thr Ala Val Met Glu Phe Leu Val Asn
225 230 235 240
Gly Met Val Ala Asp Leu Lys Ser Glu Gly Pro Ser Ile Pro Pro Ala
245 250 255
Lys Leu Gln Val Tyr Met Thr Glu Leu Ser Asn Leu Gln Ala Leu His
260 265 270
Ser Val Asn Ser Phe Phe Asp Arg Asn Ile Gly Asn Leu Glu Asn Ser
275 280 285
Leu Lys His Glu Gly His Ala Pro Ile Pro Ser Leu Thr Thr Gly Asn
290 295 300
Leu Thr Lys Thr Phe Leu Gln Leu Val Glu Asp Lys Phe Pro Ser Ser
305 310 315 320
Ser Lys Ala Gln Lys Ala Leu Asn Glu Leu Val Gly Pro Asp Thr Gly
325 330 335
Pro Gln Thr Glu Val Leu Asn Leu Phe Phe Arg Ala Leu Asn Gly Cys
340 345 350
Ser Pro Arg Ile Phe Ser Gly Ala Glu Lys Lys Gln Gln Leu Ala Ser
355 360 365
Val Ile Thr Asn Thr Leu Asp Ala Ile Asn Ala Asp Asn Glu Asp Tyr
370 375 380
Pro Lys Pro Gly Asp Phe Pro Arg Ser Ser Phe Ser Ser Thr Pro Pro
385 390 395 400
His Ala Pro Val Pro Gln Ser Glu Ile Pro Thr Ser Pro Thr Ser Thr
405 410 415
Gln Pro Pro Ser Pro
420

<210> 87

<211> 1266

<212> DNA

<213> Chlamydia trachomatis

<400> 87

atgactgcat	caggaggagc	tgaggggcta	ggcagcaccc	aaacagtaga	cggtgcgcca	60
gcacaagctg	ctgcagctac	tcaagatgca	caagagggtta	tcggctctca	ggaagcttct	120
gaggcaagta	tgctcaaagg	atgtgaggat	ctcataaatc	ctgcagctgc	aaccggaatc	180
aaaaaaaaag	gagagaagtt	tgaatcatta	gaagctcgtc	gcaaaccaac	agcggataaa	240
gcagaaaaga	aatccgagag	cacagaggaa	aaaggcgata	ctcctcttga	agatcgtttc	300
acagaagatc	tttccgaagt	ctccggagaa	gattttcgag	gattgaaaaa	ttcgttcgat	360
gatgattctt	ctcctgacga	aattctcgat	gcgctcaca	gtaaattttc	tgatcccaca	420
ataaaggatc	tagctcttga	ttatctaatt	caaacagctc	cctctgatgg	gaaacttaag	480

```

tccactctca ttcaggcaaa gcatcaactg atgagccaga atcctcaggc gattgttga 540
ggacgcaatg ttctgttagc ttcagaaacc ttigtctcca gagcaaatac atctccttca 600
tcgcttcgct ccttatattt ccaagtaacc tcatccocct ctaattgcgc taatttacat 660
caaatgcttg cttcttactt gccatcagag aaaaccgctg ttatggagtt tctagtaa 720
ggcatggttag cagatttaaa atcggagggc ccttccattc ctcctgcaa attgcaagta 780
tatatgacgg aactaagcaa tctccaagcc ttacactctg taaatagctt ttttgataga 840
aatattggga acttggaata tagcttaaa catgaaggac atgcccctat tccatcctta 900
acgacaggaa atttaactaa aaccttctta caattagtag aagataaatt cccttctct 960
tccaaagctc aaaaggcatt aaatgaactg gtaggcccag atactggtcc tcaaactgaa 1020
gttttaaaact tattcttccg cgtctttaat ggctgttcgc ctagaatatt ctctggagct 1080
gaaaaaaaaac agcagctggc atcgggttatc acaaatacgc tagatgcgat aaatgcggat 1140
aatgaggatt atcctaaacc aggtgacttc ccacgatctt ccttctctag tacgcctcct 1200
catgctccag tacctcaatc tgagattcca acgtcaccta cctcaacaca gcctccatca 1260
ccctaa

```

```

<210> 88
<211> 421
<212> PRT
<213> Chlamydia trachomatis

```

```
<400> 88
```

```

Met Thr Ala Ser Gly Gly Ala Gly Gly Leu Gly Ser Thr Gln Thr Val
1          5          10          15
Asp Val Ala Arg Ala Gln Ala Ala Ala Thr Gln Asp Ala Gln Glu
          20          25          30
Val Ile Gly Ser Gln Glu Ala Ser Glu Ala Ser Met Leu Lys Gly Cys
          35          40          45
Glu Asp Leu Ile Asn Pro Ala Ala Thr Arg Ile Lys Lys Lys Gly
          50          55          60
Glu Lys Phe Glu Ser Leu Glu Ala Arg Arg Lys Pro Thr Ala Asp Lys
65          70          75          80
Ala Glu Lys Lys Ser Glu Ser Thr Glu Glu Lys Gly Asp Thr Pro Leu
          85          90          95
Glu Asp Arg Phe Thr Glu Asp Leu Ser Glu Val Ser Gly Glu Asp Phe
          100          105          110
Arg Gly Leu Lys Asn Ser Phe Asp Asp Ser Ser Pro Asp Glu Ile
          115          120          125
Leu Asp Ala Leu Thr Ser Lys Phe Ser Asp Pro Thr Ile Lys Asp Leu
          130          135          140
Ala Leu Asp Tyr Leu Ile Gln Thr Ala Pro Ser Asp Gly Lys Leu Lys
145          150          155          160
Ser Thr Leu Ile Gln Ala Lys His Gln Leu Met Ser Gln Asn Pro Gln
          165          170          175
Ala Ile Val Gly Gly Arg Asn Val Leu Leu Ala Ser Glu Thr Phe Ala
          180          185          190
Ser Arg Ala Asn Thr Ser Pro Ser Ser Leu Arg Ser Leu Tyr Phe Gln
          195          200          205
Val Thr Ser Ser Pro Ser Asn Cys Ala Asn Leu His Gln Met Leu Ala
210          215          220

225          230          235          240
Gly Met Val Ala Asp Leu Lys Ser Glu Gly Pro Ser Ile Pro Pro Ala
          245          250          255
Lys Leu Gln Val Tyr Met Thr Glu Leu Ser Asn Leu Gln Ala Leu His
          260          265          270
Ser Val Asn Ser Phe Phe Asp Arg Asn Ile Gly Asn Leu Glu Asn Ser
          275          280          285
Leu Lys His Glu Gly His Ala Pro Ile Pro Ser Leu Thr Thr Gly Asn
290          295          300

```

Leu Thr Lys Thr Phe Leu Gln Leu Val Glu Asp Lys Phe Pro Ser Ser
 305 310 315 320
 Ser Lys Ala Gln Lys Ala Leu Asn Glu Leu Val Gly Pro Asp Thr Gly
 325 330 335
 Pro Gln Thr Glu Val Leu Asn Leu Phe Phe Arg Ala Leu Asn Gly Cys
 340 345 350
 Ser Pro Arg Ile Phe Ser Gly Ala Glu Lys Lys Gln Gln Leu Ala Ser
 355 360 365
 Val Ile Thr Asn Thr Leu Asp Ala Ile Asn Ala Asp Asn Glu Asp Tyr
 370 375 380
 Pro Lys Pro Gly Asp Phe Pro Arg Ser Ser Phe Ser Ser Thr Pro Pro
 385 390 395 400
 His Ala Pro Val Pro Gln Ser Glu Ile Pro Thr Ser Pro Thr Ser Thr
 405 410 415
 Gln Pro Pro Ser Pro
 420

<210> 89
 <211> 1266
 <212> DNA
 <213> Chlamydia trachomatis

<400> 89

atgactgcat	caggaggagc	tggagggcta	ggcagcaccc	aaacagtaga	cgttgcgcca	60
gcacaagctg	ctgcagctac	tcaagatgca	caagagggtta	tcgggtctca	ggaagcttct	120
gaggcaagta	tgctcaaaga	atgtgcggtat	ctcataaatc	ctgcagctgc	aacccgaatc	180
aaaaaaaaaa	aagagaagtt	tgaatcatta	gaagctcgtc	gcaaaccaac	agcggataaa	240
gcagaaaaga	aatccgagag	cacagaggaa	aaagggcgata	ctcctcttga	agatcgtttc	300
acagaagatc	tttccgaagt	ctctggagaa	gattttcgag	gattgaaaaa	ttcgttcgat	360
gatgattctt	cttctgacga	aattctcgat	gcgctcacia	gtaaattttc	tgatccaca	420
ataaaggatc	tagctcttga	ttatctaatt	caaatagctc	cctctgatgg	gaaacttaag	480
tccactctca	ttcaggcaaa	gcatacaactg	atgagccaga	atcctcaggc	gattgttgga	540
ggacgcaatg	ttctgttagc	ttcagaaacc	tttgcttcca	gagcaaatac	atctccttca	600
tcgcttcgct	ccttatatct	ccaagtaacc	tcataccccct	ctaattgcgc	taattttacat	660
caaagtcttg	cttcttactc	gccatcagag	aaaaccgctg	ttatggagtt	tctagtgaat	720
ggcatggtag	cagattttaa	atcgaggggc	ccttccattc	ctcctgcaaa	attgcaagta	780
tatatgacgg	aactaagcaa	tctccaagcc	ttacactctg	tagatagctt	ttttgataga	840
aattattggga	acttggaata	tagcttaaa	catgaaggac	atgcccttat	tccatcctta	900
acgacaggaa	atttaactaa	aaccttctta	caattagtag	aagataaatt	cccttcctct	960
tccaaagctc	aaaaggcatt	aaatgaactg	gtaggcccag	atactggtcc	tcaaactgaa	1020
gttttaaaact	tattcttccg	cgctcttaat	ggctgttcgc	ctagaatatt	ctctggagct	1080
gaaaaaaaaac	agcagctggc	atcggttatc	acaaatacgc	tagatgcgat	aaatgcggtat	1140
aatgaggatt	atcctaaacc	aggtgacttc	ccacgatctt	ccttctctag	tacgcctcct	1200
catgctccag	tacctcaatc	tgagattcca	acgtcaccta	cctcaacaca	gcctccatca	1260
ccctaa						1266

<210> 90
 <211> 421
 <212> PRT
 <213> Chlamydia trachomatis

<400> 90

Met Thr Ala Ser Gly Gly Ala Gly Gly Leu Gly Ser Thr Gln Thr Val
 1 5 10 15
 Asp Val Ala Arg Ala Gln Ala Ala Ala Thr Gln Asp Ala Gln Glu
 20 25 30
 Val Ile Gly Ser Gln Glu Ala Ser Glu Ala Ser Met Leu Lys Glu Cys
 35 40 45

Ala Asp Leu Ile Asn Pro Ala Ala Ala Thr Arg Ile Lys Lys Lys Lys
 50 55 60
 Glu Lys Phe Glu Ser Leu Glu Ala Arg Arg Lys Pro Thr Ala Asp Lys
 65 70 75 80
 Ala Glu Lys Lys Ser Glu Ser Thr Glu Glu Lys Gly Asp Thr Pro Leu
 85 90 95
 Glu Asp Arg Phe Thr Glu Asp Leu Ser Glu Val Ser Gly Glu Asp Phe
 100 105 110
 Arg Gly Leu Lys Asn Ser Phe Asp Asp Asp Ser Ser Ser Asp Glu Ile
 115 120 125
 Leu Asp Ala Leu Thr Ser Lys Phe Ser Asp Pro Thr Ile Lys Asp Leu
 130 135 140
 Ala Leu Asp Tyr Leu Ile Gln Ile Ala Pro Ser Asp Gly Lys Leu Lys
 145 150 155 160
 Ser Thr Leu Ile Gln Ala Lys His Gln Leu Met Ser Gln Asn Pro Gln
 165 170 175
 Ala Ile Val Gly Gly Arg Asn Val Leu Leu Ala Ser Glu Thr Phe Ala
 180 185 190
 Ser Arg Ala Asn Thr Ser Pro Ser Ser Leu Arg Ser Leu Tyr Leu Gln
 195 200 205
 Val Thr Ser Ser Pro Ser Asn Cys Ala Asn Leu His Gln Met Leu Ala
 210 215 220
 Ser Tyr Ser Pro Ser Glu Lys Thr Ala Val Met Glu Phe Leu Val Asn
 225 230 235 240
 Gly Met Val Ala Asp Leu Lys Ser Glu Gly Pro Ser Ile Pro Pro Ala
 245 250 255
 Lys Leu Gln Val Tyr Met Thr Glu Leu Ser Asn Leu Gln Ala Leu His
 260 265 270
 Ser Val Asp Ser Phe Phe Asp Arg Asn Ile Gly Asn Leu Glu Asn Ser
 275 280 285
 Leu Lys His Glu Gly His Ala Pro Ile Pro Ser Leu Thr Thr Gly Asn
 290 295 300
 Leu Thr Lys Thr Phe Leu Gln Leu Val Glu Asp Lys Phe Pro Ser Ser
 305 310 315 320
 Ser Lys Ala Gln Lys Ala Leu Asn Glu Leu Val Gly Pro Asp Thr Gly
 325 330 335
 Pro Gln Thr Glu Val Leu Asn Leu Phe Phe Arg Ala Leu Asn Gly Cys
 340 345 350
 Ser Pro Arg Ile Phe Ser Gly Ala Glu Lys Lys Gln Gln Leu Ala Ser
 355 360 365
 Val Ile Thr Asn Thr Leu Asp Ala Ile Asn Ala Asp Asn Glu Asp Tyr
 370 375 380
 Pro Lys Pro Gly Asp Phe Pro Arg Ser Ser Phe Ser Ser Thr Pro Pro
 385 390 395 400
 His Ala Pro Val Pro Gln Ser Glu Ile Pro Thr Ser Pro Thr Ser Thr
 405 410 415
 Gln Pro Pro Ser Pro
 420

<210> 91
 <211> 1266
 <212> DNA
 <213> Chlamydia trachomatis

<400> 91

atgactgcat	caggaggagc	tggagggcta	ggcagcacc	aaacagtaga	cggtgcgcga	60
gcacaagctg	ctgcagctac	tcaagatgca	caagagggtta	tccgctctca	ggaagcttct	120
gaggcaagta	tgctcaaagg	atgtgaggat	ctcataaatc	ctgcagctgc	aacccgaatc	180
aaaaaaaaag	gagagaagtt	tgaatcatta	gaagctcgtc	gcaaaccaac	agcggataaa	240

gcagaaaaga	aatccgagag	cacagaggaa	aaaggcgata	ctcctcttga	agatcgtttc	300
acagaagatc	tttccgaagt	ctccggagaa	gatttttcgag	gattgaaaaa	ttcgttcgat	360
gatgattctt	ctcctgacga	aattctcgat	gcgctcacia	gtaaattttc	tgatcccaca	420
ataaaggatc	tagctcttga	ttatctaatt	caaacagctc	cctctgatgg	gaaacttaag	480
tccactctca	ttcaggcaaa	gcatcaactg	atgagccaga	atcctcaggc	gattggttga	540
ggacgcaatg	ttctgttagc	ttcagaaacc	tttgcttcca	gagcaaatac	atctccttca	600
tcgcttcgct	ccttatattt	ccaagtaacc	tcattccccct	ctaattgcgc	taattttacat	660
caaatgcttg	cttcttactt	gccatcagag	aaaaccgctg	ttatggagtt	tctagtaaatt	720
ggcatggtag	cagattttaa	atcggagggc	ccttccattc	ctcctgcaaa	attgcaagta	780
tatatgacgg	aactaagcaa	tctccaagcc	ttacactctg	taaatagctt	ttttgataga	840
aatattggga	acttggaana	tagcttaaa	catgaaggac	atgcccctat	tccatcctta	900
acgacaggaa	atttaactaa	aaccttctta	caattagtag	aagataaatt	cccttcctct	960
tccaaagctc	aaaaggcatt	aatgaactg	gtaggcccag	atactgggtc	tcaaaactgaa	1020
gtttttaaact	tattcttccg	cgctctta	ggctgttcgc	ctagaatatt	ctctggagct	1080
gaaaaaaaaac	agcagctggc	atcgggtatc	acaaatacgc	tagatgcgat	aaatgcggat	1140
aatgaggatt	atcctaaacc	aggtgacttc	ccacgatctt	ccttctctag	tacgcctcct	1200
catgctccag	tacctcaatc	tgagattcca	acgtcaccta	cctcaacaca	gcctccatca	1260
ccctaa						1266

<210> 92
 <211> 421
 <212> PRT
 <213> Chlamydia trachomatis

<400> 92

Met	Thr	Ala	Ser	Gly	Gly	Ala	Gly	Gly	Leu	Gly	Ser	Thr	Gln	Thr	Val
1				5				10					15		
Asp	Val	Ala	Arg	Ala	Gln	Ala	Ala	Ala	Ala	Thr	Gln	Asp	Ala	Gln	Glu
			20					25					30		
Val	Ile	Gly	Ser	Gln	Glu	Ala	Ser	Glu	Ala	Ser	Met	Leu	Lys	Gly	Cys
		35					40					45			
Glu	Asp	Leu	Ile	Asn	Pro	Ala	Ala	Ala	Thr	Arg	Ile	Lys	Lys	Lys	Gly
	50					55				60					
Glu	Lys	Phe	Glu	Ser	Leu	Glu	Ala	Arg	Arg	Lys	Pro	Thr	Ala	Asp	Lys
65					70				75					80	
Ala	Glu	Lys	Lys	Ser	Glu	Ser	Thr	Glu	Glu	Lys	Gly	Asp	Thr	Pro	Leu
				85				90						95	
Glu	Asp	Arg	Phe	Thr	Glu	Asp	Leu	Ser	Glu	Val	Ser	Gly	Glu	Asp	Phe
		100					105					110			
Arg	Gly	Leu	Lys	Asn	Ser	Phe	Asp	Asp	Asp	Ser	Ser	Pro	Asp	Glu	Ile
	115					120						125			
Leu	Asp	Ala	Leu	Thr	Ser	Lys	Phe	Ser	Asp	Pro	Thr	Ile	Lys	Asp	Leu
	130					135					140				
Ala	Leu	Asp	Tyr	Leu	Ile	Gln	Thr	Ala	Pro	Ser	Asp	Gly	Lys	Leu	Lys
145					150				155					160	
Ser	Thr	Leu	Ile	Gln	Ala	Lys	His	Gln	Leu	Met	Ser	Gln	Asn	Pro	Gln
			165					170						175	
Ala	Ile	Val	Gly	Gly	Arg	Asn	Val	Leu	Leu	Ala	Ser	Glu	Thr	Phe	Ala
	180						185						190		
Ser	Arg	Ala	Asn	Thr	Ser	Pro	Ser	Ser	Leu	Arg	Ser	Leu	Tyr	Phe	Gln
	195					200						205			
Val	Thr	Ser	Ser	Pro	Ser	Asn	Cys	Ala	Asn	Leu	His	Gln	Met	Leu	Ala
	210					215					220				
Ser	Tyr	Leu	Pro	Ser	Glu	Lys	Thr	Ala	Val	Met	Glu	Phe	Leu	Val	Asn
225					230				235					240	
Gly	Met	Val	Ala	Asp	Leu	Lys	Ser	Glu	Gly	Pro	Ser	Ile	Pro	Pro	Ala
			245					250						255	
Lys	Leu	Gln	Val	Tyr	Met	Thr	Glu	Leu	Ser	Asn	Leu	Gln	Ala	Leu	His
		260						265					270		

Ser Val Asn Ser Phe Phe Asp Arg Asn Ile Gly Asn Leu Glu Asn Ser
275 280 285
Leu Lys His Glu Gly His Ala Pro Ile Pro Ser Leu Thr Thr Gly Asn
290 295 300
Leu Thr Lys Thr Phe Leu Gln Leu Val Glu Asp Lys Phe Pro Ser Ser
305 310 315 320
Ser Lys Ala Gln Lys Ala Leu Asn Glu Leu Val Gly Pro Asp Thr Gly
325 330 335
Pro Gln Thr Glu Val Leu Asn Leu Phe Phe Arg Ala Leu Asn Gly Cys
340 345 350
Ser Pro Arg Ile Phe Ser Gly Ala Glu Lys Lys Gln Gln Leu Ala Ser
355 360 365
Val Ile Thr Asn Thr Leu Asp Ala Ile Asn Ala Asp Asn Glu Asp Tyr
370 375 380
Pro Lys Pro Gly Asp Phe Pro Arg Ser Ser Phe Ser Ser Thr Pro Pro
385 390 395 400
His Ala Pro Val Pro Gln Ser Glu Ile Pro Thr Ser Pro Thr Ser Thr
405 410 415
Gln Pro Pro Ser Pro
420

<210> 93
<211> 1266
<212> DNA
<213> Chlamydia trachomatis
<400> 93

atgactgcat	caggaggagc	tggagggcta	ggcagcaccc	aaacagtaga	cgttgcgcca	60
gcacaagctg	ctgcagctac	tcaagatgca	caagagggtta	tcggtctctca	ggaagcttct	120
gaggcaagta	tgtctaaaga	atgtgaggat	ctcataaatc	ctgcagctgc	aaccggaatc	180
aaaaaaaaag	aagagaagtt	tgaatcatta	gaagctcgtc	gcaaaccaac	agcggataaa	240
gcagaaaaga	aatccgagag	cacagaggaa	aaaggcgata	ctcctcttga	agatcgtttc	300
acagaagatc	tttccgaagt	ctctggagaa	gatttttcgag	gattgaaaaa	ttcgttcgat	360
gatgattctt	cttctgacga	aattctcgat	gcgctcacaa	gtaaattttc	tgatcccaca	420
ataaaggatc	tagctcttga	ttatctaatt	caaataagctc	cctctgatgg	gaaacttaag	480
tccgctctca	ttcaggcaaa	gcatcaactg	atgagccaga	atcctcaggc	gattggttga	540
ggacgcaatg	ttctgttagc	ttcagaaacc	tttgcttcca	gagcaaatac	atctccttca	600
tgcgttcgct	ccttatatatt	ccaagtaacc	tcatccccct	ctaattgcgc	taattttacat	660
caaatgcttg	cttcttactc	gccatcagag	aaaaccgctg	ttatggagtt	tctagtgaat	720
ggcatggtag	cgattttaaa	atcggagggc	ccttccattc	ctcctgcaaa	attgcaagta	780
tatatgacgg	aactaagcaa	tctccaagcc	ttacactctg	tagatagctt	ttttgataga	840
aatattggga	acttggaaaa	tagcttaaag	catgaaggac	atgccctat	tccatcctta	900
acgacaggaa	atttaactaa	aaccttctta	caattagtag	aagataaatt	cccttctctt	960
tccaaagctc	aaaaggcatt	aatgaactg	gtaggcccg	atactggtcc	tcaaactgaa	1020
gttttaaact	tattcttccg	cgctcttaat	ggctgttcgc	ctagaatatt	ctctggagct	1080
gaaaaaaaaac	agcagctggc	atcggttatc	acaaatacgc	tagatgcgat	aaatgcggat	1140
aatgaggatt	atcctaaacc	aggtgacttc	ccacgatctt	ccttctctag	tacgcctcct	1200
catgctccag	tacctcaatc	tgagattcca	acgtcaccta	cctcaacaca	gcctccatca	1260
ccctaa						1266

<210> 94
<211> 421
<212> PRT
<213> Chlamydia trachomatis
<400> 94

Met Thr Ala Ser Gly Gly Ala Gly Gly Leu Gly Ser Thr Gln Thr Val
1 5 10 15

Asp Val Ala Arg Ala Gln Ala Ala Ala Thr Gln Asp Ala Gln Glu
 20 25 30
 Val Ile Gly Ser Gln Glu Ala Ser Glu Ala Ser Met Leu Lys Glu Cys
 35 40 45
 Glu Asp Leu Ile Asn Pro Ala Ala Ala Thr Arg Ile Lys Lys Lys Glu
 50 55 60
 Glu Lys Phe Glu Ser Leu Glu Ala Arg Arg Lys Pro Thr Ala Asp Lys
 65 70 75 80
 Ala Glu Lys Lys Ser Glu Ser Thr Glu Glu Lys Gly Asp Thr Pro Leu
 85 90 95
 Glu Asp Arg Phe Thr Glu Asp Leu Ser Glu Val Ser Gly Glu Asp Phe
 100 105 110
 Arg Gly Leu Lys Asn Ser Phe Asp Asp Ser Ser Ser Asp Glu Ile
 115 120 125
 Leu Asp Ala Leu Thr Ser Lys Phe Ser Asp Pro Thr Ile Lys Asp Leu
 130 135 140
 Ala Leu Asp Tyr Leu Ile Gln Ile Ala Pro Ser Asp Gly Lys Leu Lys
 145 150 155 160
 Ser Ala Leu Ile Gln Ala Lys His Gln Leu Met Ser Gln Asn Pro Gln
 165 170 175
 Ala Ile Val Gly Gly Arg Asn Val Leu Leu Ala Ser Glu Thr Phe Ala
 180 185 190
 Ser Arg Ala Asn Thr Ser Pro Ser Ser Leu Arg Ser Leu Tyr Phe Gln
 195 200 205
 Val Thr Ser Ser Pro Ser Asn Cys Ala Asn Leu His Gln Met Leu Ala
 210 215 220
 Ser Tyr Ser Pro Ser Glu Lys Thr Ala Val Met Glu Phe Leu Val Asn
 225 230 235 240
 Gly Met Val Ala Asp Leu Lys Ser Glu Gly Pro Ser Ile Pro Pro Ala
 245 250 255
 Lys Leu Gln Val Tyr Met Thr Glu Leu Ser Asn Leu Gln Ala Leu His
 260 265 270
 Ser Val Asp Ser Phe Phe Asp Arg Asn Ile Gly Asn Leu Glu Asn Ser
 275 280 285
 Leu Lys His Glu Gly His Ala Pro Ile Pro Ser Leu Thr Thr Gly Asn
 290 295 300
 Leu Thr Lys Thr Phe Leu Gln Leu Val Glu Asp Lys Phe Pro Ser Ser
 305 310 315 320
 Ser Lys Ala Gln Lys Ala Leu Asn Glu Leu Val Gly Pro Asp Thr Gly
 325 330 335
 Pro Gln Thr Glu Val Leu Asn Leu Phe Phe Arg Ala Leu Asn Gly Cys
 340 345 350
 Ser Pro Arg Ile Phe Ser Gly Ala Glu Lys Lys Gln Gln Leu Ala Ser
 355 360 365
 Val Ile Thr Asn Thr Leu Asp Ala Ile Asn Ala Asp Asn Glu Asp Tyr
 370 375 380
 Pro Lys Pro Gly Asp Phe Pro Arg Ser Ser Phe Ser Ser Thr Pro Pro
 385 390 395 400
 His Ala Pro Val Pro Gln Ser Glu Ile Pro Thr Ser Pro Thr Ser Thr
 405 410 415
 Gln Pro Pro Ser Pro
 420

<210> 95
 <211> 1749
 <212> DNA
 <213> Chlamydia trachomatis

<400> 95

atggtacaag	gagaaagctt	ggtttgcgaag	aatgctcttc	aagatttgag	tttttttagag	60
catttattac	agggttaaata	tgctcctaaa	acatggaaag	agcaataactt	aggatgggat	120
cttgttcaaa	gctccgtttc	tgcacagcag	aagcttgcga	cacaagaaaa	tccatcaaca	180
agtttttgcc	agcaggtcct	tgctgatttt	atcggaggat	taaatagactt	tcacgctgga	240
gtaactttct	ttgcgataga	aagtgccttac	cttccttata	ccgtacaaaa	aagtagtgac	300
ggccgtttct	actttgtaga	tatcatgact	ttttcttcag	agatccgtgt	tggagatgag	360
ttgctagagg	tggatggggc	gcctgtccaa	gatgtactcg	ctactctata	tgggaagcaat	420
cacaaaggga	ctgcagctga	agagtcggct	gctttaagaa	cactattttc	tcgcatggcc	480
tcttttaggc	acaaagtacc	ttctggggcg	actactttaa	agattcgtcg	tccttttggg	540
actacgagag	aagttcgtgt	gaaatggcgt	tatgttcctg	aaggtgtagg	agatttggct	600
accatagctc	cttctatcag	ggctccacag	ttacagaaat	cgatgagaag	ctttttcctt	660
aagaaagatg	atgcgtttca	tcggtctagt	tcgctattct	actctccaat	ggttccgcat	720
ttttgggcag	agcttcgcaa	tcattatgca	acgagtgggt	tgaaaagcgg	gtacaatatt	780
gggagtaccg	atgggtttct	ccctgtcatt	gggcctgtta	tatgggagtc	ggagggtctt	840
ttccgcgctt	atattttctt	ggtgactgat	ggggatggta	agagccataa	agtaggattt	900
ctaagaattc	ctacatatag	ttggcaggac	atggaagatt	ttgatccttc	aggaccgcct	960
ccctgggaag	aatttgctaa	gattattcaa	gtattttctt	ctaatacaga	agctttgatt	1020
atcgaccaaa	cgaacaaccc	aggtggtagt	gtcctttatc	tttatgcact	gctttccatg	1080
ttgacagacc	gtcctttaga	acttcctaaa	catagaatga	ttctgactca	ggatgaagtg	1140
gttgatgctt	tagattgggt	aacctgtgtg	gaaaacgtag	acacaaacgt	ggartctcgc	1200
cttgctctgg	gagacaacat	ggaaggatat	actgtggatc	tacagggttg	cgagtattta	1260
aaaagctttg	gacgtcaagt	attgaattgt	tggagtaaag	gggatattga	gttatcaacg	1320
cctattcctc	tttttgggtt	tgagaagatt	catccacatc	ctcgagttca	atactctaaa	1380
cogattttgt	ttttgatcaa	tgagcaagac	ttttcttgtg	ctgacttctt	ccctgtagtt	1440
ttgaaagaca	atgatcgagc	tcttattgtt	ggtactcgaa	cagctggagc	tggaggattt	1500
gtctttaatg	tgcaagttcc	aaatagaact	ggaataaaaa	cttgttcttt	aacaggatca	1560
ttagctgtta	gagagcatgg	tgcccttcatt	gagaacatcg	gagtcgaacc	gcataatcgat	1620
ctgcctttta	cagcgaatga	tattcgctat	aaaggctatt	ccgagtatct	tgataaggtc	1680
aaaaaattgg	tttgtcagct	gatcaataac	gaaggtagca	ttattcttgc	ggaagatggt	1740

agtttttag

1749

<210> 96

<211> 582

<212> PRT

<213> Chlamydia trachomatis

<400> 96

Met	Val	Gln	Gly	Glu	Ser	Leu	Val	Cys	Lys	Asn	Ala	Leu	Gln	Asp	Leu
1			5						10					15	
Ser	Phe	Leu	Glu	His	Leu	Leu	Gln	Val	Lys	Tyr	Ala	Pro	Lys	Thr	Trp
		20						25					30		
Lys	Glu	Gln	Tyr	Leu	Gly	Trp	Asp	Leu	Val	Gln	Ser	Ser	Val	Ser	Ala
		35					40						45		
Gln	Gln	Lys	Leu	Arg	Thr	Gln	Glu	Asn	Pro	Ser	Thr	Ser	Phe	Cys	Gln
		50				55					60				
Gln	Val	Leu	Ala	Asp	Phe	Ile	Gly	Gly	Leu	Asn	Asp	Phe	His	Ala	Gly
65					70				75					80	
Val	Thr	Phe	Phe	Ala	Ile	Glu	Ser	Ala	Tyr	Leu	Pro	Tyr	Thr	Val	Gln
			85					90					95		
Lys	Ser	Ser	Asp	Gly	Arg	Phe	Tyr	Phe	Val	Asp	Ile	Met	Thr	Phe	Ser
			100					105					110		
Ser	Glu	Ile	Arg	Val	Gly	Asp	Glu	Leu	Leu	Glu	Val	Asp	Gly	Ala	Pro
		115					120					125			
Val	Gln	Asp	Val	Leu	Ala	Thr	Leu	Tyr	Gly	Ser	Asn	His	Lys	Gly	Thr
		130				135					140				
Ala	Ala	Glu	Glu	Ser	Ala	Ala	Leu	Arg	Thr	Leu	Phe	Ser	Arg	Met	Ala
145					150				155					160	
Ser	Leu	Gly	His	Lys	Val	Pro	Ser	Gly	Arg	Thr	Thr	Leu	Lys	Ile	Arg

atggtacaag	gagaaagctt	ggtttgcaag	aatgctcttc	aagatttgag	tttttttagag	60
cattttattac	aggttaaata	tgctcctaaa	acatggaaaag	agcaataactt	aggatgggat	120
cttgtttcaaa	gctccgtttc	tgacacagcag	aagcttcgta	cacaagaaaa	tccatcaaca	180
agttttttgcc	agcaggtcct	tgctgatttt	atcgaggat	taaatgactt	tcacgctgga	240
gtaactttct	ttgcgataga	aagtgtttac	cttccttata	ccgtacaaaa	aagtagtgac	300
ggcggtttct	actttgtaga	tatcatgact	ttttcttcag	agatccgtgt	tgagatgag	360
ttgctagagg	tgatggggc	gcctgtccaa	gatgtactcg	ctactctata	tggaagcaat	420
cacaaaggga	ctgcagctga	agagtcgggt	gctttaagaa	cactattttc	tcgcatggcc	480
tcttttagggc	acaaagtacc	ttctggggcg	actactttaa	agattcgtcg	tccttttggg	540
actacgagag	aagttcgtgt	gaaatggcgt	tatgttcctg	aaggtgtagg	agatttggct	600
accatagctc	cttctatcag	ggctccacag	ttacagaaa	cgatgagaag	ctttttccct	660
aagaaagatg	atgcgtttca	tcggtctagt	tcgctattct	actctccaat	ggttccgcat	720
ttttgggcag	agcttcgcaa	tcattatgca	acgagtgggt	tgaaaagcgg	gtacaatatt	780
gggagtagccg	atgggtttct	ccctgtcatt	gggcctgtta	tatgggagtc	ggaggggtctt	840
ttccgcgctt	atatttcttc	ggtgactgat	ggggatggta	agagccataa	agtaggattt	900
ctaagaattc	ctacatatag	ttggcaggac	atggaagatt	ttgatccttc	aggaccgcct	960
ccttgggaag	aatttgctaa	gattattcaa	gtattttctt	ctaatacaga	agcttttgatt	1020
atcgaccaaa	cgaacaaccc	aggtggtagt	gtccttttat	tttatgcact	gctttccatg	1080
ttgacagacc	gtcctttaga	acttccataa	catagaatga	ttctgactca	ggatgaagtg	1140
ggtgatgctt	tagattgggt	aacctgtgtg	gaaaacgtag	acacaaacgt	ggaatctcgc	1200
cttgcctctg	gagacaacat	ggaaggatat	actgtggatc	tacaggttgc	cgagtattta	1260
aaaagctttg	gacgtcaagt	attgaattgt	tggagtaaag	gggatatcga	gttatcaacg	1320
cctattcctc	tttttggttt	tgagaagatt	catccacatc	ctcgagttca	atactctaaa	1380
ccgattttgtg	ttttgatcaa	tgagcaagac	ttttcttggtg	ctgacttctt	ccctgtagtt	1440
ttgaaagaca	atgatcgagc	tcttattgtt	ggtactcgaa	cagctggagc	tggaggattt	1500
gtctttaatg	tgagttccc	aaatagaact	ggaataaaaa	cttgttcttt	aacaggatca	1560
ttagctgtta	gagagcatgg	tgcccttcatt	gagaacatcg	gagtcgaacc	gcataatcgat	1620
ctgcctttta	cagcgaatga	tattcgctat	aaaggctatt	ccgagtatct	tgataaggctc	1680
aaaaaattgg	tttgtcagct	gatcaataac	gacggtacca	ttattcttgc	ggaagatggt	1740
agtttttag						1749

<210> 98

<211> 582

<212> PRT

<213> Chlamydia trachomatis

<400> 98

Met	Val	Gln	Gly	Glu	Ser	Leu	Val	Cys	Lys	Asn	Ala	Leu	Gln	Asp	Leu
1			5					10					15		
Ser	Phe	Leu	Glu	His	Leu	Leu	Gln	Val	Lys	Tyr	Ala	Pro	Lys	Thr	Trp
		20						25					30		
Lys	Glu	Gln	Tyr	Leu	Gly	Trp	Asp	Leu	Val	Gln	Ser	Ser	Val	Ser	Ala
		35					40					45			
Gln	Gln	Lys	Leu	Arg	Thr	Gln	Glu	Asn	Pro	Ser	Thr	Ser	Phe	Cys	Gln
	50					55					60				
Gln	Val	Leu	Ala	Asp	Phe	Ile	Gly	Gly	Leu	Asn	Asp	Phe	His	Ala	Gly
65				70				75						80	
Val	Thr	Phe	Phe	Ala	Ile	Glu	Ser	Ala	Tyr	Leu	Pro	Tyr	Thr	Val	Gln
			85					90						95	
Lys	Ser	Ser	Asp	Gly	Arg	Phe	Tyr	Phe	Val	Asp	Ile	Met	Thr	Phe	Ser
			100					105					110		
Ser	Glu	Ile	Arg	Val	Gly	Asp	Glu	Leu	Leu	Glu	Val	Asp	Gly	Ala	Pro
		115				120						125			
Val	Gln	Asp	Val	Leu	Ala	Thr	Leu	Tyr	Gly	Ser	Asn	His	Lys	Gly	Thr
	130					135					140				
Ala	Ala	Glu	Glu	Ser	Ala	Ala	Leu	Arg	Thr	Leu	Phe	Ser	Arg	Met	Ala
145				150				155						160	
Ser	Leu	Gly	His	Lys	Val	Pro	Ser	Gly	Arg	Thr	Thr	Leu	Lys	Ile	Arg

atggtacaag	gagaaagctt	ggtttgcaag	aatgctcttc	aagatttgag	tttttttagag	60
cattttattac	aggtttaaata	tgctoctaaa	acatggaaaag	agcaataactt	aggatgggat	120
cttggttcaaa	gctccgtttc	tgacacagcag	aagcttcgta	cacaagaaaa	tccatcaaca	180
agttttttgcc	agcaggtcct	tgctgattttt	atcggaggat	taaatgactt	tcacgctgga	240
gtaacttttct	ttgcgataga	aagtgccttac	cttccttata	ccgtacaaaa	aagtagtgac	300
ggcgcgtttct	actttgtaga	tatcatgact	ttttcttcag	agatccgtgt	tggagatgag	360
ttgctagagg	tggatggggc	gcctgtccaa	gatgtactcg	ctactctata	tggaagcaat	420
cacaaagggga	ctgcagctga	agagtcgggt	gctttaagaa	cactattttc	tcgcatggcc	480
tcttttagggc	acaaagtacc	ttctggggcg	actactttta	agattcgtcg	tccttttggg	540
actacgagag	aagttcgtgt	gaaatggcgt	tatgttcctg	aaggtgtagg	agattttggct	600
accatagctc	cttctatcag	ggctccacag	ttacagaaat	cgatgagaag	ctttttccct	660
aagaaagatg	atgcgtttca	tcggtctagt	tcgctattct	actctccaat	ggttccgcac	720
ttttgggcag	agcttcgcaa	tcattatgca	acgagtggtt	tgaaaagcgg	gtacaatatt	780
gggagtagccg	atgggttttct	ccctgtcatt	gggcctgtta	tatgggagtc	ggaggggtctt	840
ttccgcgctt	atattttctt	ggtgactgat	ggggatggta	agagccataa	agtaggattt	900
ctaagaattc	ctacatatag	ttggcaggac	atggaagatt	ttgatccctc	aggaccgcct	960
ccttggggaag	aatttgctaa	gattattcaa	gtattttctt	ctaatacaga	agcttttgatt	1020
atcgacaaaa	cgaacaaccc	aggtggtagt	gtcctttatc	tttatgcact	gctttccatg	1080
ttgacagacc	gtccttttaga	acttcctaaa	catagaatga	ttctgactca	ggatgaagtg	1140
ggtgatgctt	tagattgggt	aaccctgttg	gaaaacgtag	acacaaacgt	ggagttctcg	1200
cttgctctgg	gagacaacat	ggaaggatat	actgtggatc	tacaggttgc	cgagtattta	1260
aaaagctttg	gacgtcaagt	attgaattgt	tggagtaaag	gggatatcga	gttatcaacg	1320
cctattcctc	tttttggttt	tgagaagatt	catccacatc	ctcgagttca	atactctaaa	1380
ccgattttgtg	ttttgatcaa	tgagcaagac	ttttcttgtg	ctgacttctt	ccctgtagtt	1440
ttgaaagaca	atgatcgagc	tcttattgtt	ggtactcgaa	cagctggagc	tggaggattt	1500
gtctttaaatg	tgcagttccc	aaatagaact	ggaataaaaa	cttgttcttt	aacaggatca	1560
ttagctgtta	gagagcatgg	tgccctcatt	gagaacatcg	gagtcgaacc	gcataatcgat	1620
ctgcctttta	cagcgaatga	tattcgctat	aaaggctatt	ccgagtatct	tgataagggtc	1680
aaaaaattgg	tttgtcagct	gatcaataac	gacgggtacca	ttattcttgc	ggaagatggg	1740
agtttttag						1749

<210> 100
 <211> 582
 <212> PRT
 <213> Chlamydia trachomatis

<400> 100

Met	Val	Gln	Gly	Glu	Ser	Leu	Val	Cys	Lys	Asn	Ala	Leu	Gln	Asp	Leu
1			5						10					15	
Ser	Phe	Leu	Glu	His	Leu	Leu	Gln	Val	Lys	Tyr	Ala	Pro	Lys	Thr	Trp
			20						25				30		
Lys	Glu	Gln	Tyr	Leu	Gly	Trp	Asp	Leu	Val	Gln	Ser	Ser	Val	Ser	Ala
		35					40						45		
Gln	Gln	Lys	Leu	Arg	Thr	Gln	Glu	Asn	Pro	Ser	Thr	Ser	Phe	Cys	Gln
		50					55				60				
Gln	Val	Leu	Ala	Asp	Phe	Ile	Gly	Gly	Leu	Asn	Asp	Phe	His	Ala	Gly
65					70				75						80
Val	Thr	Phe	Phe	Ala	Ile	Glu	Ser	Ala	Tyr	Leu	Pro	Tyr	Thr	Val	Gln
				85					90					95	
			100						105				110		
Ser	Glu	Ile	Arg	Val	Gly	Asp	Glu	Leu	Leu	Glu	Val	Asp	Gly	Ala	Pro
		115					120					125			
Val	Gln	Asp	Val	Leu	Ala	Thr	Leu	Tyr	Gly	Ser	Asn	His	Lys	Gly	Thr
		130					135					140			
Ala	Ala	Glu	Glu	Ser	Ala	Ala	Leu	Arg	Thr	Leu	Phe	Ser	Arg	Met	Ala
145					150				155						160
Ser	Leu	Gly	His	Lys	Val	Pro	Ser	Gly	Arg	Thr	Thr	Leu	Lys	Ile	Arg
				165					170					175	

Arg Pro Phe Gly Thr Thr Arg Glu Val Arg Val Lys Trp Arg Tyr Val
 180 185 190
 Pro Glu Gly Val Gly Asp Leu Ala Thr Ile Ala Pro Ser Ile Arg Ala
 195 200 205
 Pro Gln Leu Gln Lys Ser Met Arg Ser Phe Phe Pro Lys Lys Asp Asp
 210 215 220
 Ala Phe His Arg Ser Ser Ser Leu Phe Tyr Ser Pro Met Val Pro His
 225 230 235 240
 Phe Trp Ala Glu Leu Arg Asn His Tyr Ala Thr Ser Gly Leu Lys Ser
 245 250 255
 Gly Tyr Asn Ile Gly Ser Thr Asp Gly Phe Leu Pro Val Ile Gly Pro
 260 265 270
 Val Ile Trp Glu Ser Glu Gly Leu Phe Arg Ala Tyr Ile Ser Ser Val
 275 280 285
 Thr Asp Gly Asp Gly Lys Ser His Lys Val Gly Phe Leu Arg Ile Pro
 290 295 300
 Thr Tyr Ser Trp Gln Asp Met Glu Asp Phe Asp Pro Ser Gly Pro Pro
 305 310 315 320
 Pro Trp Glu Glu Phe Ala Lys Ile Ile Gln Val Phe Ser Ser Asn Thr
 325 330 335
 Glu Ala Leu Ile Ile Asp Gln Thr Asn Asn Pro Gly Gly Ser Val Leu
 340 345 350
 Tyr Leu Tyr Ala Leu Leu Ser Met Leu Thr Asp Arg Pro Leu Glu Leu
 355 360 365
 Pro Lys His Arg Met Ile Leu Thr Gln Asp Glu Val Val Asp Ala Leu
 370 375 380
 Asp Trp Leu Thr Leu Leu Glu Asn Val Asp Thr Asn Val Glu Ser Arg
 385 390 395 400
 Leu Ala Leu Gly Asp Asn Met Glu Gly Tyr Thr Val Asp Leu Gln Val
 405 410 415
 Ala Glu Tyr Leu Lys Ser Phe Gly Arg Gln Val Leu Asn Cys Trp Ser
 420 425 430
 Lys Gly Asp Ile Glu Leu Ser Thr Pro Ile Pro Leu Phe Gly Phe Glu
 435 440 445
 Lys Ile His Pro His Pro Arg Val Gln Tyr Ser Lys Pro Ile Cys Val
 450 455 460
 Leu Ile Asn Glu Gln Asp Phe Ser Cys Ala Asp Phe Phe Pro Val Val
 465 470 475 480
 Leu Lys Asp Asn Asp Arg Ala Leu Ile Val Gly Thr Arg Thr Ala Gly
 485 490 495
 Ala Gly Gly Phe Val Phe Asn Val Gln Phe Pro Asn Arg Thr Gly Ile
 500 505 510
 Lys Thr Cys Ser Leu Thr Gly Ser Leu Ala Val Arg Glu His Gly Ala
 515 520 525
 Phe Ile Glu Asn Ile Gly Val Glu Pro His Ile Asp Leu Pro Phe Thr
 530 535 540
 Ala Asn Asp Ile Arg Tyr Lys Gly Tyr Ser Glu Tyr Leu Asp Lys Val
 545 550 555 560
 Lys Lys Leu Val Cys Gln Leu Ile Asn Asn Asp Gly Thr Ile Ile Leu
 565 570 575
 Ala Glu Asp Gly Ser Phe
 580

<210> 101
 <211> 1749
 <212> DNA
 <213> Chlamydia trachomatis
 <400> 101

atggtacaag	gagaaagctt	ggtttgcaag	aatgctcttc	aagatttgag	tttttagag	60
catttattac	aggttaaata	tgctcctaaa	acatggaaa	agcaatactt	aggatgggat	120
cttgttcaaa	gctccgtttc	tgacacagcag	aagcttcgta	cacaagaaaa	tccatcaaca	180
agtttttgcc	agcaggtcct	tgctgatttt	atcggaggat	taaatgactt	tcacgctgga	240
gtaactttct	ttgcgataga	aagtgccttac	cttccttata	ccgtacaaaa	aagtagtgac	300
ggcgttttct	actttgtaga	tatcatgact	ttttcttcag	agatccgtgt	tggagatgag	360
ttgctagagg	tggatggggc	gcctgtccaa	gatgtactcg	ctactctata	tggagatgag	420
cacaaagggg	ctgcagctga	agagtcgggt	gctttaagaa	cactattttc	tcgcatggcc	480
tctttagggc	acaaagtacc	ttctggggcg	actactttta	agattcgtcg	tccttttggt	540
actacgagag	aagttcgtgt	gaaatggcgt	tatgttcctg	aaggtgtagg	agatttggt	600
accatagctc	cttctatcag	ggctccacag	ttacagaaat	cgatgagaag	ctttttccct	660
aagaaagatg	atgcgtttca	tcggtctagt	tcgctattct	actctccaat	ggttccgcct	720
ttttgggcag	agcttcgcaa	tcattatgca	acgagtggtt	tgaaaagcgg	gtacaatatt	780
gggagtaccg	atgggtttct	ccctgtcatt	gggcctgtta	tatgggagtc	ggaggggtct	840
ttccgcgctt	atatttcttc	ggtgactgat	ggggatggta	agagccataa	agtaggattt	900
ctaagaattc	ctacatatag	ttggcaggac	atggaagatt	ttgatccttc	aggaccgcct	960
ccttggaag	aatttgctaa	gattattcaa	gtattttctt	ctaatacaga	agctttgatt	1020
atcgacaaa	cgaacaaccc	aggtggtagt	gtcctttatc	tttatgact	gctttccatg	1080
ttgacagacc	gtcctttaga	acttcctaaa	catagaatga	ttctgactca	ggatgaagtg	1140
gttgatgctt	tagattgggt	aaccctgttg	gaaaacgtag	acacaaacgt	ggagtctcgc	1200
cttgcctctg	gagacaacat	ggaaggatat	actgtggatc	tacaggttgc	cgagtattta	1260
aaaagctttg	gacgtcaagt	attgaattgt	tggagtaaag	gggatatcga	gttatcaacg	1320
cctattcctc	tttttggttt	tgagaagatt	catccacatc	ctcgagttca	atactctaaa	1380
ccgatttggtg	ttttgatcaa	tgagcaagac	ttttcttggtg	ctgacttctt	ccctgtagtt	1440
ttgaaagaca	atgatcgagc	tcttattgtt	ggtactcgaa	cagctggagc	tggaggattt	1500
gtctttaatg	tgagttccc	aatagaact	ggaataaaaa	cttgttcttt	aacaggatca	1560
ttagctgtta	gagagcatgg	tgcttccatt	gagaacatcg	gagtcgaacc	gcataatgat	1620
ctgcctttta	cagcgaatga	tattcgctat	aaaggctatt	ccgagtatct	tgataagggtc	1680
aaaaaattgg	tttgtcagct	gatcaataac	gacggtagca	ttattcttgc	ggaagatggt	1740
agtttttag						1749

<210> 102

<211> 582

<212> PRT

<213> Chlamydia trachomatis

<400> 102

Met	Val	Gln	Gly	Glu	Ser	Leu	Val	Cys	Lys	Asn	Ala	Leu	Gln	Asp	Leu
1			5					10					15		
Ser	Phe	Leu	Glu	His	Leu	Leu	Gln	Val	Lys	Tyr	Ala	Pro	Lys	Thr	Trp
		20					25					30			
Lys	Glu	Gln	Tyr	Leu	Gly	Trp	Asp	Leu	Val	Gln	Ser	Ser	Val	Ser	Ala
		35				40						45			
Gln	Gln	Lys	Leu	Arg	Thr	Gln	Glu	Asn	Pro	Ser	Thr	Ser	Phe	Cys	Gln
		50				55					60				
Gln	Val	Leu	Ala	Asp	Phe	Ile	Gly	Gly	Leu	Asn	Asp	Phe	His	Ala	Gly
65				70				75						80	
Val	Thr	Phe	Phe	Ala	Ile	Glu	Ser	Ala	Tyr	Leu	Pro	Tyr	Thr	Val	Gln
		85						90					95		
Lys	Ser	Ser	Asp	Gly	Arg	Phe	Tyr	Phe	Val	Asp	Ile	Met	Thr	Phe	Ser
		100					105					110			
Ser	Glu	Ile	Arg	Val	Gly	Asp	Glu	Leu	Leu	Glu	Val	Asp	Gly	Ala	Pro
		115				120					125				
Val	Gln	Asp	Val	Leu	Ala	Thr	Leu	Tyr	Gly	Ser	Asn	His	Lys	Gly	Thr
		130				135					140				
Ala	Ala	Glu	Glu	Ser	Ala	Ala	Leu	Arg	Thr	Leu	Phe	Ser	Arg	Met	Ala
145				150				155						160	
Ser	Leu	Gly	His	Lys	Val	Pro	Ser	Gly	Arg	Thr	Thr	Leu	Lys	Ile	Arg
		165						170					175		

Arg	Pro	Phe	Gly	Thr	Thr	Arg	Glu	Val	Arg	Val	Lys	Trp	Arg	Tyr	Val
			180					185						190	
Pro	Glu	Gly	Val	Gly	Asp	Leu	Ala	Thr	Ile	Ala	Pro	Ser	Ile	Arg	Ala
		195					200					205			
Pro	Gln	Leu	Gln	Lys	Ser	Met	Arg	Ser	Phe	Phe	Pro	Lys	Lys	Asp	Asp
	210					215					220				
Ala	Phe	His	Arg	Ser	Ser	Ser	Leu	Phe	Tyr	Ser	Pro	Met	Val	Pro	His
225					230					235					240
Phe	Trp	Ala	Glu	Leu	Arg	Asn	His	Tyr	Ala	Thr	Ser	Gly	Leu	Lys	Ser
			245						250					255	
Gly	Tyr	Asn	Ile	Gly	Ser	Thr	Asp	Gly	Phe	Leu	Pro	Val	Ile	Gly	Pro
		260						265					270		
Val	Ile	Trp	Glu	Ser	Glu	Gly	Leu	Phe	Arg	Ala	Tyr	Ile	Ser	Ser	Val
	275					280						285			
Thr	Asp	Gly	Asp	Gly	Lys	Ser	His	Lys	Val	Gly	Phe	Leu	Arg	Ile	Pro
	290					295					300				
Thr	Tyr	Ser	Trp	Gln	Asp	Met	Glu	Asp	Phe	Asp	Pro	Ser	Gly	Pro	Pro
305					310					315					320
Pro	Trp	Glu	Glu	Phe	Ala	Lys	Ile	Ile	Gln	Val	Phe	Ser	Ser	Asn	Thr
			325						330					335	
Glu	Ala	Leu	Ile	Asp	Gln	Thr	Asn	Asn	Pro	Gly	Gly	Ser	Val	Leu	
		340					345					350			
Tyr	Leu	Tyr	Ala	Leu	Leu	Ser	Met	Leu	Thr	Asp	Arg	Pro	Leu	Glu	Leu
	355						360					365			
Pro	Lys	His	Arg	Met	Ile	Leu	Thr	Gln	Asp	Glu	Val	Val	Asp	Ala	Leu
	370					375					380				
Asp	Trp	Leu	Thr	Leu	Leu	Glu	Asn	Val	Asp	Thr	Asn	Val	Glu	Ser	Arg
385					390					395					400
Leu	Ala	Leu	Gly	Asp	Asn	Met	Glu	Gly	Tyr	Thr	Val	Asp	Leu	Gln	Val
			405						410					415	
Ala	Glu	Tyr	Leu	Lys	Ser	Phe	Gly	Arg	Gln	Val	Leu	Asn	Cys	Trp	Ser
		420					425						430		
Lys	Gly	Asp	Ile	Glu	Leu	Ser	Thr	Pro	Ile	Pro	Leu	Phe	Gly	Phe	Glu
	435						440					445			
Lys	Ile	His	Pro	His	Pro	Arg	Val	Gln	Tyr	Ser	Lys	Pro	Ile	Cys	Val
	450					455					460				
Leu	Ile	Asn	Glu	Gln	Asp	Phe	Ser	Cys	Ala	Asp	Phe	Phe	Pro	Val	Val
465					470					475					480
Leu	Lys	Asp	Asn	Asp	Arg	Ala	Leu	Ile	Val	Gly	Thr	Arg	Thr	Ala	Gly
			485						490					495	
Ala	Gly	Gly	Phe	Val	Phe	Asn	Val	Gln	Phe	Pro	Asn	Arg	Thr	Gly	Ile
		500						505					510		
Lys	Thr	Cys	Ser	Leu	Thr	Gly	Ser	Leu	Ala	Val	Arg	Glu	His	Gly	Ala
	515					520						525			
Phe	Ile	Glu	Asn	Ile	Gly	Val	Glu	Pro	His	Ile	Asp	Leu	Pro	Phe	Thr
	530					535					540				
Ala	Asn	Asp	Ile	Arg	Tyr	Lys	Gly	Tyr	Ser	Glu	Tyr	Leu	Asp	Lys	Val
545					550					555					560
Lys	Lys	Leu	Val	Cys	Gln	Leu	Ile	Asn	Asn	Asp	Gly	Thr	Ile	Ile	Leu
			565					570						575	
Ala	Glu	Asp	Gly	Ser	Phe										
			580												

<210> 103
 <211> 1749
 <212> DNA
 <213> Chlamydia trachomatis

 <400> 103

atggtacaag	gagaaagctt	ggtttgcaag	aatgctcttc	aagatttgag	tttttttagag	60
cattttattac	agggttaaata	tgctcctaaa	acatggaaaag	agcaataactt	aggatgggat	120
cttggttcaaa	gctccggtttc	tgacacagcag	aagcttcgta	cacaagaaaa	tcctatcaaca	180
agtttttgcc	agcagggtcct	tgctgatttt	atcggaggat	taaatagactt	tcacgctgga	240
gtaactttct	ttgcgataga	aagtgccttac	cttccttata	ccgtacaaaa	aagtagtgac	300
ggcggtttct	actttgtaga	tatcatgact	ttttcttcag	agatccgtgt	tggagatgag	360
ttgctagagg	tggatggggc	gcctgtccaa	gatgtactcg	ctactctata	tggaagcaat	420
cacaaagggga	ctgcagctga	agagtcggct	gctttaagaa	cactattttc	tcgcatggcc	480
tcttttagggc	acaaagtacc	ttctggggcgc	actactttaa	agattogtgc	tccttttggt	540
actacgagag	aagttcgtgt	gaaatggcgt	tatgttcctg	aagggtgtagg	agatttggt	600
accatagctc	cttctatcag	ggctccacag	ttacagaaat	cgatgagaag	ctttttccct	660
aagaaagatg	atgcgtttca	tcgggtctagt	tcgctattct	actctccaat	ggttccgcct	720
ttttgggcag	agcttcgcaa	tcattatgca	acgagtgggt	tgaaaagcgg	gtacaatatt	780
gggagtaccg	atgggtttct	ccctgtcatt	gggcctgtta	tatgggagtc	ggagggtctt	840
ttccgcgctt	atattttctc	ggtgactgat	ggggatggta	agagccataa	agtaggattt	900
ctaagaattc	ctacatatag	ttggcaggac	atggaagatt	ttgatccttc	aggaccgcct	960
ccttggggaag	aatttgctaa	gattattcaa	gtattttctt	ctaatacaga	agctttgatt	1020
atcgacccaaa	cgaacaaccc	aggtggtagt	gtcctttatc	tttatgcact	gctttccatg	1080
ttgacagacc	gtcctttaga	acttcctaaa	catagaatga	ttctgactca	ggatgaagtgc	1140
gttgatgctt	tagattggtt	aacctgttg	gaaaacgtag	acacaaaacgt	ggagtctcgc	1200
cctgctctgg	gagacaacat	ggaaggatat	actgtggatc	tacaggttgc	cgagtattta	1260
aaaagctttg	gacgtcaagt	attgaattgt	tggagtaaag	gggatatcga	gttatcaacg	1320
cctattcctc	tttttggttt	tgagaagatt	catccacatc	ctcgagttca	atactctaaa	1380
ccgatttggtg	ttttgatcaa	tgagcaagac	ttttcttggtg	ctgacttctt	ccctgtagtt	1440
ttgaaagaca	atgatcgagc	tcttattggt	ggtactcgaa	cagctggagc	tggaggattt	1500
gtcttttaatg	tgagtttccc	aaatagaact	ggaataaaaa	cttgttcttt	aacaggatca	1560
ttagctgtta	gagagcatgg	tgcttccatt	gagaacatcg	gagtcgaacc	gcataatcgat	1620
ctgcctttta	cagcgaatga	tattcgctat	aaaggctatt	ccgagtatct	tgataagggtc	1680
aaaaaattgg	tttgtcagct	gatcaataac	gacgggtacca	ttattcttgc	ggaagatggt	1740
agtttttag						1749

<210> 104

<211> 582

<212> PRT

<213> Chlamydia trachomatis

<400> 104

Met	Val	Gln	Gly	Glu	Ser	Leu	Val	Cys	Lys	Asn	Ala	Leu	Gln	Asp	Leu
1			5					10					15		
Ser	Phe	Leu	Glu	His	Leu	Leu	Gln	Val	Lys	Tyr	Ala	Pro	Lys	Thr	Trp
		20						25					30		
Lys	Glu	Gln	Tyr	Leu	Gly	Trp	Asp	Leu	Val	Gln	Ser	Ser	Val	Ser	Ala
		35					40						45		
Gln	Gln	Lys	Leu	Arg	Thr	Gln	Glu	Asn	Pro	Ser	Thr	Ser	Phe	Cys	Gln
		50					55					60			
Gln	Val	Leu	Ala	Asp	Phe	Ile	Gly	Gly	Leu	Asn	Asp	Phe	His	Ala	Gly
65							70			75					80
Val	Thr	Phe	Phe	Ala	Ile	Glu	Ser	Ala	Tyr	Leu	Pro	Tyr	Thr	Val	Gln
			85						90					95	
Lys	Ser	Ser	Asp	Gly	Arg	Phe	Tyr	Phe	Val	Asp	Ile	Met	Thr	Phe	Ser
			100					105					110		
Ser	Glu	Ile	Arg	Val	Gly	Asp	Glu	Leu	Leu	Glu	Val	Asp	Gly	Ala	Pro
			115				120					125			
Val	Gln	Asp	Val	Leu	Ala	Thr	Leu	Tyr	Gly	Ser	Asn	His	Lys	Gly	Thr
			130				135					140			
Ala	Ala	Glu	Glu	Ser	Ala	Ala	Leu	Arg	Thr	Leu	Phe	Ser	Arg	Met	Ala
145							150			155					160
Ser	Leu	Gly	His	Lys	Val	Pro	Ser	Gly	Arg	Thr	Thr	Leu	Lys	Ile	Arg
							165			170				175	

Arg	Pro	Phe	Gly	Thr	Thr	Arg	Glu	Val	Arg	Val	Lys	Trp	Arg	Tyr	Val
			180					185						190	
Pro	Glu	Gly	Val	Gly	Asp	Leu	Ala	Thr	Ile	Ala	Pro	Ser	Ile	Arg	Ala
		195					200						205		
Pro	Gln	Leu	Gln	Lys	Ser	Met	Arg	Ser	Phe	Phe	Pro	Lys	Lys	Asp	Asp
	210					215					220				
Ala	Phe	His	Arg	Ser	Ser	Ser	Leu	Phe	Tyr	Ser	Pro	Met	Val	Pro	His
225				230						235				240	
Phe	Trp	Ala	Glu	Leu	Arg	Asn	His	Tyr	Ala	Thr	Ser	Gly	Leu	Lys	Ser
			245						250					255	
Gly	Tyr	Asn	Ile	Gly	Ser	Thr	Asp	Gly	Phe	Leu	Pro	Val	Ile	Gly	Pro
		260						265					270		
Val	Ile	Trp	Glu	Ser	Glu	Gly	Leu	Phe	Arg	Ala	Tyr	Ile	Ser	Ser	Val
	275						280					285			
Thr	Asp	Gly	Asp	Gly	Lys	Ser	His	Lys	Val	Gly	Phe	Leu	Arg	Ile	Pro
	290					295					300				
Thr	Tyr	Ser	Trp	Gln	Asp	Met	Glu	Asp	Phe	Asp	Pro	Ser	Gly	Pro	Pro
305				310						315				320	
Pro	Trp	Glu	Glu	Phe	Ala	Lys	Ile	Ile	Gln	Val	Phe	Ser	Ser	Asn	Thr
			325						330					335	
Glu	Ala	Leu	Ile	Asp	Gln	Thr	Asn	Asn	Pro	Gly	Gly	Ser	Val	Leu	
		340					345					350			
Tyr	Leu	Tyr	Ala	Leu	Leu	Ser	Met	Leu	Thr	Asp	Arg	Pro	Leu	Glu	Leu
	355						360					365			
Pro	Lys	His	Arg	Met	Ile	Leu	Thr	Gln	Asp	Glu	Val	Val	Asp	Ala	Leu
	370					375					380				
Asp	Trp	Leu	Thr	Leu	Leu	Glu	Asn	Val	Asp	Thr	Asn	Val	Glu	Ser	Arg
385				390						395				400	
Leu	Ala	Leu	Gly	Asp	Asn	Met	Glu	Gly	Tyr	Thr	Val	Asp	Leu	Gln	Val
			405						410					415	
Ala	Glu	Tyr	Leu	Lys	Ser	Phe	Gly	Arg	Gln	Val	Leu	Asn	Cys	Trp	Ser
		420					425						430		
Lys	Gly	Asp	Ile	Glu	Leu	Ser	Thr	Pro	Ile	Pro	Leu	Phe	Gly	Phe	Glu
	435						440					445			
Lys	Ile	His	Pro	His	Pro	Arg	Val	Gln	Tyr	Ser	Lys	Pro	Ile	Cys	Val
	450					455					460				
Leu	Ile	Asn	Glu	Gln	Asp	Phe	Ser	Cys	Ala	Asp	Phe	Phe	Pro	Val	Val
465				470						475				480	
Leu	Lys	Asp	Asn	Asp	Arg	Ala	Leu	Ile	Val	Gly	Thr	Arg	Thr	Ala	Gly
			485						490					495	
Ala	Gly	Gly	Phe	Val	Phe	Asn	Val	Gln	Phe	Pro	Asn	Arg	Thr	Gly	Ile
		500					505						510		
Lys	Thr	Cys	Ser	Leu	Thr	Gly	Ser	Leu	Ala	Val	Arg	Glu	His	Gly	Ala
	515					520						525			
Phe	Ile	Glu	Asn	Ile	Gly	Val	Glu	Pro	His	Ile	Asp	Leu	Pro	Phe	Thr
	530				535						540				
Ala	Asn	Asp	Ile	Arg	Tyr	Lys	Gly	Tyr	Ser	Glu	Tyr	Leu	Asp	Lys	Val
545				550						555				560	
Lys	Lys	Leu	Val	Cys	Gln	Leu	Ile	Asn	Asn	Asp	Gly	Thr	Ile	Ile	Leu
			565					570						575	
Ala	Glu	Asp	Gly	Ser	Phe										
			580												

<210> 105
 <211> 1749
 <212> DNA
 <213> Chlamydia trachomatis

 <400> 105

atggtacgag	gagaaagcct	ggtttgcaag	aatgctcttc	aagatttgag	tttttttagag	60
cattttattac	aggtttaaata	tgctcctaaa	acatggaaaag	agcaataactt	aggatgggat	120
cttggttcaaa	gctccgtttc	tgacacagcag	aagcttcgta	cacaagaaaa	tccatcaaca	180
agttttttgcc	agcaggtcct	tgctgatttt	atcgaggat	taaatgactt	tcacgctgga	240
gtaacttttct	ttgcgataga	aagtgccttac	cttccttata	ccgtacaaaa	aagtagtgac	300
ggcgcgtttct	actttgtaga	tatcatgact	ttttcttcag	agatccgtgt	tgagatgag	360
ttgctagagg	tggtatggggc	gcctgtccaa	gatgtgctcg	ctactctata	tggaagcaat	420
cacaaagggga	ctgcagctga	agagtcgggt	gctttaagaa	cactattttc	tcgcatggcc	480
tcttttagggc	acaaagtacc	ttctggggcg	actacttta	agattcgctg	tccttttggt	540
actacgagag	aagttcgtgt	gaaatggcgt	tatgttcctg	aaggtgtagg	agatttggt	600
accatagctc	cttctatcag	ggctccacag	ttacagaaat	cgatgagaag	ctttttccct	660
aagaaagatg	atgcgtttca	tcggtctagt	tcgctattct	actctccaat	ggttccgcat	720
ttttgggcag	agcttcgcaa	tcattatgca	acgagtgggt	tgaaaagcgg	gtacaatatt	780
gggagtaccg	atgggtttct	ccctgtcatt	gggcctgtta	tatgggagtc	ggaggggtct	840
ttccgcgctt	atatttcttc	ggtgactgat	ggggatggta	agagccataa	agtaggattt	900
ctaagaattc	ctacatatag	ttggcaggac	atggaagatt	ttgatccttc	aggaccgct	960
ccttggggaag	aatttgctaa	gattattcaa	gtattttctt	ctaatacaga	agctttgatt	1020
atcgacaaaa	cgaacaaccc	aggtggtagt	gtcctttatc	tttatgcact	gctttccatg	1080
ttgacagacc	gtcctttaga	acttcctaaa	catagaatga	ttctgactca	ggatgaagtg	1140
gttgatgctt	tagattgggt	aaccctgttg	gaaaacgtag	acacaaacgt	ggagtctcgc	1200
cttgctctgg	gagacaacat	ggaaggatat	actgtggatc	tacaggttgc	cgagtattta	1260
aaaagctttg	gacgtcaagt	attgaattgt	tgagataaag	gggatatcga	gttatcaaca	1320
cctatttctc	tttttggttt	tgagaagatt	catccacatc	ctcgagttca	atactctaaa	1380
ccgatttgtg	ttttgatcaa	tgagcaagac	ttttcttgtg	ctgacttctt	ccctgtagtt	1440
ttgaaagaca	atgatcgagc	tcttattggt	ggtactcgaa	cagctggagc	tgaggagattt	1500
gtctttaatg	tgagttccc	aaatagaact	ggaataaaaa	cttgttcttt	aacaggatca	1560
ttagctgtta	gagagcatgg	tgcccttcatt	gagaacatcg	gagtcgaacc	gcataatcgat	1620
ctgcctttta	cagcgaatga	tattcgctat	aaaggctatt	ccgagtatct	tgataagggtc	1680
aaaaaattgg	tttgtcagct	gatcaataac	gacggtacca	ttattcttgc	ggaagatgggt	1740
agtttttag						1749

<210> 106
 <211> 582
 <212> PRT
 <213> Chlamydia trachomatis

<400> 106

Met	Val	Arg	Gly	Glu	Ser	Leu	Val	Cys	Lys	Asn	Ala	Leu	Gln	Asp	Leu
1			5						10					15	
Ser	Phe	Leu	Glu	His	Leu	Leu	Gln	Val	Lys	Tyr	Ala	Pro	Lys	Thr	Trp
		20						25					30		
Lys	Glu	Gln	Tyr	Leu	Gly	Trp	Asp	Leu	Val	Gln	Ser	Ser	Val	Ser	Ala
		35					40						45		
Gln	Gln	Lys	Leu	Arg	Thr	Gln	Glu	Asn	Pro	Ser	Thr	Ser	Phe	Cys	Gln
		50				55						60			
Gln	Val	Leu	Ala	Asp	Phe	Ile	Gly	Gly	Leu	Asn	Asp	Phe	His	Ala	Gly
65				70					75					80	
Val	Thr	Phe	Phe	Ala	Ile	Glu	Ser	Ala	Tyr	Leu	Pro	Tyr	Thr	Val	Gln
			85					90						95	
Lys	Ser	Ser	Asp	Gly	Arg	Phe	Tyr	Phe	Val	Asp	Ile	Met	Thr	Phe	Ser
			100					105					110		
Ser	Glu	Ile	Arg	Val	Gly	Asp	Glu	Leu	Leu	Glu	Val	Asp	Gly	Ala	Pro
		115				120						125			
Val	Gln	Asp	Val	Leu	Ala	Thr	Leu	Tyr	Gly	Ser	Asn	His	Lys	Gly	Thr
		130				135						140			
Ala	Ala	Glu	Glu	Ser	Ala	Ala	Leu	Arg	Thr	Leu	Phe	Ser	Arg	Met	Ala
145				150					155					160	
Ser	Leu	Gly	His	Lys	Val	Pro	Ser	Gly	Arg	Thr	Thr	Leu	Lys	Ile	Arg
				165				170						175	

atggtacaag	gagaaagctt	ggtttgcaag	aatgctcttc	aagatttgag	tttttagag	60
catttattac	aggttaaata	tgctcctaaa	acatggaaag	agcaatactt	aggatgggat	120
cttgttcaaa	gctccgtttc	tgacacagcag	aagcttcgta	cacaagaaaa	tccatcaaca	180
agtttttgcc	agcaggtcct	tgctgatttt	atcggaggat	taaattgactt	tcacgctgga	240
gtaactttct	ttgcgataga	aagtgccttac	cttccttata	cgtacaaaa	aagtagtgac	300
ggcgcgttct	actttgtaga	tatcatgact	ttttcttcag	agatccgtgt	tggagatgag	360
ttgctagagg	tggatggggc	gcctgtccaa	gatgtactcg	ctactctata	tggagcaaat	420
cacaaagggg	ctgcagctga	agagtcgggt	gctttaagaa	cactattttc	tcgcatggcc	480
tctttagggc	acaaagtacc	ttctggggcg	actacttta	agattcgctg	tccttttggt	540
actacgagag	aagttcgtgt	gaaatggcgt	tatgttcctg	aaggtgtagg	agatttggt	600
accatagctc	cttctatcag	ggctccacag	ttacagaaat	cgatgagaag	ctttttccct	660
aagaaagatg	atgcgtttca	tcggtctagt	tcgctattct	actctccaat	ggttccgc	720
ttttgggcag	agcttcgcaa	tcattatgca	acgagtggtt	tgaaaagcgg	gtacaatatt	780
gggagtaccg	atgggtttct	ccctgtcatt	gggcctgtta	tatgggagtc	ggagggtctt	840
ttccgcgctt	atatttcttc	ggtgactgat	ggggatggta	agagccataa	agtaggattt	900
ctaagaattc	ctacatatag	ttggcaggac	atggaagatt	ttgatccttc	aggaccgcct	960
ccttggaag	aatttgctaa	gattattcaa	gtattttctt	ctaatacaga	agctttgatt	1020
atcgaccaa	cgaacaaccc	aggtggtagt	gtcctttatc	tttatgcact	gctttccatg	1080
ttgacagacc	gtcctttaga	acttcctaaa	catagaatga	ttctgactca	ggatgaagtg	1140
gttgatgctt	tagattggtt	aaccctgttg	gaaaacgtag	acacaaacgt	ggagtctcgc	1200
cttgctctgg	gagacaacat	ggaaggatat	actgtggatc	tacaggttgc	cgagtattta	1260
aaaagctttg	gacgtcaagt	attgaattgt	tggagtaaag	gggatatcga	gttatcaacg	1320
cctattcctc	tttttggttt	tgagaagatt	catccacatc	ctcgagttca	atactctaaa	1380
cggatttggtg	ttttgatcaa	tgagcaagac	ttttcttggtg	ctgacttctt	ccctgtagtt	1440
ttgaaagaca	atgatcgagc	tcttattggt	ggtactcgaa	cagctggagc	tggaggattt	1500
gtctttaatg	tgagttccc	aaatagaact	ggaataaaaa	cttggtcttt	aacaggatca	1560
ttagctgtta	gagagcatgg	tgcccttcatt	gagaacatcg	gagtcgaacc	gcataatcgat	1620
ctgcctttta	cagcgaatga	tattcgctat	aaaggctatt	ccgagtatct	tgataagggtc	1680
aaaaaattgg	ttgtcagct	gatcaataac	gacggtacca	ttattcttgc	ggaagatggt	1740
agtttttag						1749

<210> 108
 <211> 582
 <212> PRT
 <213> Chlamydia trachomatis

<400> 108

Met	Val	Gln	Gly	Glu	Ser	Leu	Val	Cys	Lys	Asn	Ala	Leu	Gln	Asp	Leu
1			5						10					15	
Ser	Phe	Leu	Glu	His	Leu	Leu	Gln	Val	Lys	Tyr	Ala	Pro	Lys	Thr	Trp
		20						25					30		
Lys	Glu	Gln	Tyr	Leu	Gly	Trp	Asp	Leu	Val	Gln	Ser	Ser	Val	Ser	Ala
		35					40						45		
Gln	Gln	Lys	Leu	Arg	Thr	Gln	Glu	Asn	Pro	Ser	Thr	Ser	Phe	Cys	Gln
		50				55					60				
Gln	Val	Leu	Ala	Asp	Phe	Ile	Gly	Gly	Leu	Asn	Asp	Phe	His	Ala	Gly
65				70					75					80	
Val	Thr	Phe	Phe	Ala	Ile	Glu	Ser	Ala	Tyr	Leu	Pro	Tyr	Thr	Val	Gln
			85						90					95	
Lys	Ser	Ser	Asp	Gly	Arg	Phe	Tyr	Phe	Val	Asp	Ile	Met	Thr	Phe	Ser
			100					105					110		
Ser	Glu	Ile	Arg	Val	Gly	Asp	Glu	Leu	Leu	Glu	Val	Asp	Gly	Ala	Pro
		115				120						125			
Val	Gln	Asp	Val	Leu	Ala	Thr	Leu	Tyr	Gly	Ser	Asn	His	Lys	Gly	Thr
		130				135					140				
Ala	Ala	Glu	Glu	Ser	Ala	Ala	Leu	Arg	Thr	Leu	Phe	Ser	Arg	Met	Ala
145				150						155				160	
Ser	Leu	Gly	His	Lys	Val	Pro	Ser	Gly	Arg	Thr	Thr	Leu	Lys	Ile	Arg
			165					170						175	

Arg	Pro	Phe	Gly	Thr	Thr	Arg	Glu	Val	Arg	Val	Lys	Trp	Arg	Tyr	Val	180	185	190
Pro	Glu	Gly	Val	Gly	Asp	Leu	Ala	Thr	Ile	Ala	Pro	Ser	Ile	Arg	Ala	195	200	205
Pro	Gln	Leu	Gln	Lys	Ser	Met	Arg	Ser	Phe	Phe	Leu	Lys	Lys	Asp	Asp	210	215	220
Ala	Phe	His	Arg	Ser	Ser	Ser	Leu	Phe	Tyr	Ser	Pro	Met	Val	Pro	His	225	230	235
Phe	Trp	Ala	Glu	Leu	Arg	Asn	His	Tyr	Ala	Thr	Ser	Gly	Leu	Lys	Ser	245	250	255
Gly	Tyr	Asn	Ile	Gly	Ser	Thr	Asp	Gly	Phe	Leu	Pro	Val	Ile	Gly	Pro	260	265	270
Val	Ile	Trp	Glu	Ser	Glu	Gly	Leu	Phe	Arg	Ala	Tyr	Ile	Ser	Ser	Val	275	280	285
Thr	Asp	Gly	Asp	Gly	Lys	Ser	His	Lys	Val	Gly	Phe	Leu	Arg	Ile	Pro	290	295	300
Thr	Tyr	Ser	Trp	Gln	Asp	Met	Glu	Asp	Phe	Asp	Pro	Ser	Gly	Pro	Pro	305	310	315
Pro	Trp	Glu	Glu	Phe	Ala	Lys	Ile	Ile	Gln	Val	Phe	Ser	Ser	Asn	Thr	325	330	335
Glu	Ala	Leu	Ile	Ile	Asp	Gln	Thr	Asn	Asn	Pro	Gly	Gly	Ser	Val	Leu	340	345	350
Tyr	Leu	Tyr	Ala	Leu	Leu	Ser	Met	Leu	Thr	Asp	Arg	Pro	Leu	Glu	Leu	355	360	365
Pro	Lys	His	Arg	Met	Ile	Leu	Thr	Gln	Asp	Glu	Val	Val	Asp	Ala	Leu	370	375	380
Asp	Trp	Leu	Thr	Leu	Leu	Glu	Asn	Val	Asp	Thr	Asn	Val	Glu	Ser	Arg	385	390	395
Leu	Ala	Leu	Gly	Asp	Asn	Met	Glu	Gly	Tyr	Thr	Val	Asp	Leu	Gln	Val	405	410	415
Ala	Glu	Tyr	Leu	Lys	Ser	Phe	Gly	Arg	Gln	Val	Leu	Asn	Cys	Trp	Ser	420	425	430
Lys	Gly	Asp	Ile	Glu	Leu	Ser	Thr	Pro	Ile	Pro	Leu	Phe	Gly	Phe	Glu	435	440	445
Lys	Ile	His	Pro	His	Pro	Arg	Val	Gln	Tyr	Ser	Lys	Pro	Ile	Cys	Val	450	455	460
Leu	Ile	Asn	Glu	Gln	Asp	Phe	Ser	Cys	Ala	Asp	Phe	Phe	Pro	Val	Val	465	470	475
Leu	Lys	Asp	Asn	Asp	Arg	Ala	Leu	Ile	Val	Gly	Thr	Arg	Thr	Ala	Gly	485	490	495
Ala	Gly	Gly	Phe	Val	Phe	Asn	Val	Gln	Phe	Pro	Asn	Arg	Thr	Gly	Ile	500	505	510
Lys	Thr	Cys	Ser	Leu	Thr	Gly	Ser	Leu	Ala	Val	Arg	Glu	His	Gly	Ala	515	520	525
Phe	Ile	Glu	Asn	Ile	Gly	Val	Glu	Pro	His	Ile	Asp	Leu	Pro	Phe	Thr	530	535	540
Ala	Asn	Asp	Ile	Arg	Tyr	Lys	Gly	Tyr	Ser	Glu	Tyr	Leu	Asp	Lys	Val	545	550	555
Lys	Lys	Leu	Val	Cys	Gln	Leu	Ile	Asn	Asn	Asp	Gly	Thr	Ile	Ile	Leu	565	570	575
Ala	Glu	Asp	Gly	Ser	Phe											580		

<210> 109
 <211> 1749
 <212> DNA
 <213> Chlamydia trachomatis
 <400> 109

atggtacgag	gagaaagcct	ggtttgcaag	aatgctcttc	aagatttgag	tttttttagag	60
catttattac	aggttaaata	tgctcctaaa	acatggaaag	agcaatactt	aggatgggat	120
cttgttcaaa	gctccgtttc	tgacacagcag	aagcttcgta	cacaagaaaa	tccatcaaca	180
agtttttgcc	agcaggtcct	tgctgatttt	atcggaggat	taaatagactt	tcacgctgga	240
gtaactttct	ttgcgataga	aagtgccttac	cttccttata	ccgtacaaaa	aagtagtgac	300
ggccgtttct	actttgtaga	tatcatgact	ttttcttcag	agatccgtgt	tggagatgag	360
ttgctagagg	tggatggggc	gcctgtccaa	gatgtgctcg	ctactctata	tgggaagcaat	420
cacaaaggga	ctgcagctga	agagtcggct	gctttaagaa	cactattttc	tcgcatggcc	480
tcttttagggc	acaaagtacc	ttctggggcg	actactttta	agattcgtcg	tccttttggt	540
actacgagag	aagttcgtgt	gaaatggcgt	tatgttctctg	aaggtgtagg	agatttggt	600
accatagctc	cttctatcag	ggctccacag	ttacagaaat	cgatgagaag	ctttttccct	660
aagaaagatg	atgcgtttca	tcggtctagt	tcgctattct	actctccaat	ggttccgcat	720
ttttgggcag	agcttcgcaa	tcattatgca	acgagtggtt	tgaaaagcgg	gtacaatatt	780
gggagtagccg	atgggtttct	ccctgtcatt	gggcctgtta	tatgggagtc	ggagggctct	840
ttccgcgctt	atatttcttc	ggtgactgat	ggggatggta	agagccataa	agtaggattt	900
ctaagaattc	ctacatatag	ttggcaggac	atggaagatt	ttgatccttc	aggaccgct	960
ccttggggaag	aatttgctaa	gattattcaa	gtattttctt	ctaatacaga	agctttgatt	1020
atcgacaaa	cgaacaaccc	aggtggtagt	gtcctttatc	tttatgcaact	gctttccatg	1080
ttgacagacc	gtcctttaga	acttcctaaa	catagaatga	ttctgactca	ggatgaagtg	1140
gttgatgctt	tagattggtt	aaccctgttg	gaaaacgtag	acacaaacgt	ggagtctcgc	1200
cttgctctgg	gagacaacat	ggaaggatat	actgtggatc	tacaggttgc	cgagtattta	1260
aaaagctttg	gacgtcaagt	attgaattgt	tggagtaaag	gggatatcga	gttatcaaca	1320
cctattcctc	tttttggttt	tgagaagatt	catccacatc	ctcgagttca	atactctaaa	1380
ccgatttggtg	ttttgatcaa	tgagcaagac	ttttcttggtg	ctgacttctt	ccctgtagtt	1440
ttgaaagaca	atgacgagc	tcttattggt	ggctactcga	cagctggagc	cggtaggattt	1500
gtctttaatg	tgacgttccc	aaatagaact	ggaataaaaa	cttgttcttt	aacaggatca	1560
ttagctgtta	gagagcatgg	tgcccttcatt	gagaacatcg	gagtcgaacc	gcataatcgat	1620
ctgcctttta	cagcgaatga	tattcgtat	aaaggctatt	ccgagtatct	tgataaggctc	1680
aaaaaattgg	tttgtcagct	gatcaataac	gacggtagca	ttattcttgc	ggaagatggt	1740
agtttttag						1749

<210> 110
 <211> 582
 <212> PRT
 <213> Chlamydia trachomatis

<400> 110

Met	Val	Arg	Gly	Glu	Ser	Leu	Val	Cys	Lys	Asn	Ala	Leu	Gln	Asp	Leu
1			5					10						15	
Ser	Phe	Leu	Glu	His	Leu	Leu	Gln	Val	Lys	Tyr	Ala	Pro	Lys	Thr	Trp
		20						25					30		
Lys	Glu	Gln	Tyr	Leu	Gly	Trp	Asp	Leu	Val	Gln	Ser	Ser	Val	Ser	Ala
		35					40						45		
Gln	Gln	Lys	Leu	Arg	Thr	Gln	Glu	Asn	Pro	Ser	Thr	Ser	Phe	Cys	Gln
		50				55					60				
Gln	Val	Leu	Ala	Asp	Phe	Ile	Gly	Gly	Leu	Asn	Asp	Phe	His	Ala	Gly
65				70				75						80	
Val	Thr	Phe	Phe	Ala	Ile	Glu	Ser	Ala	Tyr	Leu	Pro	Tyr	Thr	Val	Gln
			85					90						95	
Lys	Ser	Ser	Asp	Gly	Arg	Phe	Tyr	Phe	Val	Asp	Ile	Met	Thr	Phe	Ser
		100						105					110		
Ser	Glu	Ile	Arg	Val	Gly	Asp	Glu	Leu	Leu	Glu	Val	Asp	Gly	Ala	Pro
		115				120						125			
Val	Gln	Asp	Val	Leu	Ala	Thr	Leu	Tyr	Gly	Ser	Asn	His	Lys	Gly	Thr
		130				135					140				
Ala	Ala	Glu	Glu	Ser	Ala	Ala	Leu	Arg	Thr	Leu	Phe	Ser	Arg	Met	Ala
145				150				155						160	
Ser	Leu	Gly	His	Lys	Val	Pro	Ser	Gly	Arg	Thr	Thr	Leu	Lys	Ile	Arg
			165					170						175	

Arg	Pro	Phe	Gly	Thr	Thr	Arg	Glu	Val	Arg	Val	Lys	Trp	Arg	Tyr	Val	180	185	190
Pro	Glu	Gly	Val	Gly	Asp	Leu	Ala	Thr	Ile	Ala	Pro	Ser	Ile	Arg	Ala	195	200	205
Pro	Gln	Leu	Gln	Lys	Ser	Met	Arg	Ser	Phe	Phe	Leu	Lys	Lys	Asp	Asp	210	215	220
Ala	Phe	His	Arg	Ser	Ser	Ser	Leu	Phe	Tyr	Ser	Pro	Met	Val	Pro	His	225	230	235
Phe	Trp	Ala	Glu	Leu	Arg	Asn	His	Tyr	Ala	Thr	Ser	Gly	Leu	Lys	Ser	245	250	255
Gly	Tyr	Asn	Ile	Gly	Ser	Thr	Asp	Gly	Phe	Leu	Pro	Val	Ile	Gly	Pro	260	265	270
Val	Ile	Trp	Glu	Ser	Glu	Gly	Leu	Phe	Arg	Ala	Tyr	Ile	Ser	Ser	Val	275	280	285
Thr	Asp	Gly	Asp	Gly	Lys	Ser	His	Lys	Val	Gly	Phe	Leu	Arg	Ile	Pro	290	295	300
Thr	Tyr	Ser	Trp	Gln	Asp	Met	Glu	Asp	Phe	Asp	Pro	Ser	Gly	Pro	Pro	305	310	315
Pro	Trp	Glu	Glu	Phe	Ala	Lys	Ile	Ile	Gln	Val	Phe	Ser	Ser	Asn	Thr	325	330	335
Glu	Ala	Leu	Ile	Asp	Gln	Thr	Asn	Asn	Pro	Gly	Gly	Ser	Val	Leu		340	345	350
Tyr	Leu	Tyr	Ala	Leu	Leu	Ser	Met	Leu	Thr	Asp	Arg	Pro	Leu	Glu	Leu	355	360	365
Pro	Lys	His	Arg	Met	Ile	Leu	Thr	Gln	Asp	Glu	Val	Val	Asp	Ala	Leu	370	375	380
Asp	Trp	Leu	Thr	Leu	Leu	Glu	Asn	Val	Asp	Thr	Asn	Val	Glu	Ser	Arg	385	390	395
Leu	Ala	Leu	Gly	Asp	Asn	Met	Glu	Gly	Tyr	Thr	Val	Asp	Leu	Gln	Val	405	410	415
Ala	Glu	Tyr	Leu	Lys	Ser	Phe	Gly	Arg	Gln	Val	Leu	Asn	Cys	Trp	Ser	420	425	430
Lys	Gly	Asp	Ile	Glu	Leu	Ser	Thr	Pro	Ile	Pro	Leu	Phe	Gly	Phe	Glu	435	440	445
Lys	Ile	His	Pro	His	Pro	Arg	Val	Gln	Tyr	Ser	Lys	Pro	Ile	Cys	Val	450	455	460
Leu	Ile	Asn	Glu	Gln	Asp	Phe	Ser	Cys	Ala	Asp	Phe	Phe	Pro	Val	Val	465	470	475
Leu	Lys	Asp	Asn	Asp	Arg	Ala	Leu	Ile	Val	Gly	Thr	Arg	Thr	Ala	Gly	485	490	495
Ala	Gly	Gly	Phe	Val	Phe	Asn	Val	Gln	Phe	Pro	Asn	Arg	Thr	Gly	Ile	500	505	510
Lys	Thr	Cys	Ser	Leu	Thr	Gly	Ser	Leu	Ala	Val	Arg	Glu	His	Gly	Ala	515	520	525
Phe	Ile	Glu	Asn	Ile	Gly	Val	Glu	Pro	His	Ile	Asp	Leu	Pro	Phe	Thr	530	535	540
Ala	Asn	Asp	Ile	Arg	Tyr	Lys	Gly	Tyr	Ser	Glu	Tyr	Leu	Asp	Lys	Val	545	550	555
Lys	Lys	Leu	Val	Cys	Gln	Leu	Ile	Asn	Asn	Asp	Gly	Thr	Ile	Ile	Leu	565	570	575
Ala	Glu	Asp	Gly	Ser	Phe											580		

<210> 111
 <211> 1770
 <212> DNA
 <213> Chlamydia trachomatis
 <400> 111

atgagcatca	ggggagtagg	aggcaacggg	aatagtcgaa	tcccttctca	taatggggat	60
ggatcgaatc	gcagaagtca	aaatacgaag	aataaagttg	aagatcgagt	tcgttctcta	120
tattcatctc	gtagtaacga	aaatagagaa	tctccttatg	cagtagtaga	cgtcagctct	180
atgatcgaga	gcacccaac	gagtggagag	acgacaagag	cttcgcgtgg	agtattcagt	240
cgtttccaaa	gaggtttagg	acgagtagct	gacaaaagta	gacgagctgt	tcagcgtgcg	300
tggagttcag	tctctataag	aagatcgctc	gcaacaagag	ccacagaatc	cagatcaagt	360
agtcgtactg	ctcgtggtgc	aagttctggg	tataaggagt	attctccttc	agcagctaga	420
gggctgcgtc	ttatgttcac	agatttctgg	agaactcggg	ttttacgcca	gacctctcct	480
atggctggag	tttttgggaa	tcttgatgtg	aacgaggctc	gtttgatggc	tgcgtacaca	540
agtgagtgcg	cggatcattt	agaagcgaag	gagttggctg	gccctgacgg	ggtagcggcc	600
gccccggaaa	ttgctaaaag	atgggagaaa	agagttagag	atctacaaga	taaagggtgt	660
gcacgaaaat	tattaaatga	tccttttaggc	cgacgaacac	ctaattatca	gagcaaaaat	720
ccaggtgagt	atactgtagg	gaattccatg	ttttacgatg	gtcctcaggt	agcgaatctc	780
cagaacgtcg	acactggttt	ttggctggac	atgagcaatc	tctcagacgt	tgtattatcc	840
agagagattc	aaacaggact	tcgagcacga	gctactttgg	aagaatccat	gccgatgtta	900
gagaatttag	aagagcgttt	tagacgtttg	caagaaactt	gtgatgcggc	tcgtactgag	960
atagaagaat	cgggatggac	tcgagagtcc	gcatcaagaa	tggaaaggcga	tgaggcgcaa	1020
ggaccttcta	gagcacaaca	agcttttcag	agctttgtaa	atgaatgtaa	cagcatcgag	1080
ttctcatttg	ggagctttgg	agagcatgtg	cgagttctct	gcgctagagt	atcacgagga	1140
ttagctgccg	caggagaggc	gattcgccgt	tgcttctctt	gttgtaaagg	atcgacgcat	1200
cgctacgctc	ctcgcgatga	cctatctcct	gaaggtgcat	cgttagcaga	gactttggct	1260
agattcgcag	atgatattggg	aatagagcga	ggtgctgatg	gaacctacga	tattcctttg	1320
gtagatgatt	ggagaagagg	ggttcctagt	attgaaggag	aaggatctga	ctcgatctat	1380
gaaatcatga	tgcttatcta	tgaagttatg	aatatggatc	tagaaacacg	aagatctttt	1440
gcggtacagc	aagggcacta	tcaggaccca	agagcttcag	attatgacct	cccacgtgct	1500
agcgactatg	atltgcctag	aagcccatat	cctactccac	ctttgcctcc	tagatatcag	1560
ctacagaata	tggatgtaga	agcagggttc	cgtgaggcag	tttatgcttc	ttttgtagca	1620
ggaatgtaca	attatgtagt	gacacagccg	caagagcgta	ttcccaatag	tcagcaggtg	1680
gaagggattc	tgctgtatat	gcttaccaac	gggtcacaga	catttagaga	cctgatgaag	1740
cgttggaaata	gagaagtcga	tagggaataa				1770

<210> 112
 <211> 589
 <212> PRT
 <213> Chlamydia trachomatis

<400> 112

Met	Ser	Ile	Arg	Gly	Val	Gly	Gly	Asn	Gly	Asn	Ser	Arg	Ile	Pro	Ser
1				5					10					15	
His	Asn	Gly	Asp	Gly	Ser	Asn	Arg	Arg	Gln	Asn	Thr	Lys	Asn	Lys	
			20					25				30			
Val	Glu	Asp	Arg	Val	Arg	Ser	Leu	Tyr	Ser	Ser	Arg	Ser	Asn	Glu	Asn
		35					40					45			
Arg	Glu	Ser	Pro	Tyr	Ala	Val	Val	Asp	Val	Ser	Ser	Met	Ile	Glu	Ser
		50					55				60				
Thr	Pro	Thr	Ser	Gly	Glu	Thr	Thr	Arg	Ala	Ser	Arg	Gly	Val	Phe	Ser
65					70					75				80	
Arg	Phe	Gln	Arg	Gly	Leu	Gly	Arg	Val	Ala	Asp	Lys	Val	Arg	Arg	Ala
			85						90					95	
Val	Gln	Arg	Ala	Trp	Ser	Ser	Val	Ser	Ile	Arg	Arg	Ser	Ser	Ala	Thr
			100					105					110		
Arg	Ala	Thr	Glu	Ser	Arg	Ser	Ser	Ser	Arg	Thr	Ala	Arg	Gly	Ala	Ser
		115					120					125			
Ser	Gly	Tyr	Lys	Glu	Tyr	Ser	Pro	Ser	Ala	Ala	Arg	Gly	Leu	Arg	Leu
	130					135					140				
Met	Phe	Thr	Asp	Phe	Trp	Arg	Thr	Arg	Val	Leu	Arg	Gln	Thr	Ser	Pro
145					150					155				160	
Met	Ala	Gly	Val	Phe	Gly	Asn	Leu	Asp	Val	Asn	Glu	Ala	Arg	Leu	Met
			165						170					175	

Ala	Ala	Tyr	Thr	Ser	Glu	Cys	Ala	Asp	His	Leu	Glu	Ala	Lys	Glu	Leu	180	185	190
Ala	Gly	Pro	Asp	Gly	Val	Ala	Ala	Ala	Arg	Glu	Ile	Ala	Lys	Arg	Trp	195	200	205
Glu	Lys	Arg	Val	Arg	Asp	Leu	Gln	Asp	Lys	Gly	Ala	Ala	Arg	Lys	Leu	210	215	220
Leu	Asn	Asp	Pro	Leu	Gly	Arg	Arg	Thr	Pro	Asn	Tyr	Gln	Ser	Lys	Asn	225	230	235
Pro	Gly	Glu	Tyr	Thr	Val	Gly	Asn	Ser	Met	Phe	Tyr	Asp	Gly	Pro	Gln	245	250	255
Val	Ala	Asn	Leu	Gln	Asn	Val	Asp	Thr	Gly	Phe	Trp	Leu	Asp	Met	Ser	260	265	270
Asn	Leu	Ser	Asp	Val	Val	Leu	Ser	Arg	Glu	Ile	Gln	Thr	Gly	Leu	Arg	275	280	285
Ala	Arg	Ala	Thr	Leu	Glu	Glu	Ser	Met	Pro	Met	Leu	Glu	Asn	Leu	Glu	290	295	300
Glu	Arg	Phe	Arg	Arg	Leu	Gln	Glu	Thr	Cys	Asp	Ala	Ala	Arg	Thr	Glu	305	310	315
Ile	Glu	Glu	Ser	Gly	Trp	Thr	Arg	Glu	Ser	Ala	Ser	Arg	Met	Glu	Gly	325	330	335
Asp	Glu	Ala	Gln	Gly	Pro	Ser	Arg	Ala	Gln	Gln	Ala	Phe	Gln	Ser	Phe	340	345	350
Val	Asn	Glu	Cys	Asn	Ser	Ile	Glu	Phe	Ser	Phe	Gly	Ser	Phe	Gly	Glu	355	360	365
His	Val	Arg	Val	Leu	Cys	Ala	Arg	Val	Ser	Arg	Gly	Leu	Ala	Ala	Ala	370	375	380
Gly	Glu	Ala	Ile	Arg	Arg	Cys	Phe	Ser	Cys	Cys	Lys	Gly	Ser	Thr	His	385	390	395
Arg	Tyr	Ala	Pro	Arg	Asp	Asp	Leu	Ser	Pro	Glu	Gly	Ala	Ser	Leu	Ala	405	410	415
Glu	Thr	Leu	Ala	Arg	Phe	Ala	Asp	Asp	Met	Gly	Ile	Glu	Arg	Gly	Ala	420	425	430
Asp	Gly	Thr	Tyr	Asp	Ile	Pro	Leu	Val	Asp	Asp	Trp	Arg	Arg	Gly	Val	435	440	445
Pro	Ser	Ile	Glu	Gly	Glu	Gly	Ser	Asp	Ser	Ile	Tyr	Glu	Ile	Met	Met	450	455	460
Pro	Ile	Tyr	Glu	Val	Met	Asn	Met	Asp	Leu	Glu	Thr	Arg	Arg	Ser	Phe	465	470	475
Ala	Val	Gln	Gln	Gly	His	Tyr	Gln	Asp	Pro	Arg	Ala	Ser	Asp	Tyr	Asp	485	490	495
Leu	Pro	Arg	Ala	Ser	Asp	Tyr	Asp	Leu	Pro	Arg	Ser	Pro	Tyr	Pro	Thr	500	505	510
Pro	Pro	Leu	Pro	Pro	Arg	Tyr	Gln	Leu	Gln	Asn	Met	Asp	Val	Glu	Ala	515	520	525
Gly	Phe	Arg	Glu	Ala	Val	Tyr	Ala	Ser	Phe	Val	Ala	Gly	Met	Tyr	Asn	530	535	540
Tyr	Val	Val	Thr	Gln	Pro	Gln	Glu	Arg	Ile	Pro	Asn	Ser	Gln	Gln	Val	545	550	555
Glu	Gly	Ile	Leu	Arg	Asp	Met	Leu	Thr	Asn	Gly	Ser	Gln	Thr	Phe	Arg	565	570	575
Asp	Leu	Met	Lys	Arg	Trp	Asn	Arg	Glu	Val	Asp	Arg	Glu				580	585	

<210> 113

<211> 1770

<212> DNA

<213> Chlamydia trachomatis

<400> 113

atgagcatca	ggggagtagg	aggcaacggg	aatagtcgaa	tcccttctca	taatggggat	60
ggatcgaaatc	gcagaagtca	aaatacgaag	aataaagttg	aagatcgagt	tcgttctcta	120
tattcatctc	gtagtaacga	aaatagagaa	tctccttatg	cagtagtaga	cgtagctct	180
atgatcgaga	gcacccaac	gagtggagag	acgacaagag	cttcgctgg	agtattcagt	240
cgtttccaaa	gaggtttagg	acgagtagct	gacaaagtaa	gacgagctgt	tcagcgtgcg	300
tggagtccag	tctctataag	aagatcgtct	gcaacaagag	ccgcagaatc	cagatcaagt	360
agtcgtactg	ctcgtggtgc	aagttctggg	tatagggagt	attctccttc	agcagctaga	420
gggctgcgtc	ttatgttcac	agatttctgg	agaactcggg	ttttacgcc	gacctctct	480
atggctggag	tttttgggaa	tcttgatgtg	aacgaggctc	gtttgatggc	tgcgtacaca	540
agtgagtgcg	cggatcattt	agaagcgaag	gagttggctg	gccctgacgg	ggtagcggcc	600
gcccgggaaa	ttgctaaaag	atgggagaaa	agagtttagag	atctacaaga	taaagggtgt	660
gcacgaaaat	tattaaatga	tcttttaggc	cgacgaacac	ctaattatca	gagcaaaaat	720
ccaggtgagt	atactgtagg	gaattccatg	ttttacgatg	gtcctcaggt	agcgaatctc	780
cagaacgtcg	acactggttt	ttggctggac	atgagcaatc	tctcagacgt	tgtattatcc	840
agagagattc	aaacaggact	tcgagcacga	gctactttgg	aagaatccat	gccgatgtta	900
gagaatttag	aagagcgttt	tagacgtttg	caagaaactt	gtgatgctgc	tcgtactgag	960
atagaagaat	cgggatggac	tcgagagtc	gcatcaagaa	tggaaggcga	tgaggcgcaa	1020
ggaccttcta	gagcacaaca	agcttttcag	agctttgtaa	atgaatgtaa	cagcatcgag	1080
ttctcatttg	ggagctttgg	agagcatgtg	cgagttctct	gcgctagagt	atcacgagga	1140
ttagctgccg	caggagaggc	gattcgcctg	tgcttctctt	gttgtaaagg	atcgacgcgt	1200
cgctacgctc	ctcgcgatga	cctatctcct	gaaggtgcat	cgtagcaga	gactttggct	1260
agattcgcag	atgatatggg	aatagagcga	ggtgctgatg	gaacctacga	tattcctttg	1320
gtagatgatt	ggagaagagg	ggttcctagt	attgaaggag	aaggatctga	ctcgatctat	1380
gaaatcatga	tgcctatcta	tgaagttatg	aatatggatc	tagaaacacg	aagatctttt	1440
gcggtacagc	aagggcacta	tcaggaccca	agagcttcag	attatgacct	cccacgtgct	1500
agcgactatg	atttgcctag	aagcccatat	cctactccac	ctttgcctcc	tagatatcag	1560
ctacagaata	tggatgtaga	agcagggttc	cgtgaggcag	tttatgcttc	ttttgtagca	1620
ggaatgtaca	attatgtagt	gacacagccg	caagagcgta	ttcccaatag	tcagcagggtg	1680
gaagagattc	tgcgtgatat	gcttaccaac	gggtcacaga	catttagaga	cctgatgaag	1740
cgttggaata	gagaagtcga	tagggaataa				1770

<210> 114

<211> 589

<212> PRT

<213> Chlamydia trachomatis

<400> 114

Met	Ser	Ile	Arg	Gly	Val	Gly	Gly	Asn	Gly	Asn	Ser	Arg	Ile	Pro	Ser
1				5				10						15	
His	Asn	Gly	Asp	Gly	Ser	Asn	Arg	Arg	Ser	Gln	Asn	Thr	Lys	Asn	Lys
			20					25					30		
Val	Glu	Asp	Arg	Val	Arg	Ser	Leu	Tyr	Ser	Ser	Arg	Ser	Asn	Glu	Asn
		35					40					45			
Arg	Glu	Ser	Pro	Tyr	Ala	Val	Val	Asp	Val	Ser	Ser	Met	Ile	Glu	Ser
		50				55					60				
Thr	Pro	Thr	Ser	Gly	Glu	Thr	Thr	Arg	Ala	Ser	Arg	Gly	Val	Phe	Ser
65				70				75						80	
Arg	Phe	Gln	Arg	Gly	Leu	Gly	Arg	Val	Ala	Asp	Lys	Val	Arg	Arg	Ala
			85					90					95		
Val	Gln	Arg	Ala	Trp	Ser	Ser	Val	Ser	Ile	Arg	Arg	Ser	Ser	Ala	Thr
			100					105					110		
Arg	Ala	Ala	Glu	Ser	Arg	Ser	Ser	Ser	Arg	Thr	Ala	Arg	Gly	Ala	Ser
			115					120				125			
Ser	Gly	Tyr	Arg	Glu	Tyr	Ser	Pro	Ser	Ala	Ala	Arg	Gly	Leu	Arg	Leu
		130				135					140				
Met	Phe	Thr	Asp	Phe	Trp	Arg	Thr	Arg	Val	Leu	Arg	Gln	Thr	Ser	Pro
145				150				155						160	
Met	Ala	Gly	Val	Phe	Gly	Asn	Leu	Asp	Val	Asn	Glu	Ala	Arg	Leu	Met
			165					170						175	

atgagcatca	ggggagtagg	aggcaacggg	aatagtcgaa	tcccttctca	taatggggat	60
ggatcgaatc	gcagaagtca	aaatacgaag	ggtaataata	aagttgaaga	tcgagtttgt	120
tctctatatt	catctcgtag	taacgaaaat	agagaatctc	cttatgcagt	agtagacgtc	180
agctctatga	tcgagagcac	cccaacgagt	ggagagacga	caagagcttc	gcgtggagtg	240
ttcagtcggt	tccaaagagg	tttagtacga	gtagctgaca	aagtaagacg	agctgttcag	300
tgtgcgtgga	gttcagtcctc	tacaagaaga	tcgtctgcaa	caagagccgc	agaatccgga	360
tcaagtagtc	gtactgctcg	tggtgcaagt	tctgggtata	gggagtattc	tccttcagca	420
gctagagggc	tgctcttat	gttcacagat	ttctggagaa	ctcgggtttt	acgcagacc	480
tctcctatgg	ctggagtttt	tgggaaatctt	gatgtgaacg	aggctcggtt	gatggctgcg	540
tacacaagtg	agtgcgcgga	tcatttagaa	gcgaacaagt	tggtcgcccc	tgacggggta	600
gcgccgcgcc	gggaaattgc	taaaagatgg	gagcaaagag	ttagagatct	acaagataaa	660
ggtgctgcac	gaaaattatt	aaatgatcct	ttaggccgac	gaacacctaa	ttatcagagc	720
aaaaatccag	gtgagtatac	tgtagggaat	tccatgtttt	acgatgggtcc	tcaggtagcg	780
aatctccaga	acgtcgacac	tggttttttg	ctggacatga	gcaatctctc	agacgttgta	840
ttatccagag	agattcaaac	aggacttcga	gcacgagcta	ctttggaaga	atccatgccg	900
atggttagaga	atthagaaga	gcgtttttaga	cgtttgcaag	aaacttggtga	tgccggctcgt	960
actgagatag	aagaatcggg	atggactcga	gagtcgcgat	caagaatgga	aggcgatgag	1020
gcgcaaggac	cttctagagc	acaacaagct	tttcagagct	ttgtaaatga	atgtaacagc	1080
atcgagttct	catttgggag	ctttggagag	catgtgcgag	ttctctgcgc	tagagtatca	1140
cgaggattag	ctgccgcagg	agaggcgatt	cgcggttgct	tctcttggtg	taaaggatcg	1200
acgcacgcct	acgctcctcg	cgatgacctc	tctcctgaag	gtgcatcggt	agcagagact	1260
ttggctagat	tcgcagatga	tatgggaata	gagcgagggtg	ctgatggaac	ctacgatatt	1320
cctttggtag	atgattggag	aagaggggtt	cctagtattg	aaggagaagg	atctgactcg	1380
atctatgaaa	tcgatgctcc	tatctatgaa	gttatggata	tggatctaga	aacacgaaga	1440
tcttttgccg	tacagcaagg	gcactatcag	gacccaagag	cttcagatta	tgacctccca	1500
cgtgctagcg	actatgattt	gcctagaagc	ccatatccta	ctccaccttt	gcctcctaga	1560
tatcagctac	agaatatgga	tgtagaagca	gggttcctgt	aggcagttta	tgcttctttt	1620
gtagcaggaa	tgtacaatta	tgtagtgaac	cagccgcaag	agcgtattcc	caatagtcag	1680
cagggtggaag	ggattctgcg	tgatatgctt	accaacgggt	cacagacatt	tagagacctg	1740
atgaggcggt	ggaatagaga	agtcgatagg	gaataa			1776

<210> 116

<211> 591

<212> PRT

<213> Chlamydia trachomatis

<400> 116

Met	Ser	Ile	Arg	Gly	Val	Gly	Gly	Asn	Gly	Asn	Ser	Arg	Ile	Pro	Ser
1				5				10						15	
His	Asn	Gly	Asp	Gly	Ser	Asn	Arg	Arg	Ser	Gln	Asn	Thr	Lys	Gly	Asn
			20					25					30		
Asn	Lys	Val	Glu	Asp	Arg	Val	Cys	Ser	Leu	Tyr	Ser	Ser	Arg	Ser	Asn
		35					40					45			
Glu	Asn	Arg	Glu	Ser	Pro	Tyr	Ala	Val	Val	Asp	Val	Ser	Ser	Met	Ile
	50					55				60					
Glu	Ser	Thr	Pro	Thr	Ser	Gly	Glu	Thr	Thr	Arg	Ala	Ser	Arg	Gly	Val
65					70					75				80	
Phe	Ser	Arg	Phe	Gln	Arg	Gly	Leu	Val	Arg	Val	Ala	Asp	Lys	Val	Arg
			85						90					95	
Arg	Ala	Val	Gln	Cys	Ala	Trp	Ser	Ser	Val	Ser	Thr	Arg	Arg	Ser	Ser
		100					105					110			
Ala	Thr	Arg	Ala	Ala	Glu	Ser	Gly	Ser	Ser	Ser	Arg	Thr	Ala	Arg	Gly
	115					120					125				
Ala	Ser	Ser	Gly	Tyr	Arg	Glu	Tyr	Ser	Pro	Ser	Ala	Ala	Arg	Gly	Leu
	130					135				140					
Arg	Leu	Met	Phe	Thr	Asp	Phe	Trp	Arg	Thr	Arg	Val	Leu	Arg	Gln	Thr
145					150					155				160	
Ser	Pro	Met	Ala	Gly	Val	Phe	Gly	Asn	Leu	Asp	Val	Asn	Glu	Ala	Arg
			165					170					175		

Leu	Met	Ala	Ala	Tyr	Thr	Ser	Glu	Cys	Ala	Asp	His	Leu	Glu	Ala	Asn	180	185	190
Lys	Leu	Ala	Gly	Pro	Asp	Gly	Val	Ala	Ala	Ala	Arg	Glu	Ile	Ala	Lys	195	200	205
Arg	Trp	Glu	Gln	Arg	Val	Arg	Asp	Leu	Gln	Asp	Lys	Gly	Ala	Ala	Arg	210	215	220
Lys	Leu	Leu	Asn	Asp	Pro	Leu	Gly	Arg	Arg	Thr	Pro	Asn	Tyr	Gln	Ser	225	230	235
Lys	Asn	Pro	Gly	Glu	Tyr	Thr	Val	Gly	Asn	Ser	Met	Phe	Tyr	Asp	Gly	245	250	255
Pro	Gln	Val	Ala	Asn	Leu	Gln	Asn	Val	Asp	Thr	Gly	Phe	Trp	Leu	Asp	260	265	270
Met	Ser	Asn	Leu	Ser	Asp	Val	Val	Leu	Ser	Arg	Glu	Ile	Gln	Thr	Gly	275	280	285
Leu	Arg	Ala	Arg	Ala	Thr	Leu	Glu	Glu	Ser	Met	Pro	Met	Leu	Glu	Asn	290	295	300
Leu	Glu	Glu	Arg	Phe	Arg	Arg	Leu	Gln	Glu	Thr	Cys	Asp	Ala	Ala	Arg	305	310	315
Thr	Glu	Ile	Glu	Glu	Ser	Gly	Trp	Thr	Arg	Glu	Ser	Ala	Ser	Arg	Met	325	330	335
Glu	Gly	Asp	Glu	Ala	Gln	Gly	Pro	Ser	Arg	Ala	Gln	Gln	Ala	Phe	Gln	340	345	350
Ser	Phe	Val	Asn	Glu	Cys	Asn	Ser	Ile	Glu	Phe	Ser	Phe	Gly	Ser	Phe	355	360	365
Gly	Glu	His	Val	Arg	Val	Leu	Cys	Ala	Arg	Val	Ser	Arg	Gly	Leu	Ala	370	375	380
Ala	Ala	Gly	Glu	Ala	Ile	Arg	Arg	Cys	Phe	Ser	Cys	Cys	Lys	Gly	Ser	385	390	395
Thr	His	Arg	Tyr	Ala	Pro	Arg	Asp	Asp	Leu	Ser	Pro	Glu	Gly	Ala	Ser	405	410	415
Leu	Ala	Glu	Thr	Leu	Ala	Arg	Phe	Ala	Asp	Asp	Met	Gly	Ile	Glu	Arg	420	425	430
Gly	Ala	Asp	Gly	Thr	Tyr	Asp	Ile	Pro	Leu	Val	Asp	Asp	Trp	Arg	Arg	435	440	445
Gly	Val	Pro	Ser	Ile	Glu	Gly	Glu	Gly	Ser	Asp	Ser	Ile	Tyr	Glu	Ile	450	455	460
Met	Met	Pro	Ile	Tyr	Glu	Val	Met	Asp	Met	Asp	Leu	Glu	Thr	Arg	Arg	465	470	475
Ser	Phe	Ala	Val	Gln	Gln	Gly	His	Tyr	Gln	Asp	Pro	Arg	Ala	Ser	Asp	485	490	495
Tyr	Asp	Leu	Pro	Arg	Ala	Ser	Asp	Tyr	Asp	Leu	Pro	Arg	Ser	Pro	Tyr	500	505	510
Pro	Thr	Pro	Pro	Leu	Pro	Pro	Arg	Tyr	Gln	Leu	Gln	Asn	Met	Asp	Val	515	520	525
Glu	Ala	Gly	Phe	Arg	Glu	Ala	Val	Tyr	Ala	Ser	Phe	Val	Ala	Gly	Met	530	535	540
Tyr	Asn	Tyr	Val	Val	Thr	Gln	Pro	Gln	Glu	Arg	Ile	Pro	Asn	Ser	Gln	545	550	555
Gln	Val	Glu	Gly	Ile	Leu	Arg	Asp	Met	Leu	Thr	Asn	Gly	Ser	Gln	Thr	565	570	575
Phe	Arg	Asp	Leu	Met	Arg	Arg	Trp	Asn	Arg	Glu	Val	Asp	Arg	Glu		580	585	590

<210> 117
 <211> 1776
 <212> DNA
 <213> Chlamydia trachomatis

 <400> 117

atgagcatca	ggggagtagg	aggcaacggg	aatagtcgaa	tcctttctca	taatggggat	60
ggatcgaatc	gcagaagtca	aaatacgaag	ggtaataata	aagttgaaga	tcgagtttgt	120
tctctatatt	catctcgtag	taacgaaaat	agagaatctc	cttatgcagt	agtagacgtc	180
agctctatga	tcgagagcac	cccaacgagt	ggagagacga	caagagcttc	gcgtggagtg	240
ttcagtcggt	tccaaagagg	tttagtacga	gtagctgaca	aagtaagacg	agctgttcag	300
tgtgcgtgga	gttcagtctc	tacaagaaga	tcgtctgcaa	caagagccgc	agaatccgga	360
tcaagtagtc	gtactgctcg	tggtgcaagt	tctgggtata	gggagtattc	tccttcagca	420
gctagagggc	tgctgtctat	gttcacagat	ttctggagaa	ctcgggtttt	acgccagacc	480
tctcctatgg	ctggagtttt	tgggaatcct	gatgtgaacg	aggctcgttt	gatggctgcg	540
tacacaagtg	agtgcgcgga	tcatttagaa	gcgaacaagt	tggctggccc	tgacggggta	600
gcggccgccc	gggaaattgc	taaaagatgg	gagcaaagag	ttagagatct	acaagataaa	660
ggtgctgcac	gaaaattatt	aaatgatcct	ttaggccgac	gaacacctaa	ttatcagagc	720
aaaaatccag	gtgagtatac	tgtagggaat	tccatgtttt	acgatgggtcc	tcaggtagcg	780
aatctccaga	acgtcgacac	tggtttttgg	ctggacatga	gcaatctctc	agacgttgta	840
ttatccagag	agattcaaac	aggacttcga	gcacgagcta	ctttggaaga	atccatgccg	900
atgtagagag	atttagaaga	gcgttttaga	cgtttgcaag	aaacttgtag	tgccggctcgt	960
actgagatag	aagaatcggg	atggactcga	gagtcgcgat	caagaatgga	aggcgatgag	1020
gcgcaaggac	cttctagagc	acaacaagct	tttcagagct	ttgtaaata	atgtaacagc	1080
atcgagttct	catttgggag	ctttggagag	catgtgcgag	ttctctgcgc	tagagtatca	1140
cgaggattag	ctgccgcagg	agaggcgatt	cgccgttgct	tctcttggtg	taaaggatcg	1200
acgcacgcgt	acgctcctcg	cgatgaccta	tctcctgaag	gtgcatcggt	agcagagact	1260
ttggctagat	tcgcagatga	tatgggaata	gagcgagggt	ctgatggaac	ctacgatatt	1320
cctttggtag	atgattggag	aagaggggtt	cctagtattg	aaggagaagg	atctgactcg	1380
atctatgaaa	tcatgatgcc	tatctatgaa	gttatggata	tggatctaga	aacacgaaga	1440
tcttttgccg	tacagcaagg	gcactatcag	gaccaagag	cttcagatta	tgacctccca	1500
cgtgctagcg	actatgattt	gcctagaagc	ccatatccta	ctccaccttt	gcctcctaga	1560
tatcagctac	agaatatgga	tgtagaagca	gggttcctgt	aggcagttta	tgcttctttt	1620
gtagcaggaa	tgtataatta	tgtagtga	cagccgcaag	agcgtattcc	caatagtcag	1680
caggtggaag	ggattctgcg	tgatatgctt	accaacgggt	cacagacatt	tagagacctg	1740
atgaagcggt	ggaatagaga	agtcgatagg	gaataa			1776

<210> 118

<211> 591

<212> PRT

<213> Chlamydia trachomatis

<400> 118

Met	Ser	Ile	Arg	Gly	Val	Gly	Gly	Asn	Gly	Asn	Ser	Arg	Ile	Pro	Ser
1				5				10						15	
His	Asn	Gly	Asp	Gly	Ser	Asn	Arg	Arg	Ser	Gln	Asn	Thr	Lys	Gly	Asn
			20					25					30		
Asn	Lys	Val	Glu	Asp	Arg	Val	Cys	Ser	Leu	Tyr	Ser	Ser	Arg	Ser	Asn
		35					40					45			
Glu	Asn	Arg	Glu	Ser	Pro	Tyr	Ala	Val	Val	Asp	Val	Ser	Ser	Met	Ile
	50					55				60					
Glu	Ser	Thr	Pro	Thr	Ser	Gly	Glu	Thr	Thr	Arg	Ala	Ser	Arg	Gly	Val
65					70					75				80	
Phe	Ser	Arg	Phe	Gln	Arg	Gly	Leu	Val	Arg	Val	Ala	Asp	Lys	Val	Arg
			85					90					95		
Arg	Ala	Val	Gln	Cys	Ala	Trp	Ser	Ser	Val	Ser	Thr	Arg	Arg	Ser	Ser
		100						105					110		
Ala	Thr	Arg	Ala	Ala	Glu	Ser	Gly	Ser	Ser	Ser	Arg	Thr	Ala	Arg	Gly
	115						120					125			
Ala	Ser	Ser	Gly	Tyr	Arg	Glu	Tyr	Ser	Pro	Ser	Ala	Ala	Arg	Gly	Leu
	130					135					140				
Arg	Leu	Met	Phe	Thr	Asp	Phe	Trp	Arg	Thr	Arg	Val	Leu	Arg	Gln	Thr
145					150					155				160	
Ser	Pro	Met	Ala	Gly	Val	Phe	Gly	Asn	Leu	Asp	Val	Asn	Glu	Ala	Arg
			165					170					175		

Leu	Met	Ala	Ala	Tyr	Thr	Ser	Glu	Cys	Ala	Asp	His	Leu	Glu	Ala	Asn	180	185	190
Lys	Leu	Ala	Gly	Pro	Asp	Gly	Val	Ala	Ala	Ala	Arg	Glu	Ile	Ala	Lys	195	200	205
Arg	Trp	Glu	Gln	Arg	Val	Arg	Asp	Leu	Gln	Asp	Lys	Gly	Ala	Ala	Arg	210	215	220
Lys	Leu	Leu	Asn	Asp	Pro	Leu	Gly	Arg	Arg	Thr	Pro	Asn	Tyr	Gln	Ser	225	230	235
Lys	Asn	Pro	Gly	Glu	Tyr	Thr	Val	Gly	Asn	Ser	Met	Phe	Tyr	Asp	Gly	245	250	255
Pro	Gln	Val	Ala	Asn	Leu	Gln	Asn	Val	Asp	Thr	Gly	Phe	Trp	Leu	Asp	260	265	270
Met	Ser	Asn	Leu	Ser	Asp	Val	Val	Leu	Ser	Arg	Glu	Ile	Gln	Thr	Gly	275	280	285
Leu	Arg	Ala	Arg	Ala	Thr	Leu	Glu	Glu	Ser	Met	Pro	Met	Leu	Glu	Asn	290	295	300
Leu	Glu	Glu	Arg	Phe	Arg	Arg	Leu	Gln	Glu	Thr	Cys	Asp	Ala	Ala	Arg	305	310	315
Thr	Glu	Ile	Glu	Glu	Ser	Gly	Trp	Thr	Arg	Glu	Ser	Ala	Ser	Arg	Met	325	330	335
Glu	Gly	Asp	Glu	Ala	Gln	Gly	Pro	Ser	Arg	Ala	Gln	Gln	Ala	Phe	Gln	340	345	350
Ser	Phe	Val	Asn	Glu	Cys	Asn	Ser	Ile	Glu	Phe	Ser	Phe	Gly	Ser	Phe	355	360	365
Gly	Glu	His	Val	Arg	Val	Leu	Cys	Ala	Arg	Val	Ser	Arg	Gly	Leu	Ala	370	375	380
Ala	Ala	Gly	Glu	Ala	Ile	Arg	Arg	Cys	Phe	Ser	Cys	Cys	Lys	Gly	Ser	385	390	395
Thr	His	Arg	Tyr	Ala	Pro	Arg	Asp	Asp	Leu	Ser	Pro	Glu	Gly	Ala	Ser	405	410	415
Leu	Ala	Glu	Thr	Leu	Ala	Arg	Phe	Ala	Asp	Asp	Met	Gly	Ile	Glu	Arg	420	425	430
Gly	Ala	Asp	Gly	Thr	Tyr	Asp	Ile	Pro	Leu	Val	Asp	Asp	Trp	Arg	Arg	435	440	445
Gly	Val	Pro	Ser	Ile	Glu	Gly	Glu	Gly	Ser	Asp	Ser	Ile	Tyr	Glu	Ile	450	455	460
Met	Met	Pro	Ile	Tyr	Glu	Val	Met	Asp	Met	Asp	Leu	Glu	Thr	Arg	Arg	465	470	475
Ser	Phe	Ala	Val	Gln	Gly	His	Tyr	Gln	Asp	Pro	Arg	Ala	Ser	Asp		485	490	495
Tyr	Asp	Leu	Pro	Arg	Ala	Ser	Asp	Tyr	Asp	Leu	Pro	Arg	Ser	Pro	Tyr	500	505	510
Pro	Thr	Pro	Pro	Leu	Pro	Pro	Arg	Tyr	Gln	Leu	Gln	Asn	Met	Asp	Val	515	520	525
Glu	Ala	Gly	Phe	Arg	Glu	Ala	Val	Tyr	Ala	Ser	Phe	Val	Ala	Gly	Met	530	535	540
Tyr	Asn	Tyr	Val	Val	Thr	Gln	Pro	Gln	Glu	Arg	Ile	Pro	Asn	Ser	Gln	545	550	555
Gln	Val	Glu	Gly	Ile	Leu	Arg	Asp	Met	Leu	Thr	Asn	Gly	Ser	Gln	Thr	565	570	575
Phe	Arg	Asp	Leu	Met	Lys	Arg	Trp	Asn	Arg	Glu	Val	Asp	Arg	Glu		580	585	590

<210> 119
 <211> 1776
 <212> DNA
 <213> Chlamydia trachomatis

<400> 119

atgagcatca	ggggagtagg	aggcaacggg	aatagtcgaa	tcccttctca	taatggggat	60
ggatcgaatc	gcagaagtca	aaatacgaag	ggtaataata	aagttgaaga	tcgagtttgt	120
tctctatatt	catctcgtag	taacgaaaat	agagaatctc	cttatgcagt	agtagacgtc	180
agctctatga	tcgagagcac	cccaacgagt	ggagagacga	caagagcttc	gcgtggagtg	240
ttcagtcgtt	tccaaagagg	tttagtacga	gtagctgaca	aagtaagacg	agctgttcag	300
tgtgcgtgga	gttcagtcctc	tacaagaaga	tcgtctgcaa	caagagccgc	agaatccgga	360
tcaagtagtc	gtactgctcg	tggtgcaagt	tctgggtata	gggagtattc	tccttcagca	420
gctagagggc	tgcgtcttat	gttcacagat	ttctggagaa	ctcgggtttt	acgccagacc	480
tctcctatgg	ctggagtttt	tgggaatctt	gatgtgaacg	aggctcgttt	gatggctgcg	540
tacacaagtg	agtgcgcgga	tcatttagaa	gcgaacaagt	tggctggccc	tgacggggta	600
gcggccgccc	gggaaattgc	taaaagatgg	gagcaaagag	ttagagatct	acaagataaa	660
ggtgctgcac	gaaaattatt	aaatgatcct	ttaggccgac	gaacacctaa	ttatcagagc	720
aaaaatccag	gtgagtatac	tgtagggaat	tccatgtttt	acgatgggcc	tcaggtagcg	780
aatctccaga	acgtcgacac	tggttttttg	ctggacatga	gcaatctctc	agacgttgta	840
ttatccagag	agattcaaac	aggacttcga	gcacgagcta	ctttggaaga	atccatgccg	900
atgttagaga	atttagaaga	gcgtttttaga	cgtttgcaag	aaacttggtga	tgctggctcgt	960
actgagatag	aagaatcggg	atggactcga	gagtcgcgat	caagaatgga	aggcgatgag	1020
gcgcaaggac	cttctagagc	acaacaagct	tttcagagct	ttgtaaatga	atgtaacagc	1080
atcgagttct	catttgggag	ctttggagag	catgtgcgag	ttctctgcgc	tagagtatca	1140
cgaggattag	ctgccgcagg	agaggcgatt	cgccgttgct	tctcttggtg	taaaggatcg	1200
acgcatcgct	acgtctctcg	cgatgaccta	tctctgaag	gtgcatcggt	agcagagact	1260
ttggctagat	tcgcagatga	tatgggaata	gagcgaggtg	ctgatggaac	ctacgatatt	1320
cctttggtag	atgattggag	aagaggggtt	cctagtattg	aaggagaagg	atctgactcg	1380
atctatgaaa	tcgatgatgcc	tatctatgaa	gttatggata	tggatctaga	aacacgaaga	1440
tcttttgcgg	tacagcaagg	gcactatcag	gacccaagag	cttcagatta	tgacctccca	1500
cgtgctagcg	actatgattt	gcctagaagc	ccatataccta	ctccaccttt	gcctcctaga	1560
tatcagctac	agaatatgga	tgtagaagca	gggttcctg	aggcagttta	tgcttctttt	1620
gtagcaggaa	tgtacaatta	tgtagtgaca	cagccgcaag	agcgattatcc	caatagtcag	1680
caggtggaag	ggattctgcg	tgatatgctt	accaacgggt	cacagacatt	tagagacctg	1740
atgaggcggt	ggaatagaga	agtcgatagg	gaataa			1776

<210> 120

<211> 591

<212> PRT

<213> Chlamydia trachomatis

<400> 120

Met	Ser	Ile	Arg	Gly	Val	Gly	Gly	Asn	Gly	Asn	Ser	Arg	Ile	Pro	Ser
1				5					10					15	
His	Asn	Gly	Asp	Gly	Ser	Asn	Arg	Arg	Ser	Gln	Asn	Thr	Lys	Gly	Asn
			20					25					30		
Asn	Lys	Val	Glu	Asp	Arg	Val	Cys	Ser	Leu	Tyr	Ser	Ser	Arg	Ser	Asn
		35					40					45			
Glu	Asn	Arg	Glu	Ser	Pro	Tyr	Ala	Val	Val	Asp	Val	Ser	Ser	Met	Ile
		50					55				60				
Glu	Ser	Thr	Pro	Thr	Ser	Gly	Glu	Thr	Thr	Arg	Ala	Ser	Arg	Gly	Val
65					70					75					80
Phe	Ser	Arg	Phe	Gln	Arg	Gly	Leu	Val	Arg	Val	Ala	Asp	Lys	Val	Arg
			85						90					95	
Arg	Ala	Val	Gln	Cys	Ala	Trp	Ser	Ser	Val	Ser	Thr	Arg	Arg	Ser	Ser
			100					105					110		
Ala	Thr	Arg	Ala	Ala	Glu	Ser	Gly	Ser	Ser	Ser	Arg	Thr	Ala	Arg	Gly
		115					120					125			
Ala	Ser	Ser	Gly	Tyr	Arg	Glu	Tyr	Ser	Pro	Ser	Ala	Ala	Arg	Gly	Leu
		130					135				140				
Arg	Leu	Met	Phe	Thr	Asp	Phe	Trp	Arg	Thr	Arg	Val	Leu	Arg	Gln	Thr
145					150					155					160
Ser	Pro	Met	Ala	Gly	Val	Phe	Gly	Asn	Leu	Asp	Val	Asn	Glu	Ala	Arg
				165					170					175	

Leu	Met	Ala	Ala	Tyr	Thr	Ser	Glu	Cys	Ala	Asp	His	Leu	Glu	Ala	Asn	180	185	190
Lys	Leu	Ala	Gly	Pro	Asp	Gly	Val	Ala	Ala	Ala	Arg	Glu	Ile	Ala	Lys	195	200	205
Arg	Trp	Glu	Gln	Arg	Val	Arg	Asp	Leu	Gln	Asp	Lys	Gly	Ala	Ala	Arg	210	215	220
Lys	Leu	Leu	Asn	Asp	Pro	Leu	Gly	Arg	Arg	Thr	Pro	Asn	Tyr	Gln	Ser	225	230	235
Lys	Asn	Pro	Gly	Glu	Tyr	Thr	Val	Gly	Asn	Ser	Met	Phe	Tyr	Asp	Gly	245	250	255
Pro	Gln	Val	Ala	Asn	Leu	Gln	Asn	Val	Asp	Thr	Gly	Phe	Trp	Leu	Asp	260	265	270
Met	Ser	Asn	Leu	Ser	Asp	Val	Val	Leu	Ser	Arg	Glu	Ile	Gln	Thr	Gly	275	280	285
Leu	Arg	Ala	Arg	Ala	Thr	Leu	Glu	Glu	Ser	Met	Pro	Met	Leu	Glu	Asn	290	295	300
Leu	Glu	Glu	Arg	Phe	Arg	Arg	Leu	Gln	Glu	Thr	Cys	Asp	Ala	Ala	Arg	305	310	315
Thr	Glu	Ile	Glu	Glu	Ser	Gly	Trp	Thr	Arg	Glu	Ser	Ala	Ser	Arg	Met	325	330	335
Glu	Gly	Asp	Glu	Ala	Gln	Gly	Pro	Ser	Arg	Ala	Gln	Gln	Ala	Phe	Gln	340	345	350
Ser	Phe	Val	Asn	Glu	Cys	Asn	Ser	Ile	Glu	Phe	Ser	Phe	Gly	Ser	Phe	355	360	365
Gly	Glu	His	Val	Arg	Val	Leu	Cys	Ala	Arg	Val	Ser	Arg	Gly	Leu	Ala	370	375	380
Ala	Ala	Gly	Glu	Ala	Ile	Arg	Arg	Cys	Phe	Ser	Cys	Cys	Lys	Gly	Ser	385	390	395
Thr	His	Arg	Tyr	Ala	Pro	Arg	Asp	Asp	Leu	Ser	Pro	Glu	Gly	Ala	Ser	405	410	415
Leu	Ala	Glu	Thr	Leu	Ala	Arg	Phe	Ala	Asp	Asp	Met	Gly	Ile	Glu	Arg	420	425	430
Gly	Ala	Asp	Gly	Thr	Tyr	Asp	Ile	Pro	Leu	Val	Asp	Asp	Trp	Arg	Arg	435	440	445
Gly	Val	Pro	Ser	Ile	Glu	Gly	Glu	Gly	Ser	Asp	Ser	Ile	Tyr	Glu	Ile	450	455	460
Met	Met	Pro	Ile	Tyr	Glu	Val	Met	Asp	Met	Asp	Leu	Glu	Thr	Arg	Arg	465	470	475
Ser	Phe	Ala	Val	Gln	Gly	His	Tyr	Gln	Asp	Pro	Arg	Ala	Ser	Asp		485	490	495
Tyr	Asp	Leu	Pro	Arg	Ala	Ser	Asp	Tyr	Asp	Leu	Pro	Arg	Ser	Pro	Tyr	500	505	510
Pro	Thr	Pro	Pro	Leu	Pro	Pro	Arg	Tyr	Gln	Leu	Gln	Asn	Met	Asp	Val	515	520	525
Glu	Ala	Gly	Phe	Arg	Glu	Ala	Val	Tyr	Ala	Ser	Phe	Val	Ala	Gly	Met	530	535	540
Tyr	Asn	Tyr	Val	Val	Thr	Gln	Pro	Gln	Glu	Arg	Ile	Pro	Asn	Ser	Gln	545	550	555
Gln	Val	Glu	Gly	Ile	Leu	Arg	Asp	Met	Leu	Thr	Asn	Gly	Ser	Gln	Thr	565	570	575
Phe	Arg	Asp	Leu	Met	Arg	Arg	Trp	Asn	Arg	Glu	Val	Asp	Arg	Glu		580	585	590

<210> 121
 <211> 1773
 <212> DNA
 <213> Chlamydia trachomatis

 <400> 121

atgagcatca	ggggagtagg	aggcaacggg	aatagtcgaa	tcccttctca	taatggggat	60
ggatcgaatc	gcagaagtca	aaatacgaag	ggtaataata	aagttgaaga	tcgagttcat	120
tctctatatt	catctcttag	taacgaaaat	agagaatctc	cttatccagt	agtagacgtc	180
agctctatga	tcgagagcac	cccaacgagt	ggagagacgc	caagagcttc	gcgtggagtg	240
ttcagtcgtt	tccaaagagg	tttaggacga	gtagctgaca	aagtaagacg	agctgttcag	300
tgtgcgtggg	gttcagtcctc	tacaagaaga	tcgtctgcaa	caagagccgt	agaatccgga	360
tcaagtagtc	gtactgctcg	tggtgcaagt	tctgggaggg	agtattctcc	ttcagcagct	420
agagggctgc	gtcttatgtt	cacagatttc	tggagaactc	gggttttacg	ccagacctct	480
cctatggatg	tagttttttg	gaatcttgat	gtgaacgagg	ctcgtttgat	ggctgcttac	540
acaagtgagt	gcgcggatta	tttagaagcg	cacgatttgg	ctggccctga	cggggtagcg	600
gccgccgggg	aaattgctca	aagatgggag	aaaagagtta	gagatctaca	agataaaggt	660
gctgcacaaa	aattattaaa	tgatccttta	ggccgacgaa	cacctaatca	tcagagcaaa	720
aatccagggtg	agtatactgt	aggggaattcc	atgtttttacg	atggctctca	ggtagcgaat	780
ctccagaacg	tcgacactgg	tttttggtcg	gacatgagca	atttctcaga	cggtgtatta	840
tccagagaga	ttcaaacagg	gcttcgagca	cgagctactt	tggaagaatc	catgccgatg	900
ttagagaatt	tagaagagcg	tttttagacgt	ttgcaagaaa	cttgtgatgc	ggctcgtagt	960
gagatagaag	aatcgggatg	gactcgagag	tccgcaccaa	gaatgggagg	cgatgagacg	1020
caaggacctt	ctagagcaca	acaagctttt	cagagctttg	taaataaatg	taatagcacg	1080
gagttctcat	ttgggagctt	tggagagcat	gtgcgagttc	tctgcgctag	agtatcacga	1140
ggattagttg	cgcgaggaga	ggcgattcgc	cgttgcttct	cttgtttgta	aggatcgacg	1200
catcgctacg	ctcctcgcca	tgacctatct	cctgaagggtg	catcgtttagc	agagactttg	1260
gctagattcg	cagatgatat	gggaatagag	caagggtgctg	atggaacctc	cgatattcct	1320
tgggtagatg	attggagaag	aggggttcct	agtattgaag	gagaaggatc	tgactcgatc	1380
tatgaaatca	tgatgcctat	ctatgaagtt	atgaatatgg	atctagaaac	acgaagatct	1440
tttgcggtac	agcaagggca	ctatcaggac	ccaagagctt	cagattatga	cctcccacgt	1500
gctagcgact	atgatttgcc	tagaagccca	tatcctactc	cacctttgcc	ttctagatat	1560
cagctacaga	atatggatgt	agaagcaggg	ttccgtgagg	cagtttatgc	ctctttgtga	1620
gcaggaatgt	acaattatgt	agtgcacacg	ccgcaagagc	gtattcccaa	tagtcagcag	1680
gtggaaggga	ttctgcgtga	tatgcttacc	aacgggtcac	agacatttag	cgacctgatg	1740
aagcgttggg	atagagaagt	cgatagggaa	taa			1773

<210> 122

<211> 590

<212> PRT

<213> Chlamydia trachomatis

<400> 122

Met	Ser	Ile	Arg	Gly	Val	Gly	Gly	Asn	Gly	Asn	Ser	Arg	Ile	Pro	Ser
1				5				10						15	
His	Asn	Gly	Asp	Gly	Ser	Asn	Arg	Arg	Ser	Gln	Asn	Thr	Lys	Gly	Asn
			20					25					30		
Asn	Lys	Val	Glu	Asp	Arg	Val	His	Ser	Leu	Tyr	Ser	Ser	Leu	Ser	Asn
		35					40					45			
Glu	Asn	Arg	Glu	Ser	Pro	Tyr	Pro	Val	Val	Asp	Val	Ser	Ser	Met	Ile
	50					55				60					
Glu	Ser	Thr	Pro	Thr	Ser	Gly	Glu	Thr	Pro	Arg	Ala	Ser	Arg	Gly	Val
65					70					75				80	
Phe	Ser	Arg	Phe	Gln	Arg	Gly	Leu	Gly	Arg	Val	Ala	Asp	Lys	Val	Arg
			85						90					95	
Arg	Ala	Val	Gln	Cys	Ala	Trp	Gly	Ser	Val	Ser	Thr	Arg	Arg	Ser	Ser
		100					105						110		
Ala	Thr	Arg	Ala	Val	Glu	Ser	Gly	Ser	Ser	Ser	Arg	Thr	Ala	Arg	Gly
	115					120						125			
Ala	Ser	Ser	Gly	Arg	Glu	Tyr	Ser	Pro	Ser	Ala	Ala	Arg	Gly	Leu	Arg
	130				135					140					
Leu	Met	Phe	Thr	Asp	Phe	Trp	Arg	Thr	Arg	Val	Leu	Arg	Gln	Thr	Ser
145				150					155					160	
Pro	Met	Asp	Val	Val	Phe	Gly	Asn	Leu	Asp	Val	Asn	Glu	Ala	Arg	Leu
			165					170						175	

Met	Ala	Ala	Tyr	Thr	Ser	Glu	Cys	Ala	Asp	Tyr	Leu	Glu	Ala	His	Asp	180	185	190
Leu	Ala	Gly	Pro	Asp	Gly	Val	Ala	Ala	Arg	Glu	Ile	Ala	Gln	Arg		195	200	205
Trp	Glu	Lys	Arg	Val	Arg	Asp	Leu	Gln	Asp	Lys	Gly	Ala	Ala	Gln	Lys	210	215	220
Leu	Leu	Asn	Asp	Pro	Leu	Gly	Arg	Arg	Thr	Pro	Asn	Tyr	Gln	Ser	Lys	225	230	235
Asn	Pro	Gly	Glu	Tyr	Thr	Val	Gly	Asn	Ser	Met	Phe	Tyr	Asp	Gly	Pro	245	250	255
Gln	Val	Ala	Asn	Leu	Gln	Asn	Val	Asp	Thr	Gly	Phe	Trp	Leu	Asp	Met	260	265	270
Ser	Asn	Phe	Ser	Asp	Val	Val	Leu	Ser	Arg	Glu	Ile	Gln	Thr	Gly	Leu	275	280	285
Arg	Ala	Arg	Ala	Thr	Leu	Glu	Glu	Ser	Met	Pro	Met	Leu	Glu	Asn	Leu	290	295	300
Glu	Glu	Arg	Phe	Arg	Arg	Leu	Gln	Glu	Thr	Cys	Asp	Ala	Ala	Arg	Thr	305	310	315
Glu	Ile	Glu	Glu	Ser	Gly	Trp	Thr	Arg	Glu	Ser	Ala	Ser	Arg	Met	Gly	325	330	335
Gly	Asp	Glu	Thr	Gln	Gly	Pro	Ser	Arg	Ala	Gln	Gln	Ala	Phe	Gln	Ser	340	345	350
Phe	Val	Asn	Glu	Cys	Asn	Ser	Ile	Glu	Phe	Ser	Phe	Gly	Ser	Phe	Gly	355	360	365
Glu	His	Val	Arg	Val	Leu	Cys	Ala	Arg	Val	Ser	Arg	Gly	Leu	Val	Ala	370	375	380
Ala	Gly	Glu	Ala	Ile	Arg	Arg	Cys	Phe	Ser	Cys	Cys	Lys	Gly	Ser	Thr	385	390	395
His	Arg	Tyr	Ala	Pro	Arg	Asp	Asp	Leu	Ser	Pro	Glu	Gly	Ala	Ser	Leu	405	410	415
Ala	Glu	Thr	Leu	Ala	Arg	Phe	Ala	Asp	Asp	Met	Gly	Ile	Glu	Gln	Gly	420	425	430
Ala	Asp	Gly	Thr	Tyr	Asp	Ile	Pro	Trp	Val	Asp	Asp	Trp	Arg	Arg	Gly	435	440	445
Val	Pro	Ser	Ile	Glu	Gly	Glu	Gly	Ser	Asp	Ser	Ile	Tyr	Glu	Ile	Met	450	455	460
Met	Pro	Ile	Tyr	Glu	Val	Met	Asn	Met	Asp	Leu	Glu	Thr	Arg	Arg	Ser	465	470	475
Phe	Ala	Val	Gln	Gln	Gly	His	Tyr	Gln	Asp	Pro	Arg	Ala	Ser	Asp	Tyr	485	490	495
Asp	Leu	Pro	Arg	Ala	Ser	Asp	Tyr	Asp	Leu	Pro	Arg	Ser	Pro	Tyr	Pro	500	505	510
Thr	Pro	Pro	Leu	Pro	Ser	Arg	Tyr	Gln	Leu	Gln	Asn	Met	Asp	Val	Glu	515	520	525
Ala	Gly	Phe	Arg	Glu	Ala	Val	Tyr	Ala	Ser	Phe	Val	Ala	Gly	Met	Tyr	530	535	540
Asn	Tyr	Val	Val	Thr	Gln	Pro	Gln	Glu	Arg	Ile	Pro	Asn	Ser	Gln	Gln	545	550	555
Val	Glu	Gly	Ile	Leu	Arg	Asp	Met	Leu	Thr	Asn	Gly	Ser	Gln	Thr	Phe	565	570	575
Ser	Asp	Leu	Met	Lys	Arg	Trp	Asp	Arg	Glu	Val	Asp	Arg	Glu			580	585	590

<210> 123

<211> 1776

<212> DNA

<213> Chlamydia trachomatis

<400> 123

atgagcatca	ggggagtagg	aggcaacggg	aatagtcgaa	tcccttctca	taatggggat	60
ggatcgaatc	gcagaagtca	aaatacgaag	ggtaataata	aagttgaaga	tcgagtttgt	120
tctctatatt	catctcgtag	taacgaaaat	agagaatctc	cttatgcagt	agtagacgtc	180
agctctatga	tgcagagcac	cccaacgagt	ggagagacga	caagagcttc	gcgtggagtg	240
ttcagtcggt	tccaaagagg	tttagtacga	gtagctgaca	aagtaagacg	agctgttcag	300
tgtgcgtgga	gttcagtcctc	tacaagaaga	tcgtctgcaa	caagagccgc	agaatccgga	360
tcaagtagtc	gtactgctcg	tggtgcaagt	tctgggtata	gggagtattc	tccttcagca	420
gctagagggc	tgctgtcttat	gttcacagat	ttctggagaa	ctcgggtttt	acgccagacc	480
tctcctatgg	ctggagtttt	tgggaatcct	gatgtgaacg	aggctcgttt	gatggctgcg	540
tacacaagtg	agtgcgcgga	tcatttagaa	gcgaacaagt	tggctggccc	tgacggggta	600
gcggccgccc	gggaaattgc	taaaagatgg	gagcaaagag	ttagagatct	acaagataaa	660
ggtgctgcac	gaaaattatt	aaatgatcct	ttaggccgac	gaacacctaa	ttatcagagc	720
aaaaatccag	gtgagtatac	tgtagggaat	tccatgtttt	acgatggtec	tcaggtagcg	780
aatctccaga	acgtcgacac	tggttttttg	ctggacatga	gcaatctctc	agacgttgta	840
ttatccagag	agattcaaac	aggacttcga	gcacgagcta	ctttggaaga	atccatgccg	900
atgttagaga	atttagaaga	gcgtttttaga	cgtttgcaag	aaacttggtga	tgcggtcgt	960
actgagatag	aagaatcggg	atggactcga	gagtcgcgat	caagaatgga	aggcgatgag	1020
gcgcaaggac	cttctagagc	acaacaagct	tttcagagct	ttgtaaata	atgtaacagc	1080
atcgagttct	catttggggag	ctttggagag	catgtgcgag	ttctctgcgc	tagagtatca	1140
cgaggattag	ctgccgcagg	agaggcgatt	cgccgttgct	tctcttggtg	taaaggatcg	1200
acgcacgcct	acgtccctcg	cgatgaccta	tctcctgaag	gtgcatcggt	agcagagact	1260
ttggctagat	tgcagatga	tatgggaata	gagcgagggtg	ctgatggaac	ctacgatatt	1320
cctttggtag	atgattggag	aagaggggtt	cctagtattg	aaggagaagg	atctgactcg	1380
atctatgaaa	tcattgatgcc	tatctatgaa	gttatggata	tggatctaga	aacacgaaga	1440
tcttttgccg	tacagcaagg	gcactatcag	gacccaagag	cttcagatta	tgacctccca	1500
cgtgctagcg	actatgattt	gcctagaagc	ccatataccta	ctccaccttt	gcctcctaga	1560
tatcagctac	agaatatgga	tgtagaagca	gggttccgtg	aggcagttta	tgcttctttt	1620
gtagcaggaa	tgtacaatta	tgtagtgaca	cagccgcaag	agcgtattcc	caatagtcag	1680
caggtggaag	ggattctgcg	tgatatgctt	accaacgggt	cacagacatt	tagagacctg	1740
atgaggcggt	ggaatagaga	agtcgatagg	gaataa			1776

<210> 124
 <211> 591
 <212> PRT
 <213> Chlamydia trachomatis

<400> 124

Met	Ser	Ile	Arg	Gly	Val	Gly	Gly	Asn	Gly	Asn	Ser	Arg	Ile	Pro	Ser
1			5					10						15	
His	Asn	Gly	Asp	Gly	Ser	Asn	Arg	Arg	Ser	Gln	Asn	Thr	Lys	Gly	Asn
		20						25					30		
Asn	Lys	Val	Glu	Asp	Arg	Val	Cys	Ser	Leu	Tyr	Ser	Ser	Arg	Ser	Asn
		35					40						45		
Glu	Asn	Arg	Glu	Ser	Pro	Tyr	Ala	Val	Val	Asp	Val	Ser	Ser	Met	Ile
		50					55				60				
Glu	Ser	Thr	Pro	Thr	Ser	Gly	Glu	Thr	Thr	Arg	Ala	Ser	Arg	Gly	Val
65					70					75				80	
Phe	Ser	Arg	Phe	Gln	Arg	Gly	Leu	Val	Arg	Val	Ala	Asp	Lys	Val	Arg
			85					90						95	
Arg	Ala	Val	Gln	Cys	Ala	Trp	Ser	Ser	Val	Ser	Thr	Arg	Arg	Ser	Ser
		100						105					110		
Ala	Thr	Arg	Ala	Ala	Glu	Ser	Gly	Ser	Ser	Ser	Arg	Thr	Ala	Arg	Gly
		115					120					125			
Ala	Ser	Ser	Gly	Tyr	Arg	Glu	Tyr	Ser	Pro	Ser	Ala	Ala	Arg	Gly	Leu
		130					135				140				
Arg	Leu	Met	Phe	Thr	Asp	Phe	Trp	Arg	Thr	Arg	Val	Leu	Arg	Gln	Thr
145					150					155				160	
Ser	Pro	Met	Ala	Gly	Val	Phe	Gly	Asn	Leu	Asp	Val	Asn	Glu	Ala	Arg
			165					170						175	

Leu	Met	Ala	Ala	Tyr	Thr	Ser	Glu	Cys	Ala	Asp	His	Leu	Glu	Ala	Asn	
			180					185					190			
Lys	Leu	Ala	Gly	Pro	Asp	Gly	Val	Ala	Ala	Ala	Arg	Glu	Ile	Ala	Lys	
		195					200					205				
Arg	Trp	Glu	Gln	Arg	Val	Arg	Asp	Leu	Gln	Asp	Lys	Gly	Ala	Ala	Arg	
	210					215					220					
Lys	Leu	Leu	Asn	Asp	Pro	Leu	Gly	Arg	Arg	Thr	Pro	Asn	Tyr	Gln	Ser	
225				230						235					240	
Lys	Asn	Pro	Gly	Glu	Tyr	Thr	Val	Gly	Asn	Ser	Met	Phe	Tyr	Asp	Gly	
			245						250					255		
Pro	Gln	Val	Ala	Asn	Leu	Gln	Asn	Val	Asp	Thr	Gly	Phe	Trp	Leu	Asp	
		260						265					270			
Met	Ser	Asn	Leu	Ser	Asp	Val	Val	Leu	Ser	Arg	Glu	Ile	Gln	Thr	Gly	
		275				280						285				
Leu	Arg	Ala	Arg	Ala	Thr	Leu	Glu	Glu	Ser	Met	Pro	Met	Leu	Glu	Asn	
	290					295					300					
Leu	Glu	Glu	Arg	Phe	Arg	Arg	Leu	Gln	Glu	Thr	Cys	Asp	Ala	Ala	Arg	
305				310						315					320	
Thr	Glu	Ile	Glu	Glu	Ser	Gly	Trp	Thr	Arg	Glu	Ser	Ala	Ser	Arg	Met	
			325						330					335		
Glu	Gly	Asp	Glu	Ala	Gln	Gly	Pro	Ser	Arg	Ala	Gln	Gln	Ala	Phe	Gln	
		340					345						350			
Ser	Phe	Val	Asn	Glu	Cys	Asn	Ser	Ile	Glu	Phe	Ser	Phe	Gly	Ser	Phe	
	355					360					365					
Gly	Glu	His	Val	Arg	Val	Leu	Cys	Ala	Arg	Val	Ser	Arg	Gly	Leu	Ala	
	370					375					380					
Ala	Ala	Gly	Glu	Ala	Ile	Arg	Arg	Cys	Phe	Ser	Cys	Cys	Lys	Gly	Ser	
385				390						395					400	
Thr	His	Arg	Tyr	Ala	Pro	Arg	Asp	Asp	Leu	Ser	Pro	Glu	Gly	Ala	Ser	
			405					410						415		
Leu	Ala	Glu	Thr	Leu	Ala	Arg	Phe	Ala	Asp	Asp	Met	Gly	Ile	Glu	Arg	
		420					425						430			
Gly	Ala	Asp	Gly	Thr	Tyr	Asp	Ile	Pro	Leu	Val	Asp	Asp	Trp	Arg	Arg	
	435					440					445					
Gly	Val	Pro	Ser	Ile	Glu	Gly	Glu	Gly	Ser	Asp	Ser	Ile	Tyr	Glu	Ile	
	450				455						460					
Met	Met	Pro	Ile	Tyr	Glu	Val	Met	Asp	Met	Asp	Leu	Glu	Thr	Arg	Arg	
465				470						475					480	
Ser	Phe	Ala	Val	Gln	Gly	His	Tyr	Gln	Asp	Pro	Arg	Ala	Ser	Asp		
			485					490						495		
Tyr	Asp	Leu	Pro	Arg	Ala	Ser	Asp	Tyr	Asp	Leu	Pro	Arg	Ser	Pro	Tyr	
		500						505					510			
Pro	Thr	Pro	Pro	Leu	Pro	Pro	Arg	Tyr	Gln	Leu	Gln	Asn	Met	Asp	Val	
		515					520					525				
Glu	Ala	Gly	Phe	Arg	Glu	Ala	Val	Tyr	Ala	Ser	Phe	Val	Ala	Gly	Met	
	530					535					540					
Tyr	Asn	Tyr	Val	Val	Thr	Gln	Pro	Gln	Glu	Arg	Ile	Pro	Asn	Ser	Gln	
545				550						555					560	
Gln	Val	Glu	Gly	Ile	Leu	Arg	Asp	Met	Leu	Thr	Asn	Gly	Ser	Gln	Thr	
			565						570					575		
Phe	Arg	Asp	Leu	Met	Arg	Arg	Trp	Asn	Arg	Glu	Val	Asp	Arg	Glu		
			580					585					590			

<210> 125
 <211> 1773
 <212> DNA
 <213> Chlamydia trachomatis

 <400> 125

atgagcatca	ggggagtagg	aggcaacggg	aatagtcgaa	tcctttctca	taatggggat	60
ggatcgaatc	gcagaagtca	aaatacgaag	ggtaataata	aagttgaaga	tcgagttcat	120
tctctatatt	catctcttag	taacgaaaat	agagaatctc	cttatccagt	agtagacgtc	180
agctctatga	tcgagagcac	cccaacgagt	ggagagacgc	caagagcttc	gcgtggagtg	240
ttcagtcggt	tccaaagagg	tttaggacga	gtagctgaca	aagtaagacg	agctgttcag	300
tgtgcgtggg	gttcagtctc	tacaagaaga	tcgtctgcaa	caagagccgt	agaatccgga	360
tcaagtagtc	gtactgctcg	tgggtgcaagt	tctggggagg	agtattctcc	ttcagcagct	420
agagggctgc	gtcttatgtt	cacagatttc	tggagaactc	gggttttacg	ccagacctct	480
cctatggatg	tagtttttgg	gaatcttgat	gtgaacgagg	ctcgtttgat	ggctgcttac	540
acaagtgagt	gcgcggatta	tttagaagcg	cacgatttgg	ctggccctga	cggggtagcg	600
gccgcccggg	aaattgctca	aagatgggat	aaaagagtta	gagatctaca	agataaagg	660
gctgcacaaa	aattattaaa	tgatccttta	ggccgacgaa	cacctaatta	tcagagcaaa	720
aatccagggtg	agtatactgt	agggaattcc	atgtttttacg	atggtcctca	ggtagcgaat	780
ctccagaacg	tcgacactgg	tttttggtcg	gacatgagca	atttctcaga	cgttgattta	840
tccagagaga	ttcaaacagg	gcttcgagca	cgagctactt	tggagaatc	catgccgatg	900
ttagagaatt	tagaagagcg	ttttagacgt	ttgcaagaaa	cttgtgatgc	ggctcgtact	960
gagatagaag	aatcgggatg	gactcgagag	tccgcatcaa	gaatgggagg	cgatgagacg	1020
caaggacctt	ctagagcaca	acaagctttt	cagagctttg	taaataaatg	taatagcatc	1080
gagttctcat	ttgggagctt	tggagagcat	gtgcgagttc	tctgcgctag	agtatcacga	1140
ggattagttg	ccgcaggaga	ggcgattcgc	cgttgcttct	cttgttgtaa	aggatcgacg	1200
catcgctacg	ctcctcgcca	tgacctatct	cctgaagggtg	catcgttagc	agagactttg	1260
gctagattcg	cagatgatat	gggaatagag	caagggtgctg	atggaacctc	cgataattct	1320
tgggtagatg	attggagaag	aggggttctt	agtattgaag	gagaaggatc	tgactcgatc	1380
tatgaaatca	tgatgcctat	ctatgaagtt	atgaatatgg	atctagaaac	acgaagatct	1440
tttgcggtac	agcaagggca	ctatcaggac	ccaagagctt	cagattatga	cctccacagt	1500
gctagcgact	atgatttgcc	tagaagccca	tatcctactc	cacctttgcc	ttctagatat	1560
cagctacaga	atatggatgt	agaagcaggg	ttccgtgagg	cagtttatgc	ttcttttgta	1620
gcaggaatgt	acaattatgt	agtgcacacg	ccgcaagagc	gtattcccaa	tagtcagcag	1680
gtggaaggga	ttctgcgtga	tatgcttacc	aacgggtcac	agacatttag	caacctgatg	1740
cagcgttggg	atagagaagt	cgatagggaa	taa			1773

<210> 126

<211> 590

<212> PRT

<213> Chlamydia trachomatis

<400> 126

Met	Ser	Ile	Arg	Gly	Val	Gly	Gly	Asn	Gly	Asn	Ser	Arg	Ile	Pro	Ser
1				5				10						15	
His	Asn	Gly	Asp	Gly	Ser	Asn	Arg	Arg	Ser	Gln	Asn	Thr	Lys	Gly	Asn
			20					25					30		
Asn	Lys	Val	Glu	Asp	Arg	Val	His	Ser	Leu	Tyr	Ser	Ser	Leu	Ser	Asn
		35					40					45			
Glu	Asn	Arg	Glu	Ser	Pro	Tyr	Pro	Val	Val	Asp	Val	Ser	Ser	Met	Ile
		50				55					60				
Glu	Ser	Thr	Pro	Thr	Ser	Gly	Glu	Thr	Pro	Arg	Ala	Ser	Arg	Gly	Val
65					70					75					80
Phe	Ser	Arg	Phe	Gln	Arg	Gly	Leu	Gly	Arg	Val	Ala	Asp	Lys	Val	Arg
			85					90					95		
Arg	Ala	Val	Gln	Cys	Ala	Trp	Gly	Ser	Val	Ser	Thr	Arg	Arg	Ser	Ser
		100						105					110		
Ala	Thr	Arg	Ala	Val	Glu	Ser	Gly	Ser	Ser	Ser	Arg	Thr	Ala	Arg	Gly
		115					120					125			
Ala	Ser	Ser	Gly	Arg	Glu	Tyr	Ser	Pro	Ser	Ala	Ala	Arg	Gly	Leu	Arg
		130				135					140				
Leu	Met	Phe	Thr	Asp	Phe	Trp	Arg	Thr	Arg	Val	Leu	Arg	Gln	Thr	Ser
145					150					155					160
Pro	Met	Asp	Val	Val	Phe	Gly	Asn	Leu	Asp	Val	Asn	Glu	Ala	Arg	Leu
			165						170					175	

Met Ala Ala Tyr Thr Ser Glu Cys Ala Asp Tyr Leu Glu Ala His Asp
 180 185 190
 Leu Ala Gly Pro Asp Gly Val Ala Ala Ala Arg Glu Ile Ala Gln Arg
 195 200 205
 Trp Asp Lys Arg Val Arg Asp Leu Gln Asp Lys Gly Ala Ala Gln Lys
 210 215 220
 Leu Leu Asn Asp Pro Leu Gly Arg Arg Thr Pro Asn Tyr Gln Ser Lys
 225 230 235 240
 Asn Pro Gly Glu Tyr Thr Val Gly Asn Ser Met Phe Tyr Asp Gly Pro
 245 250 255
 Gln Val Ala Asn Leu Gln Asn Val Asp Thr Gly Phe Trp Leu Asp Met
 260 265 270
 Ser Asn Phe Ser Asp Val Val Leu Ser Arg Glu Ile Gln Thr Gly Leu
 275 280 285
 Arg Ala Arg Ala Thr Leu Glu Ser Met Pro Met Leu Glu Asn Leu
 290 295 300
 Glu Glu Arg Phe Arg Arg Leu Gln Glu Thr Cys Asp Ala Ala Arg Thr
 305 310 315 320
 Glu Ile Glu Glu Ser Gly Trp Thr Arg Glu Ser Ala Ser Arg Met Gly
 325 330 335
 Gly Asp Glu Thr Gln Gly Pro Ser Arg Ala Gln Gln Ala Phe Gln Ser
 340 345 350
 Phe Val Asn Glu Cys Asn Ser Ile Glu Phe Ser Phe Gly Ser Phe Gly
 355 360 365
 Glu His Val Arg Val Leu Cys Ala Arg Val Ser Arg Gly Leu Val Ala
 370 375 380
 Ala Gly Glu Ala Ile Arg Arg Cys Phe Ser Cys Cys Lys Gly Ser Thr
 385 390 395 400
 His Arg Tyr Ala Pro Arg Asp Asp Leu Ser Pro Glu Gly Ala Ser Leu
 405 410 415
 Ala Glu Thr Leu Ala Arg Phe Ala Asp Asp Met Gly Ile Glu Gln Gly
 420 425 430
 Ala Asp Gly Thr Tyr Asp Ile Pro Trp Val Asp Asp Trp Arg Arg Gly
 435 440 445
 Val Pro Ser Ile Glu Gly Glu Gly Ser Asp Ser Ile Tyr Glu Ile Met
 450 455 460
 Met Pro Ile Tyr Glu Val Met Asn Met Asp Leu Glu Thr Arg Arg Ser
 465 470 475 480
 Phe Ala Val Gln Gln Gly His Tyr Gln Asp Pro Arg Ala Ser Asp Tyr
 485 490 495
 Asp Leu Pro Arg Ala Ser Asp Tyr Asp Leu Pro Arg Ser Pro Tyr Pro
 500 505 510
 Thr Pro Pro Leu Pro Ser Arg Tyr Gln Leu Gln Asn Met Asp Val Glu
 515 520 525
 Ala Gly Phe Arg Glu Ala Val Tyr Ala Ser Phe Val Ala Gly Met Tyr
 530 535 540
 Asn Tyr Val Val Thr Gln Pro Gln Glu Arg Ile Pro Asn Ser Gln Gln
 545 550 555 560
 Val Glu Gly Ile Leu Arg Asp Met Leu Thr Asn Gly Ser Gln Thr Phe
 565 570 575
 Ser Asn Leu Met Gln Arg Trp Asp Arg Glu Val Asp Arg Glu
 580 585 590

WHAT IS CLAIMED IS:

1. A composition comprising a combination of two or more Chlamydia proteins or immunogenic fragments thereof or a polynucleotide or polynucleotides encoding them, said two
5 or more proteins or immunogenic fragments selected from Swib, Momp, Ct-858, Ct-875, Ct-622, Ct-089, passenger domain of PmpG (PmpGpd) and passenger domain of PmpD (PmpDpd).
2. A composition according to claim 1 which comprises a Chlamydia Ct-089 protein or an immunogenic fragment thereof, and a Chlamydia Ct-858 protein or an immunogenic fragment
10 thereof, or polynucleotides encoding them.
3. A composition according to claim 1 or 2 which comprises 2, 3, 4, 5 or 6 Chlamydia proteins or immunogenic fragments or polynucleotides encoding them.
- 15 4. A composition according to claim 2 or claim 3, further comprising a Chlamydia Ct-875 protein or an immunogenic fragment thereof or polynucleotide encoding them.
5. A composition according to any one of claims 2, 3 or 4, further comprising a Chlamydia PmpDpd protein or an immunogenic fragment thereof or polynucleotide encoding them.
20
6. A composition according to claim 5, further comprising a Chlamydia Swib protein or an immunogenic fragment thereof or polynucleotide encoding them.
7. A composition according to claim 5 or claim 6, further comprising a Chlamydia Momp
25 protein or an immunogenic fragment thereof or polynucleotide encoding them.
8. A composition according to claim 4 or claim 7, further comprising a Chlamydia Ct-622 protein or an immunogenic fragment thereof or polynucleotide encoding them.
- 30 9. A composition according to claim 7 or claim 8, further comprising a Chlamydia PmpGpd protein or an immunogenic fragment thereof or polynucleotide encoding them.
10. A composition according to any one of claims 1 to 9 further comprising a pharmaceutically acceptable carrier.
35
11. A composition according to any one of claims 1 to 10 further comprising an adjuvant.

12. A composition according to claim 11 wherein the adjuvant is a preferential stimulator of a Th1 response.

13. A composition according to claim 12 wherein the adjuvant comprises 3D-MPL, QS21 or a combination of 3D-MPL and QS21.

14. A composition according to claim 13 wherein the adjuvant further comprises an oil in water emulsion.

15. A composition according to claim 13 wherein the adjuvant further comprises liposomes.

16. A composition according to any one of claims 1 to 15 wherein two or more of the proteins or immunogenic fragments are linked to form a fusion protein, or the polynucleotide or polynucleotides encoding the protein or immunogenic fragments encodes a fusion of two or more of the proteins or immunogenic fragments.

17. A composition comprising one of the following combinations of Chlamydia polypeptides or immunogenic fragments thereof or polynucleotides encoding them:

1. Momp, PmpDpd, Ct-858, Ct-089, Swib
- 1'. PmpDpd, Ct-858, Ct-089, Swib
2. Momp, PmpDpd, Ct-858, Ct-622, Ct-089, Swib
3. Momp, PmpDpd, Ct-858, PmpGpd, Ct-622, Ct-089
4. Ct-858, Ct-875, Ct-622, Ct-089
5. Ct-858, Ct-875, Ct-089
- 5'. PmpDpd, Ct-858, Ct-875, Ct-089
6. Momp, PmpD, Ct-858, PmpGpd, Ct-089
- 1a. All five of: Momp, PmpDpd, Ct-858, PmpGpd and Ct-089
- 1'a. Three out of: PmpDpd, Ct-858, Ct-089, Swib
- 2a. Five out of: Momp, PmpDpd, Ct-858, Ct-622, Ct-089 and Swib
- 3a. Five out of: Momp, PmpDpd, Ct-858, PmpGpd, Ct-622 and Ct-089
- 4a. Three out of: Ct-858, Ct-875, Ct-622 and Ct-089
- 5a. Two out of: Ct-858, Ct-875 and Ct-089
- 5'a. Three out of: PmpDpd, Ct-858, Ct-875, Ct-089
- 6a. Four out of: Momp, PmpD, Ct-858, PmpGpd and Ct-089

provided that in all of compositions 1a to 6a, Ct-089 and Ct-858 proteins or immunogenic derivatives or polynucleotides encoding these are present.

18. A composition comprising the following combination of Chlamydia polypeptides or immunogenic fragments thereof or polynucleotides encoding them:

5 1a". Five out of: Swib, Momp, PmpDpd, Ct-858, PmpGpd and Ct-089

provided that Ct-089 and Ct-858 proteins or immunogenic derivatives or polynucleotides encoding these are present.

10 19. A composition comprising one of the following combinations of Chlamydia polypeptides or immunogenic fragments thereof or polynucleotides encoding them

1b. Momp, PmpDpd, Ct-858, Ct-875, Swib, Ct-089

1b'. PmpDpd, Ct-858, Ct-875, Swib, Ct-089

2b. Momp, PmpDpd, Ct-858, Ct-622, Ct-875, Swib, Ct-089

15 3b. Momp, PmpDpd, Ct-858, PmpGpd, Ct-622, Ct-875, Ct-089

4b. Ct-858, Ct-875

5b. Momp, Ct-858, Ct-875, Ct-089

5b'. Momp, Ct-858, Ct-875

6b. Momp, PmpD, Ct-858, PmpGpd, Ct-875, Ct-089

20 1c. Five out of: Swib Momp, PmpDpd, Ct-858, PmpGpd and Ct-875

1c'. Three out of: PmpDpd, Ct-858, Ct-0875, Swib

2c. Five out of: Momp, PmpDpd, Ct-858, Ct-622, Ct-875 and Swib

3c. Five out of: Momp, PmpDpd, Ct-858, PmpGpd, Ct-622 and Ct-875

4c. Three out of: Ct-858, Ct-875, Ct-622 and Ct-089

25 5c'. Three out of: PmpDpd, Ct-858, Ct-875, Ct-089

6c. Four out of: Momp, PmpD, Ct-858, PmpGpd and Ct-875

provided that in all of compositions 1b to 6c, Ct-875 and Ct-858 proteins or immunogenic derivatives or polynucleotides encoding these are present.

30

20. A composition according to any one of claims 1 to 19, wherein the Swib, Momp, Ct-858, Ct-875, Ct-622, Ct-089, passenger domain of PmpG (PmpGpd) and passenger domain of PmpD (PmpDpd) or immunogenic fragments thereof or polynucleotides, when present in the composition, are:

35 i. Ct-089 - a polypeptide having at least 95% homology to the polypeptide of SEQ ID NO: 16 (Ct-089 from serovar E) or an immunogenic fragment thereof, or a polynucleotide encoding these;

- ii. Ct-858 – a polypeptide having at least 95% homology to the polypeptide of SEQ ID NO: 6 (Ct-858 from serovar E) or an immunogenic fragment thereof, or a polynucleotide encoding these;
 - iii. Ct-875 – a polypeptide having at least 95% homology to the polypeptide of SEQ ID NO: 8 (Ct-858 from serovar E) or an immunogenic fragment thereof, or a polynucleotide encoding these;
 - iv. PmpD passenger domain – a polypeptide having at least 95% homology to the polypeptide of SEQ ID NO: 14 (PmpD from serovar LII) or an immunogenic fragment thereof, or a polynucleotide encoding these;
 - v. Swib – a polypeptide having at least 95% homology to the polypeptide of SEQ ID NO: 2 (Swib from serovar LII) or an immunogenic fragment thereof, or a polynucleotide encoding these;
 - vi. Momp - a polypeptide having at least 95% homology to the polypeptide of SEQ ID NO: 4 (Momp from serovar F) or an immunogenic fragment thereof, or a polynucleotide encoding these;
 - vii. Ct-622 – a polypeptide having at least 95% homology to the polypeptide of SEQ ID NO: 10 (Ct-622 from serovar E) or an immunogenic fragment thereof, or a polynucleotide encoding these;
 - viii. PmpG passenger domain - a polypeptide having at least 95% homology to the polypeptide of SEQ ID NO: 12 (PmpG from serovar LII) or an immunogenic fragment thereof, or a polynucleotide encoding these.
21. A composition according to any one of claims 1 to 20, wherein all the Chlamydia proteins or immunogenic fragments thereof or a polynucleotide or polynucleotides encoding them in the composition are from *Chlamydia trachomatis*.
22. Use of a composition according to any one of claims 1 to 21 as a medicament.
23. Use of a composition according to any one of claims 1 to 21 in the manufacture of a medicament for the treatment or prevention of Chlamydial infection.
24. Use according to claim 23, wherein the Chlamydial infection is *Chlamydia trachomatis* infection.
25. A method for the treatment or prevention of Chlamydial infection comprising the administration of a composition according to any one of claims 1 to 21.

26. The method according to claim 25, wherein the Chlamydial infection is *Chlamydia trachomatis* infection.
27. The composition, use or method according to any one of claims 1 to 26, wherein
5 PmpDpd or PmpGpd is present as part of full length PmpD or PmpG or a fragment thereof.
28. Use of one or more *Chlamydia* proteins, immunogenic fragments thereof or polynucleotides encoding them, selected from the list consisting of Ct-089, Ct-858 and Ct-875, and which are derived from a first *Chlamydia trachomatis* serovar, in the manufacture of a
10 vaccine for the treatment or prevention of *Chlamydia* infection by a second *Chlamydia trachomatis* serovar.
29. A method for the treatment or prevention of Chlamydial infection by a second *Chlamydia trachomatis* serovar, comprising the administration of a vaccine comprising one or more Chlamydial proteins, immunogenic fragments thereof or polynucleotides encoding them,
15 selected from the list consisting of Ct-089, Ct-858 and Ct-875, and which are derived from a first *Chlamydia trachomatis* serovar
30. The use or method according to either of claims 28 and 29, wherein the vaccine comprises one protein, immunogenic fragment thereof or polynucleotide encoding them, selected from the list consisting of Ct-089, Ct-858 and Ct-875.
- 20 31. The use or method according to any one of claims 28 to 30, wherein the vaccine comprises two proteins, immunogenic fragments thereof or polynucleotides encoding them, selected from the list consisting of Ct-089, Ct-858 and Ct-875.
32. The use or method according to claim 31, wherein the vaccine comprises Ct-089 and Ct-858, immunogenic fragments thereof or polynucleotides encoding them.
- 25 33. The use or method according to claim 31, wherein the vaccine comprises Ct-089 and Ct-875, immunogenic fragments thereof or polynucleotides encoding them.
34. The use or method according to claim 31, wherein the vaccine comprises Ct-858 and Ct-875, immunogenic fragments thereof or polynucleotides encoding them.
- 30 35. The use or method according to any one of claims 28 to 34, wherein the vaccine comprises Ct-089, Ct-858 and Ct-875, immunogenic fragments thereof or polynucleotides encoding them.

36. The use or method according to any one of claims 28 to 35, wherein the first *Chlamydia trachomatis* serovar is selected from the list consisting of *Chlamydia trachomatis* serovars A, B, Ba, C, D, Da, E, F, G, H, I, Ia, J, Ja, K, L1, L2 and L3.
- 5 37. The use or method according to any one of claims 28 to 36, wherein the *Chlamydia trachomatis* serovar is selected from the *Chlamydia trachomatis* ocular serovars.
38. The use or method according to claim 37, wherein the first *Chlamydia trachomatis* serovar is selected from the *Chlamydia trachomatis* ocular serovars A, B, Ba and C.
39. The use or method according to any one of claims 28 to 36, wherein the first *Chlamydia trachomatis* serovar is selected from the *Chlamydia trachomatis* oculogenital serovars.
- 10 40. The use or method according to claim 39, wherein the first *Chlamydia trachomatis* serovar is selected from the *Chlamydia trachomatis* oculogenital serovars D, Da, E, F, G, H, I, Ia, J, Ja and K.
41. The use or method according to any one of claims 28 to 36, wherein the first *Chlamydia trachomatis* serovar is selected from the *Chlamydia trachomatis* LGV serovars.
- 15 42. The use or method according to claim 41, wherein the first *Chlamydia trachomatis* serovar is selected from the *Chlamydia trachomatis* LGV serovars L1, L2 and L3.
43. The use or method according to any one of claims 28 to 42, wherein the first *Chlamydia trachomatis* serovar is selected such that it is a *Chlamydia trachomatis* serovar having a high level of sequence identity with the majority of other *Chlamydia trachomatis* serovars.
- 20 44. The use or method according to any one of claims 28 to 42, wherein the *Chlamydia trachomatis* serovar is selected such that it is a *Chlamydia trachomatis* serovar having a high level of sequence identity with the majority of common *Chlamydia trachomatis* serovars.
45. The use or method according to any one of claims 28 to 44, wherein the first and second *Chlamydia trachomatis* serovars are *Chlamydia trachomatis* serovars which are associated with
25 the same disease state.
46. The use or method according to any one of claims 28 to 44, wherein the first and second *Chlamydia trachomatis* serovars are *Chlamydia trachomatis* serovars which are associated with different disease states.

47. The use or method according to any one of claims 28 to 46, wherein the vaccine comprises one or more additional antigens.
48. The use or method according to claim 47, wherein the one or more additional antigens are *Chlamydia trachomatis* antigens.
- 5 49. The use or method according to either claim 47 or 48, wherein the one or more additional antigens are selected from the list consisting of Momp, Ct-622, PmpGpd and PmpDpd.
50. The use or method according to any one of claims 28 to 49, wherein the vaccine further comprises an adjuvant.
- 10 51. The use or method according to claim 50, wherein the adjuvant is a preferential stimulator of a Th1 response.
52. The use or method according to claim 51, wherein the adjuvant comprises 3D-MPL, QS21 or a combination of 3D-MPL and QS21.
53. The use or method according to claim 52, wherein the adjuvant further comprises an oil
15 in water emulsion.
54. The use or method according to claim 52, wherein the adjuvant further comprises liposomes.
55. A method for determining prior Chlamydial infection in an individual comprising:
 20 (i) obtaining a sample from the individual;
 (ii) contacting said sample with a combination of two or more Chlamydia proteins or immunogenic fragments thereof or a polynucleotide or polynucleotides encoding them, said two or more proteins or immunogenic fragments selected from Swib, Momp, Ct-858, Ct-875, Ct-622, Ct-089, passenger domain of PmpG (PmpGpd) and passenger domain of PmpD (PmpDpd);
 25 (iii) quantifying the sample response.
56. The method according to claim 55, wherein the combination of *Chlamydia* proteins or immunogenic fragments thereof or a polynucleotide or polynucleotides encoding them
 30 comprises one protein, immunogenic fragment thereof or polynucleotide encoding them, selected from the list consisting of Ct-089, Ct-858 and Ct-875.

57. The method according to claim 56, wherein the combination of *Chlamydia* proteins or immunogenic fragments thereof or a polynucleotide or polynucleotides encoding them comprises two proteins, immunogenic fragment thereof or polynucleotide encoding them,
5 selected from the list consisting of Ct-089, Ct-858 and Ct-875.
58. The method according to claim 57, wherein the vaccine two *Chlamydia* proteins immunogenic fragments thereof or polynucleotides encoding them are Ct-089 and Ct-858.
- 10 59. The method according to claim 57, wherein the vaccine two *Chlamydia* proteins immunogenic fragments thereof or polynucleotides encoding them are Ct-875 and Ct-858.
60. The method according to claim 57, wherein the vaccine two *Chlamydia* proteins immunogenic fragments thereof or polynucleotides encoding them are Ct-089 and Ct-875.
15
61. The method according to claim 57, wherein the a combination of *Chlamydia* proteins or immunogenic fragments thereof or a polynucleotide or polynucleotides encoding them comprises Ct-089, Ct-858 and Ct-875.
- 20 62. The method according to any one of claims 55 to 61 wherein the sample is whole blood.
63. The method according to any one of claims 55 to 61 wherein the sample is purified cells.
64. The method according to any one of claims 55 to 63 wherein the response is quantified
25 by monitoring lymphocyte proliferation.
65. The method according to any one of claims 55 to 63 wherein the response is quantified by monitoring production of cytokines.
- 30 66. The method according to any one of claims 55 to 63 wherein the response is quantified by monitoring production of specific antibodies.
67. The method according to any one of claims 55 to 66 wherein the individual is seronegative.
35
68. The method according to any one of claims 55 to 66 wherein the individual is seropositive.